{"ClinicalTrials": [{"json_id": 1386, "nct_id": "NCT03584009", "name": "A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy", "phase": "II", "outcome_measure": "Clinical benefit defined as Complete Response (CR), Partial Response (PR) or Sudden Death (SD) lasting >= 24 weeks", "location": "USA, Canada, UK, Germany, France", "contacts": "Reference Study ID Number: WO40181 www.roche.com/about_roche/roche_worldwide.htm\t888-662-6728 (U.S. and Canada)\tglobal-roche-genentech-trials@gene.com", "link": "https://clinicaltrials.gov/ct2/show/study/NCT03584009"}, {"json_id": 1385, "nct_id": "NCT03900884", "name": "Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (PALVEN)", "phase": "I", "outcome_measure": "Determination of the Maximum Tolerated Dose (MTD), dose-limiting toxicities (DLTs) and recommended phase 2 dose of drug combination of palbociclib, letrozole and venetoclax", "location": "Peter MacCallum Cancer Centre, Australia", "contacts": "Geoffrey Lindeman, MBBS FRACP, lindeman@wehi.edu.au", "link": "https://clinicaltrials.gov/ct2/show/NCT03900884"}, {"json_id": 1365, "nct_id": "NCT02999477", "name": "A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer", "phase": "I", "outcome_measure": "Change in PD-L1 Expression By Immunohistochemistry From Baseline Biopsy to Biopsy After 2-Week Treatment (biopsy 2)", "location": "Boston, United States", "contacts": "Sara Tolaney, MD MPH, 617-632-2335", "link": "https://clinicaltrials.gov/ct2/show/NCT02999477"}, {"json_id": 1366, "nct_id": "NCT02776917", "name": "Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer", "phase": "I", "outcome_measure": "The rate of dose-limiting toxicities during the first 4 weeks of treatment", "location": "La Jolla, United States", "contacts": "Jillian McCarthy, MPH, jmccarthy@ucsd.edu, 858-822-4516", "link": "https://clinicaltrials.gov/ct2/show/NCT02776917"}, {"json_id": 1371, "nct_id": "NCT03591276", "name": "Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer", "phase": "I/II", "outcome_measure": "To establish a safe dose of PLD when delivered in combination with pembrolizumab", "location": "Jerusalem, Israel", "contacts": "Alberto Gabizon, MD, PhD, alberto.gabizon@gmail.com, 0508685036", "link": "https://clinicaltrials.gov/ct2/show/NCT03591276"}, {"json_id": 1175, "nct_id": "NCT03139851", "name": "Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide", "phase": "II", "outcome_measure": "Severe Toxicities (ST) in Run-In Phase Part", "location": "Angers, France", "contacts": "Jean-Sébastien FRENEL, jean-sebastien.frenel@ico.unicancer.fr, 0240679900", "link": "https://clinicaltrials.gov/ct2/show/NCT03139851"}, {"json_id": 1183, "nct_id": "NCT02547987", "name": "Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer", "phase": "II", "outcome_measure": "Pathologic Complete Response", "location": "Cincinnati, United States", "contacts": "Nancy Firsich, RN, BSN, nancy_firsich@trihealth.com, 513-865-5569", "link": "https://clinicaltrials.gov/ct2/show/NCT02547987"}, {"json_id": 1384, "nct_id": "NCT03926091", "name": "Study Comparing 4 Cycles With 6 Cycles of TC Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer", "phase": "III", "outcome_measure": "Disease free survival", "location": "Chongqing, China", "contacts": "Xiaohua Zeng, M.D., +86-023-65311341", "link": "https://clinicaltrials.gov/ct2/show/NCT03926091"}, {"json_id": 1003, "nct_id": "NCT02730091", "name": "A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease", "phase": "III", "outcome_measure": "progression-free survival (PFS)", "location": "Besançon, France", "contacts": "Cristian VILLANUEVA, c1villanueva@chu-besancon.fr", "link": "https://clinicaltrials.gov/ct2/show/NCT02730091"}, {"json_id": 1212, "nct_id": "NCT03462251", "name": "Ribociclib and Aromatase Inhibitor or Paclitaxel and Bevacizumab for Metastatic Breast Cancer in First Line", "phase": "III", "outcome_measure": "Efficacy in terms of PFS", "location": "Ravensburg, Germany", "contacts": "Thomas Decker, Prof., thomas.decker@onkonet.eu, +49 751 3661970", "link": "https://clinicaltrials.gov/ct2/show/NCT03462251"}, {"json_id": 1344, "nct_id": "NCT03778931", "name": "Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer", "phase": "III", "outcome_measure": "Progression Free Survival (PFS) in the ESR1-mut subjects", "location": "Glendale, United States", "contacts": "Javier Valeriano, javier.valeriano@ah.org, 818-409-8009", "link": "https://clinicaltrials.gov/ct2/show/NCT03778931"}, {"json_id": 1192, "nct_id": "NCT02953860", "name": "Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer", "phase": "II", "outcome_measure": "Clinical benefit rate of the combination of enzalutamide/ fulvestrant", "location": "Aurora, United States", "contacts": "Tiffany Colvin, TIFFANY.COLVIN@UCDENVER.EDU, 303-848-0664", "link": "https://clinicaltrials.gov/ct2/show/NCT02953860"}, {"json_id": 1190, "nct_id": "NCT03386162", "name": "SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer", "phase": "II", "outcome_measure": "progression-free survival", "location": "Angers, France", "contacts": "Mario CAMPONE, MD, PhD, mario.campone@ico.unicancer.fr", "link": "https://clinicaltrials.gov/ct2/show/NCT03386162"}, {"json_id": 1189, "nct_id": "NCT02958852", "name": "A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer", "phase": "II", "outcome_measure": "Clinical benefit rate.", "location": "Lund, Sweden", "contacts": "Signe Borgquist, MD, PhD, signe.borgquist@med.lu.se, +46 46 17 75 20", "link": "https://clinicaltrials.gov/ct2/show/NCT02958852"}, {"json_id": 905, "nct_id": "NCT02738866", "name": "Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor", "phase": "II", "outcome_measure": "Progression-free survival", "location": "Washington, United States", "contacts": "Hopkins Breast Trials, HopkinsBreastTrials@jhmi.edu, 410-955-8804", "link": "https://clinicaltrials.gov/ct2/show/NCT02738866"}, {"json_id": 1186, "nct_id": "NCT02632045", "name": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer", "phase": "II", "outcome_measure": "Percent progression-free at 24 weeks", "location": "Birmingham, United States", "contacts": "Chris Vaklavas, MD, cvaklavas@uabmc.edu, 205-934-5677", "link": "https://clinicaltrials.gov/ct2/show/NCT02632045"}, {"json_id": 1157, "nct_id": "NCT03285412", "name": "CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer", "phase": "II", "outcome_measure": "Number of Participants That Complete 12 Months of Treatment", "location": "Boston, United States", "contacts": "Aditya Bardia, MD, MPH, Bardia.Aditya@mgh.harvard.edu, 617-724-4000", "link": "https://clinicaltrials.gov/ct2/show/NCT03285412"}, {"json_id": 1156, "nct_id": "NCT03555877", "name": "Anti-hormonal Therapie With or Without Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer", "phase": "II", "outcome_measure": "Locally-assessed progression-free survival (PFS)", "location": "Ravensburg, Germany", "contacts": "Thomas Decker, Prof. Dr., thomas.decker@onkonet.eu, +49 (0) 7513661970", "link": "https://clinicaltrials.gov/ct2/show/NCT03555877"}, {"json_id": 1155, "nct_id": "NCT02646735", "name": "Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients", "phase": "II", "outcome_measure": "PFS", "location": "Beijing, China", "contacts": "Binghe XU, M.D., xubinghe@medmail.com.cn, 86-10-88788826", "link": "https://clinicaltrials.gov/ct2/show/NCT02646735"}, {"json_id": 1197, "nct_id": "NCT02344550", "name": "Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer", "phase": "II", "outcome_measure": "Progression free survival (PFS)", "location": "Seoul, Korea, Republic of", "contacts": "Sung Bae Kim, M.D., Ph D., sbkim3@amc.seoul.kr, 82-2-3010-3217", "link": "https://clinicaltrials.gov/ct2/show/NCT02344550"}, {"json_id": 1195, "nct_id": "NCT03659136", "name": "The XENERA(TM)-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread", "phase": "II", "outcome_measure": "Progression free survival (PFS) as assessed by central review", "location": "Goodyear, United States", "contacts": "Cynthia Lynch, cynthia.lynch@ctca-hope.com, +001 (623) 207 3000", "link": "https://clinicaltrials.gov/ct2/show/NCT03659136"}, {"json_id": 907, "nct_id": "NCT02536742", "name": "Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer", "phase": "II", "outcome_measure": "Progression Free Survival (PFS)", "location": "Antwerpen, Belgium", "contacts": "Luc Dirix, cto@gza.be", "link": "https://clinicaltrials.gov/ct2/show/NCT02536742"}, {"json_id": 902, "nct_id": "NCT03147287", "name": "Palbociclib After CDK and Endocrine Therapy (PACE)", "phase": "II", "outcome_measure": "Progression Free Survival", "location": "Bangor, United States", "contacts": "Zarah Lucas, MD, zdlucas@emhs.org", "link": "https://clinicaltrials.gov/ct2/show/NCT03147287"}, {"json_id": 1151, "nct_id": "NCT02913430", "name": "Phase II Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib", "phase": "II", "outcome_measure": "Progression-free survival (PFS)", "location": "Pittsburgh, United States", "contacts": "Shannon L. Cieply, 412-641-2357", "link": "https://clinicaltrials.gov/ct2/show/NCT02913430"}, {"json_id": 904, "nct_id": "NCT03439735", "name": "Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC", "phase": "II", "outcome_measure": "Genetic Mutation", "location": "Baltimore, United States", "contacts": "Hopkins Breast Trials, hopkinsbreasttrials@jhmi.edu, 410-614-1361", "link": "https://clinicaltrials.gov/ct2/show/NCT03439735"}, {"json_id": 897, "nct_id": "NCT03322215", "name": "HR+/HER2- Advanced Breast Cancer and Endocrine Resistance", "phase": "II", "outcome_measure": "Progression free survival (PFS), as assessed locally by the investigator.", "location": "Göteborg, Sweden", "contacts": "Barbro Linderholm, MD PhD, barbro.linderholm@oncology.gu.se, + 46 31 342 79 41", "link": "https://clinicaltrials.gov/ct2/show/NCT03322215"}, {"json_id": 896, "nct_id": "NCT03633331", "name": "Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer", "phase": "II", "outcome_measure": "Incidence of adverse events", "location": "Lewes, United States", "contacts": "Site Public Contact, Dmiskin@Beebehealthcare.org, 302-645-3770", "link": "https://clinicaltrials.gov/ct2/show/NCT03633331"}, {"json_id": 895, "nct_id": "NCT02778685", "name": "Pembrolizumab, Letrozole, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer", "phase": "II", "outcome_measure": "Response rate (CR or PR) assessed using RECIST version 1.1", "location": "Corona, United States", "contacts": "Cheryl Corpus, 626-256-4673", "link": "https://clinicaltrials.gov/ct2/show/NCT02778685"}, {"json_id": 1149, "nct_id": "NCT03306472", "name": "A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer", "phase": "II", "outcome_measure": "Determination of change in tumour proliferation measured by Ki67 immunohistochemical (IHC) assessment (%) at baseline compared to Day 15 (+ ≤4 days).", "location": "Cambridge, United Kingdom", "contacts": "Angels Kateb Castellnou, BSc, MSc, angels.kateb@addenbrookes.nhs.uk, 01223 348073", "link": "https://clinicaltrials.gov/ct2/show/NCT03306472"}, {"json_id": 1147, "nct_id": "NCT02910050", "name": "Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer", "phase": "II", "outcome_measure": "clinical benefit rate（CBR）", "location": "Guangzhou, China", "contacts": "Fei Xu, MD, xufei@sysucc.org.cn, +86-13711277870", "link": "https://clinicaltrials.gov/ct2/show/NCT02910050"}, {"json_id": 1341, "nct_id": "NCT02299999", "name": "SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer", "phase": "II", "outcome_measure": "Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm", "location": "Angers, France", "contacts": "Mario CAMPONE, MD, mario.campone@ico.unicancer.fr", "link": "https://clinicaltrials.gov/ct2/show/NCT02299999"}, {"json_id": 1339, "nct_id": "NCT02990845", "name": "Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer", "phase": "I/II", "outcome_measure": "The PFS rate at 8 months", "location": "Taipei, Taiwan", "contacts": "Yen-Shen Lu, MD, PhD, yslu@ntu.edu.tw, +886-2-23123456", "link": "https://clinicaltrials.gov/ct2/show/NCT02990845"}, {"json_id": 881, "nct_id": "NCT02871791", "name": "Palbociclib With Everolimus + Exemestane In BC", "phase": "I/II", "outcome_measure": "Number of participants with Dose-Limiting Toxicities (DLT)", "location": "Boston, United States", "contacts": "Sara Tolaney, MD, MPH, stolaney@partners.org, 617-632-2335", "link": "https://clinicaltrials.gov/ct2/show/NCT02871791"}, {"json_id": 1139, "nct_id": "NCT02520063", "name": "Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer", "phase": "I/II", "outcome_measure": "Maximum tolerated dose (MTD)", "location": "Birmingham, United States", "contacts": "Christos Vaklavas, M.D., cvaklavas@uabmc.edu, 205-934-5677", "link": "https://clinicaltrials.gov/ct2/show/NCT02520063"}, {"json_id": 265, "nct_id": "NCT03099174", "name": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.", "phase": "I", "outcome_measure": "Cohorts A, B,C & D - Maximum Tolerated Dose (MTD)", "location": "New Haven, United States", "contacts": "Patricia LoRusso, Patricia.lorusso@yale.edu, +001 (203) 785-5944", "link": "https://clinicaltrials.gov/ct2/show/NCT03099174"}, {"json_id": 1125, "nct_id": "NCT02936206", "name": "Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.", "phase": "I", "outcome_measure": "Change in Ki67 cell percentage", "location": "New York, United States", "contacts": "Takhir Mirzoyev, Takhir.mirzoyev@mountsinai.org, 212-523-7289", "link": "https://clinicaltrials.gov/ct2/show/NCT02936206"}, {"json_id": 878, "nct_id": "NCT02626507", "name": "Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer", "phase": "I", "outcome_measure": "Number of participants with treatment-related adverse events as assessed by CTCAE v4.0", "location": "Bronx, United States", "contacts": "Anthony Hoffman, MD, Doctor@hoffmanoncology.com, 718-655-1005", "link": "https://clinicaltrials.gov/ct2/show/NCT02626507"}, {"json_id": 1121, "nct_id": "NCT03294694", "name": "Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer", "phase": "I", "outcome_measure": "Cohort A: MTD/RP2D of the Combination of Ribociclib + PDR001", "location": "Boston, United States", "contacts": "Aditya Bardia, MD, abardia1@partners.org, 617-643-2208", "link": "https://clinicaltrials.gov/ct2/show/NCT03294694"}, {"json_id": 1120, "nct_id": "NCT02599363", "name": "A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer", "phase": "I", "outcome_measure": "Number of Adverse Events", "location": "Philadelphia, United States", "contacts": "Amy Clark, MD, PennCancerTrials@emergingmed.com, 855-216-0098", "link": "https://clinicaltrials.gov/ct2/show/NCT02599363"}], "Evidences": [{"drugs": [56, 130], "variant_id": [], "assay_id": [980], "json_id": 2549, "ogt_id": "OGE-YZ-5025", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "title": "NCCN", "link": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_OTHER", "biomarker_type": null}, {"drugs": [56, 288], "variant_id": [], "assay_id": [980], "json_id": 2527, "ogt_id": "JAX_5897", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "In a Phase II trial that supported FDA approval, the combination of Faslodex (fulvestrant) with Ibrance (palbociclib) compared to Faslodex (fulvestrant) plus placebo in ERBB2 (HER2) negative-ER-positive breast cancer patients resulted in a greater progression free survival (9.5 vs 4.6 mo) (PMID: 27407089).", "title": "Clin. Cancer Res., 2018", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=27407089", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [236, 287], "variant_id": [], "assay_id": [980], "json_id": 2513, "ogt_id": "OGE-YZ-508", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В исследовании III фазы MONARCH3 изучалась эффективность Абемациклиба и нестероидных ингибиторов ароматазы (Летрозол, Анастразол) в терапии ER+ HER2- метастатического рака молочной железы. Медиана выживаемости без прогрессирования не была достигнута в группе Абемациклиба и нестероидных ингибиторов ароматазы и составила 14,7 месяцев в группе нестероидных ингибиторов ароматазы (Отношение рисков 0,54; 95% доверительный интервал 0,41-0,72; р=0,000021).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/28968163", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [288], "variant_id": [], "assay_id": [980], "json_id": 2547, "ogt_id": "OGE-YZ-5012", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В исследовании II фазы изучалась эффективность Фулвестранта (нагрузочная доза 500 мг каждые 2 недели- 3 приема, далее 500 мг/месяц) и Анастразола в первой линии терапии гормональнозависимого рака молочной железы (PMID: 19704066). Не наблюдалось различий в частоте объективного ответа составила 36,0% в группе Фулвестрантна и 35,5% в группе Анастразола. Однако медиана продолжительности ответа была достоверно выше в группе Фулвестрантна - недостигнута и составила 12,5 месяца в группе Анастразола (Относительный риск 0,63; 95% доверительный интерал, 0,39-1,00; р=0,0496).\r\n\r\nВ исследовании III фазы CONFIRM сравнивалась эффективность двух дозовых режимов Фулвестранта (250 мг и 500 мг в месяц) (PMID: 20855825). Применение Фулвестранта в дозе 500 мг в сутки было достоверно более эффективным (относительный риск прогрессирования 0,80; 95% ДИ, 0,68 -0,94; р=0,006).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/19704066", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [56, 288], "variant_id": [], "assay_id": [980], "json_id": 2544, "ogt_id": "JAX_5924", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "\"In a Phase II trial (PALOMA-3) that supported FDA approval, the combination of Faslodex (fulvestrant) with Ibrance (palbociclib)  resulted in an improved progression-free survival of 9.5 months, compared to 4.6 months with Faslodex (fulvestrant) plus placebo in ERBB2 (HER2) negative, ESR1 (ER)-positive breast cancer patients (PMID: 26947331, PMID: 27407089; NCT01942135).\"", "title": "Lancet Oncol., 2017", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=26947331", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [], "variant_id": [25324], "assay_id": [], "json_id": 2530, "ogt_id": "JAX_1147", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_C", "evidence_type": "STR_EVID_TYPE_PREDISPOSING", "description": "In multiple meta-analyses, AURKA F31I was associated with increased risk of breast cancer (PMID: 24349361, PMID: 25154511, PMID: 23803310).", "title": "Mol. Genet. Genomics, 2015", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=25154511", "comment": null, "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PREDISPOSING"}, {"drugs": [124], "variant_id": [25099, 25101], "assay_id": [], "json_id": 2515, "ogt_id": "OGE-YZ-5019", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В исследовании III фазы TNT сравнивалась эффективность Доцетаксела и Карбоплатина во второй линии терапии метастатического тройного негативного рака молочной железы. В исследование были включены 376 пациентов, рандомизированных на группы 1:1. В общей когорте пациентов не наблюдалось различий в эффективности Доцетаксела и Карбоплатина, частота объективных ответов составила 34% и 31,4% соответственно. Медианы выживаемости без прогрессирования составили 4,4 месяца и 3,1 месяца в группах Доцетаксела и Карбоплатина соответственно, различия не были статистически значимыми. В подгруппе с наличием герминальных мутаций в генах BRCA1/2 частота объективных ответов составила 33,3% (N=6/18) в группе Доцетаксела против 68% (17/25) в группе Карбоплатина (p=0,03). Медиана выживаемости без прогрессирования составила 6,8 месяцев в группе Карбоплатина против 4,4 месяцев в группе Доцетаксела, различия были статистически достоверны (p=0,002).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/29713086", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_OTHER", "biomarker_type": null}, {"drugs": [288], "variant_id": [25331], "assay_id": [], "json_id": 2524, "ogt_id": "OGE-YZ-5023", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "Наличие мутаций в гене ESR1 в плазме крови у пациенток с гормонположительным раком молочной железы, получавших гормонотерапию, ассоциировано с уменьшением медианы выживаемости без прогрессирования на фоне терапии нестероидными ингибиторами ароматазы (Относительный риск, 1,98; 95% доверительный интервал (ДИ), 1,12–3,51; р=0,02), но не связано с уменьшением медианы выживаемости без прогрессирования на фоне приема Фулвестранта (Относительный риск, 1,03; 95% ДИ, 0,79–1,34; р=0,83)(PMID: 30275706). В проспективном исследовании изучалась роль мутаций в гене ESR1 на развитие вторичной резистентности к адъювантной гормонотерапии и терапии метастатической болезни ингибиторами ароматазы (Анастразол, Летрозол) (PMID: 26560360). Авторы пришли к выводу, что вторичная резистентность к ингибиторам ароматазы, обусловленная ESR1, крайне редко встречается при адъювантном режиме приема ингибиторов ароматазы и возникает в каждом третьем случае при метастатической болезни.", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/30275706", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [], "variant_id": [25324], "assay_id": [], "json_id": 2541, "ogt_id": "JAX_1148", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_C", "evidence_type": "STR_EVID_TYPE_PREDISPOSING", "description": "In multiple meta-analyses, AURKA F31I was associated with increased risk of breast cancer (PMID: 24349361, PMID: 25154511, PMID: 23803310).", "title": "PLoS ONE, 2014", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=24349361", "comment": null, "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PREDISPOSING"}, {"drugs": [71, 72], "variant_id": [], "assay_id": [967], "json_id": 2522, "ogt_id": "OGE-YZ-500", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "Отсутствуют показания для назначения анти-HER2 терапии.", "title": "NCCN", "link": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_NONEFFECTIVE", "biomarker_type": null}, {"drugs": [320], "variant_id": [25099, 25101], "assay_id": [], "json_id": 2534, "ogt_id": "OGE-YZ-5018", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В исследовании III фазы изучалась эффективность Талазопариба по сравнению с монохимиотерапией стандартными препаратами в терапии BRCA-ассоццированного рака молочной железы у пациенток, получивших не более 3 линий химиотерапии. В исследование были включены 431 пациентки, разделенные на группы Талазопариб (N=287) и химиотерапия (M=144). Медианы выживаемости без прогрессирования составили 8,6 месяца против 5,6 месяца, соответственно (Отношение рисков 0,54; 95% ДИ, 0,41-0,71; р<0,001). Подгрупповой анализ показал, что все пациентки получили выгоду от назначения Талазопариба, кроме группы, получавшей ранее препараты платины, что может быть связано с небольшим количеством таких пациенток.", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/30110579", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_NONEFFECTIVE", "biomarker_type": null}, {"drugs": [13], "variant_id": [], "assay_id": [971], "json_id": 2539, "ogt_id": "OGE-YZ-5013", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B2", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "Опираясь на результаты исследований Keynote-012 и 086 невозможно дать оценку влияния экспрессии PD-L1 на поверхности опухолевых клеток на частоту объективного ответа и общую выживаемость пациенток с тройным негативным раком молочной железы, получающих анти-PD-1 терапию. Однако, стоит заметить, что в общей популяции пациенток с тройным негативным раком молочной железы объективный ответ наблюдается лишь в 5% случаев. Наиболее важными прогностическими маркерами ассоциированными с увеличением объективного ответа при назначении Пембролизумаба согласно данным исследования Keynote-086 являются: уровень ЛДГ ниже верхней границы нормы и отсутствие метастазов в печени.", "title": "ASCO", "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1008", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_NONEFFECTIVE", "biomarker_type": null}, {"drugs": [287, 289], "variant_id": [], "assay_id": [980], "json_id": 2528, "ogt_id": "JAX_5894", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_OTHER_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "\"In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).\"", "title": "Lancet Oncol., 2018", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=29804902", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [56, 288], "variant_id": [], "assay_id": [980], "json_id": 2521, "ogt_id": "JAX_5923", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "\"In a Phase II trial (PALOMA-3) that supported FDA approval, the combination of Faslodex (fulvestrant) with Ibrance (palbociclib)  resulted in an improved progression-free survival of 9.5 months, compared to 4.6 months with Faslodex (fulvestrant) plus placebo in ERBB2 (HER2) negative, ESR1 (ER)-positive breast cancer patients (PMID: 26947331, PMID: 27407089; NCT01942135).\"", "title": "Clin. Cancer Res., 2018", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=27407089", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [56, 288], "variant_id": [], "assay_id": [980], "json_id": 2533, "ogt_id": "OGE-YZ-502", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В исследовании III фазы PALOMA-3 изучалась эффективность комбинации Палбоциклиба и Фулвестранта во второй линии терапии метастатического ER+ HER2- рака молочной железы. Медиана выживаемости без прогрессирования была достоверно выше в группе Палбоциклиба и составила 9,5 месяца (95% Доверительный интервал (ДИ) 9,2-11,0) против 4,6 месяца (3,5-5,6) в группе Фулвестранта (Отношение рисков  0,46, 95% ДИ 0,36-0,59, p<0,0001) (PMID: 26947331). Палбоциклиб имеет тенденцию к увеличению медианы общей выживаемости пациенток, которая составила 34,9 месяца (95% ДИ, 28,8 -40,0) в группе Палбоциклиб-Фулвестрант против 28 месяцев (95% ДИ, 23,6-34,6) в группе Плацебо-Фулвестрант (0,81; 95% ДИ, 0,64 -1,03; р=0,09; абсолютный выигрыш 6,9 месяца) (PMID: 30345905).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/26947331", "comment": "<p>PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30345905\">30345905</a>,&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26947331\">26947331</a>.</p>", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [286, 288], "variant_id": [25100], "assay_id": [], "json_id": 2507, "ogt_id": "OGE-YZ-5015", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_IN_RND", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В III фазе клинического исследования SOLAR-1 изучалась эффективность комбинации ингибитора PIK3CA- Алпелисиба и Фулвестранта во второй линии терапии метастатического ER+ HER2- рака молочной железы. В исследование были включены 572 пациентки, рандомизированных 1:1 в группы Алпелисиб + Фулвестрант и Фулвестрант. Добавление Алпелисиба к Фулвестранту привело к достоверному увеличению медианы выживаемости без прогрессирования в подгруппе с наличием активирующих мутаций в гене PIK3CA, которая составила 11 месяцев (95% Доверительный интервал (ДИ), 7,5-14,5) в группе комбинации против  5,7 месяца (95% ДИ, 3,7-7,4) в группе Фулвестранта (Отношение рисков (ОР) 0,65; 95% ДИ, 0,50-0,85; p<0,001). В подгруппе с отсутствием активирующих мутаций в гене PIK3CA не наблюдалось достоверных различий между группами (ОР 0,85 95% ДИ, 0,58-1,25).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/31091374", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_NONEFFECTIVE", "biomarker_type": null}, {"drugs": [], "variant_id": [], "assay_id": [979], "json_id": 2546, "ogt_id": "CIVIC_1959", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B", "evidence_type": "STR_EVID_TYPE_PROGNOSTIC", "description": "In patients with breast cancer, those with low expression of PgR had worse disease-free survival than those with high expression.", "title": "J. Clin. Oncol., 2011", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=21422407", "comment": null, "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PROGNOSTIC"}, {"drugs": [], "variant_id": [25327], "assay_id": [], "json_id": 2545, "ogt_id": "OGE_5051", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B", "evidence_type": "STR_EVID_TYPE_DIAGNOSTIC", "description": "We extended the analysis of AKAP9 M463I, which is in strong linkage disequilibrium with AKAP9 N2792S, to 9523 breast cancer patients and 13770 healthy control subjects from seven independent European and Australian breast cancer studies. All statistical tests were two-sided. The collaborative analysis confirmed the association of M463I with increased breast cancer risk. Among all breast cancer patients, the combined adjusted odds ratio (OR) of breast cancer for individuals homozygous for the rare allele TT (frequency = 0.19) compared with GG homozygotes was 1.17 (95% confidence interval [CI] = 1.08 to 1.27, P = .0003), and the OR for TT homozygotes plus GT heterozygotes compared with GG homozygotes was 1.10 (95% CI = 1.04 to 1.17, P = .001). Among the combined subset of 2795 familial breast cancer patients, the respective ORs were 1.27 (95% CI = 1.12 to 1.45, P = .0003) and 1.16 (95% CI = 1.06 to 1.27, P = .001).", "title": "J. Natl. Cancer Inst., 2008", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=18334708", "comment": null, "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_DIAGNOSTIC"}, {"drugs": [56, 291], "variant_id": [], "assay_id": [980], "json_id": 2525, "ogt_id": "OGE-YZ-501", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В исследовании II фазы PALOMA-1 изучалась эффективность Палбоциклиба в комбинации с Летрозолом по сравнению с монотерапией Летрозолом в первой линии терапии метастатического гормонпозитивного HER2- рака молочной железы. Медиана выживаемости без прогрессирования составила 24,8 мес. в группе Палбоциклиба и 14,5 мес. в группе Летрозола  (отношение рисков 0,58; 95% доверительный интервал, 0,46-0,72; P<0,001).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/27959613", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [291], "variant_id": [25331], "assay_id": [], "json_id": 2516, "ogt_id": "OGE-YZ-5020", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "Наличие мутаций в гене ESR1 в плазме крови у пациенток с гормонположительным раком молочной железы, получавших гормонотерапию, ассоциировано с уменьшением медианы выживаемости без прогрессирования на фоне терапии нестероидными ингибиторами ароматазы (Относительный риск, 1,98; 95% доверительный интервал (ДИ), 1,12–3,51; р=0,02), но не связано с уменьшением медианы выживаемости без прогрессирования на фоне приема Фулвестранта (Относительный риск, 1,03; 95% ДИ, 0,79–1,34; р=0,83).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/30275706", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [290, 291], "variant_id": [], "assay_id": [980], "json_id": 2531, "ogt_id": "OGE-YZ-505", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "title": "NCCN", "link": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [287], "variant_id": [], "assay_id": [980], "json_id": 2529, "ogt_id": "JAX_5915", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "In a Phase III trial (ATAC) that supported FDA approval, Arimidex (anastrozole) treatment resulted in prolonged disease-free survival (HR=0.87, p=0.01) and time-to-recurrence (HR=0.79, p=0.0005), and decreased distant metastases (HR=0.86, p=0.04) and contralateral breast cancers (42% reduction, p=0.01) compared to Nolvadex (tamoxifen) in patients with hormone receptor-positive breast cancer (PMID: 15639680).", "title": "Lancet, 2005", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=15639680", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [236], "variant_id": [], "assay_id": [980], "json_id": 2526, "ogt_id": "JAX_5895", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "\"In a Phase II trial (MONARCH 1) that supported FDA approval, Verzenio (abemaciclib) treatment resulted in an objective response rate of 19.7% (26/132), a clinical benefit rate of 42.4% (56/132), median progression-free survival of 6.0 months, and median overall survival of 17.7 months in patients with refractory hormone receptor positive, Erbb2 (Her2) negative metastatic breast cancer (PMID: 28533223; NCT02102490).\"", "title": "Clin. Cancer Res., 2018", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=28533223", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_OTHER", "biomarker_type": null}, {"drugs": [289, 291], "variant_id": [], "assay_id": [980], "json_id": 2523, "ogt_id": "OGE-YZ-503", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В исследовании III фазы сранивалась эффективность Рибоциклиба и Летрозола в комбинации и монотерапии Летрозолом в первой линии терапии ER+ HER2- метастатического рака молочной железы. Частота выживаемости без прогрессирования, ВБП, через 18 месяцев была достоверно выше в группе Рибоциклиба и составила 63,0% (95% Доверительный Интервал (ДИ), 54,6-70,3) и 42,2% (95% ДИ, 34,8-49,5) в группе Летрозола. ВБП была значительно больше в группе комбинации препаратов по сравнению с группой плацебо + Летрозол.", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/27717303", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [290], "variant_id": [25331], "assay_id": [], "json_id": 2543, "ogt_id": "OGE-YZ-5022", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В ретроспективном анализе результатов исследования SoFEA изучалось влияние наличия мутаций в генах ESR1 на эффективность терапии Фулвестрантном и Экземестаном  Медиана выживаемости без прогрессирования в подгруппе с наличием мутаций в гене ESR1 составила 2,6 месяцев (95% Доверительный интервал (ДИ), 2,4-6,2) и 5,6 месяцев (95% ДИ, 3,0-8,5) для пациентов получивших Фулвестрант (Отношение рисков 0,52; 95% ДИ, 0,30-0,92; р =0,02). В подгруппе с ESR1 дикого типа медиана выживаемости без прогрессирования составила 8 месяцев в группе экземестана (95% ДИ, 3,0-11,5) и 5,4 месяцев (95% ДИ, 3,7-8,1) в группе Фулвестранта различия не были достоверными.", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/27269946", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [236], "variant_id": [], "assay_id": [979], "json_id": 2519, "ogt_id": "JAX_10722", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "\"In a Phase II trial (MONARCH 1) that supported FDA approval, Verzenio (abemaciclib) treatment resulted in an objective response rate of 19.7% (26/132), a clinical benefit rate of 42.4% (56/132), median progression-free survival of 6.0 months, and median overall survival of 17.7 months in patients with refractory hormone receptor positive, Erbb2 (Her2) negative metastatic breast cancer (PMID: 28533223; NCT02102490).\"", "title": "Clin. Cancer Res., 2018", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=28533223", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_OTHER", "biomarker_type": null}, {"drugs": [123, 318], "variant_id": [], "assay_id": [971], "json_id": 2535, "ogt_id": "OGE-YZ-5010", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_OTHER_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В III фазе клинического исследования была изучена эффективность комбинации Атезолизумаба (анти-PD-L1) с альбумин-связанным (nab) Наб-паклитакселом в лечении метастатического тройного негативного рака молочной железы. Каждая группа включала 451 пациента (медиана наблюдения 12,9 месяца). Медиана выживаемости без прогрессирования составила 7,2 месяца в группе Атезолизумабом плюс Наб-паклитаксел по сравнению с 5,5 месяцами в плацебо плюс Наб-паклитаксел (отношение рисков, ОР, для прогрессии или смерти 0,80; доверительный интервал 95% (ДИ) 0,69-0,92; р=0,002); среди пациентов с PD-L1 экспрессией на поверхности клеток микроокружения >1% опухолями медиана выживаемости без прогрессирования составила 7,5 месяцев в группе комбинации и 5,0 месяцев в группе Наб-паклитаксела (ОР прогрессирования 0,62; 95% ДИ, 0,49-0,78; р<0,001). Медиана общей выживаемости составила 21,3 месяца в группе Атезолизумаба и Наб-паклитаксела и 17,6 месяца в группе Плацебо + Наб-паклитаксел в общей популяции (ОР смерти 0,84; 95% ДИ от 0,69-1,02; р=0,08); среди пациентов с PD-L1-позитивными опухолями медиана общей выживаемости составила 25,0 и 15,5 месяца, соответственно (ОР 0,62; 95% ДИ, 0,62; 0,45-0,86). Назначение комбинации Атезолизумаб+Наб-Паклитаксел имело статистически значимое преимущество в ВБП и ОВ по сравнению с монотерапией Наб-паклитакселом в группе с экспрессией PD-L1 на 1% и более клеток микроокружения опухоли. Данные по безопасности и эффективности комбинации Атезолизумаба и Наб-Паклитаксела и анти-HER2 препаратов при HER2- раке молочной железы не опубликовано.", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/30345906", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_NONEFFECTIVE", "biomarker_type": null}, {"drugs": [130, 321], "variant_id": [], "assay_id": [975, 980], "json_id": 2550, "ogt_id": "OGE-YZ-5026", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_IN_RND", "evidence_level": "STR_EVID_LEVEL_B1", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В клиническом исследовании 1b фазы изучалась эффективность ингибитора BCL2 - Венетоклакса в комбинации с Тамоксифеном в лечении ER+ HER2- BCL2+ рака молочной железы. В исследование были включены 33 пациентки, 15 - в когорту с дозоэскалацией Венетоклакса (200-800 мг в сутки), 91% пациенток были в постменопаузе. 11 (33,3%) пациенток получили данное лечение в качестве 1 линии, 22 (66,7%) пациентки ранее получали химио- или гормонотерапию, из которых 15 (45%) получили более 2х линий терапии. Согластно критериям ESMO-ABC4 первичная гормонорезистентность наблюдалась у 3 пациенток, вторичная гормонорезистентность у 24 пациенток и 6 имели поздний рецидив после адъювантной гормонотерапии и были расценены как гормоночувствительные, 63% пациенток получили Тамоксифен в адъювантном режиме или в качестве гормонотерапии до включения в исследование. Наиболее эффективной дозой оказалась ежедневный прием 800 мг Венетоклакса и стандартного режима приема Тамоксифена (20 мг в сутки), который был рекомендован для последующих исследований. Частота объективных ответов составила 45% (n=15) в общей когорте, 27% (n=4 из 15) в группе дозоэскалации. В группе дозоэкспансии (Венетоклакс 800 мг в сутки и Тамоксифен 20 мг в сутки) у пациенток с измеряемыми очагами заболевания частота объективных ответов составила 54% (n=13) и частота стабилизаций заболевания 21% (n=5). Объективный ответ был достигнут у 1 из 3х пациенток с первичной гормонорезистентностью и у 16 из 24 со вторичной гормональной резистентностью. Выживаемость без прогрессирования составила 51 неделю в группе дозоэкспансии и 23 недели в группе дозоэскалации (ежедневный прием менее 800 мг Венетоклакса). На эффективность терапии не влияло наличие или отсутствие мутаций в генах PIK3CA, ESR1, GATA3, PTEN и MAP3K1. Прием Венетоклакса влиял на микроокружение опухоли, вызывая деплецию В-лимфоцитов и статистически значимо не влияя на количество Т-лимфоцитов.", "title": "PubMed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/30518523", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [236, 288], "variant_id": [], "assay_id": [979, 980], "json_id": 2511, "ogt_id": "JAX_10730", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В исследовании III фазы MONARCH2 изучалась эффективность комбинации Абемациклиба и Фулвестранта по сравнению с монотерапией Фулвестрантом во второй линии  метастатического ER+ PR+ HER2- рака молочной железы, а также у пациентов с прогрессированием заболевания на фоне нео-/адъювантной гормонотерапии или  менее чем через 12 месяцев после завершения гормонотерапии (PMID: 28580882). В исследование были включены 669 пациенток рандомизированных на 2 группы: комбинация препаратов или Фулвестрант и Плацебо 2:1. В группе Абемациклиба и Фулвестранта наблюдалось статистически значимое увеличение медианы выживаемости без прогрессирования  16,4 против 9,3 месяца (Отношение рисков 0,553; 95% Доверительный интервал, ДИ, 0,449-0,681; р< 0,001).\r\nВ исследовании III фазы MONARCH3 изучалась эффективность Абемациклиба и нестероидных ингибиторов ароматазы (Летрозол, Анастразол) в терапии ER+ HER2- метастатического рака молочной железы (PMID: 28968163). Медиана выживаемости без прогрессирования не была достигнута в группе Абемациклиба и нестероидных ингибиторов ароматазы составила 14,7 месяцев в группе нестероидных ингибиторов ароматазы (Отношение рисков 0,54; 95% ДИ 0,41-0,72; р=0,000021).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=28580882", "comment": "<p>PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28580882\">28580882</a>,&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28968163\">28968163</a>.</p>", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [69, 139], "variant_id": [25330], "assay_id": [], "json_id": 2538, "ogt_id": "OGE_5106", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_B4", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "Частота возникновения тошноты и рвоты средней тяжести была значительно выше у пациентов с гетерозиготным генотипом DPYD * 9 по сравнению с пациентами с диким типом DPYD * 9 (р<0,05).", "title": "Med. Oncol., 2007", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=17848752", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_TOXIC", "biomarker_type": null}, {"drugs": [], "variant_id": [], "assay_id": [968], "json_id": 2540, "ogt_id": "OGE_6209", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B2", "evidence_type": "STR_EVID_TYPE_PROGNOSTIC", "description": "\"Total AR nuclear staining demonstrated the best accuracy in predicting clinical response (area under receiver operating characteristic curve, 0.72; P = .0001). At a threshold of 10%, 74.6% of patients were AR positive, leading to 30% PPV, 90% sensitivity, and 30% specificity. These patients showed a significantly higher median progression-free survival (hazard ratio, 0.56; 95% CI, 0.36 to 0.88; P = .011) and overall survival (hazard ratio, 0.54; 95% CI, 0.32 to 0.91; P = .019) compared with those with AR-negative (< 10%) TNBC.\"", "title": "STR_WEBLINK", "link": "https://ascopubs.org/doi/full/10.1200/PO.17.00075", "comment": "triple-negative breast cancer (TNBC)", "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PROGNOSTIC"}, {"drugs": [288, 301], "variant_id": [25100], "assay_id": [], "json_id": 2509, "ogt_id": "OGE-YZ-5014", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_IN_RND", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В III фазе клинического исследования изучалась эффективность комбинации Фулвестранта и Бупарлисиба во второй и последующей линии терапии гормонпозитивного рака молочной железы у женщин в постменопаузе. В исследование было включено 432 пациентки рандомизированных на 2 группы 2:1. Медианы выживаемости без прогрессирования составили 3,9 месяца в группе Бупарлисиба против 1,8 месяца в группе Плацебо (Отношение рисков 0,67 (95% Доверительный интервал, ДИ, 0,53–0,84, p=0,0003).  В подгруппе с наличием активирующих мутаций в 10 и 21 экзонах PIK3CA (в том числе H1047L), обнаруженных в ДНК из плазмы крови пациентов, выявлен наибольший выигрыш от назначения Бупарлисиба. Медиана выживаемости в этой подгруппе Бупарлисиба составила 4,2 месяца и 1,6 месяца в группе Плацебо (Отношение рисков 0,46 (95% ДИ 0,29–0,73),  p=0,00031).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/29223745", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_NONEFFECTIVE", "biomarker_type": null}, {"drugs": [], "variant_id": [], "assay_id": [979], "json_id": 2537, "ogt_id": "CIVIC_1960", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B", "evidence_type": "STR_EVID_TYPE_PROGNOSTIC", "description": "In patients with breast cancer, those with expression of PgR (determined by immunohistochemical staining) had better relapse-free survival than those without expression.", "title": "Ann. Oncol., 2006", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=16497822", "comment": null, "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PROGNOSTIC"}, {"drugs": [], "variant_id": [25323], "assay_id": [], "json_id": 2510, "ogt_id": "OGE_693", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDISPOSING", "description": "NCCN guidelines: for lobular breast cancer with a family history of difuse gastric cancer, CDH1 gene testing should be considered", "title": "STR_WEBLINK", "link": "https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf", "comment": null, "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PREDISPOSING"}, {"drugs": [287], "variant_id": [25331], "assay_id": [], "json_id": 2548, "ogt_id": "OGE-YZ-5021", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "Наличие мутаций в гене ESR1 в плазме крови у пациенток с гормонположительным раком молочной железы, получавших гормонотерапию, ассоциировано с уменьшением медианы выживаемости без прогрессирования на фоне терапии нестероидными ингибиторами ароматазы (Относительный риск, 1,98; 95% доверительный интервал (ДИ), 1,12–3,51; р=0,02), но не связано с уменьшением медианы выживаемости без прогрессирования на фоне приема Фулвестранта (Относительный риск, 1,03; 95% ДИ, 0,79–1,34; р=0,83).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/30275706", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [287, 289], "variant_id": [], "assay_id": [979], "json_id": 2512, "ogt_id": "JAX_10731", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_OTHER_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "\"In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).\"", "title": "Lancet Oncol., 2018", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=29804902", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [], "variant_id": [], "assay_id": [978], "json_id": 2508, "ogt_id": "CIVIC_3254", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B", "evidence_type": "STR_EVID_TYPE_PROGNOSTIC", "description": "A quantitative meta-analysis was performed to assess optimal IHC-calculated cutoff values for the prognostic use of proliferative biomarker Ki67 in breast cancer. The studies included ER positive and negative cases, and the MIB-1 antibody was used in the large majority of studies. 25 studies that employed multivariate analysis were used, and a hazard ratio of 2.05 for overall survival was obtained when Ki67 cutoff value was set at greater or equal to 25%.", "title": "Breast Cancer Res. Treat., 2016", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=26341751", "comment": null, "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PROGNOSTIC"}, {"drugs": [1], "variant_id": [25099, 25101], "assay_id": [], "json_id": 2542, "ogt_id": "OGE-YZ-5016", "drug_interaction_type": null, "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В III фазе клинического исследования изучалась эффективность Олапариба у пациенток с BRCA-ассоциированным раком молочной железы, получивших 2 и более линий системной терапии по поводу метастатического рака молочной железы. В исследованиие были включены 302 пациентки, 205 были рандомизированы в группу Олапариба и 97 в группу стандартной терапии. Медиана выживаемости без прогрессирования была достоверно выше в группе Олапариба 7,0 месяцев против 4,2 месяца (Относительный риск прогрессирования заболевания - 0,58; 95% ДИ, 0,43-0,80; р<0,001)", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/28578601", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_NONEFFECTIVE", "biomarker_type": null}, {"drugs": [], "variant_id": [25324], "assay_id": [], "json_id": 2517, "ogt_id": "JAX_1146", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_C", "evidence_type": "STR_EVID_TYPE_PREDISPOSING", "description": "In multiple meta-analyses, AURKA F31I was associated with increased risk of breast cancer (PMID: 24349361, PMID: 25154511, PMID: 23803310).", "title": "J. Int. Med. Res., 2014", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=23803310", "comment": null, "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PREDISPOSING"}, {"drugs": [59, 290], "variant_id": [], "assay_id": [980], "json_id": 2514, "ogt_id": "OGE-YZ-504", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_THIS_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В исследовании III фазы BOLERO-2 изучалась эффективность комбинации Эверолимуса и Экземестана по сравнению с Экземестаном в терапии гормонположительного HER- рака молочной железы после прогрессирования на нестероидных ингибиторах ароматазы. В исследование включено 724 пациентки, рандомизированных на две группы Эверолимус и Плацебо 2:1. Медиана выживаемости без прогрессирования составила 7,8 месяцев в группе комбинации и 3,2 месяца в группе Экземестана  (Отношение рисков 0,45; 95% Доверительный интервал 0,38–0,54).", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=24158787", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_EFFECTIVE_IN_THIS_DISEASE", "biomarker_type": null}, {"drugs": [], "variant_id": [], "assay_id": [970], "json_id": 2532, "ogt_id": "OGE_6139", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B3", "evidence_type": "STR_EVID_TYPE_PROGNOSTIC", "description": "\"Based on 27 studies involving 10,231 patients, the pooled results revealed that PTEN loss was significantly more common in breast cancer than in normal tissues (OR = 12.15, 95% CI = 6.48<96>22.79, P < 0.00001) and that PTEN loss had clear associations with larger tumor size (> 2 cm, OR = 0.62, 95% CI = 0.48<96>0.82, P = 0.0006), lymph node metastasis(OR = 0.61, 95% CI = 0.45<96>0.82, P = 0.0001), later TNM stage(stage III<96>IV, OR = 0.55, 95% CI = 0.35<96>0.86, P = 0.009), poor differentiation(OR = 0.37, 95% CI = 0.24<96>0.59, P < 0.0001), and the highly aggressive triple-negative phenotype (OR = 1.62, 95% CI = 1.23<96>2.12, P = 0.0005). Moreover, patients with PTEN loss exhibited significantly worse DFS and OS(HR = 1.63, 95% CI = 1.04<96>2.22, P < 0.00001; HR = 1.41, 95% CI = 1.08<96>1.73, P < 0.0001; respectively). In conclusion, PTEN loss might predict more aggressive behavior and worse outcomes in patients with breast cancer.\"", "title": "BMC Clin Pathol, 2018", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=30305801", "comment": null, "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PROGNOSTIC"}, {"drugs": [123, 318], "variant_id": [], "assay_id": [971], "json_id": 2520, "ogt_id": "OGE-YZ-5017", "drug_interaction_type": "STR_DRUG_COMBINATION", "approved_combination": "STR_APPROVED_FOR_OTHER_DISEASE", "evidence_level": "STR_EVID_LEVEL_A", "evidence_type": "STR_EVID_TYPE_PREDICTIVE", "description": "В III фазе клинического исследования была изучена эффективность комбинации Атезолизумаба (анти-PD-L1) с альбумин-связанным (nab) Наб-паклитакселом в лечении метастатического тройного негативного рака молочной железы. Каждая группа включала 451 пациента (медиана наблюдения 12,9 месяца). Медиана выживаемости без прогрессирования составила 7,2 месяца в группе Атезолизумабом плюс Наб-паклитаксел по сравнению с 5,5 месяцами в плацебо плюс Наб-паклитаксел (отношение рисков, ОР, для прогрессии или смерти 0,80; доверительный интервал 95% (ДИ) 0,69-0,92; р=0,002); среди пациентов с PD-L1 экспрессией на поверхности клеток микроокружения >1% опухолями медиана выживаемости без прогрессирования составила 7,5 месяцев в группе комбинации и 5,0 месяцев в группе Наб-паклитаксела (ОР прогрессирования 0,62; 95% ДИ, 0,49-0,78; р<0,001). Медиана общей выживаемости составила 21,3 месяца в группе Атезолизумаба и Наб-паклитаксела и 17,6 месяца в группе Плацебо + Наб-паклитаксел в общей популяции (ОР смерти 0,84; 95% ДИ от 0,69-1,02; р=0,08); среди пациентов с PD-L1-позитивными опухолями медиана общей выживаемости составила 25,0 и 15,5 месяца, соответственно (ОР 0,62; 95% ДИ, 0,62; 0,45-0,86). Назначение комбинации Атезолизумаб+Наб-Паклитаксел имело статистически значимое преимущество в ВБП и ОВ по сравнению с монотерапией Наб-паклитакселом в группе с экспрессией PD-L1 на 1% и более клеток микроокружения опухоли. Данные по безопасности и эффективности комбинации Атезолизумаба и Наб-Паклитаксела и анти-HER2 препаратов при HER2- раке молочной железы не опубликовано.", "title": "Pubmed", "link": "https://www.ncbi.nlm.nih.gov/pubmed/30345906", "comment": "", "drug_comment": "", "drug_type": "STR_DRUG_NONEFFECTIVE", "biomarker_type": null}, {"drugs": [], "variant_id": [], "assay_id": [966], "json_id": 2536, "ogt_id": "OGE_7009", "drug_interaction_type": "", "approved_combination": null, "evidence_level": "STR_EVID_LEVEL_B4", "evidence_type": "STR_EVID_TYPE_PROGNOSTIC", "description": "Tumor immune subclasses were associated with survival in patients with high TMB (TMB-Hi,<a0>P<a0><<a0>0.001) but not in those with low TMB (TMB-Lo,<a0>P<a0>=<a0>0.44). In TMB-Hi tumors, the favorable immune-infiltrate dispositions subclass was associated with prolonged survival.", "title": "Oncoimmunology, 2018", "link": "https://www.ncbi.nlm.nih.gov/pubmed/?term=30386679", "comment": "TMB 0 - 1.63 / MB", "drug_comment": null, "drug_type": null, "biomarker_type": "STR_BIOMARKER_PROGNOSTIC"}], "Drugs": [{"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 71, "drug_name": "Трастузумаб", "drugbank_id": "DB00072_ru", "description": "<p>Относится к биологическому классу моноклональных антител; представляет собой рекомбинантное антитело IgG-каппа, которое селективно связывается со внеклеточным доменом рецептора HER2.&nbsp;</p>", "indication": "<p>Препарат назначается при лечении: 1) пациентов с HER2-положительным РМЖ 2) снижении риска развития HER2-положительных РМЖ на ранней стадии либо после хирургического вмешательства, химиотерапии или других типов лечения 3) уменьшения размеров&nbsp;распространенных форм РМЖ перед операцией.</p>", "drug_class": "Моноклональные антитела к HER2"}, {"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 130, "drug_name": "Тамоксифен", "drugbank_id": "DB00675", "description": "<p>Один из селективных модуляторов рецепторов эстрогенов (SERM) с тканеспецифической активностью для лечения и профилактики ER - положительного рака молочной железы. В ткани молочной железы Тамоксифен действует как антиэстроген (ингибитор), и, как эстроген (стимулирующий агент) при метаболизме холестерина, уплотнения костной ткани и пролиферации клеток эндометрия.</p>\r\n<p><span style=\"color: rgba(0, 0, 0, 0.87); font-family: Roboto, sans-serif; font-size: 16px;\">&nbsp;</span></p>", "indication": "<p>Тамоксифен применяется для лечения метастатического рака молочной железы у женщин и мужчин с внутрипротоковой карциномой in situ.</p>", "drug_class": "Антиэстроген"}, {"approved_in_this_disease": "STR_IN_RND", "json_id": 321, "drug_name": "Венетоклакс", "drugbank_id": "DB11581_ru", "description": "<p>Низкомолекулярный селективный ингибитор Bcl-2, аналог естественных лигандов&nbsp;Bcl-2. Связывание препарата с&nbsp;Bcl-2 репрессирует активность последнего и способствует реализации апоптотической программы в опухолевых клетках.&nbsp;</p>", "indication": "<p>Венетоклакс используется для лечения нескольких типов хронической лимфоцитарной лейкемии.</p>", "drug_class": "Ингибитор Bcl-2"}, {"approved_in_this_disease": "STR_APPROVED_FOR_OTHER_DISEASE", "json_id": 1, "drug_name": "Олапариб", "drugbank_id": "DB09074_ru", "description": "<p>Олапариб- ингибитор ферментов поли-АДФ-рибозилировния (PARP), включая PARP1-3. PARP белки вовлечены в поддержание клеточного гомеостаза, регуляцию клеточного цикла, репарацию ДНК. Олапариб ингибирует рост определенных клеточных линий in vitro и снижает темпы опухолевого роста на мышиных моделях как в монотерапии, так и в комбинации с соединениями платины. Наибольшую цитотоксичность олапариб показывает на клеточных линиях с потерей функции BRCA. In vitro ингибирует активность PARP и способствует повышению количества комплексов PARP-ДНК, нарушая клеточный гомеостаз и пиводя к клеточной гибели.</p>", "indication": "<p>Олапариб- ингибитор ферментов поли-АДФ-рибозилирования применяемый в монотерапии у пациентов с герминальными мутациями в BRCA (одобренный FDA тест) с распространенным раком яичников, у пациенток получивших более 3 линий химиотерапии.</p>", "drug_class": "PARP-ингибитор"}, {"approved_in_this_disease": "STR_APPROVED_FOR_OTHER_DISEASE", "json_id": 124, "drug_name": "Карбоплатин", "drugbank_id": "DB00958_ru", "description": "<p>Соединение платины, обладающее противоопухолевой активностью.</p>", "indication": "<p>Для первой линии терапии распространенного рака яичников в комбинации с другими хемотерапевтическими агентами. Также используется в палиативной терапии пациентов с&nbsp;прогрессированием рака яичников после химиотерапии, включая пациентов которые ранее получали цисплатин.&nbsp;</p>", "drug_class": "Препараты платины"}, {"approved_in_this_disease": "STR_APPROVED_FOR_OTHER_DISEASE", "json_id": 318, "drug_name": "Наб-паклитаксел", "drugbank_id": "DB01229_form_variant", "description": "<p style=\"text-align: justify;\">Наб-паклитаксел - лекарственная форма Паклитаксела, стабилизированного альбумином, представленная в виде наночастиц. Паклитаксел связывается и стабилизирует микротрубочки, предотвращая их деполимеризацию и, таким образом, подавляя подвижность клеток, репликацию ДНК и митоз. Эта форма Паклитаксела отличается большей растворимостью ввиду солюбилизации препарата без использования растворителя кремофора, что позволяет вводить большие дозы лекарства, избегая при этом токсических эффектов, связанных с кремофором.</p>", "indication": "<p style=\"text-align: justify;\">Наб-паклитаксел назначают при терапии:</p>\r\n<p style=\"text-align: justify;\">&bull; метастатического рака молочной железы, при неэффективности химиотерапии метастатической стадии заболевания или рецидива в течение 6 месяцев адъювантной химиотерапии. Предшествующая линия терапии должна включать антрациклины, если это клинически не противопоказано,</p>\r\n<p style=\"text-align: justify;\">&bull; местнораспространенного или метастатического немелкоклеточного рака легкого (НМРЛ), в качестве первой линии терапии в комбинации с Карбоплатином у пациентов, которые не являются кандидатами для хирургического лечения или лучевой терапии,</p>\r\n<p style=\"text-align: justify;\">&bull; метастатической аденокарциномы поджелудочной железы в первой линии, в сочетании с Гемцитабином (<a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf\">FDA drug label</a>).</p>", "drug_class": "Таксаны"}, {"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 288, "drug_name": "Фулвестрант", "drugbank_id": "DB00947_ru", "description": "<p style=\"text-align: justify;\">Фулвестрант - препарат для лечения гормонпозитивного метастатического рака молочной железы у женщин в постменопаузе с прогрессированием заболевания после антиэстрогенной терапии. Это антагонист рецептора эстрогена без агонистических эффектов, который действует как путем подавления, так и путем деградации рецептора эстрогена.</p>", "indication": "<p>Для лечения гормонпозитивного метастатического рака молочной железы у женщин в постменопаузе с прогрессированием заболевания после антиэстрогенной терапии.</p>", "drug_class": "Антагонист рецептора эстрогена"}, {"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 72, "drug_name": "Лапатиниб", "drugbank_id": "DB01259_ru", "description": "<p>Относится к классу малых молекул; является ингибитором рецепторов эпидермального фактора роста (ERBB1 и ERBB2). Препарат связывается с внутриклеточным фосфорилирующим доменом рецепторов и препятствует их активации после взаимодействия с лигандом.&nbsp;</p>", "indication": "<p>Препарат был разработан для лечения солидных опухолей, таких как РМЖ и рак легких. В 2007 году Лапатиниб получил одобрение FDA для лечения: - в комбинации с Капецитабином продвинутой стадии ERBB2 (HER2) позитивного РМЖ с метастазами, который перестал отвечать на лечение антрациклинами, таксанами и Герцептином - в комбинации с Летрозолом, для лечения женщин в постменопаузе, у которых выявлен HER2 позитивный РМЖ</p>", "drug_class": "двойной тирозин-киназный ингибитор"}, {"approved_in_this_disease": "STR_APPROVED_FOR_OTHER_DISEASE", "json_id": 13, "drug_name": "Пембролизумаб", "drugbank_id": "DB09037_ru", "description": "<p>Пембролизумаб представляет собой моноклональное антитело, которое блокирует взаимодействие между PD-1 и его лигандами, PD-L1 и PD-L2. Он используется для лечения нескольких видов рака, таких как меланома, немелкоклеточный рак легких и рак головы и шеи. Благодаря успеху в клинических испытаниях,&nbsp;пембролизумаб был утвержден на ранней стадии в качестве&nbsp; \"прорывной терапии\". Пембролизумаб был одобрен&nbsp;FDA в октябре 2015 года для лечения наиболее часто встречающихся типов распространенных злокачественных новообразований легких, немелкоклеточного рака легкого.&nbsp;Пембролизумаб&nbsp;был дополнительно одобрен для лечения классической&nbsp;лимфомы Ходжкина в марте 2017 года.</p>", "indication": "<p>Пембролизумаб представляет собой блокирующее антитело к рецептору запрограммированной - смерти-типа 1 (PD-1), предназначенное для лечения&nbsp;следующих пациентов: 1) с неоперабельной или метастатической меланомой 2) с метастатическим НМРЛ у которых опухоли&nbsp;обладают высокой экспрессией PD-L1 (показатель доли опухоли (TPS) больше 50%), в соответствие с рекомендациями&nbsp;FDA, без каких-либо аномалий&nbsp;в генах EGFR или ALK опухолевой ткани, и неиспользующих системную химиотерапию метастатического НМРЛ); 3) с метастатическим НМРЛ, у которых опухоли экспрессируют PD-L1 (TPS&nbsp;больше 1%, с прогрессированием заболевания, во время или после&nbsp;приема платиносодержащей химиотерапии). Для назначения пембролизумаба пациенты с&nbsp;мутациями в EGFR или&nbsp;ALK должны показывать прогрессирование заболевания&nbsp;на&nbsp;FDA-одобренной терапии. Препарат также показан&nbsp; пациентам&nbsp;с рецидивирующим или метастатическим&nbsp;НМРЛ с прогрессированием заболевания&nbsp;на этапе или после приема платиносодержащей химиотерапии. Это назначение одобрено в рамках ускоренного&nbsp; разрешения, основанного на частоте и продолжительности опухолевого&nbsp;ответа. Дальнейшее утверждение этого указания может зависеть от проверки и описания клинической пользы в подтверждающих испытаниях.</p>", "drug_class": "Моноклональные антитела к PD1"}, {"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 56, "drug_name": "Палбоциклиб", "drugbank_id": "DB09073_ru", "description": "<p>Палбоциклиб- пероральный, селективный, низкомолекулярный ингибитор CDK4 и CDK6 применяемый в комбинации с летрозолом в лечении женщин с метастатическим ER-позитивным и HER2-позитивным раком молочной железы в постменопаузе в качестве первой линии. CDK4 и CDK6 вместе с циклином D1 играют ключевую роль в регуляции перехода клетки из G1 в S-фазу клеточного цикла путем фосфорилирования Rb. Ингибирование этих протеинов уменьшает количество фосфорилированного Rb, который с помощью нижележащих сигнальных молекул стимулирует арест клеточного цикла.</p>", "indication": "<p>Палбоциклиб применяется в комбинации с летрозолом в лечении постменопаузальных женщин с ER-позитивным, HER2-негативным метастатическим раком молочной железы. Получил раннее одобрение FDA основанное на повышении медианы выживаемости без прогрессирования.&nbsp; Дальнейшее утверждение этого показания может зависеть от результатов последующих исследований.</p>", "drug_class": "CDK4/6 ингибитор"}, {"approved_in_this_disease": "STR_IN_RND", "json_id": 301, "drug_name": "Бупарлисиб", "drugbank_id": "DB11666_ru", "description": "<p>Орально биодоступный специфический пероральный пан-ингибитор липид-киназ фосфатидилинозитол-3-киназ (PI3K) класса I. Бупарлисиб специфически ингибирует I класс&nbsp;киназ&nbsp;PI3K в сигнальном каскаде PI3K/Akt по АТФ-конкурентному механизму, тем самым блокируя образование вторичного мессенджера фосфатидилинозитол-3,4,5-трифосфата и активацию&nbsp;PI3K-регулируемого сигнального пути. Это может привести к ингибированию процессов, контролирующих рост и выживаемость опухолевых клеток. Активация сигнального пути PI3K/Akt часто ассоциирована с канцерогенезом и может способствовать развитию лекарственной устойчивости опухолей.</p>", "indication": "<p>Бупарлисиб&nbsp;применяется в клинических испытаниях для лечения лимфом, рака легких и рака молочной железы.</p>", "drug_class": "Ингибитор PIK3"}, {"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 289, "drug_name": "Рибоциклиб", "drugbank_id": "DB11730_ru", "description": "<p style=\"text-align: justify;\">Рибоциклиб является селективным ингибитором циклин-зависимых киназ 4 и 6 (CDK4/6). При их чрезмерной активации&nbsp;происходит стимуляция деления раковых клеток. Ингибирование&nbsp;CDK4/6 позволяет остановить бесконтрольную пролиферацию&nbsp;путем блокирования прохождения клеточного цикла в G1/S. Рибоциклиб был одобрен FDA США в марте 2017 года как Kisqali.</p>\r\n<p style=\"text-align: justify;\">&nbsp;</p>", "indication": "<p style=\"text-align: justify;\">Кискали показан в сочетании с ингибитором ароматазы на начальном этапе эндокринной терапии для лечения женщин в постменопаузе с гормонпозитивным HER2-негативным прогрессирующим или метастатическим раком молочной железы. Рибоциклиб&nbsp;проходит клинические испытания для терапии различных типов рака, включая солидные опухоли.</p>", "drug_class": "Ингибитор CDK4/6"}, {"approved_in_this_disease": "STR_APPROVED_FOR_OTHER_DISEASE", "json_id": 236, "drug_name": "Абемациклиб", "drugbank_id": "DB12001_ru", "description": "<p>Абемациклиб - противоопухолевый препарат, двойной ингибитор циклинзависимых киназ 4 (CDK4) и 6 (CDK6), которые запускают клеточный цикл и промотируют деление опухолевых клеток в случае нерегулируемой активности.&nbsp;</p>\r\n<p>&nbsp;</p>", "indication": "<p>28 сентября 2017 года FDA одобрило Абемациклиб под торговым названием Verzenio для лечения HR-позитивного и HER2-негативного прогрессирующего или метастатического рака молочной железы, который спрогрессировал после предшествующей эндокринной терапии. Абемациклиб применяли либо в виде монотерапии для пациентов, получивших эндокринную терапию и химиотерапию после метастазирования рака, или в сочетании с Фулвестрантом. Применение Абемациклиба у пациентов с HR-положительным HER2-отрицательным раком молочной железы, привело к&nbsp;повышению выживаемости без прогрессирования и увеличению частоты объективного ответа.&nbsp;Абемациклиб проходит клинические испытания для лечении меланомы, лимфом, солидной опухолей, а также глиобластомы.</p>\r\n<p>Абемациклиб назначают в сочетании с Фулвестрантом при терапии женщин с&nbsp;распространенным или метастатическим HR-положительным HER2-негативным раком молочной железы после эндокринной терапии.&nbsp;Абемациклиб&nbsp; применяют в виде монотерапии для лечения взрослых пациентов с&nbsp;прогрессирующим или метастатическим HR-положительным HER2-негативным раком молочной железы с прогрессированием заболевания после эндокринной терапии и предшествующей химиотерапии при метастазировании.</p>", "drug_class": "Ингибитор CDK4/6"}, {"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 290, "drug_name": "Экземестан", "drugbank_id": "DB00990_ru", "description": "<p style=\"text-align: justify;\">Экземестан является пероральным ингибитором ароматазы. Он действует как ложный субстрат для фермента и конвертируется в промежуточное соединение, которое необратимо связывается с активным центром фермента, вызывая его инактивацию.</p>", "indication": "<p style=\"text-align: justify;\">Экземестан используется при адъювантной терапии гормонально-чувствительного (гормонпозитивного, эстрогенчувствительного) рака молочной железы у женщин в постменопаузе.</p>", "drug_class": "Ингибитор ароматазы"}, {"approved_in_this_disease": "STR_APPROVED_FOR_OTHER_DISEASE", "json_id": 69, "drug_name": "5-Фторурацил", "drugbank_id": "DB00544_ru", "description": "<p>Противоопухолевый препарат из группы антиметаболитов, антагонистов пиримидинов. Он блокирует синтез ДНК, путем ингибирования фермента тимидилат синтазы,&nbsp;который катализирует образование тимидиловой кислоты из дезксиуридиловой.</p>\r\n<p>&nbsp;</p>", "indication": "<p>Применяется в качестве местного лекарственного средства при множественных солнечных кератозах. При использовании в виде 5% -растворасти он также полезен при лечении базально-клеточных карцином, в случаях, при которых обычные методы терапии непрактичны, например, при множественных поражениях или в труднодоступных местах лечения. Инъекция флюороурацила показана при паллиативном лечении некоторых видов рака, в том числе толстой кишки, пищевода, желудка, прямой кишки, молочной железы, желчных путей, желудка, головы и шеи, шейки матки, поджелудочной железы, почек.</p>", "drug_class": "Антиметаболиты"}, {"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 320, "drug_name": "Талазопариб", "drugbank_id": "DB11760_ru", "description": "", "indication": "", "drug_class": "Ингибитор PARP"}, {"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 287, "drug_name": "Анастрозол", "drugbank_id": "DB01217_ru", "description": "<p style=\"text-align: justify;\">Анастрозол относится к классу ингибиторов ароматазы. Он&nbsp;блокирует активность&nbsp;фермента ароматазы, которая превращает андрогены, вырабатываемые в надпочечниках женщин, в эстрогены.</p>", "indication": "<p>Анастрозол - препарат, назначаемый при лечении рака молочной железы у женщин в постменопаузе. Он используется как в адъювантной терапии, так и при метастатическом раке молочной железы.</p>", "drug_class": "Ингибитор ароматазы"}, {"approved_in_this_disease": "STR_APPROVED_FOR_OTHER_DISEASE", "json_id": 139, "drug_name": "Капецитабин", "drugbank_id": "DB01101_ru", "description": "<p>Капецитабин является перорально применяемым химиотерапевтическим средством, используемым при лечении метастатического рака молочной железы и колоректального рака. Капецитабин является неактивной формой лекарства, которое затем в опухоли ферментативно превращается в фторурацил (антиметаболит), где ингибирует синтез ДНК и замедляет рост опухолевой ткани.</p>", "indication": "<p>Препарат применяется для&nbsp;лечения пациентов с метастатическим раком молочной железы, устойчивого как к Паклитакселу, так и к антрациклиновому химиотерапевтическому режиму. Может также использоваться в комбинации с Доцетакселом для лечения метастатического рака молочной железы у пациентов, которые не реагировали или не принимали во время или после антрациклиновой химиотерапии. Капецитабин используется отдельно, как адъювантная терапия после полной резекции первичной опухоли у пациентов с раком толстой кишки на стадии III, когда предпочтительна монотерапия Флуропримидином. В настоящее время исследуется применение Капецитабина в комбинированных режимах для лечения распространенного рака желудка.</p>", "drug_class": "Аналог пиримидина"}, {"approved_in_this_disease": "STR_IN_RND", "json_id": 286, "drug_name": "Алпелисиб", "drugbank_id": "DB12015_ru", "description": "<p style=\"text-align: justify;\">Алпелисиб является перорально биодоступным ингибитором фосфатидилинозитол-3-киназы a (PI3K, p110a). Алпелисиб специфически ингибирует PIK3 в сигнальном пути PI3K/AKT (или протеинкиназы B), тем самым инактивируя его. Это может привести к блокированию роста и выживания опухолевых клеток в популяциях чувствительных опухолевых клеток. Активация сигнального пути PI3K часто связана с онкогенезом и может способствовать устойчивости к различным противоопухолевым агентам.</p>", "indication": "<p>Алпелисиб проходит испытания для лечения солидных опухолей: рака молочной железы, гастроинтестинальных опухолей и колоректального рака.</p>", "drug_class": "Ингибитор PI3K"}, {"approved_in_this_disease": "STR_APPROVED_FOR_THIS_DISEASE", "json_id": 291, "drug_name": "Летрозол", "drugbank_id": "DB01006_ru", "description": "<p style=\"text-align: justify;\">Летрозол (INN, торговое название Femara&reg;) представляет собой пероральный нестероидный ингибитор ароматазы, который был введен для адъювантного лечения гормонально-чувствительного рака молочной железы. Было также показано, что Летрозол задерживает слияние ростовых пластинок у подростков. Это может повысить эффективность гормона роста, и поэтому Летрозол используется для лечения подростков и детей с низким ростом.</p>", "indication": "<p style=\"text-align: justify;\">Применяется для расширенного адъювантного лечения раннего рака молочной железы у женщин в постменопаузе, которые получили 5 лет адъювантной терапии Тамоксифеном. Также Летрозол используют для терапии первой линии женщин в постменопаузе с гормонпозитивным местнораспространенным или метастатическим раком молочной железы или для данных стадий рака молочной железы с неизвестным статусом гормональных рецепторов. Препарат также показан для лечения распространенного рака молочной железы у женщин в постменопаузе с прогрессированием заболевания после антиэстрогенной терапии.</p>", "drug_class": "Ингибитор ароматазы"}, {"approved_in_this_disease": "STR_APPROVED_FOR_OTHER_DISEASE", "json_id": 59, "drug_name": "Эверолимус", "drugbank_id": "DB01590_ru", "description": "<p>Эверолимус является производным рапамицина (сиролимуса) и работает аналогично рапамицину в качестве ингибитора mTOR. В настоящее время эверолимус используется в качестве иммунодепрессанта для предотвращения отторжения трансплантатов органов. Аналогично другим ингибиторам mTOR эверолимус воздействует исключительно на белок mTORC1, а не на белок mTORC2.</p>", "indication": "<p>Эверолимус применяется для лечения постменопаузальных женщин с метастатическим гормонпозитивным HER2-негативным раком молочной железы в комбинации с экземестаном, после прогрессирования на летрозоле или анастрозоле. Применяется для лечения пациентов с&nbsp; нерезектабельными, местнораспростаненными или метастатическими нейроэндокринными опухолями поджелудочной железы (PNET). Применяется для лечения пациентов с распространенным почечноклеточным раком после прогрессирования на сорафенибе или сунитинибе. Применяется в лечении пациентов с ангиомиолипомой почки не подходящих для хирургического лечения. Применяется в лечении субэпиндемальной гигантоклеточной астроцитомы у пациентов с туберозным склерозом (герминальная мутация TSC).</p>\r\n<p>&nbsp;</p>", "drug_class": "Ингибитор mTOR"}, {"approved_in_this_disease": "STR_APPROVED_FOR_OTHER_DISEASE", "json_id": 123, "drug_name": "Атезолизумаб", "drugbank_id": "DB11595_ru", "description": "<p>Атезолизумаб- это гуманизированное моноклональное антитело связывающееся с PD-L1 и блокирующее его взаимодействие с PD-1 и CD80 на поверхности Т-лимфоцита. Связывание PD-L1 с PD-1 или CD80 подавляет активацию лимфоцитов в лимфоузлах, что предупреждает развитие иммунного ответа во время беременности и при аутоиммунных заболеваниях. Этот механизм помогает ускользать опухолевым клеткам от иммунного надзора. Гиперэкспрессия PD-L1 и PD-1 ассоциирована с агресивностью опухоли и плохим прогнозом.&nbsp; &nbsp;</p>", "indication": "<p>Для лечения пациентов с метастатическим уротелиальным раком. которые спрогрессировали на платиносодержащей химиотерапии или имели прогрессию в течении 12 месяцев после неоадъювантной или адъювантной терапии включающей соединения платины. Также атезолизумаб одобрен для второй и последующих линий терапии метастатического немелкоклеточного рака легких.</p>\r\n<p>&nbsp;</p>", "drug_class": "Ингибитор PD-L1"}], "Genes": [{"json_id": 138414, "symbol": "FLT3", "locus": "13q12.2", "entrez_id": 2322, "chr": "chr13", "start": 28577411, "end": 28674729, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fms related tyrosine kinase 3", "description": "<p style=\"text-align: justify\"> Тирозиновая протеинкиназа, которая является поверхностным клеточным рецептором для цитокина FLT3LG и регулирует дифференцировку, пролиферацию и выживаемость гемопоэтических стволовых и дендритных клеток. Также FLT3 фосфорилирует киназы SHC1 и AKT1, которые активируют нижележащие эффекторы mTOR -сигнального пути. Стимулирует активацию сигнального пути RAS  и фосфорилирование нижележащих киназ, включая MAPK1/ERK2 и/или MAPK3/ERK1. Стимулирует фосфорилирование FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1. Активация wild-type FLT3 вызывает слабую активацию STAT5A и STAT5B. Мутации, связанные с конститутивной активностью FLT3 стимулируют клеточную пролиферацию и выживаемость клеток посредством активации многочисленных сигнальных путей. </p>  <a title=\"J. Immunol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18490735\">J. Immunol., 2008</a>&nbsp;&nbsp;  <a title=\"Leukemia, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20111072\">Leukemia, 2010</a>&nbsp;&nbsp;  <a title=\"Mol. Cancer, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21067588\">Mol. Cancer, 2011</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21262971\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21516120\">Oncogene, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138413, "symbol": "FLT1", "locus": "13q12.3", "entrez_id": 2321, "chr": "chr13", "start": 28874489, "end": 29069265, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fms related tyrosine kinase 1", "description": "<p style=\"text-align: justify\"> Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion. </p>  <a title=\"Circ. Res., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18583712\">Circ. Res., 2008</a>&nbsp;&nbsp;  <a title=\"Arthritis Res. Ther., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18593464\">Arthritis Res. Ther., 2009</a>&nbsp;&nbsp;  <a title=\"J. Cell. Biochem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20512933\">J. Cell. Biochem., 2010</a>&nbsp;&nbsp;  <a title=\"Br. J. Cancer, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20551949\">Br. J. Cancer, 2010</a>&nbsp;&nbsp;  <a title=\"NA, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21752276\">NA, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138412, "symbol": "FOXO1", "locus": "13q14.11", "entrez_id": 2308, "chr": "chr13", "start": 41129804, "end": 41240734, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "forkhead box O1", "description": "<p style=\"text-align: justify\"> Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress. Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'- TT[G/A]TTTAC-3'. Activity suppressed by insulin. Main regulator of redox balance and osteoblast numbers and controls bone mass. Orchestrates the endocrine function of the skeleton in regulating glucose metabolism. Acts synergistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity. Also suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP. In hepatocytes, promotes gluconeogenesis by acting together with PPARGC1A and CEBPA to activate the expression of genes such as IGFBP1, G6PC and PCK1. Important regulator of cell death acting downstream of CDK1, PKB/AKT1 and SKT4/MST1. Promotes neural cell death. Mediates insulin action on adipose tissue. Regulates the expression of adipogenic genes such as PPARG during preadipocyte differentiation and, adipocyte size and adipose tissue-specific gene expression in response to excessive calorie intake. Regulates the transcriptional activity of GADD45A and repair of nitric oxide- damaged DNA in beta-cells. Required for the autophagic cell death induction in response to starvation or oxidative stress in a transcription-independent manner. </p>  <a title=\"Mol. Endocrinol., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15890677\">Mol. Endocrinol., 2005</a>&nbsp;&nbsp;  <a title=\"Science, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18356527\">Science, 2008</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19221179\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20543840\">Nat. Cell Biol., 2010</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21245099\">Cancer Res., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138411, "symbol": "RB1", "locus": "13q14.2", "entrez_id": 5925, "chr": "chr13", "start": 48877887, "end": 49056122, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "RB transcriptional corepressor 1", "description": "<p style=\"text-align: justify\"> Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity. </p>  <a title=\"Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15084261\">Cell, 2004</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138410, "symbol": "ERCC5", "locus": "13q33.1", "entrez_id": 2073, "chr": "chr13", "start": 103497194, "end": 103528345, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ERCC excision repair 5, endonuclease", "description": "Single-stranded structure-specific DNA endonuclease involved in DNA excision repair. Makes the 3'incision in DNA nucleotide excision repair (NER). Acts as a cofactor for a DNA glycosylase that removes oxidized pyrimidines from DNA. May also be involved in transcription-coupled repair of this kind of damage, in transcription by RNA polymerase II, and perhaps in other processes too", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138409, "symbol": "IRS2", "locus": "13q34", "entrez_id": 8660, "chr": "chr13", "start": 110406184, "end": 110438915, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "insulin receptor substrate 2", "description": "May mediate the control of various cellular processes by insulin", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138408, "symbol": "LAMP1", "locus": "13q34", "entrez_id": 3916, "chr": "chr13", "start": 113951556, "end": 113977987, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "lysosomal associated membrane protein 1", "description": "Presents carbohydrate ligands to selectins. Also implicated in tumor cell metastasis", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138407, "symbol": "NBN", "locus": "8q21.3", "entrez_id": 4683, "chr": "chr8", "start": 90945564, "end": 91015456, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nibrin", "description": "<p style=\"text-align: justify\"> Component of the MRE11-RAD50-NBN (MRN complex) which plays a critical role in the cellular response to DNA damage and the maintenance of chromosome integrity. The complex is involved in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity, cell cycle checkpoint control and meiosis. The complex possesses single-strand endonuclease activity and double-strand-specific 3'-5' exonuclease activity, which are provided by MRE11. RAD50 may be required to bind DNA ends and hold them in close proximity. NBN modulate the DNA damage signal sensing by recruiting PI3/PI4-kinase family members ATM, ATR, and probably DNA-PKcs to the DNA damage sites and activating their functions. It can also recruit MRE11 and RAD50 to the proximity of DSBs by an interaction with the histone H2AX. NBN also functions in telomere length maintenance by generating the 3' overhang which serves as a primer for telomerase dependent telomere elongation. NBN is a major player in the control of intra-S-phase checkpoint and there is some evidence that NBN is involved in G1 and G2 checkpoints. The roles of NBS1/MRN encompass DNA damage sensor, signal transducer, and effector, which enable cells to maintain DNA integrity and genomic stability. Forms a complex with RBBP8 to link DNA double-strand break sensing to resection. Enhances AKT1 phosphorylation possibly by association with the mTORC2 complex. </p>  <a title=\"J. Biol. Chem., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9705271\">J. Biol. Chem., 1998</a>&nbsp;&nbsp;  <a title=\"Nat. Genet., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10888888\">Nat. Genet., 2000</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15616588\">EMBO J., 2005</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19759395\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23762398\">PLoS ONE, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138406, "symbol": "RUNX1T1", "locus": "8q21.3", "entrez_id": 862, "chr": "chr8", "start": 92967203, "end": 93115514, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "RUNX1 translocation partner 1", "description": "<p style=\"text-align: justify\"> Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes (PubMed:12559562, PubMed:15203199). Can repress the expression of MMP7 in a ZBTB33-dependent manner (PubMed:23251453). Can repress transactivation mediated by TCF12 (PubMed:16803958). Acts as a negative regulator of adipogenesis (By similarity). The AML1-MTG8/ETO fusion protein frequently found in leukemic cells is involved in leukemogenesis and contributes to hematopoietic stem/progenitor cell self-renewal (PubMed:23812588). </p>  <a title=\"Gene, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12559562\">Gene, 2003</a>&nbsp;&nbsp;  <a title=\"Genomics, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15203199\">Genomics, 2005</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16803958\">Proc. Natl. Acad. Sci. U.S.A., 2006</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23251453\">PLoS ONE, 2013</a>&nbsp;&nbsp;  <a title=\"Nature, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23812588\">Nature, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138405, "symbol": "UBR5", "locus": "8q22.3", "entrez_id": 51366, "chr": "chr8", "start": 103265240, "end": 103425069, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ubiquitin protein ligase E3 component n-recognin 5", "description": "<p style=\"text-align: justify\"> E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation (By similarity). Involved in maturation and/or transcriptional regulation of mRNA by activating CDK9 by polyubiquitination. May play a role in control of cell cycle progression. May have tumor suppressor function. Regulates DNA topoisomerase II binding protein (TopBP1) in the DNA damage response. Plays an essential role in extraembryonic development. Ubiquitinates acetylated PCK1. Also acts as a regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'- linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes. </p>  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21127351\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21726808\">Mol. Cell, 2011</a>&nbsp;&nbsp;  <a title=\"Cell, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22884692\">Cell, 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138404, "symbol": "CSMD3", "locus": "8q23.3", "entrez_id": 114788, "chr": "chr8", "start": 113235157, "end": 114449328, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "CUB and Sushi multiple domains 3", "description": "<p style=\"text-align: justify\"> Involved in dendrite development. </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138403, "symbol": "EXT1", "locus": "8q24.11", "entrez_id": 2131, "chr": "chr8", "start": 118806729, "end": 119124092, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "exostosin glycosyltransferase 1", "description": "<p style=\"text-align: justify\"> Glycosyltransferase required for the biosynthesis of heparan-sulfate. The EXT1/EXT2 complex possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone. Appears to be a tumor suppressor. Required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413). </p>  <a title=\"J. Clin. Invest., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11518722\">J. Clin. Invest., 2001</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22660413\">Nat. Cell Biol., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138402, "symbol": "WT1", "locus": "11p13", "entrez_id": 7490, "chr": "chr11", "start": 32409321, "end": 32457176, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Wilms tumor 1", "description": "<p style=\"text-align: justify\"> Transcription factor that plays an important role in cellular development and cell survival (PubMed:7862533). Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:7862533, PubMed:17716689, PubMed:25258363). Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors (PubMed:15520190). Isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing (PubMed:16934801). Isoform 1 has lower affinity for DNA, and can bind RNA (PubMed:19123921). </p>  <a title=\"Exp. Cell Res., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16934801\">Exp. Cell Res., 2006</a>&nbsp;&nbsp;  <a title=\"J. Mol. Biol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17716689\">J. Mol. Biol., 2008</a>&nbsp;&nbsp;  <a title=\"Biochemistry, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19123921\">Biochemistry, 2009</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19416806\">Proc. Natl. Acad. Sci. U.S.A., 2009</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25258363\">Genes Dev., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138401, "symbol": "CMPK1", "locus": "1p33", "entrez_id": 51727, "chr": "chr1", "start": 47799469, "end": 47844511, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cytidine/uridine monophosphate kinase 1", "description": "<p style=\"text-align: justify\"> Catalyzes the phosphorylation of pyrimidine nucleoside monophosphates at the expense of ATP. Plays an important role in de novo pyrimidine nucleotide biosynthesis. Has preference for UMP and CMP as phosphate acceptors. Also displays broad nucleoside diphosphate kinase activity. </p>  <a title=\"Mol. Pharmacol., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10462544\">Mol. Pharmacol., 1999</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11912132\">Cancer Res., 2002</a>&nbsp;&nbsp;  <a title=\"Int. J. Biochem. Cell Biol., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23416111\">Int. J. Biochem. Cell Biol., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138400, "symbol": "CDKN2C", "locus": "1p32.3", "entrez_id": 1031, "chr": "chr1", "start": 51426417, "end": 51440305, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin dependent kinase inhibitor 2C", "description": "Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138399, "symbol": "JUN", "locus": "1p32.1", "entrez_id": 3725, "chr": "chr1", "start": 59246465, "end": 59249785, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Jun proto-oncogene, AP-1 transcription factor subunit", "description": "<p style=\"text-align: justify\"> Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells (PubMed:24623306). Binds to the USP28 promoter in colorectal cancer (CRC) cells (PubMed:24623306). </p>  <a title=\"J. Biol. Chem., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10995748\">J. Biol. Chem., 2001</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17210646\">Mol. Cell. Biol., 2007</a>&nbsp;&nbsp;  <a title=\"Elife, 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24623306\">Elife, 2015</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138398, "symbol": "JAK1", "locus": "1p31.3", "entrez_id": 3716, "chr": "chr1", "start": 65298912, "end": 65432187, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Janus kinase 1", "description": "<p style=\"text-align: justify\"> Тирозинкиназа нерецепторного типа, вовлеченная во внутриклеточную передачу сигнала от интерферонов 1 и 2 типов (PubMed:7615558). Киназа связанная с рецептором IL-2 (PubMed:11909529).    <a title=\"PubMed\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11909529\">PubMed</a>  <a title=\"PubMed\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7615558\">PubMed</a> </p>  <a title=\"J. Biol. Chem., 1995\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7615558\">J. Biol. Chem., 1995</a>&nbsp;&nbsp;  <a title=\"Curr. Biol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11909529\">Curr. Biol., 2002</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138397, "symbol": "BCL10", "locus": "1p22.3", "entrez_id": 8915, "chr": "chr1", "start": 85731931, "end": 85742773, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "B-cell CLL/lymphoma 10", "description": "<p style=\"text-align: justify\"> Involved in adaptive immune response (PubMed:25365219). Promotes apoptosis, pro-caspase-9 maturation and activation of NF- kappa-B via NIK and IKK. May be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex. Is a substrate for MALT1 (PubMed:18264101). </p>  <a title=\"Nat. Immunol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18264101\">Nat. Immunol., 2008</a>&nbsp;&nbsp;  <a title=\"J. Clin. Invest., 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25365219\">J. Clin. Invest., 2015</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138396, "symbol": "DPYD", "locus": "1p21.3", "entrez_id": 1806, "chr": "chr1", "start": 97543299, "end": 98386605, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "dihydropyrimidine dehydrogenase", "description": "Участвует в деградации пиримидинов. Катализирует восстановление урацила и тимина. Также участвует в деградации химиотерапевтического препарата 5-Фторурацила (5-FU).", "gene_type": "STR_CLIN_SIGNIF"}, {"json_id": 138395, "symbol": "EPHB6", "locus": "7q34", "entrez_id": 2051, "chr": "chr7", "start": 142552792, "end": 142568847, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "EPH receptor B6", "description": "<p style=\"text-align: justify\"> Kinase-defective receptor for members of the ephrin-B family. Binds to ephrin-B1 and ephrin-B2. Modulates cell adhesion and migration by exerting both positive and negative effects upon stimulation with ephrin-B2. Inhibits JNK activation, T-cell receptor-induced IL-2 secretion and CD25 expression upon stimulation with ephrin-B2. </p>  <a title=\"J. Biol. Chem., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12517763\">J. Biol. Chem., 2003</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15955811\">J. Biol. Chem., 2005</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138394, "symbol": "EZH2", "locus": "7q36.1", "entrez_id": 2146, "chr": "chr7", "start": 148504475, "end": 148581413, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "enhancer of zeste 2 polycomb repressive complex 2 subunit", "description": "<p style=\"text-align: justify\"> Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys- 27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2 (PubMed:22323599). Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non- histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. </p>  <a title=\"Mol. Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19026781\">Mol. Cell, 2009</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20935635\">Nat. Cell Biol., 2010</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22323599\">Proc. Natl. Acad. Sci. U.S.A., 2012</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23063525\">Mol. Cell, 2013</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24474760\">Proc. Natl. Acad. Sci. U.S.A., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138393, "symbol": "KMT2C", "locus": "7q36.1", "entrez_id": 58508, "chr": "chr7", "start": 151832010, "end": 152133090, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "lysine methyltransferase 2C", "description": "<p style=\"text-align: justify\"> Гистоновая метилтрансфераза, метилирует лизин в 4м положении в цепи гистона Н3, создавая тем самым специфичекую метку для эпигенетической активации транскрипции. Центральный компонент комплекса MLL2/3, коактиваторного комплекса ядерных рецепторов, участвующего в активации транскрипции. KMT2C/MLL3 может выступать в роли каталитической субъединицы этого комплекса. KMT2C может быть вовлечена в развитие лейкоза и при различных нарушениях развития. </p>  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17500065\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138392, "symbol": "XRCC2", "locus": "7q36.1", "entrez_id": 7516, "chr": "chr7", "start": 152341864, "end": 152373250, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "X-ray repair cross complementing 2", "description": "<p style=\"text-align: justify\"> Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA, thought to repair chromosomal fragmentation, translocations and deletions. Part of the Rad21 paralog protein complex BCDX2 which acts in the BRCA1-BRCA2- dependent HR pathway. Upon DNA damage, BCDX2 acts downstream of BRCA2 recruitment and upstream of RAD51 recruitment. BCDX2 binds predominantly to the intersection of the four duplex arms of the Holliday junction and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. </p>  <a title=\"Genes Dev., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11751635\">Genes Dev., 2002</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11834724\">J. Biol. Chem., 2002</a>&nbsp;&nbsp;  <a title=\"Exp. Cell Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21276791\">Exp. Cell Res., 2011</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23149936\">Mol. Cell. Biol., 2013</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27233470\">Hum. Mutat., 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138391, "symbol": "WRN", "locus": "8p12", "entrez_id": 7486, "chr": "chr8", "start": 30891317, "end": 31031285, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Werner syndrome RecQ like helicase", "description": "<p style=\"text-align: justify\"> Multifunctional enzyme that has both magnesium and ATP- dependent DNA-helicase activity and 3'->5' exonuclease activity towards double-stranded DNA with a 5'-overhang. Has no nuclease activity towards single-stranded DNA or blunt-ended double- stranded DNA. Binds preferentially to DNA substrates containing alternate secondary structures, such as replication forks and Holliday junctions. May play an important role in the dissociation of joint DNA molecules that can arise as products of homologous recombination, at stalled replication forks or during DNA repair. Alleviates stalling of DNA polymerases at the site of DNA lesions. Important for genomic integrity. Plays a role in the formation of DNA replication focal centers; stably associates with foci elements generating binding sites for RP-A (By similarity). Plays a role in double-strand break repair after gamma-irradiation. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17563354\">Proc. Natl. Acad. Sci. U.S.A., 2007</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18596042\">J. Biol. Chem., 2008</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19283071\">PLoS ONE, 2009</a>&nbsp;&nbsp;  <a title=\"Cell Cycle, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19652551\">Cell Cycle, 2009</a>&nbsp;&nbsp;  <a title=\"Biochemistry Mosc., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21639834\">Biochemistry Mosc., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138390, "symbol": "ADGRA2", "locus": "8p11.23", "entrez_id": 25960, "chr": "chr8", "start": 37641709, "end": 37702414, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "adhesion G protein-coupled receptor A2", "description": "<p style=\"text-align: justify\"> Endothelial receptor which functions as a WNT7-specific coactivator of canonical Wnt signaling (By similarity). Required for normal endothelial cell sprouting and migration in the forebrain and neural tube (By similarity). Has a major role in establishing the blood-brain barrier (By similarity). Binds to the glycosaminoglycans heparin, heparin sulfate, chondroitin sulfate and dermatan sulfate (PubMed:16982628). </p>  <a title=\"Biochem. J., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22013897\">Biochem. J., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138389, "symbol": "FGFR1", "locus": "8p11.23", "entrez_id": 2260, "chr": "chr8", "start": 38268656, "end": 38326352, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fibroblast growth factor receptor 1", "description": "<p style=\"text-align: justify\"> FGFR1 является тирозиновой протеинкиназой рецепторного типа. В роли рецептора FGFR1 взаимодействует с факторами роста фибробластов и принимает существенное участие в регуляции эмбрионального развития, пролиферации клеток, дифференцировки и миграции. Функция FGFR1 требуется для нормального формирования мезодермы и правильной осевой организации во время эмбрионального развития, нормального скелетногенеза и нормального развития нейрональной системы гонадотропин-высвобождающего гормона (GnRH). В роли киназы фосфорилирует PLCG1, FRS2, GAB1 и SHB. Связывание лиганда приводит к активации нескольких сигнальных каскадов. Активация PLCG1 приводит к получению клеточных сигнальных молекул диацилглицерина и инозитола 1,4,5-трифосфата. Фосфорилирование FRS2 инициирует участие GRB2, GAB1, PIK3R1 и SOS1, с опосредованной активацией RAS, MAPK1/ERK2, MAPK3/ERK1 и MAP- киназного сигнального пути, а также сигнального пути AKT1. Способствует фосфорилированию SHC1, STAT1 и PTPN11/SHP2. В ядре усиливает активность RPS6KA1 и CREB1 и способствует регуляции транскрипции. Передача сигналов FGFR1 снижается с помощью IL17RD/SEF, а также путем убиквитинизации и деградации FGFR1. </p>  <a title=\"Mol. Biol. Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19261810\">Mol. Biol. Cell, 2009</a>&nbsp;&nbsp;  <a title=\"Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19665973\">Cell, 2009</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20133753\">Proc. Natl. Acad. Sci. U.S.A., 2010</a>&nbsp;&nbsp;  <a title=\"Hum. Reprod., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20139426\">Hum. Reprod., 2010</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21765395\">EMBO J., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138388, "symbol": "KAT6A", "locus": "8p11.21", "entrez_id": 7994, "chr": "chr8", "start": 41786997, "end": 41909508, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "lysine acetyltransferase 6A", "description": "<p style=\"text-align: justify\"> Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2. Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls its transcriptional activity via association with PML. </p>  <a title=\"Oncogene, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11965546\">Oncogene, 2002</a>&nbsp;&nbsp;  <a title=\"Nucleic Acids Res., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12771199\">Nucleic Acids Res., 2003</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16387653\">Mol. Cell, 2006</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17925393\">J. Biol. Chem., 2008</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23431171\">Proc. Natl. Acad. Sci. U.S.A., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138387, "symbol": "IKBKB", "locus": "8p11.21", "entrez_id": 3551, "chr": "chr8", "start": 42128820, "end": 42189973, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "inhibitor of nuclear factor kappa B kinase subunit beta", "description": "<p style=\"text-align: justify\"> Serine kinase that plays an essential role in the NF- kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs. Phosphorylates FOXO3, mediating the TNF- dependent inactivation of this pro-apoptotic transcription factor. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation. </p>  <a title=\"Biochem. Biophys. Res. Commun., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19716809\">Biochem. Biophys. Res. Commun., 2009</a>&nbsp;&nbsp;  <a title=\"J. Virol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20410276\">J. Virol., 2010</a>&nbsp;&nbsp;  <a title=\"Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20434986\">Cell, 2010</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20797629\">Mol. Cell, 2010</a>&nbsp;&nbsp;  <a title=\"Biochem. J., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21138416\">Biochem. J., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138386, "symbol": "HOOK3", "locus": "8p11.21", "entrez_id": 84376, "chr": "chr8", "start": 42752075, "end": 42885682, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "hook microtubule tethering protein 3", "description": "<p style=\"text-align: justify\"> Probably serves as a target for the spiC protein from Salmonella typhimurium, which inactivates it, leading to a strong alteration in cellular trafficking (By similarity). Component of the FTS/Hook/FHIP complex (FHF complex). The FHF complex may function to promote vesicle trafficking and/or fusion via the homotypic vesicular protein sorting complex (the HOPS complex). May regulate clearance of endocytosed receptors such as MSR1. Participates in defining the architecture and localization of the Golgi complex. Acts as an adapter protein linking the dynein motor complex to various cargos and converts dynein from a non- processive to a highly processive motor in the presence of dynactin. Facilitates the interaction between dynein and dynactin and activates dynein processivity (the ability to move along a microtubule for a long distance without falling off the track) (PubMed:25035494). </p>  <a title=\"J. Cell Biol., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11238449\">J. Cell Biol., 2001</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17237231\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;  <a title=\"Mol. Biol. Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18799622\">Mol. Biol. Cell, 2009</a>&nbsp;&nbsp;  <a title=\"Science, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25035494\">Science, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138385, "symbol": "PRKDC", "locus": "8q11.21", "entrez_id": 5591, "chr": "chr8", "start": 48685669, "end": 48872743, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "protein kinase, DNA-activated, catalytic polypeptide", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its catalytic properties. Promotes processing of hairpin DNA structures in V(D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step. Required to protect and align broken ends of DNA. May also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion. Also involved in modulation of transcription. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby regulating DNA damage response mechanism. Phosphorylates DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2. Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA. Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D. Contributes to the determination of the circadian period length by antagonizing phosphorylation of CRY1 'Ser-588' and increasing CRY1 protein stability, most likely through an indirect machanism. Interacts with CRY1 and CRY2; negatively regulates CRY1 phosphorylation. </p>  <a title=\"Genes Dev., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9679063\">Genes Dev., 1998</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12649176\">Cancer Res., 2003</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14734805\">Proc. Natl. Acad. Sci. U.S.A., 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15574326\">Mol. Cell, 2005</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138384, "symbol": "PLAG1", "locus": "8q12.1", "entrez_id": 5324, "chr": "chr8", "start": 57073463, "end": 57123883, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "PLAG1 zinc finger", "description": "<p style=\"text-align: justify\"> Transcription factor whose activation results in up- regulation of target genes, such as IGFII, leading to uncontrolled cell proliferation: when overexpressed in cultured cells, higher proliferation rate and transformation are observed. Other target genes such as CRLF1, CRABP2, CRIP2, PIGF are strongly induced in cells with PLAG1 induction. Proto-oncogene whose ectopic expression can trigger the development of pleomorphic adenomas of the salivary gland and lipoblastomas. Overexpression is associated with up-regulation of IGFII, is frequently observed in hepatoblastoma, common primary liver tumor in childhood. Cooperates with CBFB-MYH11, a fusion gene important for myeloid leukemia. </p>  <a title=\"Cancer Res., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11888928\">Cancer Res., 2002</a>&nbsp;&nbsp;  <a title=\"Genes Chromosomes Cancer, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14695992\">Genes Chromosomes Cancer, 2004</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14712223\">Oncogene, 2004</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138383, "symbol": "NCOA2", "locus": "8q13.3", "entrez_id": 10499, "chr": "chr8", "start": 71021997, "end": 71316040, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nuclear receptor coactivator 2", "description": "<p style=\"text-align: justify\"> Transcriptional coactivator for steroid receptors and nuclear receptors. Coactivator of the steroid binding domain (AF- 2) but not of the modulating N-terminal domain (AF-1). Required with NCOA1 to control energy balance between white and brown adipose tissues. Critical regulator of glucose metabolism regulation, acts as RORA coactivator to specifically modulate G6PC expression. Involved in the positive regulation of the transcriptional activity of the glucocorticoid receptor NR3C1 by sumoylation enhancer RWDD3. Positively regulates the circadian clock by acting as a transcriptional coactivator for the CLOCK- ARNTL/BMAL1 heterodimer (By similarity). </p>  <a title=\"EMBO J., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9430642\">EMBO J., 1998</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23508108\">Mol. Cell. Biol., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138382, "symbol": "RECQL4", "locus": "8q24.3", "entrez_id": 9401, "chr": "chr8", "start": 145736667, "end": 145743229, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "RecQ like helicase 4", "description": "<p style=\"text-align: justify\"> DNA-dependent ATPase. May modulate chromosome segregation. </p>  <a title=\"Hum. Mol. Genet., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15317757\">Hum. Mol. Genet., 2005</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138381, "symbol": "MYC", "locus": "8q24.21", "entrez_id": 4609, "chr": "chr8", "start": 128747680, "end": 128753674, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MYC proto-oncogene, bHLH transcription factor", "description": "<p style=\"text-align: justify\"> Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'- CAC[GA]TG-3'. Activates the transcription of growth-related genes. </p>  <a title=\"Am. J. Pathol., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25956029\">Am. J. Pathol., 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138380, "symbol": "BCL2L2", "locus": "14q11.2", "entrez_id": 599, "chr": "chr14", "start": 23767999, "end": 23780968, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "BCL2 like 2", "description": "<p style=\"text-align: justify\"> Promotes cell survival. Blocks dexamethasone-induced apoptosis. Mediates survival of postmitotic Sertoli cells by suppressing death-promoting activity of BAX. </p>  <a title=\"Oncogene, 1996\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8761287\">Oncogene, 1996</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138379, "symbol": "NKX2-1", "locus": "14q13.3", "entrez_id": 7080, "chr": "chr14", "start": 36985602, "end": 36990354, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "NK2 homeobox 1", "description": "<p style=\"text-align: justify\"> Transcription factor that binds and activates the promoter of thyroid specific genes such as thyroglobulin, thyroperoxidase, and thyrotropin receptor. Crucial in the maintenance of the thyroid differentiation phenotype. May play a role in lung development and surfactant homeostasis. Forms a regulatory loop with GRHL2 that coordinates lung epithelial cell morphogenesis and differentiation. Activates the transcription of GNRHR and plays a role in enhancing the circadian oscillation of its gene expression. Represses the transcription of the circadian transcriptional repressor NR1D1 (By similarity). </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138378, "symbol": "NIN", "locus": "14q22.1", "entrez_id": 51199, "chr": "chr14", "start": 51186481, "end": 51297839, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ninein", "description": "<p style=\"text-align: justify\"> Centrosomal protein required in the positioning and anchorage of the microtubule minus-end in epithelial cells. May also act as a centrosome maturation factor. May play a role in microtubule nucleation. Overexpression does not perturb nucleation or elongation of microtubules but suppresses release of microtubules (PubMed:15190203). Required for centriole organization and microtubule anchoring at the mother centriole (PubMed:23386061). </p>  <a title=\"Cell Cycle, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15190203\">Cell Cycle, 2006</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23386061\">EMBO J., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138377, "symbol": "HIF1A", "locus": "14q23.2", "entrez_id": 3091, "chr": "chr14", "start": 62162231, "end": 62214976, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "hypoxia inducible factor 1 alpha subunit", "description": "<p style=\"text-align: justify\"> HIF1A является регулятором транскрипции генов и играет ключевую роль в адаптации к гипоксии. При гипоксии этот фактор активирует транскрипцию более 40 генов, включая эритропоэтин, транспортеры глюкозы, гликолитические ферменты, фактор роста эндотелия, HILPDA и другие гены, белковыен продукты которых стимулируют доставку кислорода в ткань или метаболическую адаптацию к гипоксии. Связывается с последовательностью ДНК 5'-[AG]CGTG-3' в области промоторов таргетных генов. Для активации требуется набор транскрипционных коактиваторов, таких как CREBBP и EP300. Активность усиливается за счет взаимодействия как с NCOA1, так и с NCOA2. Взаимодействие с редокс-регуляторным белком APEX, по-видимому, активирует CTAD и потенциально активирует NCOA1 и CREBBP. Вовлечен в росте аксонов. </p>  <a title=\"J. Biol. Chem., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16973622\">J. Biol. Chem., 2006</a>&nbsp;&nbsp;  <a title=\"Biochem. Biophys. Res. Commun., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17610843\">Biochem. Biophys. Res. Commun., 2007</a>&nbsp;&nbsp;  <a title=\"J. Cell Biol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19528298\">J. Cell Biol., 2009</a>&nbsp;&nbsp;  <a title=\"FASEB J., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20624928\">FASEB J., 2010</a>&nbsp;&nbsp;  <a title=\"Endocr. Relat. Cancer, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22009797\">Endocr. Relat. Cancer, 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138376, "symbol": "TSHR", "locus": "14q31.1", "entrez_id": 7253, "chr": "chr14", "start": 81421333, "end": 81612646, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "thyroid stimulating hormone receptor", "description": "<p style=\"text-align: justify\"> Receptor for the thyroid-stimulating hormone (TSH) or thyrotropin (PubMed:11847099, PubMed:12045258). Also acts as a receptor for the heterodimeric glycoprotein hormone (GPHA2:GPHB5) or thyrostimulin (PubMed:12045258). The activity of this receptor is mediated by G proteins which activate adenylate cyclase (PubMed:11847099). Plays a central role in controlling thyroid cell metabolism (By similarity). </p>  <a title=\"EMBO J., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11847099\">EMBO J., 2002</a>&nbsp;&nbsp;  <a title=\"J. Clin. Invest., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12045258\">J. Clin. Invest., 2002</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138375, "symbol": "TRIP11", "locus": "14q32.12", "entrez_id": 9321, "chr": "chr14", "start": 92432335, "end": 92507240, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "thyroid hormone receptor interactor 11", "description": "<p style=\"text-align: justify\"> Binds the ligand binding domain of the thyroid receptor (THRB) in the presence of triiodothyronine and enhances THRB- modulated transcription. Golgi auto-antigen; probably involved in maintaining cis-Golgi structure. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9256431\">Proc. Natl. Acad. Sci. U.S.A., 1997</a>&nbsp;&nbsp;  <a title=\"J. Cell Biol., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10189370\">J. Cell Biol., 1999</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138374, "symbol": "DICER1", "locus": "14q32.13", "entrez_id": 23405, "chr": "chr14", "start": 95552565, "end": 95624347, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "dicer 1, ribonuclease III", "description": "<p style=\"text-align: justify\"> Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing. Cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two nucleotides, producing respectively short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA- induced silencing complex (RISC) to complementary RNAs to degrade them or prevent their translation. Gene silencing mediated by siRNAs, also called RNA interference, controls the elimination of transcripts from mobile and repetitive DNA elements of the genome but also the degradation of exogenous RNA of viral origin for instance. The miRNA pathway on the other side is a mean to specifically regulate the expression of target genes. </p>  <a title=\"Genes Dev., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16357216\">Genes Dev., 2006</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16424907\">EMBO J., 2006</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17452327\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18178619\">Proc. Natl. Acad. Sci. U.S.A., 2008</a>&nbsp;&nbsp;  <a title=\"Nat. Genet., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19219043\">Nat. Genet., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138373, "symbol": "TCL1A", "locus": "14q32.13", "entrez_id": 8115, "chr": "chr14", "start": 96176304, "end": 96180533, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "T-cell leukemia/lymphoma 1A", "description": "<p style=\"text-align: justify\"> Enhances the phosphorylation and activation of AKT1, AKT2 and AKT3. Promotes nuclear translocation of AKT1. Enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell survival. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10716693\">Proc. Natl. Acad. Sci. U.S.A., 2000</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10983986\">Mol. Cell, 2000</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11707444\">J. Biol. Chem., 2002</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11839817\">Mol. Cell. Biol., 2002</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138372, "symbol": "BCL11B", "locus": "14q32.2", "entrez_id": 64919, "chr": "chr14", "start": 99635624, "end": 99737861, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "B-cell CLL/lymphoma 11B", "description": "<p style=\"text-align: justify\"> Key regulator of both differentiation and survival during thymocyte development in mammals. Essential in controlling the responsiveness of hematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus (PubMed:27959755). Tumor-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element (By similarity). May also function in the P53-signaling pathway (By similarity). </p>  <a title=\"N. Engl. J. Med., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27959755\">N. Engl. J. Med., 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138371, "symbol": "HSP90AA1", "locus": "14q32.31", "entrez_id": 3320, "chr": "chr14", "start": 102547075, "end": 102606036, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "heat shock protein 90 alpha family class A member 1", "description": "<p style=\"text-align: justify\"> Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity which is essential for its chaperone activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:11274138, PubMed:15577939, PubMed:15937123, PubMed:27353360). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself. Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:27295069, PubMed:26991466). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels. In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues. Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment. Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205). Antagonizes STUB1- mediated inhibition of TGF-beta signaling via inhibition of STUB1- mediated SMAD3 ubiquitination and degradation (PubMed:24613385). </p>  <a title=\"Biochem. Biophys. Res. Commun., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24613385\">Biochem. Biophys. Res. Commun., 2014</a>&nbsp;&nbsp;  <a title=\"Front Oncol, 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25973397\">Front Oncol, 2015</a>&nbsp;&nbsp;  <a title=\"Biopolymers, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26991466\">Biopolymers, 2017</a>&nbsp;&nbsp;  <a title=\"Biochimie, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27295069\">Biochimie, 2017</a>&nbsp;&nbsp;  <a title=\"Nat Commun, 2018\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27353360\">Nat Commun, 2018</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138370, "symbol": "AKT1", "locus": "14q32.33", "entrez_id": 207, "chr": "chr14", "start": 105235686, "end": 105262088, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "AKT serine/threonine kinase 1", "description": "AKT1 is one of 3 closely related serine/threonine- protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)- response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr- 117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro- apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138369, "symbol": "THBS1", "locus": "15q14", "entrez_id": 7057, "chr": "chr15", "start": 39873280, "end": 39891667, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "thrombospondin 1", "description": "<p style=\"text-align: justify\"> Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Binds heparin. May play a role in dentinogenesis and/or maintenance of dentin and dental pulp (By similarity). Ligand for CD36 mediating antiangiogenic properties. Plays a role in ER stress response, via its interaction with the activating transcription factor 6 alpha (ATF6) which produces adaptive ER stress response factors (By similarity). </p>  <a title=\"J. Clin. Invest., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11134179\">J. Clin. Invest., 2001</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15014436\">EMBO J., 2005</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138368, "symbol": "BUB1B", "locus": "15q15.1", "entrez_id": 701, "chr": "chr15", "start": 40453224, "end": 40513337, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "BUB1 mitotic checkpoint serine/threonine kinase B", "description": "<p style=\"text-align: justify\"> Essential component of the mitotic checkpoint. Required for normal mitosis progression. The mitotic checkpoint delays anaphase until all chromosomes are properly attached to the mitotic spindle. One of its checkpoint functions is to inhibit the activity of the anaphase-promoting complex/cyclosome (APC/C) by blocking the binding of CDC20 to APC/C, independently of its kinase activity. The other is to monitor kinetochore activities that depend on the kinetochore motor CENPE. Required for kinetochore localization of CENPE. Negatively regulates PLK1 activity in interphase cells and suppresses centrosome amplification. Also implicated in triggering apoptosis in polyploid cells that exit aberrantly from mitotic arrest. May play a role for tumor suppression. </p>  <a title=\"Dev. Cell, 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11702782\">Dev. Cell, 2001</a>&nbsp;&nbsp;  <a title=\"Cancer Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14706340\">Cancer Cell, 2004</a>&nbsp;&nbsp;  <a title=\"J. Cell. Sci., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15020684\">J. Cell. Sci., 2004</a>&nbsp;&nbsp;  <a title=\"Cell Cycle, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19411850\">Cell Cycle, 2009</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19503101\">Oncogene, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138367, "symbol": "KNL1", "locus": "15q15.1", "entrez_id": 57082, "chr": "chr15", "start": 40886218, "end": 40956540, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "kinetochore scaffold 1", "description": "<p style=\"text-align: justify\"> Performs two crucial functions during mitosis: it is essential for spindle-assembly checkpoint signaling and for correct chromosome alignment. Required for attachment of the kinetochores to the spindle microtubules. Directly links BUB1 and BUB1B to kinetochores. Part of the MIS12 complex, which may be fundamental for kinetochore formation and proper chromosome segregation during mitosis. Acts in coordination with CENPK to recruit the NDC80 complex to the outer kinetochore. </p>  <a title=\"Nat. Cell Biol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15502821\">Nat. Cell Biol., 2004</a>&nbsp;&nbsp;  <a title=\"Dev. Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17981135\">Dev. Cell, 2008</a>&nbsp;&nbsp;  <a title=\"Mol. Biol. Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18045986\">Mol. Biol. Cell, 2008</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138366, "symbol": "LTK", "locus": "15q15.1", "entrez_id": 4058, "chr": "chr15", "start": 41795836, "end": 41806085, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "leukocyte receptor tyrosine kinase", "description": "<p style=\"text-align: justify\"> Receptor with a tyrosine-protein kinase activity. The exact function of this protein is not known. Studies with chimeric proteins (replacing its extracellular region with that of several known growth factor receptors, such as EGFR and CSFIR) demonstrate its ability to promote growth and specifically neurite outgrowth, and cell survival. Signaling appears to involve the PI3 kinase pathway. Involved in regulation of the secretory pathway involving endoplasmic reticulum (ER) export sites (ERESs) and ER to Golgi transport. </p>  <a title=\"J. Cell Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20548102\">J. Cell Biol., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138365, "symbol": "TGM7", "locus": "15q15.2-q15.3", "entrez_id": 116179, "chr": "chr15", "start": 43568478, "end": 43594453, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "transglutaminase 7", "description": "Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138364, "symbol": "TCF12", "locus": "15q21.3", "entrez_id": 6938, "chr": "chr15", "start": 57210821, "end": 57591479, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "transcription factor 12", "description": "Transcriptional regulator. Involved in the initiation of neuronal differentiation. Activates transcription by binding to the E box (5'-CANNTG-3')", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138363, "symbol": "MAP2K1", "locus": "15q22.31", "entrez_id": 5604, "chr": "chr15", "start": 66679155, "end": 66784650, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mitogen-activated protein kinase kinase 1", "description": "<p style=\"text-align: justify\"> Протеинкиназа двойной специфичности, которая является компонентом каскада митоген-активируемых протеинкиназ (МАРК-каскада). Связывание внеклеточных лигандов - факторов роста, цитокинов и гормонов с их рецепторами на клеточной поверхности активирует Ras, что инициирует активацию киназы Raf-1. Затем Raf-1 путем фосфорилирования активирует протеинкиназы MEK1 и MEK2, кодируемые генами MAP2K1 и MAP2K2, соответственно. Данные киназы относятся к каскаду MAPK/ERK и катализируют фосфорилирование треонина и тирозина в последовательности Thr-Glu-Tyr, расположенной во в киназах ERK1 (MAPK3) и ERK2 (MAPK1), что приводит к их активации и дальнейшей трансдукции сигнала каскада MAPK/ERK. В зависимости от клеточного контекста этот путь контролирует разнообразные биологические процессы (пролиферацию, клеточную адгезию, выживание и дифференцировку клеток) посредством регуляции транскрипции, метаболизма и реорганизации цитоскелета. Одной из мишеней каскада MAPK/ERK является ядерный рецептор γ-рецептор-активатор пролиферации пероксисом (PPARG), который регулирует процессы клеточной дифференцировки и апоптоз. Было показано, что MEK1 участвует в экспорте PPARG из ядра. Каскад MAPK/ERK также регулирует динамику формирования эндосом, лизосом и фрагментацию аппарата Гольджи во время митоза. </p>  <a title=\"Oncogene, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14737111\">Oncogene, 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17101779\">Mol. Cell. Biol., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138362, "symbol": "PML", "locus": "15q24.1", "entrez_id": 5371, "chr": "chr15", "start": 74287014, "end": 74340153, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "promyelocytic leukemia", "description": "Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Isoform PML-4 has a multifaceted role in the regulation of apoptosis and growth suppression: activates RB1 and inhibits AKT1 via interactions with PP1 and PP2A phosphatases respectively, negatively affects the PI3K pathway by inhibiting MTOR and activating PTEN, and positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Isoform PML-4 also: acts as a transcriptional repressor of TBX2 during cellular senescence and the repression is dependent on a functional RBL2/E2F4 repressor complex, regulates double-strand break repair in gamma- irradiation-induced DNA damage responses via its interaction with WRN, acts as a negative regulator of telomerase by interacting with TERT, and regulates PER2 nuclear localization and circadian function. Isoform PML-6 inhibits specifically the activity of the tetrameric form of PKM. The nuclear isoforms (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5) in concert with SATB1 are involved in local chromatin-loop remodeling and gene expression regulation at the MHC-I locus. Isoform PML-2 is required for efficient IFN-gamma induced MHC II gene transcription via regulation of CIITA. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. PML also regulates transcription activity of ELF4 and can act as an important mediator for TNF-alpha- and IFN-alpha-mediated inhibition of endothelial cell network formation and migration", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138361, "symbol": "NTRK3", "locus": "15q25.3", "entrez_id": 4916, "chr": "chr15", "start": 88418230, "end": 88799999, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "neurotrophic receptor tyrosine kinase 3", "description": "<p style=\"text-align: justify\"> Receptor tyrosine kinase involved in nervous system and probably heart development. Upon binding of its ligand NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the phosphatidylinositol 3-kinase/AKT and the MAPK pathways, that control cell survival and differentiation. </p>  <a title=\"Hum. Mutat., 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25196463\">Hum. Mutat., 2015</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138360, "symbol": "IDH2", "locus": "15q26.1", "entrez_id": 3418, "chr": "chr15", "start": 90626277, "end": 90645736, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "isocitrate dehydrogenase (NADP(+)) 2, mitochondrial", "description": "Участвует в промежуточном метаболизме и производстве энергии,  может взаимодействовать с комплексом пируватдегидрогеназы.", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138359, "symbol": "BLM", "locus": "15q26.1", "entrez_id": 641, "chr": "chr15", "start": 91260558, "end": 91358859, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Bloom syndrome RecQ like helicase", "description": "<p style=\"text-align: justify\"> Participates in DNA replication and repair. Exhibits a magnesium-dependent ATP-dependent DNA-helicase activity that unwinds single- and double-stranded DNA in a 3'-5' direction. Involved in 5'-end resection of DNA during double-strand break (DSB) repair: unwinds DNA and recruits DNA2 which mediates the cleavage of 5'-ssDNA. Negatively regulates sister chromatid exchange (SCE). </p>  <a title=\"J. Biol. Chem., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9388193\">J. Biol. Chem., 1998</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12019152\">Cancer Res., 2002</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21325134\">Genes Dev., 2011</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23509288\">Proc. Natl. Acad. Sci. U.S.A., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138358, "symbol": "IGF1R", "locus": "15q26.3", "entrez_id": 3480, "chr": "chr15", "start": 99192200, "end": 99507759, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "insulin like growth factor 1 receptor", "description": "Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K- driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138357, "symbol": "TSC2", "locus": "16p13.3", "entrez_id": 7249, "chr": "chr16", "start": 2097466, "end": 2138716, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "TSC complex subunit 2", "description": "<p style=\"text-align: justify\"> В комплексе с TSC1 этот супрессор опухолей ингибирует опосредуемое питательным веществом или стимулирующим фактором роста фосфорилирование S6K1 и EIF4EBP1, путем отрицательного регулирования сигнального пути mTORC1. Действует как белок-активатор GTP-азной активности для RHEB, прямого активатора активности протеинкиназы mTORC1. Может также играть роль в транспорте белка, опосредованного микротрубочками. Также стимулирует GTP-азную активность  Ras-родственных белков RAP1A и RAB5. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12271141\">Proc. Natl. Acad. Sci. U.S.A., 2002</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15340059\">Mol. Cell. Biol., 2004</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16707451\">Cancer Res., 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138356, "symbol": "CREBBP", "locus": "16p13.3", "entrez_id": 1387, "chr": "chr16", "start": 3775055, "end": 3930727, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "CREB binding protein", "description": "<p style=\"text-align: justify\"> Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK- ARNTL/BMAL1 heterodimers. Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER) (PubMed:24939902). </p>  <a title=\"J. Biol. Chem., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11154691\">J. Biol. Chem., 2001</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12738767\">J. Biol. Chem., 2003</a>&nbsp;&nbsp;  <a title=\"J. Bone Miner. Res., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12929931\">J. Bone Miner. Res., 2004</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14645221\">J. Biol. Chem., 2004</a>&nbsp;&nbsp;  <a title=\"Nucleic Acids Res., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24939902\">Nucleic Acids Res., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138355, "symbol": "SOCS1", "locus": "16p13.13", "entrez_id": 8651, "chr": "chr16", "start": 11348262, "end": 11350036, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "suppressor of cytokine signaling 1", "description": "<p style=\"text-align: justify\"> SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS1 is involved in negative regulation of cytokines that signal through the JAK/STAT3 pathway. Through binding to JAKs, inhibits their kinase activity. In vitro, also suppresses Tec protein- tyrosine activity. Appears to be a major regulator of signaling by interleukin 6 (IL6) and leukemia inhibitory factor (LIF). Regulates interferon-gamma mediated sensory neuron survival (By similarity). Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize JAK2. SOCS1 appears to be a negative regulator in IGF1R signaling pathway. </p>  <a title=\"J. Biol. Chem., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11278610\">J. Biol. Chem., 2001</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11313480\">Mol. Cell. Biol., 2001</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138354, "symbol": "ERCC4", "locus": "16p13.12", "entrez_id": 2072, "chr": "chr16", "start": 14014014, "end": 14046202, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ERCC excision repair 4, endonuclease catalytic subunit", "description": "<p style=\"text-align: justify\"> Catalytic component of a structure-specific DNA repair endonuclease responsible for the 5-prime incision during DNA repair. Involved in homologous recombination that assists in removing interstrand cross-link. </p>  <a title=\"Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19596235\">Cell, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138353, "symbol": "MYH11", "locus": "16p13.11", "entrez_id": 4629, "chr": "chr16", "start": 15797029, "end": 15950890, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "myosin heavy chain 11", "description": "Muscle contraction", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138352, "symbol": "PALB2", "locus": "16p12.2", "entrez_id": 79728, "chr": "chr16", "start": 23614488, "end": 23652631, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "partner and localizer of BRCA2", "description": "<p style=\"text-align: justify\"> Plays a critical role in homologous recombination repair (HRR) through its ability to recruit BRCA2 and RAD51 to DNA breaks. Strongly stimulates the DNA strand-invasion activity of RAD51, stabilizes the nucleoprotein filament against a disruptive BRC3-BRC4 polypeptide and helps RAD51 to overcome the suppressive effect of replication protein A (RPA). Functionally cooperates with RAD51AP1 in promoting of D-loop formation by RAD51. Serves as the molecular scaffold in the formation of the BRCA1-PALB2-BRCA2 complex which is essential for homologous recombination. Via its WD repeats is proposed to scaffold a HR complex containing RAD51C and BRCA2 which is thought to play a role in HR-mediated DNA repair. Essential partner of BRCA2 that promotes the localization and stability of BRCA2. Also enables its recombinational repair and checkpoint functions of BRCA2. May act by promoting stable association of BRCA2 with nuclear structures, allowing BRCA2 to escape the effects of proteasome-mediated degradation. Binds DNA with high affinity for D loop, which comprises single-stranded, double-stranded and branched DNA structures. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with BRCA2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity. </p>  <a title=\"Nat. Struct. Mol. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20871615\">Nat. Struct. Mol. Biol., 2010</a>&nbsp;&nbsp;  <a title=\"Nat. Struct. Mol. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20871616\">Nat. Struct. Mol. Biol., 2010</a>&nbsp;&nbsp;  <a title=\"Nucleic Acids Res., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22941656\">Nucleic Acids Res., 2013</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24141787\">Oncogene, 2014</a>&nbsp;&nbsp;  <a title=\"Cell Rep, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24485656\">Cell Rep, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138351, "symbol": "IL21R", "locus": "16p12.1", "entrez_id": 50615, "chr": "chr16", "start": 27413483, "end": 27462115, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "interleukin 21 receptor", "description": "This is a receptor for interleukin-21", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138350, "symbol": "CYLD", "locus": "16q12.1", "entrez_id": 1540, "chr": "chr16", "start": 50775961, "end": 50835846, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "CYLD lysine 63 deubiquitinase", "description": "<p style=\"text-align: justify\"> Deubiquitinase that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation (PubMed:12917689, PubMed:12917691). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed:12917690). Negative regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed:19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed:18222923, PubMed:20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed:18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity). Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane; this process does not depend on NF-kappa-B activation (By similarity). Also able to remove linear ('Met-1'-linked) polyubiquitin chains to regulate innate immunity: recruited to the LUBAC complex and, together with OTULIN, restricts linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation (PubMed:26670046, PubMed:26997266). </p>  <a title=\"EMBO J., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19893491\">EMBO J., 2010</a>&nbsp;&nbsp;  <a title=\"Blood, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20194890\">Blood, 2010</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20227366\">Mol. Cell, 2010</a>&nbsp;&nbsp;  <a title=\"Cell Rep, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26670046\">Cell Rep, 2016</a>&nbsp;&nbsp;  <a title=\"Cell Rep, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26997266\">Cell Rep, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138349, "symbol": "MMP2", "locus": "16q12.2", "entrez_id": 4313, "chr": "chr16", "start": 55423612, "end": 55540603, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "matrix metallopeptidase 2", "description": "Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14 FUNCTION: Isoform 2: Mediates the proteolysis of CHUK/IKKA and initiates a primary innate immune response by inducing mitochondrial-nuclear stress signaling with activation of the pro- inflammatory NF-kappaB, NFAT and IRF transcriptional pathways.;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138348, "symbol": "CDH11", "locus": "16q21", "entrez_id": 1009, "chr": "chr16", "start": 64977656, "end": 65160015, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cadherin 11", "description": "Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138347, "symbol": "CDH5", "locus": "16q21", "entrez_id": 1003, "chr": "chr16", "start": 66400533, "end": 66438686, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cadherin 5", "description": "<p style=\"text-align: justify\"> Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction. </p>  <a title=\"J. Cell. Sci., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20332120\">J. Cell. Sci., 2010</a>&nbsp;&nbsp;  <a title=\"J. Mol. Biol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21269602\">J. Mol. Biol., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138346, "symbol": "CDH1", "locus": "16q22.1", "entrez_id": 999, "chr": "chr16", "start": 68771128, "end": 68869451, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cadherin 1", "description": "<p style=\"text-align: justify\"> Cadherins are calcium-dependent cell adhesion proteins (PubMed:11976333). They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells (PubMed:11976333). Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7. </p>  <a title=\"J. Biol. Chem., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11976333\">J. Biol. Chem., 2002</a>&nbsp;&nbsp;  <a title=\"J. Neurochem., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16417575\">J. Neurochem., 2006</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138345, "symbol": "MAF", "locus": "16q23.2", "entrez_id": 4094, "chr": "chr16", "start": 79619740, "end": 79634611, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MAF bZIP transcription factor", "description": "<p style=\"text-align: justify\"> Acts as a transcriptional activator or repressor. Involved in embryonic lens fiber cell development. Recruits the transcriptional coactivators CREBBP and/or EP300 to crystallin promoters leading to up-regulation of crystallin gene during lens fiber cell differentiation. Activates the expression of IL4 in T helper 2 (Th2) cells. Increases T-cell susceptibility to apoptosis by interacting with MYB and decreasing BCL2 expression. Together with PAX6, transactivates strongly the glucagon gene promoter through the G1 element. Activates transcription of the CD13 proximal promoter in endothelial cells. Represses transcription of the CD13 promoter in early stages of myelopoiesis by affecting the ETS1 and MYB cooperative interaction. Involved in the initial chondrocyte terminal differentiation and the disappearance of hypertrophic chondrocytes during endochondral bone development. Binds to the sequence 5'-[GT]G[GC]N[GT]NCTCAGNN-3' in the L7 promoter. Binds to the T-MARE (Maf response element) sites of lens-specific alpha- and beta-crystallin gene promoters. Binds element G1 on the glucagon promoter. Binds an AT-rich region adjacent to the TGC motif (atypical Maf response element) in the CD13 proximal promoter in endothelial cells (By similarity). When overexpressed, represses anti-oxidant response element (ARE)- mediated transcription. Involved either as an oncogene or as a tumor suppressor, depending on the cell context. Binds to the ARE sites of detoxifying enzyme gene promoters. </p>  <a title=\"Oncogene, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12149651\">Oncogene, 2002</a>&nbsp;&nbsp;  <a title=\"Cancer Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14998494\">Cancer Cell, 2004</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15007382\">Oncogene, 2004</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16247450\">Oncogene, 2006</a>&nbsp;&nbsp;  <a title=\"Nat. Rev. Cancer, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19143053\">Nat. Rev. Cancer, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138344, "symbol": "FANCA", "locus": "16q24.3", "entrez_id": 2175, "chr": "chr16", "start": 89803957, "end": 89883065, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Fanconi anemia complementation group A", "description": "Ген участвующий в репарации ДНК, который может функционировать при пострепликационной репарации или в контрольной точке клеточного цикла. Белок может быть задействован в восстановлении перекрестных сшивок  ДНК и в поддержании стабильности хромосом.", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138343, "symbol": "NLRP1", "locus": "17p13.2", "entrez_id": 22861, "chr": "chr17", "start": 5402747, "end": 5522744, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "NLR family pyrin domain containing 1", "description": "<p style=\"text-align: justify\"> As the sensor component of the NLRP1 inflammasome, plays a crucial role in innate immunity and inflammation. In response to pathogens and other damage-associated signals, initiates the formation of the inflammasome polymeric complex, made of NLRP1, CASP1, and possibly PYCARD. Recruitment of proCASP1 to the inflammasome promotes its activation and CASP1-catalyzed IL1B and IL18 maturation and secretion in the extracellular milieu. Activation of NLRP1 inflammasome is also required for HMGB1 secretion. The active cytokines and HMGB1 stimulate inflammatory responses. Inflammasomes can also induce pyroptosis, an inflammatory form of programmed cell death (PubMed:22665479, PubMed:17418785). May be activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, in a NOD2-dependent manner (PubMed:18511561). Contrary to its mouse ortholog, not activated by Bacillus anthracis lethal toxin (PubMed:19651869). It is unclear whether isoform 2 is involved in inflammasome formation. It is not cleaved within the FIIND domain, does not assemble into specks, nor promote IL1B release (PubMed:22665479). However, in an vitro cell-free system, it has been shown to be activated by MDP (PubMed:17349957). Binds ATP (PubMed:11113115, PubMed:15212762). </p>  <a title=\"Cell, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17418785\">Cell, 2007</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18511561\">Proc. Natl. Acad. Sci. U.S.A., 2008</a>&nbsp;&nbsp;  <a title=\"Infect. Immun., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19651869\">Infect. Immun., 2009</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22665479\">J. Biol. Chem., 2012</a>&nbsp;&nbsp;  <a title=\"Cell, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27662089\">Cell, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138342, "symbol": "TP53", "locus": "17p13.1", "entrez_id": 7157, "chr": "chr17", "start": 7565097, "end": 7590856, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "tumor protein p53", "description": "<p style=\"text-align: justify\"> Действует как супрессор во многих типах опухолей; индуцирует остановку роста или апоптоз в зависимости от физиологических обстоятельств и типа клеток. Участвует в регуляции клеточного цикла в качестве транс-активатора, который отрицательно регулирует деление клеток, контролируя набор генов, необходимых для этого процесса. Один из активируемых генов является ингибитором циклин-зависимых киназ. Индукция апоптоза, по-видимому, опосредована либо стимуляцией экспрессии антигена BAX и FAS, либо репрессией экспрессии Bcl-2. В кооперации с митохондриальным PPIF участвует в активации некроза, вызванного окислительным стрессом; функция в значительной степени не зависит от транскрипции. Индуцирует транскрипцию длинных некодирующих РНК р21 (lincRNA-p21) и lincRNA-Mkln1. LincRNA-p21 участвует в TP53-зависимой транскрипционной репрессии, приводящей к апоптозу и, видимо, влияет на регуляцию клеточного цикла. Учатсвует в перекрестной передаче сигналов Notch. Предотвращает активность киназы CDK7 при связывании с комплексом CAK в ответ на повреждение ДНК, тем самым останавливая прогрессирование клеточного цикла. Изоформа 2 усиливает трансактивирующую активность изоформы 1 у некоторых, но не всех TP53-индуцируемых промоторов. Изоформа 4 подавляет активность трансактивации и снижает подавление роста, опосредованное изоформой 1. Изоформа 7 ингибирует апоптоз, опосредуемый изоформой 1. Регулирует циркадные часы, подавляя CLOCK-ARNTL / BMAL1-опосредованную транскрипционную активацию PER2. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19556538\">Proc. Natl. Acad. Sci. U.S.A., 2009</a>&nbsp;&nbsp;  <a title=\"Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20673990\">Cell, 2010</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20959462\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"Cell, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22726440\">Cell, 2012</a>&nbsp;&nbsp;  <a title=\"Nat Commun, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24051492\">Nat Commun, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138341, "symbol": "PER1", "locus": "17p13.1", "entrez_id": 5187, "chr": "chr17", "start": 8043790, "end": 8059824, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "period circadian clock 1", "description": "<p style=\"text-align: justify\"> Transcriptional repressor which forms a core component of the circadian clock. The circadian clock, an internal time- keeping system, regulates various physiological processes through the generation of approximately 24 hour circadian rhythms in gene expression, which are translated into rhythms in metabolism and behavior. It is derived from the Latin roots 'circa' (about) and 'diem' (day) and acts as an important regulator of a wide array of physiological functions including metabolism, sleep, body temperature, blood pressure, endocrine, immune, cardiovascular, and renal function. Consists of two major components: the central clock, residing in the suprachiasmatic nucleus (SCN) of the brain, and the peripheral clocks that are present in nearly every tissue and organ system. Both the central and peripheral clocks can be reset by environmental cues, also known as Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the central clock is light, which is sensed by retina and signals directly to the SCN. The central clock entrains the peripheral clocks through neuronal and hormonal signals, body temperature and feeding-related cues, aligning all clocks with the external light/dark cycle. Circadian rhythms allow an organism to achieve temporal homeostasis with its environment at the molecular level by regulating gene expression to create a peak of protein expression once every 24 hours to control when a particular physiological process is most active with respect to the solar day. Transcription and translation of core clock components (CLOCK, NPAS2, ARNTL/BMAL1, ARNTL2/BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a critical role in rhythm generation, whereas delays imposed by post-translational modifications (PTMs) are important for determining the period (tau) of the rhythms (tau refers to the period of a rhythm and is the length, in time, of one complete cycle). A diurnal rhythm is synchronized with the day/night cycle, while the ultradian and infradian rhythms have a period shorter and longer than 24 hours, respectively. Disruptions in the circadian rhythms contribute to the pathology of cardiovascular diseases, cancer, metabolic syndromes and aging. A transcription/translation feedback loop (TTFL) forms the core of the molecular circadian clock mechanism. Transcription factors, CLOCK or NPAS2 and ARNTL/BMAL1 or ARNTL2/BMAL2, form the positive limb of the feedback loop, act in the form of a heterodimer and activate the transcription of core clock genes and clock-controlled genes (involved in key metabolic processes), harboring E-box elements (5'-CACGTG-3') within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which are transcriptional repressors form the negative limb of the feedback loop and interact with the CLOCK|NPAS2-ARNTL/BMAL1|ARNTL2/BMAL2 heterodimer inhibiting its activity and thereby negatively regulating their own expression. This heterodimer also activates nuclear receptors NR1D1/2 and RORA/B/G, which form a second feedback loop and which activate and repress ARNTL/BMAL1 transcription, respectively. Regulates circadian target genes expression at post-transcriptional levels, but may not be required for the repression at transcriptional level. Controls PER2 protein decay. Represses CRY2 preventing its repression on CLOCK/ARNTL target genes such as FXYD5 and SCNN1A in kidney and PPARA in liver. Besides its involvement in the maintenance of the circadian clock, has an important function in the regulation of several processes. Participates in the repression of glucocorticoid receptor NR3C1/GR-induced transcriptional activity by reducing the association of NR3C1/GR to glucocorticoid response elements (GREs) by ARNTL:CLOCK. Plays a role in the modulation of the neuroinflammatory state via the regulation of inflammatory mediators release, such as CCL2 and IL6. In spinal astrocytes, negatively regulates the MAPK14/p38 and MAPK8/JNK MAPK cascades as well as the subsequent activation of NFkappaB. Coordinately regulates the expression of multiple genes that are involved in the regulation of renal sodium reabsorption. Can act as gene expression activator in a gene and tissue specific manner, in kidney enhances WNK1 and SLC12A3 expression in collaboration with CLOCK. Modulates hair follicle cycling. Represses the CLOCK- ARNTL/BMAL1 induced transcription of BHLHE40/DEC1. </p>  <a title=\"J. Invest. Dermatol., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24005054\">J. Invest. Dermatol., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138340, "symbol": "AURKB", "locus": "17p13.1", "entrez_id": 9212, "chr": "chr17", "start": 8108056, "end": 8113918, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "aurora kinase B", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. Required for central/midzone spindle assembly and cleavage furrow formation. Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: phosphorylates CHMP4C, leading to retain abscission- competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis (PubMed:22422861, PubMed:24814515). AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP. Phosphorylation of INCENP leads to increased AURKB activity. Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, GSG2/Haspin, and histone H3. A positive feedback loop involving GSG2 and AURKB contributes to localization of CPC to centromeres. Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis (H3S10ph and H3S28ph, respectively). A positive feedback between GSG2 and AURKB contributes to CPC localization. AURKB is also required for kinetochore localization of BUB1 and SGO1. Phosphorylation of p53/TP53 negatively regulates its transcriptional activity. Key regulator of active promoters in resting B- and T-lymphocytes: acts by mediating phosphorylation of H3S28ph at active promoters in resting B-cells, inhibiting RNF2/RING1B-mediated ubiquitination of histone H2A and enhancing binding and activity of the USP16 deubiquitinase at transcribed genes. </p>  <a title=\"Cell Cycle, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17617734\">Cell Cycle, 2007</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20959462\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"Curr. Biol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21658950\">Curr. Biol., 2011</a>&nbsp;&nbsp;  <a title=\"Science, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22422861\">Science, 2012</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24814515\">Nat. Cell Biol., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138339, "symbol": "MAP2K4", "locus": "17p12", "entrez_id": 6416, "chr": "chr17", "start": 11924141, "end": 12047147, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mitogen-activated protein kinase kinase 4", "description": "<p style=\"text-align: justify\"> Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK activation at least in response to proinflammatory cytokines, while other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate JNKs. MAP2K4 is required for maintaining peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. </p>  <a title=\"Science, 1995\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7716521\">Science, 1995</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138338, "symbol": "FLCN", "locus": "17p11.2", "entrez_id": 201163, "chr": "chr17", "start": 17115526, "end": 17140502, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "folliculin", "description": "<p style=\"text-align: justify\"> May be a tumor suppressor. May be involved in energy and/or nutrient sensing through the AMPK and mTOR signaling pathways. May regulate phosphorylation of RPS6KB1. </p>  <a title=\"Cancer Cell, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12204536\">Cancer Cell, 2003</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17028174\">Proc. Natl. Acad. Sci. U.S.A., 2007</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18663353\">Oncogene, 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138337, "symbol": "NF1", "locus": "17q11.2", "entrez_id": 4763, "chr": "chr17", "start": 29421945, "end": 29709134, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "neurofibromin 1", "description": "<p style=\"text-align: justify\"> Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity. </p>  <a title=\"Cell, 1990\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/2121371\">Cell, 1990</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 1993\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8417346\">Mol. Cell. Biol., 1993</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138336, "symbol": "CDK12", "locus": "17q12", "entrez_id": 51755, "chr": "chr17", "start": 37617764, "end": 37721160, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin dependent kinase 12", "description": "<p style=\"text-align: justify\"> Cyclin-dependent kinase that phosphorylates the C- terminal domain (CTD) of the large subunit of RNA polymerase II (POLR2A), thereby acting as a key regulator of transcription elongation. Regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability. Preferentially phosphorylates 'Ser-5' in CTD repeats that are already phosphorylated at 'Ser-7', but can also phosphorylate 'Ser-2'. Required for RNA splicing, possibly by phosphorylating SRSF1/SF2. Involved in regulation of MAP kinase activity, possibly leading to affect the response to estrogen inhibitors. </p>  <a title=\"J. Cell. Sci., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11683387\">J. Cell. Sci., 2002</a>&nbsp;&nbsp;  <a title=\"Carcinogenesis, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19651820\">Carcinogenesis, 2009</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20952539\">Genes Dev., 2010</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22012619\">Genes Dev., 2011</a>&nbsp;&nbsp;  <a title=\"Nat Commun, 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24662513\">Nat Commun, 2015</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138335, "symbol": "PGAP3", "locus": "17q12", "entrez_id": 93210, "chr": "chr17", "start": 37827375, "end": 37853050, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "post-GPI attachment to proteins 3", "description": "<p style=\"text-align: justify\"> Involved in the lipid remodeling steps of GPI-anchor maturation. Lipid remodeling steps consist in the generation of 2 saturated fatty chains at the sn-2 position of GPI-anchors proteins. Required for phospholipase A2 activity that removes an acyl-chain at the sn-2 position of GPI-anchors during the remodeling of GPI (Probable). </p>  <a title=\"Mol. Biol. Cell, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17021251\">Mol. Biol. Cell, 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138334, "symbol": "ERBB2", "locus": "17q12", "entrez_id": 2064, "chr": "chr17", "start": 37844167, "end": 37886679, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "erb-b2 receptor tyrosine kinase 2", "description": "<p style=\"text-align: justify\"> Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138333, "symbol": "RARA", "locus": "17q21.2", "entrez_id": 5914, "chr": "chr17", "start": 38465444, "end": 38513094, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "retinoic acid receptor alpha", "description": "<p style=\"text-align: justify\"> Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Regulates expression of target genes in a ligand- dependent manner by recruiting chromatin complexes containing KMT2E/MLL5. Mediates retinoic acid-induced granulopoiesis. </p>  <a title=\"Biochem. J., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16417524\">Biochem. J., 2006</a>&nbsp;&nbsp;  <a title=\"Nature, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19377461\">Nature, 2009</a>&nbsp;&nbsp;  <a title=\"Endocrinology, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19850744\">Endocrinology, 2010</a>&nbsp;&nbsp;  <a title=\"Endocrinology, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20215566\">Endocrinology, 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138332, "symbol": "ETV4", "locus": "17q21.31", "entrez_id": 2118, "chr": "chr17", "start": 41605212, "end": 41656988, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ETS variant 4", "description": "<p style=\"text-align: justify\"> Transcriptional activator that binds to the enhancer of the adenovirus E1A gene; the core-binding sequence is 5'[AC]GGA[AT]GT-3'. </p>  <a title=\"Mol. Cell. Biol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19307308\">Mol. Cell. Biol., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138331, "symbol": "ITGB3", "locus": "17q21.32", "entrez_id": 3690, "chr": "chr17", "start": 45331212, "end": 45421658, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "integrin subunit beta 3", "description": "<p style=\"text-align: justify\"> Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha- IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha- IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity). ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415, PubMed:24789099). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887). </p>  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19578119\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20682778\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23125415\">J. Immunol., 2013</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24789099\">PLoS ONE, 2015</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25398877\">J. Biol. Chem., 2015</a>&nbsp;&nbsp;", "gene_type": "STR_VUS"}, {"json_id": 138330, "symbol": "COL1A1", "locus": "17q21.33", "entrez_id": 1277, "chr": "chr17", "start": 48260650, "end": 48278993, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "collagen type I alpha 1 chain", "description": "Type I collagen is a member of group I collagen (fibrillar forming collagen)", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138329, "symbol": "HLF", "locus": "17q22", "entrez_id": 3131, "chr": "chr17", "start": 53342373, "end": 53402426, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "HLF, PAR bZIP transcription factor", "description": "-", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138328, "symbol": "BRIP1", "locus": "17q23.2", "entrez_id": 83990, "chr": "chr17", "start": 59758627, "end": 59940882, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "BRCA1 interacting protein C-terminal helicase 1", "description": "<p style=\"text-align: justify\"> ДНК-зависимая АТФаза и 5'-3'-ДНК-хеликаза, необходимая для поддержания стабильности хромосом. Действует на поздних этапах в молекулярном пути анемии Фанкони, после убиквитинирования FANCD2. При ассоциации с BRCA1 BRIP1 участвует в репарации двунитевых разрывов ДНК путем гомологичной рекомбинации. </p>  <a title=\"Cell, 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11301010\">Cell, 2001</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14983014\">Proc. Natl. Acad. Sci. U.S.A., 2004</a>&nbsp;&nbsp;  <a title=\"Nat. Genet., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16116421\">Nat. Genet., 2005</a>&nbsp;&nbsp;  <a title=\"Cancer Cell, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16153896\">Cancer Cell, 2005</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138327, "symbol": "CD79B", "locus": "17q23.3", "entrez_id": 974, "chr": "chr17", "start": 62006100, "end": 62009714, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "CD79b molecule", "description": "<p style=\"text-align: justify\"> Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. </p>  <a title=\"J. Biol. Chem., 1996\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8617796\">J. Biol. Chem., 1996</a>&nbsp;&nbsp;  <a title=\"Blood, 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9057631\">Blood, 1997</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12097390\">J. Immunol., 2002</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138326, "symbol": "PRKAR1A", "locus": "17q24.2", "entrez_id": 5573, "chr": "chr17", "start": 66507921, "end": 66547460, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "protein kinase cAMP-dependent type I regulatory subunit alpha", "description": "<p style=\"text-align: justify\"> Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. </p>  <a title=\"Oncogene, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16491121\">Oncogene, 2006</a>&nbsp;&nbsp;  <a title=\"Endocrinology, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20215566\">Endocrinology, 2010</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26405036\">J. Biol. Chem., 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138325, "symbol": "SEPT9", "locus": "17q25.3", "entrez_id": 10801, "chr": "chr17", "start": 75276651, "end": 75496678, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "septin 9", "description": "<p style=\"text-align: justify\"> Filament-forming cytoskeletal GTPase (By similarity). May play a role in cytokinesis (Potential). May play a role in the internalization of 2 intracellular microbial pathogens, Listeria monocytogenes and Shigella flexneri. </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138324, "symbol": "BIRC5", "locus": "17q25.3", "entrez_id": 332, "chr": "chr17", "start": 76210267, "end": 76221717, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "baculoviral IAP repeat containing 5", "description": "<p style=\"text-align: justify\"> Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis (PubMed:9859993, PubMed:21364656, PubMed:20627126). Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis (PubMed:16322459). Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules (PubMed:20826784). Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis (PubMed:20929775). The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules (PubMed:18591255). May counteract a default induction of apoptosis in G2/M phase (PubMed:9859993). The acetylated form represses STAT3 transactivation of target gene promoters (PubMed:20826784). May play a role in neoplasia (PubMed:10626797). Inhibitor of CASP3 and CASP7 (PubMed:21536684). Isoform 2 and isoform 3 do not appear to play vital roles in mitosis (PubMed:12773388, PubMed:16291752). Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform (PubMed:10626797). </p>  <a title=\"Mol. Cell. Neurosci., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20627126\">Mol. Cell. Neurosci., 2011</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20826784\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"Science, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20929775\">Science, 2010</a>&nbsp;&nbsp;  <a title=\"Cell Death Dis, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21364656\">Cell Death Dis, 2011</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21536684\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138323, "symbol": "RNF213", "locus": "17q25.3", "entrez_id": 57674, "chr": "chr17", "start": 78234665, "end": 78372586, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ring finger protein 213", "description": "<p style=\"text-align: justify\"> E3 ubiquitin-protein ligase involved in angiogenesis (PubMed:21799892, PubMed:26278786, PubMed:26766444, PubMed:26126547). Involved in the non-canonical Wnt signaling pathway in vascular development: acts by mediating ubiquitination and degradation of FLNA and NFATC2 downstream of RSPO3, leading to inhibit the non-canonical Wnt signaling pathway and promoting vessel regression (PubMed:26766444). Also has ATPase activity (PubMed:24658080, PubMed:26126547). </p>  <a title=\"PLoS ONE, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21799892\">PLoS ONE, 2011</a>&nbsp;&nbsp;  <a title=\"Sci Rep, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24658080\">Sci Rep, 2014</a>&nbsp;&nbsp;  <a title=\"J Am Heart Assoc, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26126547\">J Am Heart Assoc, 2016</a>&nbsp;&nbsp;  <a title=\"Sci Rep, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26278786\">Sci Rep, 2016</a>&nbsp;&nbsp;  <a title=\"Dev. Cell, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26766444\">Dev. Cell, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138322, "symbol": "ZNF521", "locus": "18q11.2", "entrez_id": 25925, "chr": "chr18", "start": 22641890, "end": 22932154, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "zinc finger protein 521", "description": "<p style=\"text-align: justify\"> Transcription factor that can both act as an activator or a repressor depending on the context. Involved in BMP signaling and in the regulation of the immature compartment of the hematopoietic system. Associates with SMADs in response to BMP2 leading to activate transcription of BMP target genes. Acts as a transcriptional repressor via its interaction with EBF1, a transcription factor involved specification of B-cell lineage; this interaction preventing EBF1 to bind DNA and activate target genes. </p>  <a title=\"Blood, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14630787\">Blood, 2004</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138321, "symbol": "CDH2", "locus": "18q12.1", "entrez_id": 1000, "chr": "chr18", "start": 25530930, "end": 25757410, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cadherin 2", "description": "<p style=\"text-align: justify\"> Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. Acts as a regulator of neural stem cells quiescence by mediating anchorage of neural stem cells to ependymocytes in the adult subependymal zone: upon cleavage by MMP24, CDH2-mediated anchorage is affected, leading to modulate neural stem cell quiescence. CDH2 may be involved in neuronal recognition mechanism. In hippocampal neurons, may regulate dendritic spine density (By similarity). </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138320, "symbol": "SMAD2", "locus": "18q21.1", "entrez_id": 4087, "chr": "chr18", "start": 45357922, "end": 45457515, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SMAD family member 2", "description": "<p style=\"text-align: justify\"> Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD2/SMAD4 complex, activates transcription. May act as a tumor suppressor in colorectal carcinoma. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. </p>  <a title=\"Mol. Endocrinol., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9892009\">Mol. Endocrinol., 1999</a>&nbsp;&nbsp;  <a title=\"Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16751101\">Cell, 2006</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16862174\">Oncogene, 2007</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17327236\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;  <a title=\"Dev. Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19289081\">Dev. Cell, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138319, "symbol": "MBD1", "locus": "18q21.1", "entrez_id": 4152, "chr": "chr18", "start": 47793252, "end": 47808144, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "methyl-CpG binding domain protein 1", "description": "<p style=\"text-align: justify\"> Transcriptional repressor that binds CpG islands in promoters where the DNA is methylated at position 5 of cytosine within CpG dinucleotides. Binding is abolished by the presence of 7-mG that is produced by DNA damage by methylmethanesulfonate (MMS). Acts as transcriptional repressor and plays a role in gene silencing by recruiting AFT7IP, which in turn recruits factors such as the histone methyltransferase SETDB1. Probably forms a complex with SETDB1 and ATF7IP that represses transcription and couples DNA methylation and histone 'Lys-9' trimethylation. Isoform 1 and isoform 2 can also repress transcription from unmethylated promoters. </p>  <a title=\"Mol. Cell. Biol., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12697822\">Mol. Cell. Biol., 2003</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12711603\">J. Biol. Chem., 2003</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14555760\">Proc. Natl. Acad. Sci. U.S.A., 2004</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14610093\">J. Biol. Chem., 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15327775\">Mol. Cell, 2004</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138318, "symbol": "SMAD4", "locus": "18q21.2", "entrez_id": 4089, "chr": "chr18", "start": 48494410, "end": 48611415, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SMAD family member 4", "description": "<p style=\"text-align: justify\"> In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions (By similarity). Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for synergistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. </p>  <a title=\"Genes Dev., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9389648\">Genes Dev., 1998</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17327236\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138317, "symbol": "DCC", "locus": "18q21.2", "entrez_id": 1630, "chr": "chr18", "start": 49866542, "end": 51057784, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "DCC netrin 1 receptor", "description": "<p style=\"text-align: justify\"> Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signaling for axon repulsion. It also acts as a dependence receptor required for apoptosis induction when not associated with netrin ligand. Implicated as a tumor suppressor gene. </p>  <a title=\"Cancer Res., 1994\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8187090\">Cancer Res., 1994</a>&nbsp;&nbsp;  <a title=\"Cell, 1996\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8861902\">Cell, 1996</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138316, "symbol": "MALT1", "locus": "18q21.32", "entrez_id": 10892, "chr": "chr18", "start": 56338618, "end": 56417371, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MALT1 paracaspase", "description": "<p style=\"text-align: justify\"> Enhances BCL10-induced activation of NF-kappa-B. Involved in nuclear export of BCL10. Binds to TRAF6, inducing TRAF6 oligomerization and activation of its ligase activity. Has ubiquitin ligase activity. MALT1-dependent BCL10 cleavage plays an important role in T-cell antigen receptor-induced integrin adhesion. </p>  <a title=\"J. Biol. Chem., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11262391\">J. Biol. Chem., 2001</a>&nbsp;&nbsp;  <a title=\"Nature, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14695475\">Nature, 2004</a>&nbsp;&nbsp;  <a title=\"Nat. Immunol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18264101\">Nat. Immunol., 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138315, "symbol": "CDH20", "locus": "18q21.33", "entrez_id": 28316, "chr": "chr18", "start": 59000815, "end": 59223006, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cadherin 20", "description": "Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138314, "symbol": "BCL2", "locus": "18q21.33", "entrez_id": 596, "chr": "chr18", "start": 60790579, "end": 60987361, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "BCL2, apoptosis regulator", "description": "<p style=\"text-align: justify\"> Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785). </p>  <a title=\"Cell, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17418785\">Cell, 2007</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18570871\">Mol. Cell, 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138313, "symbol": "STK11", "locus": "19p13.3", "entrez_id": 6794, "chr": "chr19", "start": 1189406, "end": 1228428, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "serine/threonine kinase 11", "description": "<p style=\"text-align: justify\"> STK11 может выполнять функцию опухолевого супрессора, представляет собой серин/треониновую протеинкиназу, которая контролирует активность представителей семейства AMP-активируемых протеинкиназ (AMPK), тем самым играя роль в различных процессах: метаболизм, поддержание полярности клеток, апоптоз и ответ на повреждение ДНК. Действует путем фосфорилирования Т-петли белков семейства AMPK, способствуя их активации: фосфорилирует PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 и SNRK, но не MELK. Также фосфорилирует белки STRADA, PTEN и участвует в фосфорилировании p53. STK11 действует как ключевой регулятор AMPK-зависимой сигнализации, опосредуя фосфорилирование и активацию каталитических субъединиц AMPK – PRKAA1 и PRKAA2, тем самым регулирует активность сигнальных путей, контролирующих рост и пролиферацию клеток при низком энергетическом статусе, контролирует гомеостаз глюкозы в печени, активацию аутофагии при недостатке питательных веществ и дифференцировку В-клеток в герминальных центрах лимфатических узлов в ответ на повреждение ДНК. Также действует как регулятор клеточной полярности путем ремоделирования актинового цитоскелета. STK11 требуется для поляризации кортикальных нейронов, опосредует фосфорилирование и активацию BRSK1 и BRSK2, что приводит к инициации и формированию аксона. Участвует в реакции на повреждения ДНК: взаимодействует с p53 и связывается в промоторе гена CDKN1A/WAF1, участвуя в активации транскрипции. STK11 может фосфорилировать р53: напрямую или опосредованно через эффекторную киназу NUAK1. Также выступает в качестве медиатора p53-зависимого апоптоза посредством взаимодействия с p53, транслоцируется в митохондрии во время апоптоза. В эндотелиальных клетках вен ингибирует сигнальную активность PI3K/Akt и, таким образом, индуцирует апоптоз в ответ на воздействие оксиданта пероксинитрита in vitro. STK11 по р21-опосредуемому пути регулирует ответ на повреждение ДНК, вызванное УФ-излучением. Совместно с NUAK1 фосфорилирует р21 в ответ на УФ-излучение и способствует его деградации, что необходимо для оптимального восстановления ДНК. </p>  <a title=\"Hum. Mol. Genet., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15987703\">Hum. Mol. Genet., 2005</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17108107\">Cancer Res., 2006</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18321849\">J. Biol. Chem., 2008</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21317932\">Oncogene, 2011</a>&nbsp;&nbsp;  <a title=\"PLoS Genet., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25329316\">PLoS Genet., 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138312, "symbol": "TCF3", "locus": "19p13.3", "entrez_id": 6929, "chr": "chr19", "start": 1609291, "end": 1652604, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "transcription factor 3", "description": "<p style=\"text-align: justify\"> Transcriptional regulator. Involved in the initiation of neuronal differentiation. Heterodimers between TCF3 and tissue- specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E- box motifs: 5'-CANNTG-3'. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region. </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138311, "symbol": "GNA11", "locus": "19p13.3", "entrez_id": 2767, "chr": "chr19", "start": 3094408, "end": 3124002, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "G protein subunit alpha 11", "description": "Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. Acts as an activator of phospholipase C", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138310, "symbol": "FZR1", "locus": "19p13.3", "entrez_id": 51343, "chr": "chr19", "start": 3506271, "end": 3538328, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fizzy and cell division cycle 20 related 1", "description": "<p style=\"text-align: justify\"> Substrate-specific adapter for the anaphase promoting complex/cyclosome (APC/C) E3 ubiquitin-protein ligase complex. Associates with the APC/C in late mitosis, in replacement of CDC20, and activates the APC/C during anaphase and telophase. The APC/C remains active in degrading substrates to ensure that positive regulators of the cell cycle do not accumulate prematurely. At the G1/S transition FZR1 is phosphorylated, leading to its dissociation from the APC/C. Following DNA damage, it is required for the G2 DNA damage checkpoint: its dephosphorylation and reassociation with the APC/C leads to the ubiquitination of PLK1, preventing entry into mitosis. Acts as an adapter for APC/C to target the DNA-end resection factor RBBP8/CtIP for ubiquitination and subsequent proteasomal degradation. Through the regulation of RBBP8/CtIP protein turnover, may play a role in DNA damage response, favoring DNA double-strand repair through error-prone non-homologous end joining (NHEJ) over error-free, RBBP8-mediated homologous recombination (HR) (PubMed:25349192). </p>  <a title=\"Mol. Cell, 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9734353\">Mol. Cell, 1998</a>&nbsp;&nbsp;  <a title=\"Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18662541\">Cell, 2008</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21596315\">Mol. Cell, 2011</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25349192\">EMBO J., 2015</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138309, "symbol": "MAP2K2", "locus": "19p13.3", "entrez_id": 5605, "chr": "chr19", "start": 4090319, "end": 4124126, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mitogen-activated protein kinase kinase 2", "description": "<p style=\"text-align: justify\"> Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138308, "symbol": "KEAP1", "locus": "19p13.2", "entrez_id": 9817, "chr": "chr19", "start": 10596796, "end": 10614417, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "kelch like ECH associated protein 1", "description": "<p style=\"text-align: justify\"> Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. </p>  <a title=\"Mol. Cell. Biol., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14585973\">Mol. Cell. Biol., 2003</a>&nbsp;&nbsp;  <a title=\"Biochemistry, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15379550\">Biochemistry, 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15572695\">Mol. Cell. Biol., 2004</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15983046\">J. Biol. Chem., 2005</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17046835\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138307, "symbol": "SMARCA4", "locus": "19p13.2", "entrez_id": 6597, "chr": "chr19", "start": 11071598, "end": 11176071, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4", "description": "<p style=\"text-align: justify\"> Transcriptional coactivator cooperating with nuclear hormone receptors to potentiate transcriptional activation. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a post-mitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to post-mitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron- specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth. SMARCA4/BAF190A may promote neural stem cell self- renewal/proliferation by enhancing Notch-dependent proliferative signals, while concurrently making the neural stem cell insensitive to SHH-dependent differentiating cues (By similarity). Acts as a corepressor of ZEB1 to regulate E-cadherin transcription and is required for induction of epithelial-mesenchymal transition (EMT) by ZEB1. </p>  <a title=\"Nature, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19571879\">Nature, 2009</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20418909\">Oncogene, 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138306, "symbol": "JAK3", "locus": "19p13.11", "entrez_id": 3718, "chr": "chr19", "start": 17935589, "end": 17958880, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Janus kinase 3", "description": "<p style=\"text-align: justify\"> Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion. </p>  <a title=\"Blood, 1995\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7662955\">Blood, 1995</a>&nbsp;&nbsp;  <a title=\"Nature, 1994\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8022485\">Nature, 1994</a>&nbsp;&nbsp;  <a title=\"Curr. Biol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11909529\">Curr. Biol., 2002</a>&nbsp;&nbsp;  <a title=\"J. Clin. Invest., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20440074\">J. Clin. Invest., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138305, "symbol": "PIK3R2", "locus": "19p13.11", "entrez_id": 5296, "chr": "chr19", "start": 18263928, "end": 18281350, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phosphoinositide-3-kinase regulatory subunit 2", "description": "<p style=\"text-align: justify\"> Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5- trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Binds to activated (phosphorylated) protein-tyrosine kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Indirectly regulates autophagy (PubMed:23604317). Promotes nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin- dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (By similarity). </p>  <a title=\"Nat. Cell Biol., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23604317\">Nat. Cell Biol., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138304, "symbol": "CRTC1", "locus": "19p13.11", "entrez_id": 23373, "chr": "chr19", "start": 18794487, "end": 18893004, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "CREB regulated transcription coactivator 1", "description": "<p style=\"text-align: justify\"> Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates the expression of specific CREB-activated genes such as the steroidogenic gene, StAR. Potent coactivator of PGC1alpha and inducer of mitochondrial biogenesis in muscle cells. Also coactivator for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeats (LTR). In the hippocampus, involved in late-phase long- term potentiation (L-LTP) maintenance at the Schaffer collateral- CA1 synapses. May be required for dendritic growth of developing cortical neurons (By similarity). In concert with SIK1, regulates the light-induced entrainment of the circadian clock. In response to light stimulus, coactivates the CREB-mediated transcription of PER1 which plays an important role in the photic entrainment of the circadian clock. </p>  <a title=\"J. Neurosci., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23699513\">J. Neurosci., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138303, "symbol": "CCNE1", "locus": "19q12", "entrez_id": 898, "chr": "chr19", "start": 30302805, "end": 30315215, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin E1", "description": "<p style=\"text-align: justify\"> Essential for the control of the cell cycle at the G1/S (start) transition. </p>  <a title=\"Mol. Cell. Biol., 1995\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7739542\">Mol. Cell. Biol., 1995</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138302, "symbol": "CEBPA", "locus": "19q13.11", "entrez_id": 1050, "chr": "chr19", "start": 33790840, "end": 33793470, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "CCAAT/enhancer binding protein alpha", "description": "<p style=\"text-align: justify\"> Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Downregulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex (PubMed:14660596). In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity). </p>  <a title=\"Nat. Genet., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11242107\">Nat. Genet., 2001</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14660596\">J. Biol. Chem., 2004</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20075868\">EMBO J., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138301, "symbol": "AKT2", "locus": "19q13.2", "entrez_id": 208, "chr": "chr19", "start": 40736224, "end": 40791443, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "AKT serine/threonine kinase 2", "description": "AKT2 is one of 3 closely related serine/threonine- protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)- response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138300, "symbol": "AXL", "locus": "19q13.2", "entrez_id": 558, "chr": "chr19", "start": 41725108, "end": 41767671, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "AXL receptor tyrosine kinase", "description": "<p style=\"text-align: justify\"> Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, ALX binds and induces tyrosine phosphorylation of PI3- kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. </p>  <a title=\"Circ. Res., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12364394\">Circ. Res., 2002</a>&nbsp;&nbsp;  <a title=\"Thyroid, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12490074\">Thyroid, 2003</a>&nbsp;&nbsp;  <a title=\"Blood, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15507525\">Blood, 2005</a>&nbsp;&nbsp;  <a title=\"J. Thromb. Haemost., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15733062\">J. Thromb. Haemost., 2005</a>&nbsp;&nbsp;  <a title=\"Blood, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18840707\">Blood, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138299, "symbol": "CD79A", "locus": "19q13.2", "entrez_id": 973, "chr": "chr19", "start": 42381190, "end": 42385439, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "CD79a molecule", "description": "<p style=\"text-align: justify\"> Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src- family tyrosine kinases. Represses BCR signaling during development of immature B-cells. </p>  <a title=\"J. Biol. Chem., 1996\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8617796\">J. Biol. Chem., 1996</a>&nbsp;&nbsp;  <a title=\"Blood, 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9057631\">Blood, 1997</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138298, "symbol": "CIC", "locus": "19q13.2", "entrez_id": 23152, "chr": "chr19", "start": 42772689, "end": 42799949, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "capicua transcriptional repressor", "description": "Transcriptional repressor which may play a role in development of the central nervous system (CNS)", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138297, "symbol": "BCL3", "locus": "19q13.32", "entrez_id": 602, "chr": "chr19", "start": 45250962, "end": 45263301, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "B-cell CLL/lymphoma 3", "description": "<p style=\"text-align: justify\"> Contributes to the regulation of transcriptional activation of NF-kappa-B target genes. In the cytoplasm, inhibits the nuclear translocation of the NF-kappa-B p50 subunit. In the nucleus, acts as transcriptional activator that promotes transcription of NF-kappa-B target genes. Contributes to the regulation of cell proliferation (By similarity). </p>  <a title=\"Cell, 1993\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8453667\">Cell, 1993</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138296, "symbol": "MARK4", "locus": "19q13.32", "entrez_id": 57787, "chr": "chr19", "start": 45582546, "end": 45808541, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "microtubule affinity regulating kinase 4", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase (PubMed:15009667, PubMed:14594945, PubMed:23666762, PubMed:23184942). Phosphorylates the microtubule-associated protein MAPT (PubMed:14594945, PubMed:23666762). Also phosphorylates the microtubule-associated proteins MAP2 and MAP4 (PubMed:14594945). Involved in regulation of the microtubule network, causing reorganization of microtubules into bundles (PubMed:14594945, PubMed:25123532). Required for the initiation of axoneme extension during cilium assembly (PubMed:23400999). Regulates the centrosomal location of ODF2 and phosphorylates ODF2 in vitro (PubMed:23400999). Plays a role in cell cycle progression, specifically in the G1/S checkpoint (PubMed:25123532). Reduces neuronal cell survival (PubMed:15009667). Plays a role in energy homeostasis by regulating satiety and metabolic rate (By similarity). Promotes adipogenesis by activating JNK1 and inhibiting the p38MAPK pathway, and triggers apoptosis by activating the JNK1 pathway (By similarity). Phosphorylates mTORC1 complex member RPTOR and acts as a negative regulator of the mTORC1 complex, probably due to disruption of the interaction between phosphorylated RPTOR and the RRAGA/RRAGC heterodimer which is required for mTORC1 activation (PubMed:23184942). </p>  <a title=\"J. Neurochem., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15009667\">J. Neurochem., 2004</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23184942\">J. Biol. Chem., 2013</a>&nbsp;&nbsp;  <a title=\"J. Cell Biol., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23400999\">J. Cell Biol., 2013</a>&nbsp;&nbsp;  <a title=\"Neuromolecular Med., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23666762\">Neuromolecular Med., 2014</a>&nbsp;&nbsp;  <a title=\"Eur. J. Cell Biol., 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25123532\">Eur. J. Cell Biol., 2015</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138295, "symbol": "ERCC2", "locus": "19q13.32", "entrez_id": 2068, "chr": "chr19", "start": 45853095, "end": 45874176, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ERCC excision repair 2, TFIIH core complex helicase subunit", "description": "<p style=\"text-align: justify\"> АТФ-зависимая 5’-3’ ДНК хеликаза, компонент TFIIH базального транскрипционного фактора. Участвует в эксцизионной репарации (NER) ДНК. Также участвует в траскрипции РНК с помощью связывания комплекса, активирующего CDK-киназу, состоящего из CDK7, циклина H, MAT1 и комплекса TFIIH. Вовлечен в регуляцию рецепторной активности витамина D. Как часть комплекса связанного с митотическим веретеном деления, играет роль в сегрегации хромосом. Может влиять на возрастные процессы и стимулировать развитие злокачественных новообразований кожи. </p>  <a title=\"Nature, 1993\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8413672\">Nature, 1993</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10024882\">Mol. Cell, 1999</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15494306\">Mol. Cell, 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20797633\">Mol. Cell, 2010</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138294, "symbol": "ERCC1", "locus": "19q13.32", "entrez_id": 2067, "chr": "chr19", "start": 45910591, "end": 45982086, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ERCC excision repair 1, endonuclease non-catalytic subunit", "description": "Изоформа 1: Некаталитический компонент семейства ДНК-репарирующих эндонуклеаз, надрезающих ДНК с 5'-конца в процессе репарации. Совсместно с белком SLX4 отвечает за первый этап репарации при возникновении внутрицепочечных сшивок. Участвует в обработке анафазных мостообразующих структур ДНК, которые состоят из неполностью устраненных ДНК-повреждений, возникающих во время  S или G2-фазы, и могут приводить к нарушению цитокинеза; также  сочетании с SLX4 участвует в гомологичном восстановлении разрывов двухцепочечных ДНК.", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138293, "symbol": "PPP2R1A", "locus": "19q13.41", "entrez_id": 5518, "chr": "chr19", "start": 52693292, "end": 52730687, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "protein phosphatase 2 scaffold subunit Aalpha", "description": "<p style=\"text-align: justify\"> The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. Upon interaction with GNA12 promotes dephosphorylation of microtubule associated protein TAU/MAPT (PubMed:15525651). Required for proper chromosome segregation and for centromeric localization of SGO1 in mitosis (PubMed:16580887). </p>  <a title=\"J. Biol. Chem., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15525651\">J. Biol. Chem., 2005</a>&nbsp;&nbsp;  <a title=\"Dev. Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16580887\">Dev. Cell, 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138292, "symbol": "AURKC", "locus": "19q13.43", "entrez_id": 6795, "chr": "chr19", "start": 57742377, "end": 57746916, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "aurora kinase C", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Plays also a role in meiosis and more particularly in spermatogenesis. Has redundant cellular functions with AURKB and can rescue an AURKB knockdown. Like AURKB, AURKC phosphorylates histone H3 at 'Ser-10' and 'Ser-28'. AURKC phosphorylates the CPC complex subunits BIRC5/survivin and INCENP leading to increased AURKC activity. Phosphorylates TACC1, another protein involved in cell division, at 'Ser-228'. </p>  <a title=\"Biochem. Biophys. Res. Commun., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15670791\">Biochem. Biophys. Res. Commun., 2005</a>&nbsp;&nbsp;  <a title=\"Genes Cells, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15938719\">Genes Cells, 2005</a>&nbsp;&nbsp;  <a title=\"Hum. Reprod., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21493633\">Hum. Reprod., 2011</a>&nbsp;&nbsp;  <a title=\"Biochem. Biophys. Res. Commun., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21531210\">Biochem. Biophys. Res. Commun., 2011</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27332895\">PLoS ONE, 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138291, "symbol": "SOX11", "locus": "2p25.2", "entrez_id": 6664, "chr": "chr2", "start": 5832799, "end": 5841516, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SRY-box 11", "description": "<p style=\"text-align: justify\"> Transcriptional factor involved in the embryonic neurogenesis. May also have a role in tissue modeling during development. </p>  <a title=\"Nat Commun, 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24886874\">Nat Commun, 2015</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138290, "symbol": "MYCN", "locus": "2p24.3", "entrez_id": 4613, "chr": "chr2", "start": 16080686, "end": 16087129, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MYCN proto-oncogene, bHLH transcription factor", "description": "<p style=\"text-align: justify\"> Positively regulates the transcription of NCYM in neuroblastoma cells (PubMed:24391509). </p>  <a title=\"PLoS Genet., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24391509\">PLoS Genet., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138289, "symbol": "NCOA1", "locus": "2p23.3", "entrez_id": 8648, "chr": "chr2", "start": 24714783, "end": 24993571, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nuclear receptor coactivator 1", "description": "<p style=\"text-align: justify\"> Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs). Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription factors. Displays histone acetyltransferase activity toward H3 and H4; the relevance of such activity remains however unclear. Plays a central role in creating multisubunit coactivator complexes that act via remodeling of chromatin, and possibly acts by participating in both chromatin remodeling and recruitment of general transcription factors. Required with NCOA2 to control energy balance between white and brown adipose tissues. Required for mediating steroid hormone response. Isoform 2 has a higher thyroid hormone-dependent transactivation activity than isoform 1 and isoform 3. </p>  <a title=\"Biochem. Biophys. Res. Commun., 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9223431\">Biochem. Biophys. Res. Commun., 1997</a>&nbsp;&nbsp;  <a title=\"Nature, 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9296499\">Nature, 1997</a>&nbsp;&nbsp;  <a title=\"EMBO J., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9427757\">EMBO J., 1998</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10449719\">Proc. Natl. Acad. Sci. U.S.A., 1999</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12954634\">J. Biol. Chem., 2003</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138288, "symbol": "DNMT3A", "locus": "2p23.3", "entrez_id": 1788, "chr": "chr2", "start": 25455845, "end": 25565459, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "DNA methyltransferase 3 alpha", "description": "<p style=\"text-align: justify\"> Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development. DNA methylation is coordinated with methylation of histones. It modifies DNA in a non-processive manner and also methylates non-CpG sites. May preferentially methylate DNA linker between 2 nucleosomal cores and is inhibited by histone H1. Plays a role in paternal and maternal imprinting. Required for methylation of most imprinted loci in germ cells. Acts as a transcriptional corepressor for ZBTB18. Recruited to trimethylated 'Lys-36' of histone H3 (H3K36me3) sites. Can actively repress transcription through the recruitment of HDAC activity. </p>  <a title=\"Nature, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16357870\">Nature, 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138287, "symbol": "ALK", "locus": "2p23.2-p23.1", "entrez_id": 238, "chr": "chr2", "start": 29415640, "end": 30144432, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ALK receptor tyrosine kinase", "description": "<p style=\"text-align: justify\"> Нейрональный рецептор тирозинкиназ играет важнейшую роль в дифференцировке специфических отделах центральной и периферической нервной системы. Трансдуцирует сигналы от лигандов с наружной клеточной мембраны через активацию MAPK сигнального пути. фосфорилирует специфический тирозиновый мотив Y- x-x-x-Y- белковCBL, FRS2, IRS1 и SHC1. а также MAPK1/ERK2 и MAPK3/ERK1. Действует как рецептор для лигандов плейотрофина (PTN) и мидкина (MDK), фактора, связанного с PTN, таким образом участвуя в передаче сигнала от PTN и MDK. Связывание PTN индуцирует активацию MAPK сигнального пути, что важно для антиапоптотической сигнализации PTN и регуляции клеточной пролиферации. Связывание MDK индуцирует фосфорилирование субстрата-рецептора ALK-мишеней (IRS1), а также активирует митоген-активированные протеинкиназы (MAPKs) и PI3-киназу, что приводит к стимулированию клеточной пролиферации. Предположительно активирует NF-kappa-B через IRS1 и AKT1. Активация IRS1 и NF-каппа-B необходимы для аутокринной MDK-опосредованной активации пролиферации и выживаемости клеток. </p>  <a title=\"J. Cell. Sci., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15226403\">J. Cell. Sci., 2005</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15908427\">J. Biol. Chem., 2005</a>&nbsp;&nbsp;  <a title=\"J. Cell. Sci., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16317043\">J. Cell. Sci., 2007</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16878150\">Oncogene, 2007</a>&nbsp;&nbsp;  <a title=\"FEBS Lett., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17274988\">FEBS Lett., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138286, "symbol": "EML4", "locus": "2p21", "entrez_id": 27436, "chr": "chr2", "start": 42396490, "end": 42559688, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "echinoderm microtubule associated protein like 4", "description": "<p style=\"text-align: justify\"> May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic. </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138285, "symbol": "MSH2", "locus": "2p21-p16.3", "entrez_id": 4436, "chr": "chr2", "start": 47630108, "end": 47789450, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mutS homolog 2", "description": "<p style=\"text-align: justify\"> Компонент пострепликативной системы репарации неспаренных оснований ДНК (mismatch repair system, MMR). Образует два разных гетеродимера: MutSα (гетеродимер MSH2-MSH6) и MutSβ (гетеродимер MSH2-MSH3), которые связываются с неспаренными основаниями ДНК, тем самым инициируя ее восстановление. При связывании гетеродимеры изгибают спираль ДНК и занимают приблизительно 20 пар оснований. MutSα распознает несоответствия отдельных оснований и петли вставки-делеции динуклеотидов (IDL) в ДНК. MutSβ узнает более крупные петли вставки-делеции длиной до 13 нуклеотидов. После связывания некомплиментарных матричной цепи участков комплексы MutSα или MutSβ образуют тройной комплекс с гетеродимером MutLα, который, как полагают, контролирует последующие процессы репарации (MMR), включая распознавание цепей, эксцизию и ресинтез. Связывание АТФ и гидролиз играют ключевую роль при функционировании белка в системе MMR. АТФазная активность MutSα определяет связывание с ДНК: сайты с неспаренными основаниями способствуют замене АДФ на АТФ в активном центре фермента, что приводит к конформационному переходу, который позволяет MutSα функционировать в качестве скользящего зажима, способного к перемещению по основной цепи ДНК независимо от гидролиза АТФ. Этот переход имеет решающее значение для устранения ошибок репликации по механизму MMR. MutSα также может играть роль в процессах гомологичной рекомбинации ДНК. В меланоцитах MSH2 может участвовать УФ-В-зависимой регуляции клеточного цикла и апоптоза. </p>  <a title=\"Mol. Cell, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10078208\">Mol. Cell, 1999</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10660545\">J. Biol. Chem., 2000</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15064730\">Oncogene, 2004</a>&nbsp;&nbsp;  <a title=\"J. Invest. Dermatol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17611581\">J. Invest. Dermatol., 2008</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21120944\">Hum. Mutat., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138284, "symbol": "MSH6", "locus": "2p16.3", "entrez_id": 2956, "chr": "chr2", "start": 47922669, "end": 48037240, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mutS homolog 6", "description": "<p style=\"text-align: justify\"> Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches thereby initiating DNA repair. When bound, MutS alpha bends the DNA helix and shields approximately 20 base pairs, and recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. Recruited on chromatin in G1 and early S phase via its PWWP domain that specifically binds trimethylated 'Lys-36' of histone H3 (H3K36me3): early recruitment to chromatin to be replicated allowing a quick identification of mismatch repair to initiate the DNA mismatch repair reaction. </p>  <a title=\"Mol. Cell, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10078208\">Mol. Cell, 1999</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10660545\">J. Biol. Chem., 2000</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15064730\">Oncogene, 2004</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21120944\">Hum. Mutat., 2011</a>&nbsp;&nbsp;  <a title=\"Cell, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23622243\">Cell, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138283, "symbol": "BCL11A", "locus": "2p16.1", "entrez_id": 53335, "chr": "chr2", "start": 60678302, "end": 60780702, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "B-cell CLL/lymphoma 11A", "description": "<p style=\"text-align: justify\"> Transcription factor associated with the BAF SWI/SNF chromatin remodeling complex (By similarity). Repressor of fetal hemoglobin (HbF) level (PubMed:26375765). Involved in brain development (PubMed:27453576). Functions as a myeloid and B-cell proto-oncogene. May play important roles in leukemogenesis and hematopoiesis. Essential factor in lymphopoiesis required for B- cell formation in fetal liver. May function as a modulator of the transcriptional repression activity of ARP1 (By similarity). </p>  <a title=\"Curr. Opin. Genet. Dev., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26375765\">Curr. Opin. Genet. Dev., 2016</a>&nbsp;&nbsp;  <a title=\"Am. J. Hum. Genet., 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27453576\">Am. J. Hum. Genet., 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138282, "symbol": "REL", "locus": "2p16.1", "entrez_id": 5966, "chr": "chr2", "start": 61108656, "end": 61158745, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "REL proto-oncogene, NF-kB subunit", "description": "Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF- kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138281, "symbol": "XPO1", "locus": "2p15", "entrez_id": 7514, "chr": "chr2", "start": 61704984, "end": 61765761, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "exportin 1", "description": "<p style=\"text-align: justify\"> Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs. In the nucleus, in association with RANBP3, binds cooperatively to the NES on its target protein and to the GTPase RAN in its active GTP-bound form (Ran-GTP). Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the cargo from the export receptor. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. Involved in U3 snoRNA transport from Cajal bodies to nucleoli. Binds to late precursor U3 snoRNA bearing a TMG cap. Several viruses, among them HIV-1, HTLV-1 and influenza A use it to export their unspliced or incompletely spliced RNAs out of the nucleus. Interacts with, and mediates the nuclear export of HIV-1 Rev and HTLV-1 Rex proteins. Involved in HTLV-1 Rex multimerization. </p>  <a title=\"Cell, 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9323133\">Cell, 1997</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9837918\">J. Biol. Chem., 1999</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14612415\">Mol. Cell. Biol., 2003</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15574332\">Mol. Cell, 2005</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20921223\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138280, "symbol": "TCF7L1", "locus": "2p11.2", "entrez_id": 83439, "chr": "chr2", "start": 85360533, "end": 85537511, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "transcription factor 7 like 1", "description": "<p style=\"text-align: justify\"> Participates in the Wnt signaling pathway. Binds to DNA and acts as a repressor in the absence of CTNNB1, and as an activator in its presence. Necessary for the terminal differentiation of epidermal cells, the formation of keratohyalin granules and the development of the barrier function of the epidermis (By similarity). Down-regulates NQO1, leading to increased mitomycin c resistance. </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138279, "symbol": "AFF3", "locus": "2q11.2", "entrez_id": 3899, "chr": "chr2", "start": 100162323, "end": 100759201, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "AF4/FMR2 family member 3", "description": "Putative transcription activator that may function in lymphoid development and oncogenesis. Binds, in vitro, to double- stranded DNA", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138278, "symbol": "PAX8", "locus": "2q14.1", "entrez_id": 7849, "chr": "chr2", "start": 113973574, "end": 114036527, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "paired box 8", "description": "Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells", "gene_type": "STR_VUS"}, {"json_id": 138277, "symbol": "ERCC3", "locus": "2q14.3", "entrez_id": 2071, "chr": "chr2", "start": 128014866, "end": 128051752, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ERCC excision repair 3, TFIIH core complex helicase subunit", "description": "<p style=\"text-align: justify\"> ATP-dependent 3'-5' DNA helicase, component of the core- TFIIH basal transcription factor, involved in nucleotide excision repair (NER) of DNA and, when complexed to CAK, in RNA transcription by RNA polymerase II. Acts by opening DNA either around the RNA transcription start site or the DNA damage. </p>  <a title=\"EMBO J., 1994\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8157004\">EMBO J., 1994</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10024882\">Mol. Cell, 1999</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138276, "symbol": "LRP1B", "locus": "2q22.1-q22.2", "entrez_id": 53353, "chr": "chr2", "start": 140988992, "end": 142889270, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "LDL receptor related protein 1B", "description": "Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138275, "symbol": "ACVR2A", "locus": "2q22.3-q23.1", "entrez_id": 92, "chr": "chr2", "start": 148602086, "end": 148688393, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "activin A receptor type 2A", "description": "<p style=\"text-align: justify\"> On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A. Mediates induction of adipogenesis by GDF6 (By similarity). </p>  <a title=\"Biochem. Biophys. Res. Commun., 1992\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/1314589\">Biochem. Biophys. Res. Commun., 1992</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138274, "symbol": "NFE2L2", "locus": "2q31.2", "entrez_id": 4780, "chr": "chr2", "start": 178092323, "end": 178257425, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nuclear factor, erythroid 2 like 2", "description": "<p style=\"text-align: justify\"> Transcription activator that binds to antioxidant response (ARE) elements in the promoter regions of target genes. Important for the coordinated up-regulation of genes in response to oxidative stress. May be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11035812\">Proc. Natl. Acad. Sci. U.S.A., 2001</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138273, "symbol": "PMS1", "locus": "2q32.2", "entrez_id": 5378, "chr": "chr2", "start": 190649107, "end": 190742355, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "PMS1 homolog 1, mismatch repair system component", "description": "<p style=\"text-align: justify\"> Probably involved in the repair of mismatches in DNA. </p>  <a title=\"J. Biol. Chem., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10748105\">J. Biol. Chem., 2000</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138272, "symbol": "SF3B1", "locus": "2q33.1", "entrez_id": 23451, "chr": "chr2", "start": 198254508, "end": 198299815, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "splicing factor 3b subunit 1", "description": "Subunit of the splicing factor SF3B required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA. Sequence independent binding of SF3A/SF3B complex upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA. May also be involved in the assembly of the 'E' complex. Belongs also to the minor U12-dependent spliceosome, which is involved in the splicing of rare class of nuclear pre-mRNA intron", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138271, "symbol": "CREB1", "locus": "2q33.3", "entrez_id": 1385, "chr": "chr2", "start": 208394461, "end": 208468155, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cAMP responsive element binding protein 1", "description": "Phosphorylation-dependent transcription factor that stimulates transcription upon binding to the DNA cAMP response element (CRE), a sequence present in many viral and cellular promoters. Transcription activation is enhanced by the TORC coactivators which act independently of Ser-133 phosphorylation. Involved in different cellular processes including the synchronization of circadian rhythmicity and the differentiation of adipose cells", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138270, "symbol": "IDH1", "locus": "2q34", "entrez_id": 3417, "chr": "chr2", "start": 209100951, "end": 209130798, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "isocitrate dehydrogenase (NADP(+)) 1, cytosolic", "description": "Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types.", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138269, "symbol": "ERBB4", "locus": "2q34", "entrez_id": 2066, "chr": "chr2", "start": 212240446, "end": 213403565, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "erb-b2 receptor tyrosine kinase 4", "description": "<p style=\"text-align: justify\"> Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis. </p>  <a title=\"Mol. Biol. Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16837552\">Mol. Biol. Cell, 2006</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17486069\">Oncogene, 2007</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17638867\">Cancer Res., 2007</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19098003\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"Mol. Cancer Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20858735\">Mol. Cancer Res., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138268, "symbol": "FN1", "locus": "2q35", "entrez_id": 2335, "chr": "chr2", "start": 216225163, "end": 216300895, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fibronectin 1", "description": "Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization. Participates in the regulation of type I collagen deposition by osteoblasts", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138267, "symbol": "STK36", "locus": "2q35", "entrez_id": 27148, "chr": "chr2", "start": 219536749, "end": 219567439, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "serine/threonine kinase 36", "description": "<p style=\"text-align: justify\"> Serine/threonine protein kinase which plays an important role in the sonic hedgehog (Shh) pathway by regulating the activity of GLI transcription factors (PubMed:10806483). Controls the activity of the transcriptional regulators GLI1, GLI2 and GLI3 by opposing the effect of SUFU and promoting their nuclear localization (PubMed:10806483). GLI2 requires an additional function of STK36 to become transcriptionally active, but the enzyme does not need to possess an active kinase catalytic site for this to occur (PubMed:10806483). Required for postnatal development, possibly by regulating the homeostasis of cerebral spinal fluid or ciliary function (By similarity). Essential for construction of the central pair apparatus of motile cilia. </p>  <a title=\"Nat. Cell Biol., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10806483\">Nat. Cell Biol., 2000</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138266, "symbol": "PAX3", "locus": "2q36.1", "entrez_id": 5077, "chr": "chr2", "start": 223064607, "end": 223163715, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "paired box 3", "description": "<p style=\"text-align: justify\"> Transcription factor that may regulate cell proliferation, migration and apoptosis. Involved in neural development and myogenesis. </p>  <a title=\"Cancer Res., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16951170\">Cancer Res., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138265, "symbol": "UGT1A1", "locus": "2q37.1", "entrez_id": 54658, "chr": "chr2", "start": 234668894, "end": 234681945, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "UDP glucuronosyltransferase family 1 member A1", "description": "<p style=\"text-align: justify\"> UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX- alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4- methylumbelliferone, 1-naphthol, paranitrophenol, scopoletin, and umbelliferone. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1. </p>  <a title=\"Pharmacogenet. Genomics, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18004206\">Pharmacogenet. Genomics, 2008</a>&nbsp;&nbsp;  <a title=\"Mol. Pharm., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19545173\">Mol. Pharm., 2009</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19830808\">Hum. Mutat., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138264, "symbol": "BCL2L1", "locus": "20q11.21", "entrez_id": 598, "chr": "chr20", "start": 30252255, "end": 30311792, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "BCL2 like 1", "description": "Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage- dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis FUNCTION: Isoform Bcl-X(S) promotes apoptosis.;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138263, "symbol": "ASXL1", "locus": "20q11.21", "entrez_id": 171023, "chr": "chr20", "start": 30946155, "end": 31027122, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "additional sex combs like 1, transcriptional regulator", "description": "<p style=\"text-align: justify\"> Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG). Acts as coactivator of RARA and RXRA through association with NCOA1. Acts as corepressor through recruitment of KDM1A and CBX5 to target genes in a cell-type specific manner; the function seems to involve differential recruitment of methylated histone H3 to respective promoters. Acts as corepressor for PPARG and suppresses its adipocyte differentiation-inducing activity (By similarity). Non-catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1). </p>  <a title=\"J. Biol. Chem., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16606617\">J. Biol. Chem., 2006</a>&nbsp;&nbsp;  <a title=\"Nature, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20436459\">Nature, 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138262, "symbol": "SRC", "locus": "20q11.23", "entrez_id": 6714, "chr": "chr20", "start": 35973088, "end": 36034453, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SRC proto-oncogene, non-receptor tyrosine kinase", "description": "<p style=\"text-align: justify\"> Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein- coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin- 43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1. Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors. Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated calcium-activated chloride channel activation. Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr- 1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of GRK2, leading to beta- arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor. Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus. Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances DDX58/RIG-I-elicited antiviral signaling. Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr- 128'. Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3 activity. Required for podosome formation (By similarity). </p>  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20100835\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20525694\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"Biochem. J., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21309750\">Biochem. J., 2011</a>&nbsp;&nbsp;  <a title=\"Mol. Biol. Cell, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21411625\">Mol. Biol. Cell, 2011</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22710723\">Oncogene, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138261, "symbol": "MAFB", "locus": "20q12", "entrez_id": 9935, "chr": "chr20", "start": 39314488, "end": 39317880, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MAF bZIP transcription factor B", "description": "<p style=\"text-align: justify\"> Acts as a transcriptional activator or repressor (PubMed:27181683). Plays a pivotal role in regulating lineage- specific hematopoiesis by repressing ETS1-mediated transcription of erythroid-specific genes in myeloid cells. Required for monocytic, macrophage, osteoclast, podocyte and islet beta cell differentiation. Involved in renal tubule survival and F4/80 maturation. Activates the insulin and glucagon promoters. Together with PAX6, transactivates weakly the glucagon gene promoter through the G1 element. SUMO modification controls its transcriptional activity and ability to specify macrophage fate. Binds element G1 on the glucagon promoter (By similarity). Involved either as an oncogene or as a tumor suppressor, depending on the cell context. </p>  <a title=\"Nat. Rev. Cancer, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19143053\">Nat. Rev. Cancer, 2009</a>&nbsp;&nbsp;  <a title=\"Am. J. Hum. Genet., 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27181683\">Am. J. Hum. Genet., 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138260, "symbol": "TOP1", "locus": "20q12", "entrez_id": 7150, "chr": "chr20", "start": 39657458, "end": 39753127, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "topoisomerase (DNA) I", "description": "<p style=\"text-align: justify\"> Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component ARNTL/BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the ARNTL/BMAL1 promoter. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 1988\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/2833744\">Proc. Natl. Acad. Sci. U.S.A., 1988</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14594810\">J. Biol. Chem., 2004</a>&nbsp;&nbsp;  <a title=\"J. Med. Chem., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16033260\">J. Med. Chem., 2005</a>&nbsp;&nbsp;  <a title=\"Circ. Res., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19168442\">Circ. Res., 2009</a>&nbsp;&nbsp;  <a title=\"Nucleic Acids Res., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22904072\">Nucleic Acids Res., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138259, "symbol": "PLCG1", "locus": "20q12", "entrez_id": 5335, "chr": "chr20", "start": 39765600, "end": 39811629, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phospholipase C gamma 1", "description": "<p style=\"text-align: justify\"> Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an important role in the regulation of intracellular signaling cascades. Becomes activated in response to ligand- mediated activation of receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, FGFR1, FGFR2, FGFR3 and FGFR4. Plays a role in actin reorganization and cell migration. </p>  <a title=\"Am. J. Physiol., Cell Physiol., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17229814\">Am. J. Physiol., Cell Physiol., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138258, "symbol": "PTPRT", "locus": "20q12-q13.11", "entrez_id": 11122, "chr": "chr20", "start": 40701392, "end": 41818610, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "protein tyrosine phosphatase, receptor type T", "description": "May be involved in both signal transduction and cellular adhesion in the CNS", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138257, "symbol": "AURKA", "locus": "20q13.2", "entrez_id": 6790, "chr": "chr20", "start": 54944445, "end": 54967393, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "aurora kinase A", "description": "<p style=\"text-align: justify\"> Аurora kinase A - протеинкиназа серин/треониновой специфичности, регулятор митотических процессов. Активность киназы важна для формирования микротрубочек и/или их стабилизации. Контролирует функционирование центросом и микротрубочек веретена деления во время митоза и играет критическую роль в различных митотических событиях, включая организацию веретена деления, дупликацию центросомы, расхождение центросом, а также участвует в выравнивании хромосом, необходима для прохождения контрольной точки сборки веретена и цитокинеза. Требуется для начальной активации CDK1 в центросомах. Фосфорилирует ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53 и TPX2. Регулирует тубулин-деполимеризующую активность KIF2A. Требуется для нормального образования аксонов. Играет роль в ремоделировании микротрубочек при формировании нейритов. Также выступает в качестве ключевого регулятора  p53-контролируемых сигнальных путей, и в частности - путей контрольных точек клеточного цикла, критических для онкогенной трансформации клеток, путем фосфорилирования и стабилизации p53. Фосфорилирует свои собственные ингибиторы, изоформы протеинфосфатазы типа 1 (PP1), блокируя их активность. Необходима для правильной разборки ресничек перед митозом. </p>  <a title=\"J. Cell. Sci., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19351716\">J. Cell. Sci., 2009</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19357306\">Proc. Natl. Acad. Sci. U.S.A., 2009</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19668197\">Nat. Cell Biol., 2009</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19812038\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"Dev. Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20643351\">Dev. Cell, 2010</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138256, "symbol": "GNAS", "locus": "20q13.32", "entrez_id": 2778, "chr": "chr20", "start": 57414773, "end": 57486247, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "GNAS complex locus", "description": "Guanine nucleotide-binding proteins (G proteins) function as transducers in numerous signaling pathways controlled by G protein-coupled receptors (GPCRs) (PMID:17110384). Signaling involves the activation of adenylyl cyclases, resulting in increased levels of the signaling molecule cAMP (PMID:26206488, PMID:8702665). GNAS functions downstream of several GPCRs, including beta-adrenergic receptors (PMID:21488135). Stimulates the Ras signaling pathway via RAPGEF2 (PMID:12391161).", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138255, "symbol": "RUNX1", "locus": "21q22.12", "entrez_id": 861, "chr": "chr21", "start": 36160098, "end": 37376965, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "runt related transcription factor 1", "description": "<p style=\"text-align: justify\"> CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B- dependent transcriptional activation. Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down- regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells (PubMed:17377532). </p>  <a title=\"Mol. Cell. Biol., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10207087\">Mol. Cell. Biol., 1999</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11965546\">Oncogene, 2002</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14970218\">J. Biol. Chem., 2004</a>&nbsp;&nbsp;  <a title=\"Nature, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17377532\">Nature, 2007</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17431401\">EMBO J., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138254, "symbol": "ERG", "locus": "21q22.2", "entrez_id": 2078, "chr": "chr21", "start": 39751949, "end": 40033704, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ERG, ETS transcription factor", "description": "Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138253, "symbol": "ITGB2", "locus": "21q22.3", "entrez_id": 3689, "chr": "chr21", "start": 46305868, "end": 46351904, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "integrin subunit beta 2", "description": "<p style=\"text-align: justify\"> Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrins alpha-M/beta-2 and alpha-X/beta-2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin alpha-X/beta-2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin alpha-M/beta-2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin alpha-M/beta-2 is also a receptor for factor X. Integrin alpha- D/beta-2 is a receptor for ICAM3 and VCAM1. Contributes to natural killer cell cytotoxicity (PubMed:15356110). Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils (PubMed:11812992). Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation (PubMed:18587400). Integrin alpha-L/beta-2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:23775590). </p>  <a title=\"Nat. Immunol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11812992\">Nat. Immunol., 2002</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15356110\">J. Immunol., 2004</a>&nbsp;&nbsp;  <a title=\"Nat. Immunol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18587400\">Nat. Immunol., 2008</a>&nbsp;&nbsp;  <a title=\"Apoptosis, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23775590\">Apoptosis, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138252, "symbol": "CRKL", "locus": "22q11.21", "entrez_id": 1399, "chr": "chr22", "start": 21271714, "end": 21308037, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "CRK like proto-oncogene, adaptor protein", "description": "May mediate the transduction of intracellular signals", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138251, "symbol": "MAPK1", "locus": "22q11.22", "entrez_id": 5594, "chr": "chr22", "start": 22108789, "end": 22221970, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mitogen-activated protein kinase 1", "description": "<p style=\"text-align: justify\"> Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Mediates phosphorylation of TPR in respons to EGF stimulation. May play a role in the spindle assembly checkpoint. Phosphorylates PML and promotes its interaction with PIN1, leading to PML degradation. Phosphorylates CDK2AP2 (By similarity). </p>  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19265199\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"Biofactors, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19565474\">Biofactors, 2010</a>&nbsp;&nbsp;  <a title=\"Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19879846\">Cell, 2009</a>&nbsp;&nbsp;  <a title=\"Genes Cancer, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21779493\">Genes Cancer, 2011</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22033920\">J. Biol. Chem., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138250, "symbol": "BCR", "locus": "22q11.23", "entrez_id": 613, "chr": "chr22", "start": 23521891, "end": 23660224, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "BCR, RhoGEF and GTPase activating protein", "description": "<p style=\"text-align: justify\"> GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity. </p>  <a title=\"Cell, 1991\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/1657398\">Cell, 1991</a>&nbsp;&nbsp;  <a title=\"Nature, 1991\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/1903516\">Nature, 1991</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138249, "symbol": "SMARCB1", "locus": "22q11.23", "entrez_id": 6598, "chr": "chr22", "start": 24129150, "end": 24176703, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1", "description": "<p style=\"text-align: justify\"> hSNF5, кодируемый геном SMARCB1, является основным компонентом комплекса BAF (hSWI/SNF). hSWI/SNF - АТФ-зависимый ремоделирующий хроматин комплекс, который играет важную роль в пролиферации и дифференцировке клеток, в клеточной антивирусной активности и ингибировании онкогенеза. Комплекс BAF способен создавать стабильную, измененную форму хроматина, которая содержит меньше отрицательных супервитков, чем обычно. Это изменение в суперскручивании обеспечивается ремоделированием вплоть до половины нуклеосом в асимметричные структуры, называемые альтосомами, каждая из которых состоит из двух октамеров гистонов. hSNF5 стимулирует ремоделирующую активность SMARCA4/BRG1/BAF190A in vitro. hSNF5 участвует в активации промотора CSF1. hSNF5 принадлежит к специфическому для предшественников нейронов комплексу ремоделирования хроматина (npBAF) и нейрон-специфическому комплексу ремоделирования хроматина (nBAF). Белковые субъединицы npBAF и nBAF участвуют в процессе перехода пролиферирующих нейронных стволовых клеток/клеток-предшественников к постмитотическим нейронам. Когда нейронные предшественники выходят из митоза и дифференцируются в нейроны, комплексы npBAF, которые содержат ACTL6A/BAF53A и PHF10/BAF45A, заменяются на гомологичные альтернативные субъединицы ACTL6B/BAF53B и DPF1/BAF45B или DPF3/BAF45C в нейрон-специфических комплексах nBAF. Комплекс npBAF необходим для поддержания способности к пролиферации и самообновления мультипотентных нейронных стволовых клеток. Комплекс nBAF также играет роль в регуляции активности генов, необходимых для роста дендритов. hSNF5 участвует в контроле клеточного цикла, вызывая его остановку в G0/G1. </p>  <a title=\"Mol. Cell, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10078207\">Mol. Cell, 1999</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12226744\">Oncogene, 2002</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14604992\">J. Biol. Chem., 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cells, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16267391\">Mol. Cells, 2006</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16314535\">Mol. Cell. Biol., 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138248, "symbol": "MN1", "locus": "22q12.1", "entrez_id": 4330, "chr": "chr22", "start": 28144265, "end": 28197486, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MN1 proto-oncogene, transcriptional regulator", "description": "<p style=\"text-align: justify\"> Transcriptional activator which specifically regulates expression of TBX22 in the posterior region of the developing palate. Required during later stages of palate development for growth and medial fusion of the palatal shelves. Promotes maturation and normal function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11/RANKL. Necessary for normal development of the membranous bones of the skull (By similarity). May play a role in tumor suppression (Probable). </p>  <a title=\"Oncogene, 1995\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7731706\">Oncogene, 1995</a>&nbsp;&nbsp;", "gene_type": "STR_VUS"}, {"json_id": 138247, "symbol": "CHEK2", "locus": "22q12.1", "entrez_id": 11200, "chr": "chr22", "start": 29083731, "end": 29138410, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "checkpoint kinase 2", "description": "<p style=\"text-align: justify\"> Серин/треонин-протеинкиназа, которая необходима для регуляции клеточного цикла, активации репарации ДНК и апоптоза в ответ на наличие разрывов двух нитей ДНК. После активации фосфорилирует многочисленные эффекторы преимущественно на консенсусной последовательности [L-X-R-X-X-S / T]. Регулирует остановку клеточного цикла в контрольной точкие клеточного цикла посредством фосфорилирования CDC25A, CDC25B и CDC25C, что приводит к ингибированию их активности. Ингибирование активности фосфатазы CDC25 приводит к увеличению ингибирующего фосфорилирования тирозина комплексов CDK-циклина, что блокирует прогрессирование клеточного цикла. Может также фосфорилировать NEK6, который участвует в остановке клеточного цикла в фазе G2 / M. Регулирует репарацию ДНК посредством фосфорилирования BRCA2, усиливая ассоциацию RAD51 с хроматином, который способствует репарации ДНК путем гомологичной рекомбинации. Также стимулирует транскрипцию генов, участвующих в репарации ДНК (включая BRCA2), путем фосфорилирования и активации транскрипционного фактора FOXM1. Регулирует апоптоз через фосфорилирование p53 / TP53, MDM4 и PML. Фосфорилирование p53 / TP53 в позиции  Ser-20 способствует ингибирование MDM2, что приводит к накоплению активного p53 / TP53. Фосфорилирование MDM4 также может снизить деградацию p53 / TP53. Также CHEK2 контролирует транскрипцию проапоптотических генов путем фосфорилирования транскрипционного фактора E2F1. Его отсутствие может быть причиной хромосомной неустойчивости, наблюдаемой в некоторых раковых клетках. Способствует ассоциации CCAR2-SIRT1 и требуется для CCAR2-опосредованного ингибирования SIRT1. </p>  <a title=\"Mol. Cell. Biol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18644861\">Mol. Cell. Biol., 2008</a>&nbsp;&nbsp;  <a title=\"Cell Cycle, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18728393\">Cell Cycle, 2008</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20364141\">Nat. Cell Biol., 2010</a>&nbsp;&nbsp;  <a title=\"Nucleic Acids Res., 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25361978\">Nucleic Acids Res., 2015</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25619829\">Oncogene, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138246, "symbol": "NF2", "locus": "22q12.2", "entrez_id": 4771, "chr": "chr22", "start": 29999545, "end": 30094587, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "neurofibromin 2", "description": "<p style=\"text-align: justify\"> Вместе с WWC1 индуцирует фосфорилирование LATS1 и LATS2 и регулирует Hippo/SWH (Sav/Wts/Hpo) сигнальный каскад, который играет важную роль в подавлении пролиферации опухолевых клеток и запуске апоптоза. Также ингибирует активность PI3K, связываясь с AGAP2 и уменьшая его стимулирующую активность. Снижает клеточную пролиферацию, ингибируя убиквинтинлигазный комплекс CUL4A-RBX1-DDB1-VprBP/DCAF1 E3. </p>  <a title=\"Dev. Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20159598\">Dev. Cell, 2010</a>&nbsp;&nbsp;  <a title=\"Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20178741\">Cell, 2010</a>&nbsp;&nbsp;  <a title=\"Int. J. Biochem. Cell Biol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21167305\">Int. J. Biochem. Cell Biol., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138245, "symbol": "TIMP3", "locus": "22q12.3", "entrez_id": 7078, "chr": "chr22", "start": 33197687, "end": 33259030, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "TIMP metallopeptidase inhibitor 3", "description": "Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. May form part of a tissue-specific acute response to remodeling stimuli. Known to act on MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138244, "symbol": "MYH9", "locus": "22q12.3", "entrez_id": 4627, "chr": "chr22", "start": 36677327, "end": 36784063, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "myosin heavy chain 9", "description": "<p style=\"text-align: justify\"> Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. During cell spreading, plays an important role in cytoskeleton reorganization, focal contacts formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; this function is mechanically antagonized by MYH10. </p>  <a title=\"PLoS ONE, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20052411\">PLoS ONE, 2010</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138243, "symbol": "PDGFB", "locus": "22q13.1", "entrez_id": 5155, "chr": "chr22", "start": 39619364, "end": 39640756, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "platelet derived growth factor subunit B", "description": "<p style=\"text-align: justify\"> Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin (PubMed:26599395). Required for normal proliferation and recruitment of pericytes and vascular smooth muscle cells in the central nervous system, skin, lung, heart and placenta. Required for normal blood vessel development, and for normal development of kidney glomeruli. Plays an important role in wound healing. Signaling is modulated by the formation of heterodimers with PDGFA (By similarity). </p>  <a title=\"PLoS ONE, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26599395\">PLoS ONE, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138242, "symbol": "EP300", "locus": "22q13.2", "entrez_id": 2033, "chr": "chr22", "start": 41487790, "end": 41576081, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "E1A binding protein p300", "description": "<p style=\"text-align: justify\"> Functions as histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Mediates acetylation of histone H3 at 'Lys-122' (H3K122ac), a modification that localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Mediates acetylation of histone H3 at 'Lys-27' (H3K27ac). Also functions as acetyltransferase for nonhistone targets. Acetylates 'Lys-131' of ALX1 and acts as its coactivator. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Acetylates FOXO1 and enhances its transcriptional activity. Acetylates BCL6 wich disrupts its ability to recruit histone deacetylases and hinders its transcriptional repressor activity. Participates in CLOCK or NPAS2-regulated rhythmic gene transcription; exhibits a circadian association with CLOCK or NPAS2, correlating with increase in PER1/2 mRNA and histone H3 acetylation on the PER1/2 promoter. Acetylates MTA1 at 'Lys-626' which is essential for its transcriptional coactivator activity (PubMed:10733570, PubMed:11430825, PubMed:11701890, PubMed:12402037, PubMed:12586840, PubMed:12929931, PubMed:14645221, PubMed:15186775, PubMed:15890677, PubMed:16617102, PubMed:16762839, PubMed:18722353, PubMed:18995842, PubMed:23415232, PubMed:23911289, PubMed:23934153, PubMed:8945521). Acetylates XBP1 isoform 2; acetylation increases protein stability of XBP1 isoform 2 and enhances its transcriptional activity (PubMed:20955178). Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER) (PubMed:24939902). Acetylates MEF2D. </p>  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21030595\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"Cell, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23415232\">Cell, 2013</a>&nbsp;&nbsp;  <a title=\"Cell Rep, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23911289\">Cell Rep, 2014</a>&nbsp;&nbsp;  <a title=\"Nat. Struct. Mol. Biol., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23934153\">Nat. Struct. Mol. Biol., 2013</a>&nbsp;&nbsp;  <a title=\"Nucleic Acids Res., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24939902\">Nucleic Acids Res., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138241, "symbol": "CYP2D6", "locus": "22q13.2", "entrez_id": 1565, "chr": "chr22", "start": 42522501, "end": 42526908, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cytochrome P450 family 2 subfamily D member 6", "description": "<p style=\"text-align: justify\"> ген CYP2D6 кодирует белок, который является представителем семейства цитохромов P450 и является важным ферментом, который вовлечен в процессы метаболизма ксенобиотиков в организме. В частности, CYP2D6 отвечает за метаболизм и выведение примерно 25% клинически используемых препаратов путем добавления или удаления определенных функциональных групп, путем гидроксилирования, деметилирования и деалкилирования. Другие препараты, известные как пролекарства, активируются действием CYP2D6. Этот фермент также метаболизирует несколько эндогенных веществ, таких как гидрокситриптамины, нейростероиды, а также м-тирамин, ир-тирамин, которые  посредством CYP2D6 метаболизируются в допамин в мозгу и печени. Для CYP2D6 характерна значительна генетическая полиморфность, от которой зависит эффективности и количество фермента, которая отличается у каждого носителя полиморфизма. </p>  <a title=\"J. Biol. Chem., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16352597\">J. Biol. Chem., 2006</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138240, "symbol": "CRBN", "locus": "3p26.2", "entrez_id": 51185, "chr": "chr3", "start": 3190676, "end": 3221394, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cereblon", "description": "<p style=\"text-align: justify\"> Substrate recognition component of a DCX (DDB1-CUL4-X- box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly and neuronal surface expression of large-conductance calcium-activated potassium channels in brain regions involved in memory and learning via its interaction with KCNT1. Binding of pomalidomide and other thalidomide-related drugs changes the substrate specificity of the human protein, leading to decreased degradation of MEIS2 and other target proteins and increased degradation of MYC, IRF4, IKZF1 and IKZF3. </p>  <a title=\"Neurogenetics, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18414909\">Neurogenetics, 2009</a>&nbsp;&nbsp;  <a title=\"Science, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20223979\">Science, 2010</a>&nbsp;&nbsp;  <a title=\"Br. J. Haematol., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24328678\">Br. J. Haematol., 2014</a>&nbsp;&nbsp;  <a title=\"Nature, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25043012\">Nature, 2014</a>&nbsp;&nbsp;  <a title=\"Nat. Struct. Mol. Biol., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25108355\">Nat. Struct. Mol. Biol., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138239, "symbol": "FANCD2", "locus": "3p25.3", "entrez_id": 2177, "chr": "chr3", "start": 10068098, "end": 10143614, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Fanconi anemia complementation group D2", "description": "<p style=\"text-align: justify\"> Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching. </p>  <a title=\"Blood, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15454491\">Blood, 2005</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15650050\">Proc. Natl. Acad. Sci. U.S.A., 2005</a>&nbsp;&nbsp;  <a title=\"Hum. Mol. Genet., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15661754\">Hum. Mol. Genet., 2005</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15671039\">J. Biol. Chem., 2005</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19465921\">Nat. Cell Biol., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138238, "symbol": "VHL", "locus": "3p25.3", "entrez_id": 7428, "chr": "chr3", "start": 10182692, "end": 10193904, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "von Hippel-Lindau tumor suppressor", "description": "<p style=\"text-align: justify\"> Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia- inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2. </p>  <a title=\"EMBO J., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10944113\">EMBO J., 2000</a>&nbsp;&nbsp;  <a title=\"Cell, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17981124\">Cell, 2007</a>&nbsp;&nbsp;  <a title=\"Sci Signal, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19584355\">Sci Signal, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138237, "symbol": "PPARG", "locus": "3p25.2", "entrez_id": 5468, "chr": "chr3", "start": 12328867, "end": 12475855, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "peroxisome proliferator activated receptor gamma", "description": "<p style=\"text-align: justify\"> Ядерный рецептор связанный с пролиферацией пероксисом и действием гиполипидемических препаратов. Активируется лигандом и в последствиии связывается со специфичным фрагментом ДНК и изменяет транскрипцию таргетных генов таких как ацил-КоА оксидаза. Поэтому он контролирует бета-окисление жирных кислот. Ключевой регулятор дифференцировки адипоцитов и гомеостаза глюкозы. </p>  <a title=\"J. Biol. Chem., 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9065481\">J. Biol. Chem., 1997</a>&nbsp;&nbsp;  <a title=\"Mol. Endocrinol., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16150867\">Mol. Endocrinol., 2006</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20829347\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"Mol. Endocrinol., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23525231\">Mol. Endocrinol., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138236, "symbol": "RAF1", "locus": "3p25.2", "entrez_id": 5894, "chr": "chr3", "start": 12625100, "end": 12705725, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Raf-1 proto-oncogene, serine/threonine kinase", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2- antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation. </p>  <a title=\"Mol. Pharmacol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15385642\">Mol. Pharmacol., 2004</a>&nbsp;&nbsp;  <a title=\"Science, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15618521\">Science, 2005</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15849194\">J. Biol. Chem., 2005</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16892053\">Nat. Cell Biol., 2006</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16924233\">Oncogene, 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138235, "symbol": "XPC", "locus": "3p25.1", "entrez_id": 7508, "chr": "chr3", "start": 14186647, "end": 14220283, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "XPC complex subunit, DNA damage recognition and repair factor", "description": "Involved in global genome nucleotide excision repair (GG-NER) by acting as damage sensing and DNA-binding factor component of the XPC complex. Has only a low DNA repair activity by itself which is stimulated by RAD23B and RAD23A. Has a preference to bind DNA containing a short single-stranded segment but not to damaged oligonucleotides. This feature is proposed to be related to a dynamic sensor function: XPC can rapidly screen duplex DNA for non-hydrogen-bonded bases by forming a transient nucleoprotein intermediate complex which matures into a stable recognition complex through an intrinsic single-stranded DNA- binding activity", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138234, "symbol": "TGFBR2", "locus": "3p24.1", "entrez_id": 7048, "chr": "chr3", "start": 30647994, "end": 30735634, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "transforming growth factor beta receptor 2", "description": "<p style=\"text-align: justify\"> Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non- promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non- canonical, SMAD-independent TGF-beta signaling pathways. </p>  <a title=\"EMBO J., 1995\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7774578\">EMBO J., 1995</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138233, "symbol": "MLH1", "locus": "3p22.2", "entrez_id": 4292, "chr": "chr3", "start": 37034823, "end": 37107380, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mutL homolog 1", "description": "<p style=\"text-align: justify\"> Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS- heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis. </p>  <a title=\"Am. J. Hum. Genet., 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9311737\">Am. J. Hum. Genet., 1997</a>&nbsp;&nbsp;  <a title=\"Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16873062\">Cell, 2006</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18206974\">Mol. Cell, 2008</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20020535\">Hum. Mutat., 2010</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21120944\">Hum. Mutat., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138232, "symbol": "ITGA9", "locus": "3p22.2", "entrez_id": 3680, "chr": "chr3", "start": 37493606, "end": 37865005, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "integrin subunit alpha 9", "description": "<p style=\"text-align: justify\"> Integrin alpha-9/beta-1 (ITGA9:ITGB1) is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E- I-D-G-I-E-L in cytotactin. </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138231, "symbol": "MYD88", "locus": "3p22.2", "entrez_id": 4615, "chr": "chr3", "start": 38179969, "end": 38184513, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "myeloid differentiation primary response 88", "description": "<p style=\"text-align: justify\"> Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response. Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription. Involved in IL-18-mediated signaling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. MyD88-mediated signaling in intestinal epithelial cells is crucial for maintenance of gut homeostasis and controls the expression of the antimicrobial lectin REG3G in the small intestine. </p>  <a title=\"FEBS Lett., 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9013863\">FEBS Lett., 1997</a>&nbsp;&nbsp;  <a title=\"Nat. Immunol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15361868\">Nat. Immunol., 2004</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18292575\">J. Immunol., 2008</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19506249\">Proc. Natl. Acad. Sci. U.S.A., 2009</a>&nbsp;&nbsp;  <a title=\"Mol. Immunol., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24316379\">Mol. Immunol., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138230, "symbol": "CTNNB1", "locus": "3p22.1", "entrez_id": 1499, "chr": "chr3", "start": 41236328, "end": 41301587, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "catenin beta 1", "description": "<p style=\"text-align: justify\"> Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion, as component of an E- cadherin:catenin adhesion complex. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML (PubMed:17524503, PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, PubMed:22647378, PubMed:22699938, PubMed:22155184). Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle (By similarity). </p>  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18957423\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"Cell. Signal., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21262353\">Cell. Signal., 2011</a>&nbsp;&nbsp;  <a title=\"Gastroenterology, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22155184\">Gastroenterology, 2012</a>&nbsp;&nbsp;  <a title=\"Cell Cycle, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22647378\">Cell Cycle, 2012</a>&nbsp;&nbsp;  <a title=\"EMBO Rep., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22699938\">EMBO Rep., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138229, "symbol": "LTF", "locus": "3p21.31", "entrez_id": 4057, "chr": "chr3", "start": 46477136, "end": 46526724, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "lactotransferrin", "description": "Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate FUNCTION: Lactoferricin binds to the bacterial surface and is crucial for the bactericidal functions. Has some antiviral activity against papillomavirus infection. N-terminal region shows strong antifungal activity against C.albicans. Contains two BBXB heparin-binding consensus sequences that appear to form the predominate functional GAG-binding site.; FUNCTION: Lactoferroxins A, B and C have opioid antagonist activity. Lactoferroxin A shows preference for mu-receptors, while lactoferroxin B and C have somewhat higher degrees of preference for kappa-receptors than for mu-receptors.; FUNCTION: Isoform DeltaLf: transcription factor with antiproliferative properties and ability to induce cell cycle arrest. Binds to the DeltaLf response element found in the SKP1, BAX, DCPS, and SELENOH promoters.;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138228, "symbol": "SETD2", "locus": "3p21.31", "entrez_id": 29072, "chr": "chr3", "start": 47057919, "end": 47205457, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SET domain containing 2", "description": "<p style=\"text-align: justify\"> Histone methyltransferase that specifically trimethylates 'Lys-36' of histone H3 (H3K36me3) using dimethylated 'Lys-36' (H3K36me2) as substrate. Represents the main enzyme generating H3K36me3, a specific tag for epigenetic transcriptional activation. Plays a role in chromatin structure modulation during elongation by coordinating recruitment of the FACT complex and by interacting with hyperphosphorylated POLR2A. Acts as a key regulator of DNA mismatch repair in G1 and early S phase by generating H3K36me3, a mark required to recruit MSH6 subunit of the MutS alpha complex: early recruitment of the MutS alpha complex to chromatin to be replicated allows a quick identification of mismatch DNA to initiate the mismatch repair reaction. H3K36me3 also plays an essential role in the maintenance of a heterochromatic state, by recruiting DNA methyltransferase DNMT3A. H3K36me3 is also enhanced in intron-containing genes, suggesting that SETD2 recruitment is enhanced by splicing and that splicing is coupled to recruitment of elongating RNA polymerase. Required during angiogenesis. Recruited to the promoters of adenovirus 12 E1A gene in case of infection, possibly leading to regulate its expression. Trimethylates 'Lys-40' of alpha-tubulins such as TUBA1B (alpha-TubK40me3) (PubMed:27518565). Alpha- TubK40me3 is required for normal mitosis and cytokinesis and is proposed to be a specific tag in cytoskeletal remodeling (PubMed:27518565). </p>  <a title=\"Nat. Struct. Mol. Biol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21792193\">Nat. Struct. Mol. Biol., 2011</a>&nbsp;&nbsp;  <a title=\"J. Am. Chem. Soc., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23043551\">J. Am. Chem. Soc., 2013</a>&nbsp;&nbsp;  <a title=\"Nucleic Acids Res., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23325844\">Nucleic Acids Res., 2013</a>&nbsp;&nbsp;  <a title=\"Cell, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23622243\">Cell, 2013</a>&nbsp;&nbsp;  <a title=\"Cell, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27518565\">Cell, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138227, "symbol": "BAP1", "locus": "3p21.1", "entrez_id": 8314, "chr": "chr3", "start": 52435029, "end": 52444366, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "BRCA1 associated protein 1", "description": "<p style=\"text-align: justify\"> Фермент, деубиквитинизирующий такие компоненты хроматина, как  H2A и HCFC1. Является каталитическим компонентом деубиквитинизирующего комплекса PR-DUB, который деубиквитинизирует моноубиквитинизированный по положению Lys-119 гистон H2A. Выступает как регулятор клеточного роста, так как деубиквитинизирует HCFC1. Взаимодействует с гетородиммером BRCA1-BARD1  и ингибирует их убиквитинизацию, однако не способствует их деубиквитинизации. Может стимулировать через молекулярные взаимодействия аутодеубиквитинизации NLS, таким образом защищая его от цитоплазматической секвестрации (PubMed:24703950). Выступает в качестве опухолевого супрессора. </p>  <a title=\"Cancer Res., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19117993\">Cancer Res., 2009</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19188440\">Mol. Cell. Biol., 2009</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19815555\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"Nature, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20436459\">Nature, 2010</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24703950\">Mol. Cell, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138226, "symbol": "PBRM1", "locus": "3p21.1", "entrez_id": 55193, "chr": "chr3", "start": 52579368, "end": 52719933, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "polybromo 1", "description": "<p style=\"text-align: justify\"> Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Acts as a negative regulator of cell proliferation. </p>  <a title=\"Nature, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21248752\">Nature, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138225, "symbol": "MAGI1", "locus": "3p14.1", "entrez_id": 9223, "chr": "chr3", "start": 65339200, "end": 66024509, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "membrane associated guanylate kinase, WW and PDZ domain containing 1", "description": "<p style=\"text-align: justify\"> May play a role as scaffolding protein at cell-cell junctions. May regulate acid-induced ASIC3 currents by modulating its expression at the cell surface (By similarity). </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138224, "symbol": "MITF", "locus": "3p13", "entrez_id": 4286, "chr": "chr3", "start": 69788586, "end": 70017488, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "melanogenesis associated transcription factor", "description": "<p style=\"text-align: justify\"> Transcription factor that regulates the expression of genes with essential roles in cell differentiation, proliferation and survival. Binds to M-boxes (5'-TCATGTG-3') and symmetrical DNA sequences (E-boxes) (5'-CACGTG-3') found in the promoters of target genes, such as BCL2 and tyrosinase (TYR). Plays an important role in melanocyte development by regulating the expression of tyrosinase (TYR) and tyrosinase-related protein 1 (TYRP1). Plays a critical role in the differentiation of various cell types, such as neural crest-derived melanocytes, mast cells, osteoclasts and optic cup-derived retinal pigment epithelium. </p>  <a title=\"Biochem. Biophys. Res. Commun., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9647758\">Biochem. Biophys. Res. Commun., 1998</a>&nbsp;&nbsp;  <a title=\"Hum. Mol. Genet., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10587587\">Hum. Mol. Genet., 2000</a>&nbsp;&nbsp;  <a title=\"Cell Cycle, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22647378\">Cell Cycle, 2012</a>&nbsp;&nbsp;  <a title=\"Am. J. Hum. Genet., 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27889061\">Am. J. Hum. Genet., 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138223, "symbol": "FOXP1", "locus": "3p13", "entrez_id": 27086, "chr": "chr3", "start": 71003844, "end": 71633140, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "forkhead box P1", "description": "<p style=\"text-align: justify\"> Transcriptional repressor (PubMed:18347093, PubMed:26647308). Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential (By similarity). Plays an important role in the specification and differentiation of lung epithelium. Acts cooperatively with FOXP4 to regulate lung secretory epithelial cell fate and regeneration by restricting the goblet cell lineage program; the function may involve regulation of AGR2. Essential transcriptional regulator of B-cell development. Involved in regulation of cardiac muscle cell proliferation. Involved in the columnar organization of spinal motor neurons. Promotes the formation of the lateral motor neuron column (LMC) and the preganglionic motor column (PGC) and is required for respective appropriate motor axon projections. The segment-appropriate generation of spinal chord motor columns requires cooperation with other Hox proteins. Can regulate PITX3 promoter activity; may promote midbrain identity in embryonic stem cell-derived dopamine neurons by regulating PITX3. Negatively regulates the differentiation of T follicular helper cells T(FH)s. Involved in maintenance of hair follicle stem cell quiescence; the function probably involves regulation of FGF18 (By similarity). Represses transcription of various pro-apoptotic genes and cooperates with NF-kappa B-signaling in promoting B-cell expansion by inhibition of caspase-dependent apoptosis (PubMed:25267198). Binds to CSF1R promoter elements and is involved in regulation of monocyte differentiation and macrophage functions; repression of CSF1R in monocytes seems to involve NCOR2 as corepressor (PubMed:15286807, PubMed:18799727, PubMed:18347093). Involved in endothelial cell proliferation, tube formation and migration indicative for a role in angiogenesis; the role in neovascularization seems to implicate suppression of SEMA5B (PubMed:24023716). Can negatively regulate androgen receptor signaling (PubMed:18640093). </p>  <a title=\"Blood, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18799727\">Blood, 2009</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24023716\">PLoS ONE, 2014</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24023716\">PLoS ONE, 2014</a>&nbsp;&nbsp;  <a title=\"Blood, 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25267198\">Blood, 2015</a>&nbsp;&nbsp;  <a title=\"Hum. Mol. Genet., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26647308\">Hum. Mol. Genet., 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138222, "symbol": "EPHA3", "locus": "3p11.1", "entrez_id": 2042, "chr": "chr3", "start": 89156674, "end": 89531284, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "EPH receptor A3", "description": "<p style=\"text-align: justify\"> Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous for ephrin-A ligands it binds preferentially EFNA5. Upon activation by EFNA5 regulates cell-cell adhesion, cytoskeletal organization and cell migration. Plays a role in cardiac cells migration and differentiation and regulates the formation of the atrioventricular canal and septum during development probably through activation by EFNA1. Involved in the retinotectal mapping of neurons. May also control the segregation but not the guidance of motor and sensory axons during neuromuscular circuit development. </p>  <a title=\"J. Cell. Sci., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11870224\">J. Cell. Sci., 2002</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138221, "symbol": "GATA2", "locus": "3q21.3", "entrez_id": 2624, "chr": "chr3", "start": 128198270, "end": 128212028, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "GATA binding protein 2", "description": "Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138220, "symbol": "EPHB1", "locus": "3q22.2", "entrez_id": 2047, "chr": "chr3", "start": 134316643, "end": 134979309, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "EPH receptor B1", "description": "<p style=\"text-align: justify\"> Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Cognate/functional ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3. During nervous system development, regulates retinal axon guidance redirecting ipsilaterally ventrotemporal retinal ganglion cells axons at the optic chiasm midline. This probably requires repulsive interaction with EFNB2. In the adult nervous system together with EFNB3, regulates chemotaxis, proliferation and polarity of the hippocampus neural progenitors. In addition to its role in axon guidance plays also an important redundant role with other ephrin-B receptors in development and maturation of dendritic spines and synapse formation. May also regulate angiogenesis. More generally, may play a role in targeted cell migration and adhesion. Upon activation by EFNB1 and probably other ephrin-B ligands activates the MAPK/ERK and the JNK signaling cascades to regulate cell migration and adhesion respectively. Involved in the maintenance of the pool of satellite cells (muscle stem cells) by promoting their self-renewal and reducing their activation and differentiation (By similarity). </p>  <a title=\"J. Biol. Chem., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9430661\">J. Biol. Chem., 1998</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9499402\">Genes Dev., 1998</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12223469\">J. Biol. Chem., 2003</a>&nbsp;&nbsp;  <a title=\"J. Cell Biol., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12925710\">J. Cell Biol., 2003</a>&nbsp;&nbsp;  <a title=\"Traffic, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18034775\">Traffic, 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138219, "symbol": "PIK3CB", "locus": "3q22.3", "entrez_id": 5291, "chr": "chr3", "start": 138372860, "end": 138553780, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta", "description": "<p style=\"text-align: justify\"> Ген PIK3CB кодирует фосфоинозитид-3-киназу (PI3K) p110β, которая фосфорилирует фосфатидилинозитол и другие соединения с образованием фосфатидилинозитола 3,4,5-трифосфата (PIP3). PIP3 играет ключевую роль, рекрутируя белки, содержащие домен PH, на мембрану клеток, включая Akt1 и PDPK1, приводя к активации сигнальных каскадов, участвующих в регуляции пролиферации, выживания и подвижности клеток, а также контролирующих их морфологию.  Под действием p110β происходит активация Akt1, вызванная стимуляцией рецепторов, сопряженных  с G-белками (GPCRs), лигандами – CXCL12, сфингозин-1-фосфатом и лизофосфатидной кислотой.  p110β также является одним из эффекторов тирозинкиназных рецепторов. Компонент разных сигнальных путей, обеспечивающих стабильную адгезию и агрегацию тромбоцитов. Играет роль в сигнальном пути активации тромбоцитов, регулируемом рецепторами – GPCR, α2β/β3-интегринами (ITGA2B/ITGB3) и рецепторами, содержащими мотив активации ITAM, такими как GP6. Регулирует силу адгезии активированных α2β/β3-интегриновых рецепторов к субстрату. Требуется для агрегации тромбоцитов, индуцированной тромбином (F2) и тромбоксаном A2 (TXA2).  p110β  выполняет регуляторную функцию в процессах, обеспечивающих выживание и миграцию клеток, участвует на ранних стадиях формирования аутофагосом. Модулирует внутриклеточный уровень PIP3 и активирует киназу PIK3C3. p110β может выступать как скаффолд-белок, независимо от активности липидкиназы, в инсулин-зависимой сигнализации и  при активации аутофагии. Также независимо от своей киназной функции p110β может принимать участие в регуляции клеточной пролиферации и клатрин-опосредованного эндоцитоза. Является одним из эффекторов онкогенной сигнализации в клеточных линиях c потерей PTEN. Активность липидкиназы p110β необходима для реализации ее функции в онкогенной трансформации. Требуется для роста опухолей с драйверными мутациями в генах ERBB2 и RAS. </p>  <a title=\"Nature, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18594509\">Nature, 2008</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18755892\">Proc. Natl. Acad. Sci. U.S.A., 2008</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21030680\">Proc. Natl. Acad. Sci. U.S.A., 2010</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21383062\">Mol. Cell. Biol., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138218, "symbol": "FOXL2", "locus": "3q22.3", "entrez_id": 668, "chr": "chr3", "start": 138663066, "end": 138665982, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "forkhead box L2", "description": "<p style=\"text-align: justify\"> Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans- differentiation of ovary to testis through transcriptional repression of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of CYP19 expression (By similarity). Participates in SMAD3-dependent transcription of FST via the intronic SMAD-binding element (By similarity). Is a transcriptional repressor of STAR. Activates SIRT1 transcription under cellular stress conditions. Activates transcription of OSR2. </p>  <a title=\"Biochem. Biophys. Res. Commun., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16153597\">Biochem. Biophys. Res. Commun., 2005</a>&nbsp;&nbsp;  <a title=\"Hum. Mol. Genet., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19010791\">Hum. Mol. Genet., 2009</a>&nbsp;&nbsp;  <a title=\"J. Med. Genet., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19429596\">J. Med. Genet., 2009</a>&nbsp;&nbsp;  <a title=\"Cell. Signal., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19744555\">Cell. Signal., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138217, "symbol": "ATR", "locus": "3q23", "entrez_id": 545, "chr": "chr3", "start": 142168077, "end": 142297668, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ATR serine/threonine kinase", "description": "<p style=\"text-align: justify\"> Serine/threonine protein kinase which activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates BRCA1, CHEK1, MCM2, RAD17, RPA2, SMC1 and p53/TP53, which collectively inhibit DNA replication and mitosis and promote DNA repair, recombination and apoptosis. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at sites of DNA damage, thereby regulating DNA damage response mechanism. Required for FANCD2 ubiquitination. Critical for maintenance of fragile site stability and efficient regulation of centrosome duplication. </p>  <a title=\"Hum. Mol. Genet., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15496423\">Hum. Mol. Genet., 2005</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16260606\">Mol. Cell. Biol., 2005</a>&nbsp;&nbsp;  <a title=\"Biochem. Biophys. Res. Commun., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21144835\">Biochem. Biophys. Res. Commun., 2011</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27723717\">Nat. Cell Biol., 2017</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27723720\">Nat. Cell Biol., 2017</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138216, "symbol": "SOX2", "locus": "3q26.33", "entrez_id": 6657, "chr": "chr3", "start": 181429714, "end": 181432221, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SRY-box 2", "description": "<p style=\"text-align: justify\"> Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206 (By similarity). Critical for early embryogenesis and for embryonic stem cell pluripotency. May function as a switch in neuronal development. Downstream SRRT target that mediates the promotion of neural stem cell self-renewal (By similarity). Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation (By similarity). </p>  <a title=\"Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18035408\">Cell, 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138215, "symbol": "BCL6", "locus": "3q27.3", "entrez_id": 604, "chr": "chr3", "start": 187439165, "end": 187463515, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "B-cell CLL/lymphoma 6", "description": "<p style=\"text-align: justify\"> Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6- binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4(+) T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53- dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH- dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation. </p>  <a title=\"Mol. Cell. Biol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18212045\">Mol. Cell. Biol., 2008</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18280243\">Mol. Cell, 2008</a>&nbsp;&nbsp;  <a title=\"Nature, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22113614\">Nature, 2012</a>&nbsp;&nbsp;  <a title=\"J. Exp. Med., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23166356\">J. Exp. Med., 2013</a>&nbsp;&nbsp;  <a title=\"Cell Rep, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23911289\">Cell Rep, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138214, "symbol": "LPP", "locus": "3q27.3-q28", "entrez_id": 4026, "chr": "chr3", "start": 187871072, "end": 188608460, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "LIM domain containing preferred translocation partner in lipoma", "description": "<p style=\"text-align: justify\"> May play a structural role at sites of cell adhesion in maintaining cell shape and motility. In addition to these structural functions, it may also be implicated in signaling events and activation of gene transcription. May be involved in signal transduction from cell adhesion sites to the nucleus allowing successful integration of signals arising from soluble factors and cell-cell adhesion sites. Also suggested to serve as a scaffold protein upon which distinct protein complexes are assembled in the cytoplasm and in the nucleus. </p>  <a title=\"Mol. Biol. Cell, 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10637295\">Mol. Biol. Cell, 2000</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138213, "symbol": "TNK2", "locus": "3q29", "entrez_id": 10188, "chr": "chr3", "start": 195590235, "end": 195638816, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "tyrosine kinase non receptor 2", "description": "<p style=\"text-align: justify\"> Non-receptor tyrosine-protein and serine/threonine- protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin. Binds to both poly- and mono-ubiquitin and regulates ligand-induced degradation of EGFR, thereby contributing to the accumulation of EGFR at the limiting membrane of early endosomes. Downstream effector of CDC42 which mediates CDC42-dependent cell migration via phosphorylation of BCAR1. May be involved both in adult synaptic function and plasticity and in brain development. Activates AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' and 'Tyr-363' thereby promoting its recruitment to androgen-responsive enhancers (AREs). Phosphorylates WWOX on 'Tyr- 287'. Phosphorylates MCF2, thereby enhancing its activity as a guanine nucleotide exchange factor (GEF) toward Rho family proteins. Contributes to the control of AXL receptor levels. Confers metastatic properties on cancer cells and promotes tumor growth by negatively regulating tumor suppressor such as WWOX and positively regulating pro-survival factors such as AKT1 and AR. </p>  <a title=\"Exp. Cell Res., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18262180\">Exp. Cell Res., 2008</a>&nbsp;&nbsp;  <a title=\"Breast Cancer Res., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18435854\">Breast Cancer Res., 2008</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19815557\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20333297\">PLoS ONE, 2011</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20383201\">Oncogene, 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138212, "symbol": "FGFR3", "locus": "4p16.3", "entrez_id": 2261, "chr": "chr4", "start": 1795034, "end": 1810599, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fibroblast growth factor receptor 3", "description": "<p style=\"text-align: justify\"> Тирозин-протеинкиназа, которая действует как рецептор на клеточной поверхности для факторов роста фибробластов и играет существенную роль в регуляции клеточной пролиферации, дифференцировки и апоптоза. Играет существенную роль в регуляции дифференцировки хондроцитов, пролиферации и апоптоза и требуется для нормального развития скелета. Регулирует остеогенез и постнатальную костную минерализацию. Способствует апоптозу в хондроцитах и может способствовать распространению раковых клеток. Требуется для нормального развития внутреннего уха. Фосфорилирует PLCG1, CBL и FRS2. Связывание лиганда приводит к активации нескольких сигнальных каскадов. Активация PLCG1 приводит к получению клеточных сигнальных молекул диацилглицерина и инозитол-1,4,5-трифосфата. Фосфорилирование FRS2 инициирует привлечение GRB2, GAB1, PIK3R1 и SOS1 и опосредует активацию RAS, MAPK1 / ERK2, MAPK3 / ERK1 и MAP-киназного сигнального пути , а также сигнального пути AKT1. Играет роль в регуляции метаболизма витамина D. Мутации, которые приводят к конститутивной активности или нарушают нормальную сборку, интернализацию или деградацию FGFR3, приводят к аберрантной передаче сигналов. Гиперэкспрессированная или конститутивно активированная FGFR3 способствует активации PTPN11 / SHP2, STAT1, STAT5A и STAT5B. Изоформа 3 сохраняет способность связывать FGF1 и FGF2. </p>  <a title=\"J. Cell. Physiol., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17311277\">J. Cell. Physiol., 2007</a>&nbsp;&nbsp;  <a title=\"FEBS J., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17509076\">FEBS J., 2007</a>&nbsp;&nbsp;  <a title=\"Bone, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17561467\">Bone, 2007</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19088846\">PLoS ONE, 2009</a>&nbsp;&nbsp;  <a title=\"Hum. Mol. Genet., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19286672\">Hum. Mol. Genet., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138211, "symbol": "NSD2", "locus": "4p16.3", "entrez_id": 7468, "chr": "chr4", "start": 1873151, "end": 1983934, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nuclear receptor binding SET domain protein 2", "description": "<p style=\"text-align: justify\"> Histone methyltransferase with histone H3 'Lys-27' (H3K27me) methyltransferase activity. Isoform 2 may act as a transcription regulator that binds DNA and suppresses IL5 transcription through HDAC recruitment. </p>  <a title=\"Am. J. Respir. Cell Mol. Biol., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11152655\">Am. J. Respir. Cell Mol. Biol., 2001</a>&nbsp;&nbsp;  <a title=\"Br. J. Haematol., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16115125\">Br. J. Haematol., 2005</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18172012\">Mol. Cell. Biol., 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138210, "symbol": "RHOH", "locus": "4p14", "entrez_id": 399, "chr": "chr4", "start": 40192673, "end": 40248587, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ras homolog family member H", "description": "<p style=\"text-align: justify\"> Negative regulator of hematopoietic progenitor cell proliferation, survival and migration. Critical regulator of thymocyte development and T-cell antigen receptor (TCR) signaling by mediating recruitment and activation of ZAP70. Required for phosphorylation of CD3Z, membrane translocation of ZAP70 and subsequent activation of the ZAP70-mediated pathways. Essential for efficient beta-selection and positive selection by promoting the ZAP70-dependent phosphorylation of the LAT signalosome during pre-TCR and TCR signaling. Crucial for thymocyte maturation during DN3 to DN4 transition and during positive selection. Plays critical roles in mast cell function by facilitating phosphorylation of SYK in Fc epsilon RI-mediated signal transduction. Essential for the phosphorylation of LAT, LCP2, PLCG1 and PLCG2 and for Ca(2+) mobilization in mast cells (By similarity). Binds GTP but lacks intrinsic GTPase activity and is resistant to Rho-specific GTPase-activating proteins. Inhibits the activation of NF-kappa-B by TNF and IKKB and the activation of CRK/p38 by TNF. Inhibits activities of RAC1, RHOA and CDC42. Negatively regulates leukotriene production in neutrophils. </p>  <a title=\"Mol. Cell. Biol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11809807\">Mol. Cell. Biol., 2002</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19414807\">J. Immunol., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_VUS"}, {"json_id": 138209, "symbol": "PHOX2B", "locus": "4p13", "entrez_id": 8929, "chr": "chr4", "start": 41746099, "end": 41750987, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "paired like homeobox 2b", "description": "Involved in the development of several major noradrenergic neuron populations, including the locus coeruleus. Transcription factor which could determine a neurotransmitter phenotype in vertebrates. Enhances second-messenger-mediated activation of the dopamine beta-hydrolase and c-fos promoters, and of several enhancers including cAMP-response element and serum- response element", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138208, "symbol": "PDGFRA", "locus": "4q12", "entrez_id": 5156, "chr": "chr4", "start": 55095264, "end": 55164414, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "platelet derived growth factor receptor alpha", "description": "<p style=\"text-align: justify\"> Киназа тирозинового типа, являющаяся рецептором для PDGFA, PDGFB и PDGFC и играющая значимую роль в регуляции эмбрионального развития, клеточной пролиферации, выживании и хемотаксисе. В зависимости от микроокружения может как способствовать, так и подавлять клеточную пролиферацию и миграцию. Играет важную роль в дифференцировке мезенхимальных стволовых клеток костномозгового происхождения. Требуется для нормального развития скелета и закрытия спинномозговой трубки, развития слизистых тканей ЖКТ во время эмбрионального развития. Участвует в миграции клеток и хемотаксисе во время заживления раны. Играет роль в активации тромбоцитов, экзоцитозе медиаторов коагуляционного каскада и тромбин-опосредованной агрегации. Связывание со своими лигандами- гомодимерным  PDGFA, гомодимерным PDGFB, гомодимерным PDGFC , гетеродимерными PDGFA и PDGFB- приводит к активации нескольких сигнальных путей; ответ зависит от природы лиганда. Фосфорилирует PIK3R1, PLCG1, and PTPN11. Активация PLCG1 приводит к продукции диацилглицерола и инозитол-трифосфата, мобилизации внутриклеточного кальция и активации PKC. Фосфорилирование PIK3R1 приводит к активации AKT1 сигнального пути. Способствует активации HRAS, MAPK1/ERK2 или MAPK3/ERK1, STAT1, STAT3 и STAT5A или STAT5B. Фосфатаза ингибирует сигнальный путь этого рецептора, так как дефосфорилирует его и способствует интернализации рецептора. </p>  <a title=\"Science, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12522257\">Science, 2003</a>&nbsp;&nbsp;  <a title=\"FEBS Lett., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17141222\">FEBS Lett., 2007</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20972453\">Oncogene, 2011</a>&nbsp;&nbsp;  <a title=\"Blood, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21224473\">Blood, 2011</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21596750\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138207, "symbol": "KIT", "locus": "4q12", "entrez_id": 3815, "chr": "chr4", "start": 55524085, "end": 55606881, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "KIT proto-oncogene receptor tyrosine kinase", "description": "<p style=\"text-align: justify\"> Тирозин-протеинкиназа, которая действует как мембранный рецептор для цитокинов KITLG / SCF и играет существенную роль в регуляции выживания и пролиферации клеток, гемопоэза, поддержания стволовых клеток, гаметогенеза, развития, миграции и функции тучных клеток, а также в меланогенезе. В ответ на связывание KITLG / SCF KIT может активировать несколько сигнальных путей. Фосфорилирует PIK3R1, PLCG1, SH2B2 / APS и CBL. Активирует сигнальный путь AKT1 путем фосфорилирования PIK3R1, регуляторной субъединицы фосфатидилинозитол-3-киназы. Активированный KIT также передает сигналы через GRB2 и активацию RAS, RAF1 и MAP киназ MAPK1 / ERK2 и/или MAPK3 / ERK1. Способствует активации членов семейства STAT STAT1, STAT3, STAT5A и STAT5B. Активация PLCG1 приводит к продуцированию клеточных сигнальных молекул диацилглицерина и инозитола 1,4,5-трифосфата. Передача сигналов KIT модулируется белковыми фосфатазами и быстрой интернализацией и деградацией рецептора. Активированный KIT способствует фосфорилированию белковых фосфатаз PTPN6 / SHP-1 и PTPRU и транскрипционных факторов STAT1, STAT3, STAT5A и STAT5B. Способствует фосфорилированию PIK3R1, CBL, CRK (изоформа Crk-II), LYN, MAPK1 / ERK2 и / или MAPK3 / ERK1, PLCG1, SRC и SHC1. </p>  <a title=\"Exp. Cell Res., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12878163\">Exp. Cell Res., 2003</a>&nbsp;&nbsp;  <a title=\"Exp. Cell Res., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17904548\">Exp. Cell Res., 2007</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19265199\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21135090\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"Biochem. Biophys. Res. Commun., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21640708\">Biochem. Biophys. Res. Commun., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138206, "symbol": "KDR", "locus": "4q12", "entrez_id": 3791, "chr": "chr4", "start": 55944644, "end": 55991756, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "kinase insert domain receptor", "description": "<p style=\"text-align: justify\"> Тирозиновая протеинкиназа, которая действует как мембранный рецептор для факторов роста эндотелия сосудов VEGFA, VEGFC и VEGFD. Играет существенную роль в регуляции ангиогенеза, сосудистой проницаемости и эмбрионального гемопоэза. Способствует пролиферации, выживанию, миграции и дифференцировке эндотелиальных клеток. Способствует реорганизации актинового цитоскелета. Изоформы KDR, лишенные трансмембранного домена, такие как изоформа 2 и изоформа 3, могут функционировать в качестве рецепторов-ловушек для VEGFA, VEGFC и/или VEGFD. Изоформа 2 KDR функционирует как отрицательный регулятор VEGFA- и VEGFC-опосредованного лимфангиогенеза путем ограничения количества свободных лигандов VEGFA и/или VEGFC, предотвращая их связывание с FLT4. Модулирует активность сигнальных путей, регулируемых VEGFR1 (FLT1) и VEGFR3 (FLT4), путем формирования гетеродимеров. Связывание факторов роста эндотелия сосудов с изоформой 1 KDR приводит к активации нескольких сигнальных каскадов. Фосфорилирует и активирует PLCG1, что приводит к продукции клеточных сигнальных молекул - диацилглицерола и инозитола 1,4,5-трифосфата и активации протеинкиназы С. Опосредует активацию MAPК-каскадов Erk2(MAPK1) и Erk1 (MAPK3), а также Akt1-регулируемого пути. Опосредует фосфорилирование PI3KR1, регуляторной субъединицы фосфатидилинозитол-3-киназы PI3K, участвует в реорганизации актинового цитоскелета и активации PTK2/FAK1. Требуется для VEGFA-опосредованной индукции NOS2 и NOS3, что приводит к продуцированию эндотелиальными клетками сигнальной молекулы оксида азота NO. Способствует фосфорилированию FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 и SRC.\r\n\r\nCell Death Differ., 2010   Proc. Natl. Acad. Sci. U.S.A., 2010   EMBO J., 2010   Blood, 2011   Cell. Signal., 2012 </p>  <a title=\"Cell Death Differ., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19834490\">Cell Death Differ., 2010</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20080685\">Proc. Natl. Acad. Sci. U.S.A., 2010</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20224550\">EMBO J., 2010</a>&nbsp;&nbsp;  <a title=\"Blood, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20705758\">Blood, 2011</a>&nbsp;&nbsp;  <a title=\"Cell. Signal., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21893193\">Cell. Signal., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138205, "symbol": "ADGRL3", "locus": "4q13.1", "entrez_id": 23284, "chr": "chr4", "start": 62066976, "end": 62944053, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "adhesion G protein-coupled receptor L3", "description": "<p style=\"text-align: justify\"> Plays a role in cell-cell adhesion and neuron guidance via its interactions with FLRT2 and FLRT3 that are expressed at the surface of adjacent cells (PubMed:26235030). Plays a role in the development of glutamatergic synapses in the cortex. Important in determining the connectivity rates between the principal neurons in the cortex. </p>  <a title=\"Structure, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26235030\">Structure, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138204, "symbol": "AFF1", "locus": "4q21.3-q22.1", "entrez_id": 4299, "chr": "chr4", "start": 87856154, "end": 88062206, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "AF4/FMR2 family member 1", "description": "-", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138203, "symbol": "NFKB1", "locus": "4q24", "entrez_id": 4790, "chr": "chr4", "start": 103422486, "end": 103538459, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nuclear factor kappa B subunit 1", "description": "<p style=\"text-align: justify\"> NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105. </p>  <a title=\"Mol. Cell. Biol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15485931\">Mol. Cell. Biol., 2004</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138202, "symbol": "TET2", "locus": "4q24", "entrez_id": 54790, "chr": "chr4", "start": 106067032, "end": 106200973, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "tet methylcytosine dioxygenase 2", "description": "<p style=\"text-align: justify\"> Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5- hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Has a preference for 5-hydroxymethylcytosine in CpG motifs. Also mediates subsequent conversion of 5hmC into 5- formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position of cytosine bases is an epigenetic modification of the mammalian genome which plays an important role in transcriptional regulation. In addition to its role in DNA demethylation, also involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT. </p>  <a title=\"Nature, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21057493\">Nature, 2011</a>&nbsp;&nbsp;  <a title=\"Science, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21817016\">Science, 2011</a>&nbsp;&nbsp;  <a title=\"Nature, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23222540\">Nature, 2013</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23353889\">EMBO J., 2013</a>&nbsp;&nbsp;  <a title=\"Cell, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24315485\">Cell, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138201, "symbol": "IL2", "locus": "4q27", "entrez_id": 3558, "chr": "chr4", "start": 123372625, "end": 123377880, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "interleukin 2", "description": "Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine- activated killer cells, natural killer cells, and glioma cells", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138200, "symbol": "FBXW7", "locus": "4q31.3", "entrez_id": 55294, "chr": "chr4", "start": 153242410, "end": 153457253, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "F-box and WD repeat domain containing 7", "description": "<p style=\"text-align: justify\"> Распознающий субстрат компонент SCF (SKP1-CUL1-F- box protein) Е3-убиквитин-лигазного комплекса, который способствует убиквитинизации и последующей протеасомой деградации белка-мишени. Распознает и связывается с фосфорилированным сайтом или с фософодегроном на белке-мишени и после этого связывает его с SCF комплексом для последующей убиквитинизации (PubMed:17434132). Его идентифицированные субстраты: циклин-E (CCNE1 or CCNE2), JUN, MYC, NICD (NOTCH1 released notch intracellular domain) , и вероятно PSEN1 (PubMed:11565034, PubMed:12354302, PubMed:11585921, PubMed:15103331, PubMed:14739463, PubMed:17558397, PubMed:17873522, PubMed:22608923). Функционирует как негативный регулятор JNK-пути, т.к. связывается с фосфорилированным JUN и способствует его последующей убиквитинизации и протеасомой деградации. (PubMed:14739463). </p>  <a title=\"EMBO J., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15103331\">EMBO J., 2005</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17434132\">Mol. Cell, 2007</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17558397\">Nat. Cell Biol., 2007</a>&nbsp;&nbsp;  <a title=\"Cell Cycle, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17873522\">Cell Cycle, 2007</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22608923\">Mol. Cell, 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138199, "symbol": "SDHA", "locus": "5p15.33", "entrez_id": 6389, "chr": "chr5", "start": 218356, "end": 256815, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "succinate dehydrogenase complex flavoprotein subunit A", "description": "<p style=\"text-align: justify\"> Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed:24781757). Can act as a tumor suppressor (PubMed:20484225). </p>  <a title=\"Hum. Mol. Genet., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20484225\">Hum. Mol. Genet., 2010</a>&nbsp;&nbsp;  <a title=\"Eur. J. Hum. Genet., 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24781757\">Eur. J. Hum. Genet., 2015</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138198, "symbol": "MTRR", "locus": "5p15.31", "entrez_id": 4552, "chr": "chr5", "start": 7851299, "end": 7906138, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "5-methyltetrahydrofolate-homocysteine methyltransferase reductase", "description": "<p style=\"text-align: justify\"> Involved in the reductive regeneration of cob(I)alamin (vitamin B12) cofactor required for the maintenance of methionine synthase in a functional state. Necessary for utilization of methylgroups from the folate cycle, thereby affecting transgenerational epigenetic inheritance. Folate pathway donates methyl groups necessary for cellular methylation and affects different pathways such as DNA methylation, possibly explaining the transgenerational epigenetic inheritance effects. </p>  <a title=\"Biochemistry, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17892308\">Biochemistry, 2007</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138197, "symbol": "IL7R", "locus": "5p13.2", "entrez_id": 3575, "chr": "chr5", "start": 35852797, "end": 35879705, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "interleukin 7 receptor", "description": "Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP)", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138196, "symbol": "GDNF", "locus": "5p13.2", "entrez_id": 2668, "chr": "chr5", "start": 37812779, "end": 37839788, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "glial cell derived neurotrophic factor", "description": "<p style=\"text-align: justify\"> Neurotrophic factor that enhances survival and morphological differentiation of dopaminergic neurons and increases their high-affinity dopamine uptake. </p>  <a title=\"Science, 1993\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8493557\">Science, 1993</a>&nbsp;&nbsp;", "gene_type": "STR_VUS"}, {"json_id": 138195, "symbol": "LIFR", "locus": "5p13.1", "entrez_id": 3977, "chr": "chr5", "start": 38475065, "end": 38608456, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "LIF receptor alpha", "description": "Signal-transducing molecule. May have a common pathway with IL6ST. The soluble form inhibits the biological activity of LIF by blocking its binding to receptors on target cells", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138194, "symbol": "IL6ST", "locus": "5q11.2", "entrez_id": 3572, "chr": "chr5", "start": 55230923, "end": 55290821, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "interleukin 6 signal transducer", "description": "<p style=\"text-align: justify\"> Signal-transducing molecule. The receptor systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize IL6ST for initiating signal transmission. Binding of IL6 to IL6R induces IL6ST homodimerization and formation of a high-affinity receptor complex, which activates Janus kinases (PubMed:2261637). That causes phosphorylation of IL6ST tyrosine residues which in turn activates STAT3 (PubMed:19915009, PubMed:23294003). Mediates signals which regulate immune response, hematopoiesis, pain control and bone metabolism (By similarity). Has a role in embryonic development (By similarity). Does not bind IL6 (PubMed:2261637). Essential for survival of motor and sensory neurons and for differentiation of astrocytes (By similarity). Required for expression of TRPA1 in nociceptive neurons (By similarity). Required for the maintenance of PTH1R expression in the osteoblast lineage and for the stimulation of PTH-induced osteoblast differentiation (By similarity). Required for normal trabecular bone mass and cortical bone composition (By similarity). </p>  <a title=\"Cell, 1991\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/2261637\">Cell, 1991</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19915009\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"Biochem. J., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23294003\">Biochem. J., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138193, "symbol": "PIK3R1", "locus": "5q13.1", "entrez_id": 5295, "chr": "chr5", "start": 67511548, "end": 67597649, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phosphoinositide-3-kinase regulatory subunit 1", "description": "<p style=\"text-align: justify\"> Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (PubMed:17626883, PubMed:19805105, PubMed:7518429). Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (PubMed:20348923). </p>  <a title=\"J. Biol. Chem., 1994\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7518429\">J. Biol. Chem., 1994</a>&nbsp;&nbsp;  <a title=\"Science, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17626883\">Science, 2007</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19805105\">Proc. Natl. Acad. Sci. U.S.A., 2010</a>&nbsp;&nbsp;  <a title=\"Nat. Med., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20348923\">Nat. Med., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138192, "symbol": "APC", "locus": "5q22.2", "entrez_id": 324, "chr": "chr5", "start": 112043195, "end": 112181936, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "APC, WNT signaling pathway regulator", "description": "<p style=\"text-align: justify\"> Опухолевый супрессор. АРС способствует быстрой деградации β-катенина, и, таким образом, является негативным регулятором сигнального пути Wnt/β-катенин. Активность APC коррелирует с его фосфорилированием. Активирует GEF-активность для SPATA13 и ARHGEF4. Участвует в миграции клеток, индуцированной факторам роста гепатоцитов (Hepatocyte Growth Factor, HGF). Требуется для повышения уровня MMP9 через сигнальный путь JNK при колоректальном раке. Действует как медиатор Her2-зависимой стабилизации микротрубочек в кортикальном слое. </p>  <a title=\"Science, 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10947987\">Science, 2000</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17599059\">Oncogene, 2008</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19151759\">Oncogene, 2009</a>&nbsp;&nbsp;  <a title=\"EMBO Rep., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19893577\">EMBO Rep., 2010</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20937854\">Proc. Natl. Acad. Sci. U.S.A., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138191, "symbol": "RAD50", "locus": "5q31.1", "entrez_id": 10111, "chr": "chr5", "start": 131891711, "end": 131980313, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "RAD50 double strand break repair protein", "description": "<p style=\"text-align: justify\"> Component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis. The complex possesses single-strand endonuclease activity and double-strand- specific 3'-5' exonuclease activity, which are provided by MRE11. RAD50 may be required to bind DNA ends and hold them in close proximity. This could facilitate searches for short or long regions of sequence homology in the recombining DNA templates, and may also stimulate the activity of DNA ligases and/or restrict the nuclease activity of MRE11 to prevent nucleolytic degradation past a given point (PubMed:11741547, PubMed:9590181, PubMed:9705271, PubMed:9651580). The complex may also be required for DNA damage signaling via activation of the ATM kinase (PubMed:15064416). In telomeres the MRN complex may modulate t-loop formation (PubMed:10888888). </p>  <a title=\"Mol. Cell, 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9651580\">Mol. Cell, 1998</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9705271\">J. Biol. Chem., 1998</a>&nbsp;&nbsp;  <a title=\"Nat. Genet., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10888888\">Nat. Genet., 2000</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11741547\">Mol. Cell, 2002</a>&nbsp;&nbsp;  <a title=\"Science, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15064416\">Science, 2004</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138190, "symbol": "CTNNA1", "locus": "5q31.2", "entrez_id": 1495, "chr": "chr5", "start": 137946656, "end": 138270723, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "catenin alpha 1", "description": "<p style=\"text-align: justify\"> Associates with the cytoplasmic domain of a variety of cadherins. The association of catenins to cadherins produces a complex which is linked to the actin filament network, and which seems to be of primary importance for cadherins cell-adhesion properties. Can associate with both E- and N-cadherins. Originally believed to be a stable component of E-cadherin/catenin adhesion complexes and to mediate the linkage of cadherins to the actin cytoskeleton at adherens junctions. In contrast, cortical actin was found to be much more dynamic than E-cadherin/catenin complexes and CTNNA1 was shown not to bind to F-actin when assembled in the complex suggesting a different linkage between actin and adherens junctions components. The homodimeric form may regulate actin filament assembly and inhibit actin branching by competing with the Arp2/3 complex for binding to actin filaments. May play a crucial role in cell differentiation. </p>  <a title=\"J. Cell. Sci., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25653389\">J. Cell. Sci., 2016</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138189, "symbol": "CSF1R", "locus": "5q32", "entrez_id": 1436, "chr": "chr5", "start": 149432854, "end": 149492935, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "colony stimulating factor 1 receptor", "description": "<p style=\"text-align: justify\"> Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone and tooth development. Required for normal male and female fertility, and for normal development of milk ducts and acinar structures in the mammary gland during pregnancy. Promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration, and promotes cancer cell invasion. Activates several signaling pathways in response to ligand binding. Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL. Activation of PLCG2 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5- trisphosphate, that then lead to the activation of protein kinase C family members, especially PRKCD. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to activation of the AKT1 signaling pathway. Activated CSF1R also mediates activation of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1, and of the SRC family kinases SRC, FYN and YES1. Activated CSF1R transmits signals both via proteins that directly interact with phosphorylated tyrosine residues in its intracellular domain, or via adapter proteins, such as GRB2. Promotes activation of STAT family members STAT3, STAT5A and/or STAT5B. Promotes tyrosine phosphorylation of SHC1 and INPP5D/SHIP- 1. Receptor signaling is down-regulated by protein phosphatases, such as INPP5D/SHIP-1, that dephosphorylate the receptor and its downstream effectors, and by rapid internalization of the activated receptor. </p>  <a title=\"J. Med. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19193011\">J. Med. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19934330\">Cancer Res., 2010</a>&nbsp;&nbsp;  <a title=\"Cell Death Differ., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20489731\">Cell Death Differ., 2011</a>&nbsp;&nbsp;  <a title=\"J. Leukoc. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20504948\">J. Leukoc. Biol., 2010</a>&nbsp;&nbsp;  <a title=\"Cytokine, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20829061\">Cytokine, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138188, "symbol": "PDGFRB", "locus": "5q32", "entrez_id": 5159, "chr": "chr5", "start": 149493400, "end": 149535435, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "platelet derived growth factor receptor beta", "description": "<p style=\"text-align: justify\"> Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5- trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. </p>  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20529858\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21098708\">Cancer Res., 2011</a>&nbsp;&nbsp;  <a title=\"J. Am. Coll. Cardiol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21679854\">J. Am. Coll. Cardiol., 2011</a>&nbsp;&nbsp;  <a title=\"Br. J. Nutr., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21733313\">Br. J. Nutr., 2012</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26599395\">PLoS ONE, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138187, "symbol": "NPM1", "locus": "5q35.1", "entrez_id": 4869, "chr": "chr5", "start": 170814120, "end": 170838141, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nucleophosmin 1", "description": "<p style=\"text-align: justify\"> Involved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors p53/TP53 and ARF. Binds ribosome presumably to drive ribosome nuclear export. Associated with nucleolar ribonucleoprotein structures and bind single-stranded nucleic acids. Acts as a chaperonin for the core histones H3, H2B and H4. Stimulates APEX1 endonuclease activity on apurinic/apyrimidinic (AP) double- stranded DNA but inhibits APEX1 endonuclease activity on AP single-stranded RNA. May exert a control of APEX1 endonuclease activity within nucleoli devoted to repair AP on rDNA and the removal of oxidized rRNA molecules. In concert with BRCA2, regulates centrosome duplication. Regulates centriole duplication: phosphorylation by PLK2 is able to trigger centriole replication. Negatively regulates the activation of EIF2AK2/PKR and suppresses apoptosis through inhibition of EIF2AK2/PKR autophosphorylation. Antagonizes the inhibitory effect of ATF5 on cell proliferation and relieves ATF5-induced G2/M blockade (PubMed:22528486). In complex with MYC enhances the transcription of MYC target genes (PubMed:25956029). </p>  <a title=\"PLoS ONE, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20352051\">PLoS ONE, 2011</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21084279\">Cancer Res., 2011</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22002061\">J. Biol. Chem., 2012</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22528486\">J. Biol. Chem., 2012</a>&nbsp;&nbsp;  <a title=\"Am. J. Pathol., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25956029\">Am. J. Pathol., 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138186, "symbol": "FGFR4", "locus": "5q35.2", "entrez_id": 2264, "chr": "chr5", "start": 176513887, "end": 176525145, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fibroblast growth factor receptor 4", "description": "<p style=\"text-align: justify\"> Рецептор с тирозинкиназной активностью, связывается с факторами роста фибробластов (FGF), регулирует пролиферацию, дифференцировку и миграцию, а также процессы метаболизма. В норме подавляет экспрессию CYP7A1 и ингибирует синтез желчных кислот в ответ на FGF19. После активации лигандом FGFR4 фосфорилирует PLCG1 и FRS2. Активация PLCG1 приводит к образованию вторичных мессенджеров диацилглицерола (DAG) и инозитол-1,4,5-фосфата. Фосфорилирование FRS2 приводит к активации комплекса GRB2, GAB1, PIK3R1 и SOS1, что связано с запуском Ras/MEK/Erk и Akt/PI3K/mTOR сигнальных путей, что приводит к повышению пролиферации клеток. </p>  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20018895\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"Hepatology, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20683963\">Hepatology, 2010</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20798051\">Proc. Natl. Acad. Sci. U.S.A., 2010</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20876804\">Cancer Res., 2010</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21653700\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138185, "symbol": "NSD1", "locus": "5q35.3", "entrez_id": 64324, "chr": "chr5", "start": 176560026, "end": 176727216, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nuclear receptor binding SET domain protein 1", "description": "<p style=\"text-align: justify\"> Histone methyltransferase. Preferentially methylates 'Lys-36' of histone H3 and 'Lys-20' of histone H4 (in vitro). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context. </p>  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21196496\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138184, "symbol": "FLT4", "locus": "5q35.3", "entrez_id": 2324, "chr": "chr5", "start": 180028506, "end": 180076624, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fms related tyrosine kinase 4", "description": "<p style=\"text-align: justify\"> Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3- kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr- 185', and of AKT1 at 'Ser-473'. </p>  <a title=\"Am. J. Pathol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19779139\">Am. J. Pathol., 2009</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20224550\">EMBO J., 2010</a>&nbsp;&nbsp;  <a title=\"Circ. Res., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20431062\">Circ. Res., 2010</a>&nbsp;&nbsp;  <a title=\"Nature, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20445537\">Nature, 2010</a>&nbsp;&nbsp;  <a title=\"Invest. Ophthalmol. Vis. Sci., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21273538\">Invest. Ophthalmol. Vis. Sci., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138183, "symbol": "IRF4", "locus": "6p25.3", "entrez_id": 3662, "chr": "chr6", "start": 391739, "end": 411447, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "interferon regulatory factor 4", "description": "<p style=\"text-align: justify\"> Transcriptional activator. Binds to the interferon- stimulated response element (ISRE) of the MHC class I promoter. Binds the immunoglobulin lambda light chain enhancer, together with PU.1. Probably plays a role in ISRE-targeted signal transduction mechanisms specific to lymphoid cells. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF4 and activation of genes (By similarity). </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138182, "symbol": "DEK", "locus": "6p22.3", "entrez_id": 7913, "chr": "chr6", "start": 18224099, "end": 18265054, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "DEK proto-oncogene", "description": "<p style=\"text-align: justify\"> Involved in chromatin organization. </p>  <a title=\"Biochem. Biophys. Res. Commun., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17524367\">Biochem. Biophys. Res. Commun., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138181, "symbol": "POU5F1", "locus": "6p21.33", "entrez_id": 5460, "chr": "chr6", "start": 31132119, "end": 31148508, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "POU class 5 homeobox 1", "description": "<p style=\"text-align: justify\"> Transcription factor that binds to the octamer motif (5'-ATTTGCAT-3'). Forms a trimeric complex with SOX2 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206. Critical for early embryogenesis and for embryonic stem cell pluripotency. </p>  <a title=\"Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18035408\">Cell, 2008</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138180, "symbol": "NOTCH4", "locus": "6p21.32", "entrez_id": 4855, "chr": "chr6", "start": 32162620, "end": 32191844, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "notch 4", "description": "<p style=\"text-align: justify\"> Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. May regulate branching morphogenesis in the developing vascular system (By similarity). </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138179, "symbol": "DAXX", "locus": "6p21.32", "entrez_id": 1616, "chr": "chr6", "start": 33286335, "end": 33297046, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "death domain associated protein", "description": "<p style=\"text-align: justify\"> Transcription corepressor known to repress transcriptional potential of several sumoylated transcription factors. Down-regulates basal and activated transcription. Its transcription repressor activity is modulated by recruiting it to subnuclear compartments like the nucleolus or PML/POD/ND10 nuclear bodies through interactions with MCSR1 and PML, respectively. Seems to regulate transcription in PML/POD/ND10 nuclear bodies together with PML and may influence TNFRSF6-dependent apoptosis thereby. Inhibits transcriptional activation of PAX3 and ETS1 through direct protein-protein interactions. Modulates PAX5 activity; the function seems to involve CREBBP. Acts as an adapter protein in a MDM2-DAXX-USP7 complex by regulating the RING-finger E3 ligase MDM2 ubiquitination activity. Under non-stress condition, in association with the deubiquitinating USP7, prevents MDM2 self-ubiquitination and enhances the intrinsic E3 ligase activity of MDM2 towards TP53, thereby promoting TP53 ubiquitination and subsequent proteasomal degradation. Upon DNA damage, its association with MDM2 and USP7 is disrupted, resulting in increased MDM2 autoubiquitination and consequently, MDM2 degradation, which leads to TP53 stabilization. Acts as histone chaperone that facilitates deposition of histone H3.3. Acts as targeting component of the chromatin remodeling complex ATRX:DAXX which has ATP-dependent DNA translocase activity and catalyzes the replication-independent deposition of histone H3.3 in pericentric DNA repeats outside S-phase and telomeres, and the in vitro remodeling of H3.3-containing nucleosomes. Does not affect the ATPase activity of ATRX but alleviates its transcription repression activity. Upon neuronal activation associates with regulatory elements of selected immediate early genes where it promotes deposition of histone H3.3 which may be linked to transcriptional induction of these genes. Required for the recruitment of histone H3.3:H4 dimers to PML-nuclear bodies (PML- NBs); the process is independent of ATRX and facilitated by ASF1A; PML-NBs are suggested to function as regulatory sites for the incorporation of newly synthesized histone H3.3 into chromatin. In case of overexpression of centromeric histone variant CENPA (as found in various tumors) is involved in its mislocalization to chromosomes; the ectopic localization involves a heterotypic tetramer containing CENPA, and histones H3.3 and H4 and decreases binding of CTCF to chromatin. Proposed to mediate activation of the JNK pathway and apoptosis via MAP3K5 in response to signaling from TNFRSF6 and TGFBR2. Interaction with HSPB1/HSP27 may prevent interaction with TNFRSF6 and MAP3K5 and block DAXX-mediated apoptosis. In contrast, in lymphoid cells JNC activation and TNFRSF6-mediated apoptosis may not involve DAXX. Shows restriction activity towards human cytomegalovirus (HCMV). Plays a role as a positive regulator of the heat shock transcription factor HSF1 activity during the stress protein response (PubMed:15016915). </p>  <a title=\"Genes Dev., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20504901\">Genes Dev., 2010</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20651253\">Proc. Natl. Acad. Sci. U.S.A., 2010</a>&nbsp;&nbsp;  <a title=\"Genome Res., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23222847\">Genome Res., 2013</a>&nbsp;&nbsp;  <a title=\"Cell Cycle, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24200965\">Cell Cycle, 2014</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24530302\">Mol. Cell, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138178, "symbol": "PIM1", "locus": "6p21.2", "entrez_id": 5292, "chr": "chr6", "start": 37137979, "end": 37143202, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Pim-1 proto-oncogene, serine/threonine kinase", "description": "<p style=\"text-align: justify\"> Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl- X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post- translational levels. Phosphorylation of CDKN1B,induces 14-3-3- proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis. </p>  <a title=\"Biochim. Biophys. Acta, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12431783\">Biochim. Biophys. Acta, 2003</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15528381\">J. Immunol., 2004</a>&nbsp;&nbsp;  <a title=\"Int. J. Biochem. Cell Biol., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16356754\">Int. J. Biochem. Cell Biol., 2006</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18593906\">Cancer Res., 2008</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19749799\">Oncogene, 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138177, "symbol": "FOXP4", "locus": "6p21.1", "entrez_id": 116113, "chr": "chr6", "start": 41514164, "end": 41570122, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "forkhead box P4", "description": "<p style=\"text-align: justify\"> Transcriptional repressor that represses lung-specific expression. </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138176, "symbol": "HSP90AB1", "locus": "6p21.1", "entrez_id": 3326, "chr": "chr6", "start": 44214824, "end": 44221620, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "heat shock protein 90 alpha family class B member 1", "description": "<p style=\"text-align: justify\"> Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:16478993, PubMed:19696785). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself. Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co- chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:27295069, PubMed:26991466). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels. In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues. Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment. Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation (PubMed:24613385). Promotes cell differentiation by chaperoning BIRC2 and thereby protecting from auto-ubiquitination and degradation by the proteasomal machinery (PubMed:18239673). Main chaperone that is involved in the phosphorylation/activation of the STAT1 by chaperoning both JAK2 and PRKCE under heat shock and in turn, activates its own transcription (PubMed:20353823). </p>  <a title=\"Cell. Signal., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20353823\">Cell. Signal., 2010</a>&nbsp;&nbsp;  <a title=\"Biochem. Biophys. Res. Commun., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24613385\">Biochem. Biophys. Res. Commun., 2014</a>&nbsp;&nbsp;  <a title=\"Front Oncol, 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25973397\">Front Oncol, 2015</a>&nbsp;&nbsp;  <a title=\"Biopolymers, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26991466\">Biopolymers, 2017</a>&nbsp;&nbsp;  <a title=\"Biochimie, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27295069\">Biochimie, 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138175, "symbol": "PKHD1", "locus": "6p12.3-p12.2", "entrez_id": 5314, "chr": "chr6", "start": 51480098, "end": 51952423, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "PKHD1, fibrocystin/polyductin", "description": "<p style=\"text-align: justify\"> May be required for correct bipolar cell division through the regulation of centrosome duplication and mitotic spindle assembly. May be a receptor protein that acts in collecting-duct and biliary differentiation. </p>  <a title=\"Hum. Mol. Genet., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20554582\">Hum. Mol. Genet., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138174, "symbol": "ICK", "locus": "6p12.1", "entrez_id": 22858, "chr": "chr6", "start": 52866077, "end": 52926600, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "intestinal cell kinase", "description": "<p style=\"text-align: justify\"> Required for ciliogenesis (PubMed:24797473). Phosphorylates KIF3A (By similarity). Involved in the control of ciliary length (PubMed:24853502). Regulates the ciliary localization of SHH pathway components as well as the localization of IFT components at ciliary tips (By similarity). May play a key role in the development of multiple organ systems and particularly in cardiac development (By similarity). Regulates intraflagellar transport (IFT) speed and negatively regulates cilium length in a cAMP and mTORC1 signaling-dependent manner and this regulation requires its kinase activity (By similarity). </p>  <a title=\"EMBO J., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24797473\">EMBO J., 2014</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24853502\">Proc. Natl. Acad. Sci. U.S.A., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138173, "symbol": "DST", "locus": "6p12.1", "entrez_id": 667, "chr": "chr6", "start": 56322785, "end": 56819426, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "dystonin", "description": "<p style=\"text-align: justify\"> Cytoskeletal linker protein. Acts as an integrator of intermediate filaments, actin and microtubule cytoskeleton networks. Required for anchoring either intermediate filaments to the actin cytoskeleton in neural and muscle cells or keratin- containing intermediate filaments to hemidesmosomes in epithelial cells. The proteins may self-aggregate to form filaments or a two- dimensional mesh. Regulates the organization and stability of the microtubule network of sensory neurons to allow axonal transport. Mediates docking of the dynein/dynactin motor complex to vesicle cargos for retrograde axonal transport through its interaction with TMEM108 and DCTN1 (By similarity). </p>  <a title=\"Cell, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10428034\">Cell, 1999</a>&nbsp;&nbsp;  <a title=\"J. Cell. Sci., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12482924\">J. Cell. Sci., 2003</a>&nbsp;&nbsp;  <a title=\"Mol. Biol. Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19403692\">Mol. Biol. Cell, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138172, "symbol": "ADGRB3", "locus": "6q12-q13", "entrez_id": 577, "chr": "chr6", "start": 69345259, "end": 70099403, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "adhesion G protein-coupled receptor B3", "description": "<p style=\"text-align: justify\"> Receptor that plays a role in the regulation of synaptogenesis and dendritic spine formation at least partly via interaction with ELMO1 and RAC1 activity (By similarity). Promotes myoblast fusion through ELMO/DOCK1 (PubMed:24567399). </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24567399\">Proc. Natl. Acad. Sci. U.S.A., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138171, "symbol": "MAP3K7", "locus": "6q15", "entrez_id": 6885, "chr": "chr6", "start": 91223292, "end": 91296764, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mitogen-activated protein kinase kinase kinase 7", "description": "<p style=\"text-align: justify\"> Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2- induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity. </p>  <a title=\"Nature, 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11460167\">Nature, 2001</a>&nbsp;&nbsp;  <a title=\"Mol. Biol. Cell, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12589052\">Mol. Biol. Cell, 2003</a>&nbsp;&nbsp;  <a title=\"EMBO Rep., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16845370\">EMBO Rep., 2006</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16893890\">J. Biol. Chem., 2006</a>&nbsp;&nbsp;  <a title=\"Nature, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21512573\">Nature, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138170, "symbol": "EPHA7", "locus": "6q16.1", "entrez_id": 2045, "chr": "chr6", "start": 93949738, "end": 94129265, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "EPH receptor A7", "description": "<p style=\"text-align: justify\"> Receptor tyrosine kinase which binds promiscuously GPI- anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Among GPI-anchored ephrin-A ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their interaction regulates brain development modulating cell-cell adhesion and repulsion. Has a repellent activity on axons and is for instance involved in the guidance of corticothalamic axons and in the proper topographic mapping of retinal axons to the colliculus. May also regulate brain development through a caspase(CASP3)-dependent proapoptotic activity. Forward signaling may result in activation of components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1 AND MAPK3 which are phosphorylated upon activation of EPHA7. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17726105\">Proc. Natl. Acad. Sci. U.S.A., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138169, "symbol": "PRDM1", "locus": "6q21", "entrez_id": 639, "chr": "chr6", "start": 106534195, "end": 106557814, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "PR/SET domain 1", "description": "<p style=\"text-align: justify\"> Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote the egress of tissue-resident T-cell populations from non-lymphoid organs. Plays a role in the development, retention and long-term establishment of adaptive and innate tissue-resident lymphocyte T cell types in non-lymphoid organs, such as the skin and gut, but also in other nonbarrier tissues like liver and kidney, and therefore may provide immediate immunological protection against reactivating infections or viral reinfection (By similarity). Binds specifically to the PRDI element in the promoter of the beta-interferon gene (PubMed:1851123). Drives the maturation of B- lymphocytes into Ig secreting cells (PubMed:12626569). Associates with the transcriptional repressor ZNF683 to chromatin at gene promoter regions (By similarity). </p>  <a title=\"Genes Dev., 1991\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/1851123\">Genes Dev., 1991</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12626569\">J. Immunol., 2003</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138168, "symbol": "FOXO3", "locus": "6q21", "entrez_id": 2309, "chr": "chr6", "start": 108881038, "end": 109005977, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "forkhead box O3", "description": "<p style=\"text-align: justify\"> Transcriptional activator which triggers apoptosis in the absence of survival factors, including neuronal cell death upon oxidative stress. Recognizes and binds to the DNA sequence 5'-[AG]TAAA[TC]A-3'. Participates in post-transcriptional regulation of MYC: following phosphorylation by MAPKAPK5, promotes induction of miR-34b and miR-34c expression, 2 post- transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent its translation. </p>  <a title=\"Cell, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10102273\">Cell, 1999</a>&nbsp;&nbsp;  <a title=\"Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16751106\">Cell, 2006</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21329882\">Mol. Cell, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138167, "symbol": "ROS1", "locus": "6q22.1", "entrez_id": 6098, "chr": "chr6", "start": 117609463, "end": 117747018, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ROS proto-oncogene 1, receptor tyrosine kinase", "description": "<p style=\"text-align: justify\"> Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2. </p>  <a title=\"Mol. Cell. Biol., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11094073\">Mol. Cell. Biol., 2001</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16885344\">Cancer Res., 2006</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138166, "symbol": "SGK1", "locus": "6q23.2", "entrez_id": 6446, "chr": "chr6", "start": 134490384, "end": 134639250, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "serum/glucocorticoid regulated kinase 1", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarization and memory consolidation. Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na(+)/dicarboxylate cotransporter: SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Stimulates sodium transport into epithelial cells by enhancing the stability and expression of SCNN1A/ENAC. This is achieved by phosphorylating the NEDD4L ubiquitin E3 ligase, promoting its interaction with 14-3-3 proteins, thereby preventing it from binding to SCNN1A/ENAC and targeting it for degradation. Regulates store-operated Ca(+2) entry (SOCE) by stimulating ORAI1 and STIM1. Regulates KCNJ1/ROMK1 directly via its phosphorylation or indirectly via increased interaction with SLC9A3R2/NHERF2. Phosphorylates MDM2 and activates MDM2-dependent ubiquitination of p53/TP53. Phosphorylates MAPT/TAU and mediates microtubule depolymerization and neurite formation in hippocampal neurons. Phosphorylates SLC2A4/GLUT4 and up-regulates its activity. Phosphorylates APBB1/FE65 and promotes its localization to the nucleus. Phosphorylates MAPK1/ERK2 and activates it by enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. Phosphorylates FBXW7 and plays an inhibitory role in the NOTCH1 signaling. Phosphorylates FOXO1 resulting in its relocalization from the nucleus to the cytoplasm. Phosphorylates FOXO3, promoting its exit from the nucleus and interference with FOXO3-dependent transcription. Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits their activity. Phosphorylates SLC9A3/NHE3 in response to dexamethasone, resulting in its activation and increased localization at the cell membrane. Phosphorylates CREB1. Necessary for vascular remodeling during angiogenesis. Sustained high levels and activity may contribute to conditions such as hypertension and diabetic nephropathy. Isoform 2 exhibited a greater effect on cell plasma membrane expression of SCNN1A/ENAC and Na(+) transport than isoform 1. </p>  <a title=\"J. Hepatol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19447520\">J. Hepatol., 2009</a>&nbsp;&nbsp;  <a title=\"J. Mol. Med., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19756449\">J. Mol. Med., 2010</a>&nbsp;&nbsp;  <a title=\"Cell. Physiol. Biochem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20511718\">Cell. Physiol. Biochem., 2010</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20730100\">PLoS ONE, 2010</a>&nbsp;&nbsp;  <a title=\"Mol. Biol. Cell, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21865597\">Mol. Biol. Cell, 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138165, "symbol": "MYB", "locus": "6q23.3", "entrez_id": 4602, "chr": "chr6", "start": 135502453, "end": 135540311, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MYB proto-oncogene, transcription factor", "description": "Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'. Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138164, "symbol": "TNFAIP3", "locus": "6q23.3", "entrez_id": 7128, "chr": "chr6", "start": 138188351, "end": 138204449, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "TNF alpha induced protein 3", "description": "<p style=\"text-align: justify\"> Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS- induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages. </p>  <a title=\"J. Mol. Biol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18164316\">J. Mol. Biol., 2008</a>&nbsp;&nbsp;  <a title=\"Biochim. Biophys. Acta, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18952128\">Biochim. Biophys. Acta, 2009</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19494296\">J. Immunol., 2009</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22099304\">Mol. Cell, 2012</a>&nbsp;&nbsp;  <a title=\"Cell, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23827681\">Cell, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138163, "symbol": "ESR1", "locus": "6q25.1-q25.2", "entrez_id": 2099, "chr": "chr6", "start": 151977826, "end": 152450754, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "estrogen receptor 1", "description": "<p style=\"text-align: justify\"> Ген, кодирующий ядерный рецептор эстрогена. Стероидные гормоны и их рецепторы участвуют в регуляции экспрессии эукариотических генов и влияют на пролиферацию и дифференцировку клеток в тканях-мишенях. Лиганд-зависимая ядерная трансактивация включает либо прямое связывание гомодимера с последовательностью палиндромного эстрогенового респонсивного элемента (ERE), либо ассоциацию с другими ДНК-связывающими факторами транскрипции, такими как AP-1/c-Jun, c-Fos, ATF-2, Sp1 и Sp3, для передачи ERE-независимой сигнализации. Связывание лиганда индуцирует конформационные изменения, допускающие последовательную или комбинаторную ассоциацию с мультипротеиновыми комплексами коактиваторов через мотивы LXXLL их соответствующих компонентов. Возможна взаимная трансрепрессия между рецептором эстрогена ER1 и NF-κB, специфичная для разных типов клеток. ER Снижает ДНК-связывающую активность NF-κB и ингибирует NF-κB-опосредованную транскрипцию с промотора IL6 и вытесняет p65 и связанные корегуляторы с промотора. Привлекается к респонсивному элементу NF-κB-регулируемых промоторов CCL2 и IL8 и может вытеснять CREBBP. Присутствует с компонентами NF-κB-пути RELA/p65 и NFKB1/p50 на ERE-последовательностях. ER может также действовать синергетически с NF-κB для активации транскрипции с участием соответствующих соседних респонсивных элементов, включая взаимодействие с CREBBP. Может активировать транскрипционную активность TFF1. ER опосредует передачу сигналов эстрогена с участием различных киназных каскадов. Изоформа 3 ER участвует в активации NOS3 и эндотелиальной продукции оксида азота. Предполагается, что изоформы ER, лишенные одного или нескольких функциональных доменов, модулируют транскрипционную активность путем конкурентного связывания лиганда или ДНК и/или гетеродимеризации с полноразмерным рецептором. Необходим для MTA1-опосредованной регуляции транскрипции BRCA1 и BCAS3. Изоформа 3 ER может связываться с ERE и ингибировать изоформу 1 ER. </p>  <a title=\"J. Cell. Biochem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19350539\">J. Cell. Biochem., 2009</a>&nbsp;&nbsp;  <a title=\"Biochem. Biophys. Res. Commun., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20074560\">Biochem. Biophys. Res. Commun., 2010</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20705611\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"Mol. Endocrinol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21330404\">Mol. Endocrinol., 2011</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22083956\">Mol. Cell. Biol., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_CLIN_SIGNIF"}, {"json_id": 138162, "symbol": "SYNE1", "locus": "6q25.2", "entrez_id": 23345, "chr": "chr6", "start": 152442819, "end": 152958936, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "spectrin repeat containing nuclear envelope protein 1", "description": "<p style=\"text-align: justify\"> Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. As a component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and positioning. May be involved in nucleus-centrososme attachment and nuclear migration in neural progenitors implicating LINC complex association with SUN1/2 and probably association with cytoplasmic dynein-dynactin motor complexes; SYNE1 and SYNE2 may act redundantly. Required for centrosome migration to the apical cell surface during early ciliogenesis. May be involved in nuclear remodeling during sperm head formation in spermatogenenis; a probable SUN3:SYNE1/KASH1 LINC complex may tether spermatid nuclei to posterior cytoskeletal structures such as the manchette. </p>  <a title=\"J. Cell. Sci., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11792814\">J. Cell. Sci., 2002</a>&nbsp;&nbsp;  <a title=\"Exp. Cell Res., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18396275\">Exp. Cell Res., 2008</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138161, "symbol": "IGF2R", "locus": "6q25.3", "entrez_id": 3482, "chr": "chr6", "start": 160390131, "end": 160534539, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "insulin like growth factor 2 receptor", "description": "<p style=\"text-align: justify\"> Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6- phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. This receptor also binds IGF2. Acts as a positive regulator of T-cell coactivation, by binding DPP4. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10900005\">Proc. Natl. Acad. Sci. U.S.A., 2000</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138160, "symbol": "RPS6KA2", "locus": "6q27", "entrez_id": 6196, "chr": "chr6", "start": 166822852, "end": 167319939, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ribosomal protein S6 kinase A2", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of transcription factors, regulates translation, and mediates cellular proliferation, survival, and differentiation. May function as tumor suppressor in epithelial ovarian cancer cells. </p>  <a title=\"Mol. Cell. Biol., 1995\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7623830\">Mol. Cell. Biol., 1995</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16878154\">Oncogene, 2007</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138159, "symbol": "CARD11", "locus": "7p22.2", "entrez_id": 84433, "chr": "chr7", "start": 2945775, "end": 3083579, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "caspase recruitment domain family member 11", "description": "Involved in the costimulatory signal essential for T- cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Activates NF-kappa-B via BCL10 and IKK. Stimulates the phosphorylation of BCL10", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138158, "symbol": "PMS2", "locus": "7p22.1", "entrez_id": 5395, "chr": "chr7", "start": 6012870, "end": 6048756, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "PMS1 homolog 2, mismatch repair system component", "description": "<p style=\"text-align: justify\"> Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2- MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. </p>  <a title=\"Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16873062\">Cell, 2006</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18206974\">Mol. Cell, 2008</a>&nbsp;&nbsp;  <a title=\"J. Med. Genet., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23709753\">J. Med. Genet., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138157, "symbol": "ETV1", "locus": "7p21.2", "entrez_id": 2115, "chr": "chr7", "start": 13930853, "end": 14031050, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ETS variant 1", "description": "Transcriptional activator that binds to DNA sequences containing the consensus pentanucleotide 5'-CGGA[AT]-3'", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138156, "symbol": "IKZF1", "locus": "7p12.2", "entrez_id": 10320, "chr": "chr7", "start": 50343720, "end": 50472799, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "IKAROS family zinc finger 1", "description": "<p style=\"text-align: justify\"> Transcription regulator of hematopoietic cell differentiation (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265, PubMed:19141594). Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2 chromatin-remodeling complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex), to the beta- globin locus in adult erythrocytes. Increases normal apoptosis in adult erythroid cells. Confers early temporal competence to retinal progenitor cells (RPCs) (By similarity). Function is isoform-specific and is modulated by dominant-negative inactive isoforms (PubMed:17135265, PubMed:17934067). </p>  <a title=\"Immunity, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10204490\">Immunity, 1999</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17135265\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;  <a title=\"Blood, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17934067\">Blood, 2008</a>&nbsp;&nbsp;  <a title=\"Genome Res., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19141594\">Genome Res., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138155, "symbol": "EGFR", "locus": "7p11.2", "entrez_id": 1956, "chr": "chr7", "start": 55086714, "end": 55324313, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "epidermal growth factor receptor", "description": "<p style=\"text-align: justify\"> Рецептор с тирозинкиназной активностью, связывающий лиганды EGF-семейства и передающий сигнал внутрь клетки. К известным лигандам относят EGF, TGFA/TGFα, amphiregulin, EPGN, BTC/β-cellulin, EREG и HBEGF/связанный с гепарином EGF. После связывания лиганда запускается гомо-, гетеродимеризация и аутофосфорилирование рецептора. Фосфорилированный рецептор активирует GRB2, который активирует нижележащие сигнальные каскады, а именно RAS- RAF-MEK-ERK, PI3K-AKT-mTOR, PLCγ-PKC и STAT. Также может активировать NF-kappa-B сигнальный каскад. Напрямую фосфорилирует другие протеины, такие как RGS16, активируя его ГТФазную активновность и, вероятно, активируя EGF сигналинг с помощью G-белков. Также фосфорилирует MUC1 и способствует его взаимодействию с SRC и CTNNB1 / β-катенином. </p>  <a title=\"Nat. Med., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21516087\">Nat. Med., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138154, "symbol": "SBDS", "locus": "7q11.21", "entrez_id": 51119, "chr": "chr7", "start": 66452664, "end": 66460588, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SBDS, ribosome maturation factor", "description": "<p style=\"text-align: justify\"> Required for the assembly of mature ribosomes and ribosome biogenesis. Together with EFL1, triggers the GTP- dependent release of EIF6 from 60S pre-ribosomes in the cytoplasm, thereby activating ribosomes for translation competence by allowing 80S ribosome assembly and facilitating EIF6 recycling to the nucleus, where it is required for 60S rRNA processing and nuclear export. Required for normal levels of protein synthesis. May play a role in cellular stress resistance. May play a role in cellular response to DNA damage. May play a role in cell proliferation. </p>  <a title=\"Exp. Cell Res., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17643419\">Exp. Cell Res., 2008</a>&nbsp;&nbsp;  <a title=\"Hum. Mol. Genet., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19602484\">Hum. Mol. Genet., 2009</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19759903\">PLoS ONE, 2010</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21536732\">Genes Dev., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138153, "symbol": "AKAP9", "locus": "7q21.2", "entrez_id": 10142, "chr": "chr7", "start": 91570181, "end": 91739987, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "A-kinase anchoring protein 9", "description": "<p style=\"text-align: justify\"> Scaffolding protein that assembles several protein kinases and phosphatases on the centrosome and Golgi apparatus. Required to maintain the integrity of the Golgi apparatus (PubMed:10202149, PubMed:15047863). Recruited to the Golgi apparatus by GM130/GOLGA2 and is required for microtubule nucleation at the cis-side of the Golgi apparatusGM130/GOLGA2. Required for association of the centrosomes with the poles of the bipolar mitotic spindle during metaphase (PubMed:25657325). </p>  <a title=\"EMBO J., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10202149\">EMBO J., 1999</a>&nbsp;&nbsp;  <a title=\"Mol. Biol. Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15047863\">Mol. Biol. Cell, 2004</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19242490\">EMBO J., 2009</a>&nbsp;&nbsp;  <a title=\"Mol. Biol. Cell, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25657325\">Mol. Biol. Cell, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138152, "symbol": "CDK6", "locus": "7q21.2", "entrez_id": 1021, "chr": "chr7", "start": 92234235, "end": 92465908, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin dependent kinase 6", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition. Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase at G1 to form a pRB/RB1 kinase and controls the entrance into the cell cycle. Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation and regulates negatively cell differentiation, but is required for the proliferation of specific cell types (e.g. erythroid and hematopoietic cells). Essential for cell proliferation within the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles. Required during thymocyte development. Promotes the production of newborn neurons, probably by modulating G1 length. Promotes, at least in astrocytes, changes in patterns of gene expression, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. Prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation activity, but promotes proliferation of normal myeloid progenitors. Delays senescence. Promotes the proliferation of beta-cells in pancreatic islets of Langerhans. May play a role in the centrosome organization during the cell cycle phases (PubMed:23918663). </p>  <a title=\"Mol. Cell. Biol., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17420273\">Mol. Cell. Biol., 2007</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17431401\">EMBO J., 2007</a>&nbsp;&nbsp;  <a title=\"PLoS Pathog., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20333249\">PLoS Pathog., 2010</a>&nbsp;&nbsp;  <a title=\"Diabetes, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20668294\">Diabetes, 2010</a>&nbsp;&nbsp;  <a title=\"Hum. Mol. Genet., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23918663\">Hum. Mol. Genet., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138151, "symbol": "SAMD9", "locus": "7q21.2", "entrez_id": 54809, "chr": "chr7", "start": 92728829, "end": 92747336, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "sterile alpha motif domain containing 9", "description": "<p style=\"text-align: justify\"> May play a role in the inflammatory response to tissue injury and the control of extra-osseous calcification, acting as a downstream target of TNF-alpha signaling. Involved in the regulation of EGR1, in coordination with RGL2. May be involved in endosome fusion. </p>  <a title=\"Am. J. Hum. Genet., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16960814\">Am. J. Hum. Genet., 2006</a>&nbsp;&nbsp;  <a title=\"J. Invest. Dermatol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18094730\">J. Invest. Dermatol., 2008</a>&nbsp;&nbsp;  <a title=\"J. Invest. Dermatol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21160498\">J. Invest. Dermatol., 2011</a>&nbsp;&nbsp;  <a title=\"Cancer Cell, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24029230\">Cancer Cell, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138150, "symbol": "TRRAP", "locus": "7q22.1", "entrez_id": 8295, "chr": "chr7", "start": 98475556, "end": 98610866, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "transformation/transcription domain associated protein", "description": "<p style=\"text-align: justify\"> Adapter protein, which is found in various multiprotein chromatin complexes with histone acetyltransferase activity (HAT), which gives a specific tag for epigenetic transcription activation. Component of the NuA4 histone acetyltransferase complex which is responsible for acetylation of nucleosomal histones H4 and H2A. Plays a central role in MYC transcription activation, and also participates in cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4-mediated transcription activation. Also involved in transcription activation mediated by the adenovirus E1A, a viral oncoprotein that deregulates transcription of key genes. Probably acts by linking transcription factors such as E1A, MYC or E2F1 to HAT complexes such as STAGA thereby allowing transcription activation. Probably not required in the steps following histone acetylation in processes of transcription activation. May be required for the mitotic checkpoint and normal cell cycle progression. Component of a SWR1- like complex that specifically mediates the removal of histone H2A.Z/H2AFZ from the nucleosome. </p>  <a title=\"J. Biol. Chem., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12660246\">J. Biol. Chem., 2003</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12743606\">Oncogene, 2003</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14966270\">Mol. Cell. Biol., 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17967892\">Mol. Cell. Biol., 2008</a>&nbsp;&nbsp;  <a title=\"Nature, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24463511\">Nature, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138149, "symbol": "EPHB4", "locus": "7q22.1", "entrez_id": 2050, "chr": "chr7", "start": 100400187, "end": 100425121, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "EPH receptor B4", "description": "<p style=\"text-align: justify\"> Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cognate ligand/functional ligand EFNB2 plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. EPHB4- mediated forward signaling controls cellular repulsion and segregation form EFNB2-expressing cells. Plays also a role in postnatal blood vessel remodeling, morphogenesis and permeability and is thus important in the context of tumor angiogenesis. </p>  <a title=\"J. Cell. Sci., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12734395\">J. Cell. Sci., 2004</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16424904\">EMBO J., 2006</a>&nbsp;&nbsp;  <a title=\"J. Clin. Invest., 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27400125\">J. Clin. Invest., 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138148, "symbol": "PIK3CG", "locus": "7q22.3", "entrez_id": 5294, "chr": "chr7", "start": 106505723, "end": 106547590, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma", "description": "<p style=\"text-align: justify\"> Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G-protein coupled receptor activation to PIP3 production. Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarization and migration by regulating the spatial accumulation of PIP3 and by regulating the organization of F-actin formation and integrin- based adhesion at the leading edge. Controls motility of dendritic cells. Together with PIK3CD is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in T-lymphocyte migration. Regulates T-lymphocyte proliferation and cytokine production. Together with PIK3CD participates in T-lymphocyte development. Required for B- lymphocyte development and signaling. Together with PIK3CD participates in neutrophil respiratory burst. Together with PIK3CD is involved in neutrophil chemotaxis and extravasation. Together with PIK3CB promotes platelet aggregation and thrombosis. Regulates alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) adhesive function in platelets downstream of P2Y12 through a lipid kinase activity-independent mechanism. May have also a lipid kinase activity-dependent function in platelet aggregation. Involved in endothelial progenitor cell migration. Negative regulator of cardiac contractility. Modulates cardiac contractility by anchoring protein kinase A (PKA) and PDE3B activation, reducing cAMP levels. Regulates cardiac contractility also by promoting beta-adrenergic receptor internalization by binding to GRK2 and by non-muscle tropomyosin phosphorylation. Also has serine/threonine protein kinase activity: both lipid and protein kinase activities are required for beta-adrenergic receptor endocytosis. May also have a scaffolding role in modulating cardiac contractility. Contributes to cardiac hypertrophy under pathological stress. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis. </p>  <a title=\"Science, 1995\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7624799\">Science, 1995</a>&nbsp;&nbsp;  <a title=\"J. Cell Biol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12163475\">J. Cell Biol., 2002</a>&nbsp;&nbsp;  <a title=\"Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15294162\">Cell, 2004</a>&nbsp;&nbsp;  <a title=\"Nat. Cell Biol., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16094730\">Nat. Cell Biol., 2005</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21393242\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138147, "symbol": "MET", "locus": "7q31.2", "entrez_id": 4233, "chr": "chr7", "start": 116312444, "end": 116438440, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MET proto-oncogene, receptor tyrosine kinase", "description": "<p style=\"text-align: justify\"> Ген МЕТ кодирует рецепторную тирозинкиназу с-МЕТ, которая передает сигналы из внеклеточного матрикса в цитоплазму путем связывания с лигандом - гепатоцитарным фактором роста HGF. с-МЕТ регулирует многие физиологические процессы, включая пролиферацию, выживание, миграцию и морфогенез. Связывание лиганда на поверхности клетки индуцирует аутофосфорилирование с-МЕТ во внутриклеточном домене белка, сайты которого узнаются соответствующими эффекторными молекулами. После активации лигандом с-МЕТ взаимодействует с регуляторной субъединицей PI3-киназы PIK3R1, а также с PLCG1, SRC, GRB2, STAT3 или адаптерным белком GAB1. Взаимодействие с-MET с этими эффекторными молекулами приводит к активации нескольких сигнальных каскадов, включая пути Ras/MAPK/Erk, PI3K/Akt или PLC/PKC. Активация каскада Ras/MAPK/Erk обеспечивает в основном морфогенетическую регуляцию, в то время как путь PI3K/Akt координирует процессы выживания клеток. Во время эмбрионального развития с-MET-регулируемый путь передачи сигналов функционирует в процессах гаструляции, миграции предшественников миоцитов и нейронов, в ангиогенезе и при органогенезе почек. В постнатальном периоде с-MET-сигнализация участвует в процессах заживления ран, регенерации органов и тканей. Обеспечивает дифференцировку и пролиферацию гемопоэтических клеток. </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138146, "symbol": "POT1", "locus": "7q31.33", "entrez_id": 25913, "chr": "chr7", "start": 124462440, "end": 124570037, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "protection of telomeres 1", "description": "<p style=\"text-align: justify\"> Component of the telomerase ribonucleoprotein (RNP) complex that is essential for the replication of chromosome termini. Is a component of the double-stranded telomeric DNA- binding TRF1 complex which is involved in the regulation of telomere length by cis-inhibition of telomerase. Also acts as a single-stranded telomeric DNA-binding protein and thus may act as a downstream effector of the TRF1 complex and may transduce information about telomere maintenance and/or length to the telomere terminus. Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection. Shelterin associates with arrays of double-stranded TTAGGG repeats added by telomerase and protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage surveillance and chromosome ends are inappropriately processed by DNA repair pathways. Binds to two or more telomeric single-stranded 5'-TTAGGG-3' repeats (G-strand) and with high specificity to a minimal telomeric single-stranded 5'- TAGGGTTAG-3' sequence. Binds telomeric single-stranded sequences internally or at proximity of a 3'-end. Its activity is TERT dependent but it does not increase TERT activity by itself. In contrast, the ACD-POT1 heterodimer enhances telomere elongation by increasing telomerase processivity. </p>  <a title=\"Nature, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12768206\">Nature, 2003</a>&nbsp;&nbsp;  <a title=\"Curr. Biol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12781132\">Curr. Biol., 2004</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16166375\">Genes Dev., 2005</a>&nbsp;&nbsp;  <a title=\"Nature, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17237768\">Nature, 2007</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20231318\">Genes Dev., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138145, "symbol": "GRM8", "locus": "7q31.33", "entrez_id": 2918, "chr": "chr7", "start": 126078652, "end": 126893348, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "glutamate metabotropic receptor 8", "description": "<p style=\"text-align: justify\"> G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. </p>  <a title=\"Brain Res. Mol. Brain Res., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9473604\">Brain Res. Mol. Brain Res., 1998</a>&nbsp;&nbsp;", "gene_type": "STR_VUS"}, {"json_id": 138144, "symbol": "SMO", "locus": "7q32.1", "entrez_id": 6608, "chr": "chr7", "start": 128828713, "end": 128853386, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "smoothened, frizzled class receptor", "description": "<p style=\"text-align: justify\"> Рецептор представляет собой белок G-подобного типа, который в ассоциации с белком PTCH активирует Хеджхог сигнальный путь. SMO является известной мишенью для препарата Висмодегиба, первого разработанного ингибитора Хеджхог-сигналинга и сертифицированного FDA. Считается, что будучи стимулированным, SMO перемещается ввдоль плазматической мембраны и этот процесс контролируется cAMP-PKA, комплексом, который также способствует активации Хеджхог - сигналинга в целом. SMO принимает также участие в процессе трансляции путем активации и репрессии. </p>  <a title=\"Curr. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19592253\">Curr. Biol., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138143, "symbol": "TRIM24", "locus": "7q33-q34", "entrez_id": 8805, "chr": "chr7", "start": 138145079, "end": 138274738, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "tripartite motif containing 24", "description": "<p style=\"text-align: justify\"> Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes. Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity. Promotes ubiquitination and proteasomal degradation of p53/TP53. Plays a role in the regulation of cell proliferation and apoptosis, at least in part via its effects on p53/TP53 levels. Up-regulates ligand-dependent transcription activation by AR, GCR/NR3C1, thyroid hormone receptor (TR) and ESR1. Modulates transcription activation by retinoic acid (RA) receptors, including RARA. Plays a role in regulating retinoic acid-dependent proliferation of hepatocytes (By similarity). </p>  <a title=\"Mol. Endocrinol., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16322096\">Mol. Endocrinol., 2006</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19556538\">Proc. Natl. Acad. Sci. U.S.A., 2009</a>&nbsp;&nbsp;  <a title=\"Nature, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21164480\">Nature, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138142, "symbol": "BRAF", "locus": "7q34", "entrez_id": 673, "chr": "chr7", "start": 140419127, "end": 140624564, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "B-Raf proto-oncogene, serine/threonine kinase", "description": "<p style=\"text-align: justify\"> Ген BRAF кодирует протеинкиназу, участвующую в трансдукции митогенных сигналов от клеточной мембраны к ядру. Может играть роль в постсинаптических реакциях нейронов гиппокампа. Фосфорилирует MAP2K1 и, тем самым, способствуют внутриклеточной сигнализации через MAP-киназы. </p>  <a title=\"Nature, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21441910\">Nature, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138141, "symbol": "TNFRSF14", "locus": "1p36.32", "entrez_id": 8764, "chr": "chr1", "start": 2487078, "end": 2496821, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "TNF receptor superfamily member 14", "description": "<p style=\"text-align: justify\"> Receptor for BTLA. Receptor for TNFSF14/LIGHT and homotrimeric TNFSF1/lymphotoxin-alpha. Involved in lymphocyte activation. Plays an important role in HSV pathogenesis because it enhanced the entry of several wild-type HSV strains of both serotypes into CHO cells, and mediated HSV entry into activated human T-cells. </p>  <a title=\"Cell, 1996\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8898196\">Cell, 1996</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138140, "symbol": "PLEKHG5", "locus": "1p36.31", "entrez_id": 57449, "chr": "chr1", "start": 6526152, "end": 6580121, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "pleckstrin homology and RhoGEF domain containing G5", "description": "<p style=\"text-align: justify\"> Guanine nucleotide exchange factor that activates RHOA and maybe the NF-kappa-B signaling pathway. Involved in the control of neuronal cell differentiation. Plays a role in angiogenesis through regulation of endothelial cells chemotaxis. </p>  <a title=\"Oncogene, 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11704860\">Oncogene, 2001</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12761501\">Oncogene, 2003</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138139, "symbol": "PIK3CD", "locus": "1p36.22", "entrez_id": 5293, "chr": "chr1", "start": 9711790, "end": 9789172, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta", "description": "<p style=\"text-align: justify\"> Phosphoinositide-3-kinase (PI3K) that phosphorylates PftdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Have a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Have important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity. </p>  <a title=\"Blood, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20081091\">Blood, 2010</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22020336\">Oncogene, 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138138, "symbol": "MTOR", "locus": "1p36.22", "entrez_id": 2475, "chr": "chr1", "start": 11166592, "end": 11322564, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mechanistic target of rapamycin", "description": "<p style=\"text-align: justify\"> Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4. Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1- mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1- pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex. Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor. In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1. To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A. mTORC1 also negatively regulates autophagy through phosphorylation of ULK1. Under nutrient sufficiency, phosphorylates ULK1 at 'Ser- 758', disrupting the interaction with AMPK and preventing activation of ULK1. Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP. mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor. Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules. As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton. Plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1. mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B. mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422'. Regulates osteoclastogensis by adjusting the expression of CEBPB isoforms (By similarity). </p>  <a title=\"Mol. Cell. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20516213\">Mol. Cell. Biol., 2010</a>&nbsp;&nbsp;  <a title=\"Curr. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20537536\">Curr. Biol., 2010</a>&nbsp;&nbsp;  <a title=\"Science, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21659604\">Science, 2011</a>&nbsp;&nbsp;  <a title=\"Science, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23429703\">Science, 2013</a>&nbsp;&nbsp;  <a title=\"Science, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23429704\">Science, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138137, "symbol": "SDHB", "locus": "1p36.13", "entrez_id": 6390, "chr": "chr1", "start": 17345217, "end": 17380665, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "succinate dehydrogenase complex iron sulfur subunit B", "description": "Прикрепляющаяся к мембране субъединица сукцинатдегидрогеназы (SDH), которая входит в комплекс II электронно-транспортной цепи митохондрии и ответственна за перенос электронов с сукцината на убихинон (коэнзим Q).", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138136, "symbol": "PAX7", "locus": "1p36.13", "entrez_id": 5081, "chr": "chr1", "start": 18957500, "end": 19075360, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "paired box 7", "description": "<p style=\"text-align: justify\"> Transcription factor playing a role in myogenesis through regulation of muscle precursor cells proliferation. </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138135, "symbol": "ARID1A", "locus": "1p36.11", "entrez_id": 8289, "chr": "chr1", "start": 27022524, "end": 27108595, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "AT-rich interaction domain 1A", "description": "<p style=\"text-align: justify\"> Участвует в процессах транскрипции путем активации/репрессии соответствующих генов и ремоделирования хроматина (изменение топологии ДНК-нуклеосомы); неспецифически связывается с ДНК. Входит в состав хроматинремоделирующего белкового комплекса, специфичного для нейронов (npBAF-комплекс). Белковые субъединицы npBAF и nBAF участвуют в процессе перехода пролиферирующих нейронных стволовых клеток/клеток-предшественников к постмитотическим нейронам. Комплекс npBAF необходим для поддержания способности к пролиферации и самообновления мультипотентных нейронных стволовых клеток. Комплекс nBAF также играет роль в регуляции активности генов, необходимых для роста дендритов. </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138134, "symbol": "LCK", "locus": "1p35.2", "entrez_id": 3932, "chr": "chr1", "start": 32716840, "end": 32751766, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "LCK proto-oncogene, Src family tyrosine kinase", "description": "<p style=\"text-align: justify\"> Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T- cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated LCK protein to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAM) of the cytoplasmic tails of the TCR-gamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70, that becomes phosphorylated and activated by LCK. Following this, a large number of signaling molecules are recruited, ultimately leading to lymphokine production. LCK also contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, which leads to hyperphosphorylation and activation of LCK. Also plays a role in the IL2 receptor-linked signaling pathway that controls the T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR. Phosphorylates other substrates including RUNX3, PTK2B/PYK2, the microtubule-associated protein MAPT, RHOH or TYROBP. Interacts with ARAP (PubMed:27335501). </p>  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20100835\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"Cell. Signal., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20851766\">Cell. Signal., 2011</a>&nbsp;&nbsp;  <a title=\"Mol Neurodegener, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21269457\">Mol Neurodegener, 2011</a>&nbsp;&nbsp;  <a title=\"J. Clin. Invest., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22080863\">J. Clin. Invest., 2012</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27335501\">J. Immunol., 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138133, "symbol": "MYCL", "locus": "1p34.2", "entrez_id": 4610, "chr": "chr1", "start": 40361098, "end": 40367928, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MYCL proto-oncogene, bHLH transcription factor", "description": "-", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138132, "symbol": "MPL", "locus": "1p34.2", "entrez_id": 4352, "chr": "chr1", "start": 43803478, "end": 43818443, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MPL proto-oncogene, thrombopoietin receptor", "description": "Receptor for thrombopoietin. May represent a regulatory molecule specific for TPO-R-dependent immune responses", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138131, "symbol": "MUTYH", "locus": "1p34.1", "entrez_id": 4595, "chr": "chr1", "start": 45794835, "end": 45806142, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mutY DNA glycosylase", "description": "<p style=\"text-align: justify\"> Involved in oxidative DNA damage repair. Initiates repair of A*oxoG to C*G by removing the inappropriately paired adenine base from the DNA backbone. Possesses both adenine and 2- OH-A DNA glycosylase activities. </p>  <a title=\"Nucleic Acids Res., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10684930\">Nucleic Acids Res., 2000</a>&nbsp;&nbsp;  <a title=\"DNA Repair (Amst.), 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20418187\">DNA Repair (Amst.), 2010</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20848659\">Hum. Mutat., 2010</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25820570\">Hum. Mutat., 2016</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26694661\">Hum. Mutat., 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138130, "symbol": "TAL1", "locus": "1p33", "entrez_id": 6886, "chr": "chr1", "start": 47681962, "end": 47697892, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "TAL bHLH transcription factor 1, erythroid differentiation factor", "description": "<p style=\"text-align: justify\"> Implicated in the genesis of hemopoietic malignancies. It may play an important role in hemopoietic differentiation. Serves as a positive regulator of erythroid differentiation (By similarity). </p>  <a title=\"EMBO J., 1992\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/1396592\">EMBO J., 1992</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138129, "symbol": "TRIM33", "locus": "1p13.2", "entrez_id": 51592, "chr": "chr1", "start": 114935399, "end": 115053781, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "tripartite motif containing 33", "description": "<p style=\"text-align: justify\"> Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4 ubiquitination, nuclear exclusion and degradation via the ubiquitin proteasome pathway. According to PubMed:16751102, does not promote a decrease in the level of endogenous SMAD4. May act as a transcriptional repressor. Inhibits the transcriptional response to TGF-beta/BMP signaling cascade. Plays a role in the control of cell proliferation. Its association with SMAD2 and SMAD3 stimulates erythroid differentiation of hematopoietic stem/progenitor (By similarity). Monoubiquitinates SMAD4 and acts as an inhibitor of SMAD4-dependent TGF-beta/BMP signaling cascade (Monoubiquitination of SMAD4 hampers its ability to form a stable complex with activated SMAD2/3 resulting in inhibition of TGF- beta/BMP signaling cascade). </p>  <a title=\"Oncogene, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10022127\">Oncogene, 1999</a>&nbsp;&nbsp;  <a title=\"Cell, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15820681\">Cell, 2005</a>&nbsp;&nbsp;  <a title=\"Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16751102\">Cell, 2006</a>&nbsp;&nbsp;  <a title=\"Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19135894\">Cell, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138128, "symbol": "NRAS", "locus": "1p13.2", "entrez_id": 4893, "chr": "chr1", "start": 115247090, "end": 115259515, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "NRAS proto-oncogene, GTPase", "description": "Белки семейства Ras связывают ГТФ/ГДФ и обладают собственной ГТФазной активностью. Играют важную роль в регуляции клеточной пролиферации (PMID:23698361, 22711838). Являются промоторами онкогенеза, индуцируя подавление транскрипции генов опухолевых супрессоров в клеточных культурах колоректальных карцином (PMID:24623306).", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138127, "symbol": "NOTCH2", "locus": "1p12", "entrez_id": 4853, "chr": "chr1", "start": 120454176, "end": 120612240, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "notch 2", "description": "<p style=\"text-align: justify\"> Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation. Positively regulates self-renewal of liver cancer cells (PubMed:25985737). </p>  <a title=\"Nat. Genet., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21378985\">Nat. Genet., 2011</a>&nbsp;&nbsp;  <a title=\"Nat. Genet., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21378989\">Nat. Genet., 2011</a>&nbsp;&nbsp;  <a title=\"Nat Commun, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25985737\">Nat Commun, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138126, "symbol": "PDE4DIP", "locus": "1q21.2", "entrez_id": 9659, "chr": "chr1", "start": 144836157, "end": 145076186, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phosphodiesterase 4D interacting protein", "description": "<p style=\"text-align: justify\"> May function as an anchor sequestering components of the cAMP-dependent pathway to Golgi and/or centrosomes. </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138125, "symbol": "ITGA10", "locus": "1q21.1", "entrez_id": 8515, "chr": "chr1", "start": 145524891, "end": 145543868, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "integrin subunit alpha 10", "description": "Integrin alpha-10/beta-1 is a receptor for collagen", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138124, "symbol": "BCL9", "locus": "1q21.2", "entrez_id": 607, "chr": "chr1", "start": 147013182, "end": 147098017, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "B-cell CLL/lymphoma 9", "description": "<p style=\"text-align: justify\"> Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity (By similarity). </p>  <a title=\"Cell, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11955446\">Cell, 2002</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138123, "symbol": "MCL1", "locus": "1q21.2", "entrez_id": 4170, "chr": "chr1", "start": 150547032, "end": 150552066, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MCL1, BCL2 family apoptosis regulator", "description": "<p style=\"text-align: justify\"> Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. Mediates its effects by interactions with a number of other regulators of apoptosis. Isoform 1 inhibits apoptosis. Isoform 2 promotes apoptosis. </p>  <a title=\"J. Biol. Chem., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10766760\">J. Biol. Chem., 2000</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16543145\">Mol. Cell, 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138122, "symbol": "ARNT", "locus": "1q21.3", "entrez_id": 405, "chr": "chr1", "start": 150782181, "end": 150849244, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "aryl hydrocarbon receptor nuclear translocator", "description": "Required for activity of the Ah (dioxin) receptor. This protein is required for the ligand-binding subunit to translocate from the cytosol to the nucleus after ligand binding. The complex then initiates transcription of genes involved in the activation of PAH procarcinogens. The heterodimer with HIF1A or EPAS1/HIF2A functions as a transcriptional regulator of the adaptive response to hypoxia", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138121, "symbol": "CKS1B", "locus": "1q21.3", "entrez_id": 1163, "chr": "chr1", "start": 154947129, "end": 154951725, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "CDC28 protein kinase regulatory subunit 1B", "description": "Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138120, "symbol": "MUC1", "locus": "1q22", "entrez_id": 4582, "chr": "chr1", "start": 155158300, "end": 155162707, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mucin 1, cell surface associated", "description": "The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138119, "symbol": "NTRK1", "locus": "1q23.1", "entrez_id": 4914, "chr": "chr1", "start": 156785432, "end": 156851642, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "neurotrophic receptor tyrosine kinase 1", "description": "<p style=\"text-align: justify\"> Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand (PubMed:1850821, PubMed:1849459, PubMed:1281417, PubMed:8325889, PubMed:15488758, PubMed:17196528). Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival (By similarity). Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:1281417). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that regulates cell differentiation and survival. Through PLCG1 controls NF-Kappa-B activation and the transcription of genes involved in cell survival. Through SHC1 and SH2B1 controls a Ras- PI3 kinase-AKT1 signaling cascade that is also regulating survival. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors. </p>  <a title=\"J. Biol. Chem., 1993\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8325889\">J. Biol. Chem., 1993</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11244088\">J. Biol. Chem., 2001</a>&nbsp;&nbsp;  <a title=\"Cancer Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15488758\">Cancer Cell, 2004</a>&nbsp;&nbsp;  <a title=\"Neuron, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17196528\">Neuron, 2007</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2018\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27676246\">Hum. Mutat., 2018</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138118, "symbol": "SDHC", "locus": "1q23.3", "entrez_id": 6391, "chr": "chr1", "start": 161284047, "end": 161332984, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "succinate dehydrogenase complex subunit C", "description": "Прикрепляющаяся к мембране субъединица сукцинатдегидрогеназы (SDH), которая входит в комплекс II электронно-транспортной цепи митохондрии и ответственна за перенос электронов с сукцината на убихинон (коэнзим Q).", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138117, "symbol": "DDR2", "locus": "1q23.3", "entrez_id": 4921, "chr": "chr1", "start": 162601163, "end": 162757190, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "discoidin domain receptor tyrosine kinase 2", "description": "<p style=\"text-align: justify\"> Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell differentiation, remodeling of the extracellular matrix, cell migration and cell proliferation. Required for normal bone development. Regulates osteoblast differentiation and chondrocyte maturation via a signaling pathway that involves MAP kinases and leads to the activation of the transcription factor RUNX2. Regulates remodeling of the extracellular matrix by up-regulation of the collagenases MMP1, MMP2 and MMP13, and thereby facilitates cell migration and tumor cell invasion. Promotes fibroblast migration and proliferation, and thereby contributes to cutaneous wound healing. </p>  <a title=\"Arthritis Rheum., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17665456\">Arthritis Rheum., 2007</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18201965\">J. Biol. Chem., 2008</a>&nbsp;&nbsp;  <a title=\"Structure, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20004161\">Structure, 2010</a>&nbsp;&nbsp;  <a title=\"J. Bone Miner. Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20564243\">J. Bone Miner. Res., 2011</a>&nbsp;&nbsp;  <a title=\"J. Bone Miner. Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20734453\">J. Bone Miner. Res., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138116, "symbol": "PBX1", "locus": "1q23.3", "entrez_id": 5087, "chr": "chr1", "start": 164524821, "end": 164868533, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "PBX homeobox 1", "description": "<p style=\"text-align: justify\"> Binds the sequence 5'-ATCAATCAA-3'. Acts as a transcriptional activator of PF4 in complex with MEIS1. Converted into a potent transcriptional activator by the (1;19) translocation. May have a role in steroidogenesis and, subsequently, sexual development and differentiation. Isoform PBX1b as part of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells is involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element. Probably in complex with MEIS2, is involved in transcriptional regulation by KLF4. Acts as a transcriptional activator of NKX2-5 and a transcriptional repressor of CDKN2B. Together with NKX2-5, it is required for spleen development through a mechanism that involves CDKN2B repression (By similarity). </p>  <a title=\"Blood, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12609849\">Blood, 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21746878\">Mol. Cell. Biol., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138115, "symbol": "ABL2", "locus": "1q25.2", "entrez_id": 27, "chr": "chr1", "start": 179068462, "end": 179198819, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ABL proto-oncogene 2, non-receptor tyrosine kinase", "description": "<p style=\"text-align: justify\"> Non-receptor tyrosine-protein kinase that plays an ABL1- overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin- bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 acts also as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. </p>  <a title=\"Oncogene, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15735735\">Oncogene, 2005</a>&nbsp;&nbsp;  <a title=\"Curr. Biol., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15886098\">Curr. Biol., 2005</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16678104\">Mol. Cell, 2006</a>&nbsp;&nbsp;  <a title=\"Curr. Biol., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17306540\">Curr. Biol., 2007</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18945674\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138114, "symbol": "RNASEL", "locus": "1q25.3", "entrez_id": 6041, "chr": "chr1", "start": 182542769, "end": 182558391, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ribonuclease L", "description": "<p style=\"text-align: justify\"> Endoribonuclease that functions in the interferon (IFN) antiviral response. In INF treated and virus infected cells, RNASEL probably mediates its antiviral effects through a combination of direct cleavage of single-stranded viral RNAs, inhibition of protein synthesis through the degradation of rRNA, induction of apoptosis, and induction of other antiviral genes. RNASEL mediated apoptosis is the result of a JNK-dependent stress- response pathway leading to cytochrome c release from mitochondria and caspase-dependent apoptosis. Therefore, activation of RNASEL could lead to elimination of virus infected cells under some circumstances. In the crosstalk between autophagy and apoptosis proposed to induce autophagy as an early stress response to small double-stranded RNA and at later stages of prolonged stress to activate caspase-dependent proteolytic cleavage of BECN1 to terminate autophagy and promote apoptosis (PubMed:26263979). Might play a central role in the regulation of mRNA turnover (PubMed:11585831). Cleaves 3' of UpNp dimers, with preference for UU and UA sequences, to sets of discrete products ranging from between 4 and 22 nucleotides in length. </p>  <a title=\"J. Biol. Chem., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11585831\">J. Biol. Chem., 2002</a>&nbsp;&nbsp;  <a title=\"Int J Mol Sci, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26263979\">Int J Mol Sci, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138113, "symbol": "RNF2", "locus": "1q25.3", "entrez_id": 6045, "chr": "chr1", "start": 185014496, "end": 185071740, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ring finger protein 2", "description": "<p style=\"text-align: justify\"> E3 ubiquitin-protein ligase that mediates monoubiquitination of 'Lys-119' of histone H2A (H2AK119Ub), thereby playing a central role in histone code and gene regulation. H2AK119Ub gives a specific tag for epigenetic transcriptional repression and participates in X chromosome inactivation of female mammals. May be involved in the initiation of both imprinted and random X inactivation. Essential component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones, rendering chromatin heritably changed in its expressibility. E3 ubiquitin-protein ligase activity is enhanced by BMI1/PCGF4. Acts as the main E3 ubiquitin ligase on histone H2A of the PRC1 complex, while RING1 may rather act as a modulator of RNF2/RING2 activity. In resting B- and T-lymphocytes, interaction with AURKB leads to block its activity, thereby maintaining transcription in resting lymphocytes. </p>  <a title=\"FEBS Lett., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11513855\">FEBS Lett., 2001</a>&nbsp;&nbsp;  <a title=\"Nature, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15386022\">Nature, 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16359901\">Mol. Cell, 2006</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16714294\">J. Biol. Chem., 2006</a>&nbsp;&nbsp;  <a title=\"Structure, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20696397\">Structure, 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138112, "symbol": "TPR", "locus": "1q31.1", "entrez_id": 7175, "chr": "chr1", "start": 186280784, "end": 186344825, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "translocated promoter region, nuclear basket protein", "description": "<p style=\"text-align: justify\"> Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope. Functions as a scaffolding element in the nuclear phase of the NPC essential for normal nucleocytoplasmic transport of proteins and mRNAs, plays a role in the establishment of nuclear-peripheral chromatin compartmentalization in interphase, and in the mitotic spindle checkpoint signaling during mitosis. Involved in the quality control and retention of unspliced mRNAs in the nucleus; in association with NUP153, regulates the nuclear export of unspliced mRNA species bearing constitutive transport element (CTE) in a NXF1- and KHDRBS1-independent manner. Negatively regulates both the association of CTE-containing mRNA with large polyribosomes and translation initiation. Does not play any role in Rev response element (RRE)-mediated export of unspliced mRNAs. Implicated in nuclear export of mRNAs transcribed from heat shock gene promoters; associates both with chromatin in the HSP70 promoter and with mRNAs transcribed from this promoter under stress-induced conditions. Modulates the nucleocytoplasmic transport of activated MAPK1/ERK2 and huntingtin/HTT and may serve as a docking site for the XPO1/CRM1-mediated nuclear export complex. According to some authors, plays a limited role in the regulation of nuclear protein export (PubMed:22253824 and PubMed:11952838). Plays also a role as a structural and functional element of the perinuclear chromatin distribution; involved in the formation and/or maintenance of NPC-associated perinuclear heterochromatin exclusion zones (HEZs). Finally, acts as a spatial regulator of the spindle-assembly checkpoint (SAC) response ensuring a timely and effective recruitment of spindle checkpoint proteins like MAD1L1 and MAD2L1 to unattached kinetochore during the metaphase-anaphase transition before chromosome congression. Its N-terminus is involved in activation of oncogenic kinases. </p>  <a title=\"J. Cell Biol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19273613\">J. Cell Biol., 2009</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20133940\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20407419\">EMBO J., 2010</a>&nbsp;&nbsp;  <a title=\"RNA, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21613532\">RNA, 2011</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22253824\">PLoS ONE, 2012</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138111, "symbol": "PTGS2", "locus": "1q31.1", "entrez_id": 5743, "chr": "chr1", "start": 186640923, "end": 186649559, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "prostaglandin-endoperoxide synthase 2", "description": "<p style=\"text-align: justify\"> Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis. </p>  <a title=\"Science, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16373578\">Science, 2006</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138110, "symbol": "CDC73", "locus": "1q31.2", "entrez_id": 79577, "chr": "chr1", "start": 193091147, "end": 193223031, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cell division cycle 73", "description": "<p style=\"text-align: justify\"> Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non- phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both indepentently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19136632\">Proc. Natl. Acad. Sci. U.S.A., 2009</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19952111\">Genes Dev., 2009</a>&nbsp;&nbsp;  <a title=\"Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20178742\">Cell, 2010</a>&nbsp;&nbsp;  <a title=\"Cancer Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20541477\">Cancer Cell, 2010</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21329879\">Mol. Cell, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138109, "symbol": "PIK3C2B", "locus": "1q32.1", "entrez_id": 5287, "chr": "chr1", "start": 204391756, "end": 204463852, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta", "description": "<p style=\"text-align: justify\"> Phosphorylates PtdIns and PtdIns4P with a preference for PtdIns. Does not phosphorylate PtdIns(4,5)P2. May be involved in EGF and PDGF signaling cascades. </p>  <a title=\"Mol. Cell. Biol., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10805725\">Mol. Cell. Biol., 2000</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138108, "symbol": "MDM4", "locus": "1q32.1", "entrez_id": 4194, "chr": "chr1", "start": 204485511, "end": 204542871, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MDM4, p53 regulator", "description": "<p style=\"text-align: justify\"> Inhibits p53/TP53- and TP73/p73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Inhibits degradation of MDM2. Can reverse MDM2-targeted degradation of TP53 while maintaining suppression of TP53 transactivation and apoptotic functions. </p>  <a title=\"EMBO J., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16163388\">EMBO J., 2006</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16511572\">EMBO J., 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138107, "symbol": "IKBKE", "locus": "1q32.1", "entrez_id": 9641, "chr": "chr1", "start": 206643791, "end": 206670223, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "inhibitor of nuclear factor kappa B kinase subunit epsilon", "description": "<p style=\"text-align: justify\"> Serine/threonine kinase that plays an essential role in regulating inflammatory responses to viral infection, through the activation of the type I IFN, NF-kappa-B and STAT signaling. Also involved in TNFA and inflammatory cytokines, like Interleukin-1, signaling. Following activation of viral RNA sensors, such as RIG- I-like receptors, associates with DDX3X and phosphorylates interferon regulatory factors (IRFs), IRF3 and IRF7, as well as DDX3X. This activity allows subsequent homodimerization and nuclear translocation of the IRF3 leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNB. In order to establish such an antiviral state, IKBKE forms several different complexes whose composition depends on the type of cell and cellular stimuli. Thus, several scaffolding molecules including IPS1/MAVS, TANK, AZI2/NAP1 or TBKBP1/SINTBAD can be recruited to the IKBKE-containing-complexes. Activated by polyubiquitination in response to TNFA and interleukin-1, regulates the NF-kappa-B signaling pathway through, at least, the phosphorylation of CYLD. Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. In addition, is also required for the induction of a subset of ISGs which displays antiviral activity, may be through the phosphorylation of STAT1 at 'Ser-708'. Phosphorylation of STAT1 at 'Ser-708' seems also to promote the assembly and DNA binding of ISGF3 (STAT1:STAT2:IRF9) complexes compared to GAF (STAT1:STAT1) complexes, in this way regulating the balance between type I and type II IFN responses. Protects cells against DNA damage-induced cell death. Also plays an important role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, wich leads to a negative impact on insulin sensitivity. Phosphorylates AKT1. </p>  <a title=\"Biochem. J., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21138416\">Biochem. J., 2011</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21464307\">Proc. Natl. Acad. Sci. U.S.A., 2011</a>&nbsp;&nbsp;  <a title=\"J. Virol., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22532683\">J. Virol., 2012</a>&nbsp;&nbsp;  <a title=\"Cell Rep, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23453969\">Cell Rep, 2013</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23478265\">Mol. Cell. Biol., 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138106, "symbol": "MARK1", "locus": "1q41", "entrez_id": 4139, "chr": "chr1", "start": 220701568, "end": 220837803, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "microtubule affinity regulating kinase 1", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase involved in cell polarity and microtubule dynamics regulation. Phosphorylates DCX, MAP2, MAP4 and MAPT/TAU. Involved in cell polarity by phosphorylating the microtubule-associated proteins MAP2, MAP4 and MAPT/TAU at KXGS motifs, causing detachment from microtubules, and their disassembly. Involved in the regulation of neuronal migration through its dual activities in regulating cellular polarity and microtubule dynamics, possibly by phosphorylating and regulating DCX. Also acts as a positive regulator of the Wnt signaling pathway, probably by mediating phosphorylation of dishevelled proteins (DVL1, DVL2 and/or DVL3). </p>  <a title=\"Nat. Cell Biol., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11433294\">Nat. Cell Biol., 2001</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17573348\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138105, "symbol": "SSX1", "locus": "Xp11.23", "entrez_id": 6756, "chr": "chrX", "start": 48114752, "end": 48126879, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SSX family member 1", "description": "Could act as a modulator of transcription", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138104, "symbol": "WAS", "locus": "Xp11.23", "entrez_id": 7454, "chr": "chrX", "start": 48534985, "end": 48549818, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Wiskott-Aldrich syndrome", "description": "<p style=\"text-align: justify\"> Effector protein for Rho-type GTPases. Regulates actin filament reorganization via its interaction with the Arp2/3 complex. Important for efficient actin polymerization. Possible regulator of lymphocyte and platelet function. Mediates actin filament reorganization and the formation of actin pedestals upon infection by pathogenic bacteria. </p>  <a title=\"J. Biol. Chem., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12235133\">J. Biol. Chem., 2003</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16275905\">Proc. Natl. Acad. Sci. U.S.A., 2006</a>&nbsp;&nbsp;  <a title=\"Nature, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18650809\">Nature, 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138103, "symbol": "GATA1", "locus": "Xp11.23", "entrez_id": 2623, "chr": "chrX", "start": 48644962, "end": 48652716, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "GATA binding protein 1", "description": "<p style=\"text-align: justify\"> Transcriptional activator or repressor which probably serves as a general switch factor for erythroid development. It binds to DNA sites with the consensus sequence 5'-[AT]GATA[AG]-3' within regulatory regions of globin genes and of other genes expressed in erythroid cells. Activates the transcription of genes involved in erythroid differentiation of K562 erythroleukemia cells, including HBB, HBG1/2, ALAS2 and HMBS (PubMed:24245781). </p>  <a title=\"PLoS ONE, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22235304\">PLoS ONE, 2012</a>&nbsp;&nbsp;  <a title=\"Genes Cells, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24245781\">Genes Cells, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138102, "symbol": "TFE3", "locus": "Xp11.23", "entrez_id": 7030, "chr": "chrX", "start": 48886242, "end": 48901012, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "transcription factor binding to IGHM enhancer 3", "description": "Transcription factor that specifically recognizes and binds E-box sequences (5'-CANNTG-3'). Efficient DNA-binding requires dimerization with itself or with another MiT/TFE family member such as TFEB or MITF. In association with TFEB, activates the expression of CD40L in T-cells, thereby playing a role in T- cell-dependent antibody responses in activated CD4(+) T-cells and thymus-dependent humoral immunity. Specifically recognizes the MUE3 box, a subset of E-boxes, present in the immunoglobulin enhancer. It also binds very well to a USF/MLTF site", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138101, "symbol": "KDM5C", "locus": "Xp11.22", "entrez_id": 8242, "chr": "chrX", "start": 53220503, "end": 53254604, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "lysine demethylase 5C", "description": "<p style=\"text-align: justify\"> Histone demethylase that specifically demethylates 'Lys- 4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Participates in transcriptional repression of neuronal genes by recruiting histone deacetylases and REST at neuron-restrictive silencer elements. Represses the CLOCK-ARNTL/BMAL1 heterodimer-mediated transcriptional activation of the core clock component PER2 (By similarity). </p>  <a title=\"Cell, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17320160\">Cell, 2007</a>&nbsp;&nbsp;  <a title=\"Cell, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17320161\">Cell, 2007</a>&nbsp;&nbsp;  <a title=\"Nature, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17468742\">Nature, 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138100, "symbol": "AMER1", "locus": "Xq11.2", "entrez_id": 139285, "chr": "chrX", "start": 63404997, "end": 63425624, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "APC membrane recruitment protein 1", "description": "<p style=\"text-align: justify\"> Regulator of the canonical Wnt signaling pathway. Acts by specifically binding phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), translocating to the cell membrane and interacting with key regulators of the canonical Wnt signaling pathway, such as components of the beta-catenin destruction complex. Acts both as a positive and negative regulator of the Wnt signaling pathway, depending on the context: acts as a positive regulator by promoting LRP6 phosphorylation. Also acts as a negative regulator by acting as a scaffold protein for the beta- catenin destruction complex and promoting stabilization of Axin at the cell membrane. Promotes CTNNB1 ubiquitination and degradation. Involved in kidney development. </p>  <a title=\"Science, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17510365\">Science, 2007</a>&nbsp;&nbsp;  <a title=\"J. Cell. Sci., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17925383\">J. Cell. Sci., 2008</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19416806\">Proc. Natl. Acad. Sci. U.S.A., 2009</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21304492\">EMBO J., 2011</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21498506\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138099, "symbol": "AR", "locus": "Xq12", "entrez_id": 367, "chr": "chrX", "start": 66764465, "end": 66950461, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "androgen receptor", "description": "<p style=\"text-align: justify\"> Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. </p>  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17591767\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17911242\">Proc. Natl. Acad. Sci. U.S.A., 2007</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18084323\">Oncogene, 2008</a>&nbsp;&nbsp;  <a title=\"Cancer Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19345326\">Cancer Cell, 2009</a>&nbsp;&nbsp;  <a title=\"Mol. Endocrinol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20980437\">Mol. Endocrinol., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138098, "symbol": "TAF1", "locus": "Xq13.1", "entrez_id": 6872, "chr": "chrX", "start": 70586114, "end": 70752224, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "TATA-box binding protein associated factor 1", "description": "<p style=\"text-align: justify\"> Largest component and core scaffold of the TFIID basal transcription factor complex (PubMed:25412659, PubMed:27007846). Contains novel N- and C-terminal Ser/Thr kinase domains which can autophosphorylate or transphosphorylate other transcription factors. Phosphorylates TP53 on 'Thr-55' which leads to MDM2- mediated degradation of TP53. Phosphorylates GTF2A1 and GTF2F1 on Ser residues. Possesses DNA-binding activity (PubMed:25412659). Essential for progression of the G1 phase of the cell cycle (PubMed:11278496, PubMed:15053879, PubMed:2038334, PubMed:8450888, PubMed:8625415, PubMed:9660973, PubMed:9858607). Exhibits histone acetyltransferase activity towards histones H3 and H4 (PubMed:15870300). </p>  <a title=\"J. Biol. Chem., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11278496\">J. Biol. Chem., 2001</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15053879\">Mol. Cell, 2004</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15870300\">Mol. Cell. Biol., 2005</a>&nbsp;&nbsp;  <a title=\"Cell Res., 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25412659\">Cell Res., 2015</a>&nbsp;&nbsp;  <a title=\"Nature, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27007846\">Nature, 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138097, "symbol": "ATRX", "locus": "Xq21.1", "entrez_id": 546, "chr": "chrX", "start": 76760356, "end": 77041702, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ATRX, chromatin remodeler", "description": "<p style=\"text-align: justify\"> Involved in transcriptional regulation and chromatin remodeling. Facilitates DNA replication in multiple cellular environments and is required for efficient replication of a subset of genomic loci. Binds to DNA tandem repeat sequences in both telomeres and euchromatin and in vitro binds DNA quadruplex structures. May help stabilizing G-rich regions into regular chromatin structures by remodeling G4 DNA and incorporating H3.3- containing nucleosomes. Catalytic component of the chromatin remodeling complex ATRX:DAXX which has ATP-dependent DNA translocase activity and catalyzes the replication-independent deposition of histone H3.3 in pericentric DNA repeats outside S- phase and telomeres, and the in vitro remodeling of H3.3- containing nucleosomes. Its heterochromatin targeting is proposed to involve a combinatorial readout of histone H3 modifications (specifically methylation states of H3K9 and H3K4) and association with CBX5. Involved in maintaining telomere structural integrity in embryonic stem cells which probably implies recruitment of CBX5 to telomers. Reports on the involvement in transcriptional regulation of telomeric repeat-containing RNA (TERRA) are conflicting; according to a report, it is not sufficient to decrease chromatin condensation at telomers nor to increase expression of telomeric RNA in fibroblasts (PubMed:24500201). May be involved in telomere maintenance via recombination in ALT (alternative lengthening of telomeres) cell lines. Acts as negative regulator of chromatin incorporation of transcriptionally repressive histone H2AFY, particularily at telomeres and the alpha-globin cluster in erythroleukemic cells. Participates in the allele-specific gene expression at the imprinted IGF2/H19 gene locus. On the maternal allele, required for the chromatin occupancy of SMC1 and CTCTF within the H19 imprinting control region (ICR) and involved in esatblishment of histone tails modifications in the ICR. May be involved in brain development and facial morphogenesis. Binds to zinc-finger coding genes with atypical chromatin signatures and regulates its H3K9me3 levels. Forms a complex with ZNF274, TRIM28 and SETDB1 to facilitate the deposition and maintenance of H3K9me3 at the 3' exons of zinc- finger genes (PubMed:27029610). </p>  <a title=\"Cell, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21029860\">Cell, 2010</a>&nbsp;&nbsp;  <a title=\"Genes Dev., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22391447\">Genes Dev., 2012</a>&nbsp;&nbsp;  <a title=\"PLoS Genet., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22829774\">PLoS Genet., 2013</a>&nbsp;&nbsp;  <a title=\"Nucleic Acids Res., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24500201\">Nucleic Acids Res., 2014</a>&nbsp;&nbsp;  <a title=\"Epigenetics, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27029610\">Epigenetics, 2017</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138096, "symbol": "TBX22", "locus": "Xq21.1", "entrez_id": 50945, "chr": "chrX", "start": 79270255, "end": 79287268, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "T-box 22", "description": "Probable transcriptional regulator involved in developmental processes. This is major determinant crucial to palatogenesis", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138095, "symbol": "BTK", "locus": "Xq22.1", "entrez_id": 695, "chr": "chrX", "start": 100604435, "end": 100641183, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Bruton tyrosine kinase", "description": "<p style=\"text-align: justify\"> Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members. PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK. BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways. Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway. The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense. Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells. Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation. BTK plays also a critical role in transcription regulation. Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes. BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR. GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression. ARID3A and NFAT are other transcriptional target of BTK. BTK is required for the formation of functional ARID3A DNA-binding complexes. There is however no evidence that BTK itself binds directly to DNA. BTK has a dual role in the regulation of apoptosis. </p>  <a title=\"J. Biol. Chem., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11606584\">J. Biol. Chem., 2002</a>&nbsp;&nbsp;  <a title=\"Nat. Immunol., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16415872\">Nat. Immunol., 2006</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16517732\">J. Immunol., 2006</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16738337\">Mol. Cell. Biol., 2006</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17932028\">J. Biol. Chem., 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138094, "symbol": "PAK3", "locus": "Xq23", "entrez_id": 5063, "chr": "chrX", "start": 110187513, "end": 110470589, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "p21 (RAC1) activated kinase 3", "description": "<p style=\"text-align: justify\"> Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, or cell cycle regulation. Plays a role in dendrite spine morphogenesis as well as synapse formation and plasticity. Acts as downstream effector of the small GTPases CDC42 and RAC1. Activation by the binding of active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Phosphorylates MAPK4 and MAPK6 and activates the downstream target MAPKAPK5, a regulator of F-actin polymerization and cell migration. Additionally, phosphorylates TNNI3/troponin I to modulate calcium sensitivity and relaxation kinetics of thin myofilaments. May also be involved in early neuronal development. </p>  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21177870\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138093, "symbol": "SH2D1A", "locus": "Xq25", "entrez_id": 4068, "chr": "chrX", "start": 123480194, "end": 123507005, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SH2 domain containing 1A", "description": "<p style=\"text-align: justify\"> Cytoplasmic adapter regulating receptors of the signaling lymphocytic activation molecule (SLAM) family such as SLAMF1, CD244, LY9, CD84, SLAMF6 and SLAMF7. In SLAM signaling seems to cooperate with SH2D1B/EAT-2. Initially it has been proposed that association with SLAMF1 prevents SLAMF1 binding to inhibitory effectors including INPP5D/SHIP1 and PTPN11/SHP-2 (PubMed:11806999). However, by simultaneous interactions, recruits FYN which subsequently phosphorylates and activates SLAMF1 (PubMed:12458214). Positively regulates CD244/2B4- and CD84- mediated natural killer (NK) cell functions. Can also promote CD48-, SLAMF6 -, LY9-, and SLAMF7-mediated NK cell activation. In the context of NK cell-mediated cytotoxicity enhances conjugate formation with target cells (By similarity). May also regulate the activity of the neurotrophin receptors NTRK1, NTRK2 and NTRK3. </p>  <a title=\"Blood, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11806999\">Blood, 2002</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12458214\">J. Biol. Chem., 2003</a>&nbsp;&nbsp;  <a title=\"Annu. Rev. Immunol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21219180\">Annu. Rev. Immunol., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138092, "symbol": "MAGEA1", "locus": "Xq28", "entrez_id": 4100, "chr": "chrX", "start": 152481522, "end": 152486115, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MAGE family member A1", "description": "<p style=\"text-align: justify\"> May be involved in transcriptional regulation through interaction with SNW1 and recruiting histone deactelyase HDAC1. May inhibit notch intracellular domain (NICD) transactivation. May play a role in embryonal development and tumor transformation or aspects of tumor progression. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. </p>  <a title=\"Nucleic Acids Res., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15316101\">Nucleic Acids Res., 2004</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138091, "symbol": "G6PD", "locus": "Xq28", "entrez_id": 2539, "chr": "chrX", "start": 153759606, "end": 153775787, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "glucose-6-phosphate dehydrogenase", "description": "<p style=\"text-align: justify\"> Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis. The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis. </p>  <a title=\"Acta Crystallogr. D Biol. Crystallogr., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15858258\">Acta Crystallogr. D Biol. Crystallogr., 2005</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24769394\">EMBO J., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138090, "symbol": "PARP1", "locus": "1q42.12", "entrez_id": 142, "chr": "chr1", "start": 226548392, "end": 226595780, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "poly(ADP-ribose) polymerase 1", "description": "<p style=\"text-align: justify\"> Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks (PubMed:17177976, PubMed:18172500, PubMed:19344625, PubMed:19661379, PubMed:23230272). Mediates the poly(ADP-ribosyl)ation of APLF and CHFR (PubMed:17396150). Positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. With EEF1A1 and TXK, forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFN-gamma to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production (PubMed:17177976). Required for PARP9 and DTX3L recruitment to DNA damage sites (PubMed:23230272). PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites (PubMed:23230272). Mediates serine ADP-ribosylation of target proteins following interaction with HPF1; HPF1 conferring serine specificity (PubMed:28190768). Mediates the poly(ADP-ribosyl)ation of histones in a HPF1-dependent manner (PubMed:27067600). Involved in the synthesis of ATP in the nucleus, together with NMNAT1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy- consuming (PubMed:27257257). </p>  <a title=\"Science, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19661379\">Science, 2009</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23230272\">Mol. Cell. Biol., 2013</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27067600\">Mol. Cell, 2017</a>&nbsp;&nbsp;  <a title=\"Science, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27257257\">Science, 2016</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/28190768\">Mol. Cell, 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138089, "symbol": "MTR", "locus": "1q43", "entrez_id": 4548, "chr": "chr1", "start": 236958610, "end": 237067281, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "5-methyltetrahydrofolate-homocysteine methyltransferase", "description": "<p style=\"text-align: justify\"> Catalyzes the transfer of a methyl group from methyl- cobalamin to homocysteine, yielding enzyme-bound cob(I)alamin and methionine. Subsequently, remethylates the cofactor using methyltetrahydrofolate (By similarity). </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138088, "symbol": "FH", "locus": "1q43", "entrez_id": 2271, "chr": "chr1", "start": 241660903, "end": 241683061, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fumarate hydratase", "description": "Also acts as a tumor suppressor", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138087, "symbol": "TSC1", "locus": "9q34.13", "entrez_id": 7248, "chr": "chr9", "start": 135766735, "end": 135820020, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "TSC complex subunit 1", "description": "<p style=\"text-align: justify\"> В комплексе с TSC2 негативно регулирует активность mTORC1-зависимой сигнализации, путем ингибирования фосфорилирования S6K1 и EIF4EBP1, запускаемого ростовыми факторами или энергетическим дисбалансом. TSC1 обладает опухолесупрессорными функциями, играет роль в транспорте белков, связанным с нарушением функции mTOR-регулируемого каскада. Proc. Natl. Acad. Sci. U.S.A., 2002   Mol. Cell. Biol., 2004 </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12271141\">Proc. Natl. Acad. Sci. U.S.A., 2002</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15340059\">Mol. Cell. Biol., 2004</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138086, "symbol": "RALGDS", "locus": "9q34.13-q34.2", "entrez_id": 5900, "chr": "chr9", "start": 135973107, "end": 136039301, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ral guanine nucleotide dissociation stimulator", "description": "Stimulates the dissociation of GDP from the Ras-related RalA and RalB GTPases which allows GTP binding and activation of the GTPases. Interacts and acts as an effector molecule for R-Ras, H-Ras, K-Ras, and Rap", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138085, "symbol": "BRD3", "locus": "9q34.2", "entrez_id": 8019, "chr": "chr9", "start": 136895427, "end": 136933657, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "bromodomain containing 3", "description": "<p style=\"text-align: justify\"> Binds hyperacetylated chromatin and plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors. Regulates transcription by promoting the binding of the transcription factor GATA1 to its targets (By similarity). Regulates transcription of the CCND1 gene. </p>  <a title=\"Mol. Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18406326\">Mol. Cell, 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138084, "symbol": "NOTCH1", "locus": "9q34.3", "entrez_id": 4851, "chr": "chr9", "start": 139388896, "end": 139440314, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "notch 1", "description": "<p style=\"text-align: justify\"> Функционирует как рецептор для мембрано-связанных лигандов Jagged1, Jagged2 и Delta1, определяя судьбу клетки. После активации лигандом через свободный внутриклеточный домен NOTCH (NICD) происходит формирование комплекса RBPJ/RBPSUH, активирующего гены-энхансеры split локуса. Таким образом происходит регулирование клеточной дифференцировки, пролиферации и апоптоза, активация ангиогенеза; негативная регуляция пролиферации и пролиферации клеток эндотелия, а также формирования сосудов (sprouting). Также ICAP регулирует созревание CD4+ и CD8+ лимфоцитов в тимусе, а также дифференцировку и выживаемость B-клеток в фолликулах. Во время развития мозжечка ICAP функционирует как рецептор для нейронального DNER и участвует в дифференцировке Бергмановской глии. ICAP подавляет нейрональную и мышечную дифференцировку. Также данный ген может играть важную роль в постинплатационном развитии, вероятно, в клеточной дифференцировке. Может участвовать в развитии мезодермы, формировании сомитов и нейрогенезе. Вероятно, способствует усилению функции HIF1A, изолируя HIF1AN от HIF1A. Необходим для работы THBS4, регулирующего протективный астрогенез в субвентрикулярной зоне после травмы. Вовлечен в определение левой / правой симметрии путем изменения баланса между подвижными и неподвижными (сенсорными) ресничками в лево-правом organizer (LRO). </p>  <a title=\"Circ. Res., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20616313\">Circ. Res., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138083, "symbol": "USP9X", "locus": "Xp11.4", "entrez_id": 8239, "chr": "chrX", "start": 40944888, "end": 41095832, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ubiquitin specific peptidase 9, X-linked", "description": "<p style=\"text-align: justify\"> Deubiquitinase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. May therefore play an important regulatory role at the level of protein turnover by preventing degradation of proteins through the removal of conjugated ubiquitin. Essential component of TGF-beta/BMP signaling cascade. Regulates chromosome alignment and segregation in mitosis by regulating the localization of BIRC5/survivin to mitotic centromeres. Specifically hydrolyzes both 'Lys-29'- and 'Lys-33'-linked polyubiquitins chains. Specifically deubiquitinates monoubiquitinated SMAD4, opposing the activity of E3 ubiquitin-protein ligase TRIM33. Involved in axonal growth and neuronal cell migration. </p>  <a title=\"Science, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16322459\">Science, 2005</a>&nbsp;&nbsp;  <a title=\"Biochem. J., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18254724\">Biochem. J., 2008</a>&nbsp;&nbsp;  <a title=\"Cell, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19135894\">Cell, 2009</a>&nbsp;&nbsp;  <a title=\"Am. J. Hum. Genet., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24607389\">Am. J. Hum. Genet., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138082, "symbol": "KDM6A", "locus": "Xp11.3", "entrez_id": 7403, "chr": "chrX", "start": 44732757, "end": 44971847, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "lysine demethylase 6A", "description": "<p style=\"text-align: justify\"> Histone demethylase that specifically demethylates 'Lys- 27' of histone H3, thereby playing a central role in histone code (PubMed:17851529, PubMed:17713478, PubMed:17761849). Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-27' (PubMed:17851529, PubMed:17713478, PubMed:17761849). Plays a central role in regulation of posterior development, by regulating HOX gene expression (PubMed:17851529). Demethylation of 'Lys-27' of histone H3 is concomitant with methylation of 'Lys-4' of histone H3, and regulates the recruitment of the PRC1 complex and monoubiquitination of histone H2A (PubMed:17761849). </p>  <a title=\"Nature, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17713478\">Nature, 2007</a>&nbsp;&nbsp;  <a title=\"Science, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17761849\">Science, 2007</a>&nbsp;&nbsp;  <a title=\"Nature, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17851529\">Nature, 2007</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18003914\">Proc. Natl. Acad. Sci. U.S.A., 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138081, "symbol": "HACK_DUMMY_GENE", "locus": "1", "entrez_id": 2, "chr": "3", "start": 4, "end": 5, "panel_coverage": null, "full_name": "-", "description": "<p>-</p>", "gene_type": "STR_CLIN_SIGNIF"}, {"json_id": 138080, "symbol": "AKT3", "locus": "1q43-q44", "entrez_id": 10000, "chr": "chr1", "start": 243651535, "end": 244014381, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "AKT serine/threonine kinase 3", "description": "<p style=\"text-align: justify\"> AKT3 is one of 3 closely related serine/threonine- protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase- dependent apoptosis. </p>  <a title=\"FASEB J., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18524868\">FASEB J., 2008</a>&nbsp;&nbsp;  <a title=\"J. Invest. Dermatol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21191416\">J. Invest. Dermatol., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138079, "symbol": "KLF6", "locus": "10p15.2", "entrez_id": 1316, "chr": "chr10", "start": 3818188, "end": 3827473, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Kruppel like factor 6", "description": "<p style=\"text-align: justify\"> Transcriptional activator (By similarity). Binds a GC box motif. Could play a role in B-cell growth and development. </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138078, "symbol": "GATA3", "locus": "10p14", "entrez_id": 2625, "chr": "chr10", "start": 8095567, "end": 8117161, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "GATA binding protein 3", "description": "<p style=\"text-align: justify\"> Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process following immune and inflammatory responses. </p>  <a title=\"PLoS ONE, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23824597\">PLoS ONE, 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138077, "symbol": "MLLT10", "locus": "10p12.31", "entrez_id": 8028, "chr": "chr10", "start": 21823094, "end": 22032559, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MLLT10, histone lysine methyltransferase DOT1L cofactor", "description": "<p style=\"text-align: justify\"> Probably involved in transcriptional regulation. In vitro or as fusion protein with KMT2A/MLL1 has transactivation activity. Binds to cruciform DNA. </p>  <a title=\"Biol. Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17868029\">Biol. Cell, 2008</a>&nbsp;&nbsp;", "gene_type": "STR_VUS"}, {"json_id": 138076, "symbol": "RET", "locus": "10q11.21", "entrez_id": 5979, "chr": "chr10", "start": 43572475, "end": 43625799, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ret proto-oncogene", "description": "<p style=\"text-align: justify\"> Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut- associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration. </p>  <a title=\"Neuron, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20064382\">Neuron, 2010</a>&nbsp;&nbsp;  <a title=\"Front Horm Res, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20616503\">Front Horm Res, 2010</a>&nbsp;&nbsp;  <a title=\"J. Clin. Endocrinol. Metab., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20702524\">J. Clin. Endocrinol. Metab., 2010</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21357690\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21454698\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138075, "symbol": "MAPK8", "locus": "10q11.22", "entrez_id": 5599, "chr": "chr10", "start": 49514698, "end": 49647403, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mitogen-activated protein kinase 8", "description": "<p style=\"text-align: justify\"> Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK8/JNK1. In turn, MAPK8/JNK1 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1 transcriptional activity. Phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Contributes to the survival of erythroid cells by phosphorylating the antagonist of cell death BAD upon EPO stimulation. Mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy. Phosphorylates STMN2 and hence regulates microtubule dynamics, controlling neurite elongation in cortical neurons. In the developing brain, through its cytoplasmic activity on STMN2, negatively regulates the rate of exit from multipolar stage and of radial migration from the ventricular zone. Phosphorylates several other substrates including heat shock factor protein 4 (HSF4), the deacetylase SIRT1, ELK1, or the E3 ligase ITCH. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock (PubMed:22441692). Phosphorylates the heat shock transcription factor HSF1, suppressing HSF1-induced transcriptional activity (PubMed:10747973). </p>  <a title=\"J. Biol. Chem., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10747973\">J. Biol. Chem., 2000</a>&nbsp;&nbsp;  <a title=\"EMBO Rep., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22441692\">EMBO Rep., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138444, "symbol": "EXT2", "locus": "11p11.2", "entrez_id": 2132, "chr": "chr11", "start": 44117099, "end": 44266979, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "exostosin glycosyltransferase 2", "description": "<p style=\"text-align: justify\"> Glycosyltransferase required for the biosynthesis of heparan-sulfate. The EXT1/EXT2 complex possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone. Appears to be a tumor suppressor. Required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413). </p>  <a title=\"Nat. Cell Biol., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22660413\">Nat. Cell Biol., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_VUS"}, {"json_id": 138443, "symbol": "DDB2", "locus": "11p11.2", "entrez_id": 1643, "chr": "chr11", "start": 47236493, "end": 47260767, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "damage specific DNA binding protein 2", "description": "<p style=\"text-align: justify\"> Required for DNA repair. Binds to DDB1 to form the UV- damaged DNA-binding protein complex (the UV-DDB complex). The UV- DDB complex may recognize UV-induced DNA damage and recruit proteins of the nucleotide excision repair pathway (the NER pathway) to initiate DNA repair. The UV-DDB complex preferentially binds to cyclobutane pyrimidine dimers (CPD), 6-4 photoproducts (6-4 PP), apurinic sites and short mismatches. Also appears to function as the substrate recognition module for the DCX (DDB1- CUL4-X-box) E3 ubiquitin-protein ligase complex DDB1-CUL4-ROC1 (also known as CUL4-DDB-ROC1 and CUL4-DDB-RBX1). The DDB1-CUL4- ROC1 complex may ubiquitinate histone H2A, histone H3 and histone H4 at sites of UV-induced DNA damage. The ubiquitination of histones may facilitate their removal from the nucleosome and promote subsequent DNA repair. The DDB1-CUL4-ROC1 complex also ubiquitinates XPC, which may enhance DNA-binding by XPC and promote NER. Isoform D1 and isoform D2 inhibit UV-damaged DNA repair. </p>  <a title=\"Cell, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15882621\">Cell, 2005</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16260596\">Mol. Cell. Biol., 2005</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16473935\">Proc. Natl. Acad. Sci. U.S.A., 2006</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16678110\">Mol. Cell, 2006</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18593899\">Cancer Res., 2008</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138442, "symbol": "MEN1", "locus": "11q13.1", "entrez_id": 4221, "chr": "chr11", "start": 64570982, "end": 64578766, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "menin 1", "description": "<p style=\"text-align: justify\"> Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11274402\">Proc. Natl. Acad. Sci. U.S.A., 2001</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11526476\">Oncogene, 2001</a>&nbsp;&nbsp;  <a title=\"Cell, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12837246\">Cell, 2003</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12874027\">Cancer Res., 2003</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14992727\">Mol. Cell, 2004</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138441, "symbol": "CCND1", "locus": "11q13.3", "entrez_id": 595, "chr": "chr11", "start": 69455855, "end": 69469242, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin D1", "description": "<p style=\"text-align: justify\"> Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner. </p>  <a title=\"Genes Dev., 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9106657\">Genes Dev., 1997</a>&nbsp;&nbsp;  <a title=\"Nature, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15241418\">Nature, 2004</a>&nbsp;&nbsp;  <a title=\"Biochem. J., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16569215\">Biochem. J., 2006</a>&nbsp;&nbsp;  <a title=\"J. Endocrinol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18417529\">J. Endocrinol., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138440, "symbol": "NUMA1", "locus": "11q13.4", "entrez_id": 4926, "chr": "chr11", "start": 71713910, "end": 71791739, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nuclear mitotic apparatus protein 1", "description": "<p style=\"text-align: justify\"> Microtubule (MT)-binding protein that plays a role in the formation and maintenance of the spindle poles and the alignement and the segregation of chromosomes during mitotic cell division (PubMed:7769006, PubMed:17172455, PubMed:19255246, PubMed:24996901, PubMed:26195665, PubMed:27462074). Functions to tether the minus ends of MTs at the spindle poles, which is critical for the establishment and maintenance of the spindle poles (PubMed:12445386, PubMed:11956313). Plays a role in the establishment of the mitotic spindle orientation during metaphase and elongation during anaphase in a dynein-dynactin-dependent manner (PubMed:23870127, PubMed:24109598, PubMed:24996901, PubMed:26765568). In metaphase, part of a ternary complex composed of GPSM2 and G(i) alpha proteins, that regulates the recruitment and anchorage of the dynein-dynactin complex in the mitotic cell cortex regions situated above the two spindle poles, and hence regulates the correct oritentation of the mitotic spindle (PubMed:23027904, PubMed:22327364, PubMed:23921553). During anaphase, mediates the recruitment and accumulation of the dynein- dynactin complex at the cell membrane of the polar cortical region through direct association with phosphatidylinositol 4,5- bisphosphate (PI(4,5)P2), and hence participates in the regulation of the spindle elongation and chromosome segregation (PubMed:22327364, PubMed:23921553, PubMed:24996901, PubMed:24371089). Binds also to other polyanionic phosphoinositides, such as phosphatidylinositol 3-phosphate (PIP), lysophosphatidic acid (LPA) and phosphatidylinositol triphosphate (PIP3), in vitro (PubMed:24996901, PubMed:24371089). Also required for proper orientation of the mitotic spindle during asymmetric cell divisions (PubMed:21816348). Plays a role in mitotic MT aster assembly (PubMed:11163243, PubMed:11229403, PubMed:12445386). Involved in anastral spindle assembly (PubMed:25657325). Positively regulates TNKS protein localization to spindle poles in mitosis (PubMed:16076287). Highly abundant component of the nuclear matrix where it may serve a non-mitotic structural role, occupies the majority of the nuclear volume (PubMed:10075938). Required for epidermal differentiation and hair follicle morphogenesis (By similarity). </p>  <a title=\"EMBO J., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24996901\">EMBO J., 2014</a>&nbsp;&nbsp;  <a title=\"Mol. Biol. Cell, 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25657325\">Mol. Biol. Cell, 2016</a>&nbsp;&nbsp;  <a title=\"J. Cell Biol., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26195665\">J. Cell Biol., 2016</a>&nbsp;&nbsp;  <a title=\"Elife, 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26765568\">Elife, 2017</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2017\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/27462074\">J. Biol. Chem., 2017</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138439, "symbol": "MRE11", "locus": "11q21", "entrez_id": 4361, "chr": "chr11", "start": 94152895, "end": 94227074, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MRE11 homolog, double strand break repair nuclease", "description": "<p style=\"text-align: justify\"> Component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis. The complex possesses single-strand endonuclease activity and double-strand- specific 3'-5' exonuclease activity, which are provided by MRE11. RAD50 may be required to bind DNA ends and hold them in close proximity. This could facilitate searches for short or long regions of sequence homology in the recombining DNA templates, and may also stimulate the activity of DNA ligases and/or restrict the nuclease activity of MRE11 to prevent nucleolytic degradation past a given point (PubMed:9651580, PubMed:9590181, PubMed:9705271, PubMed:11741547). The complex may also be required for DNA damage signaling via activation of the ATM kinase (PubMed:15064416). In telomeres the MRN complex may modulate t-loop formation (PubMed:10888888). </p>  <a title=\"Cell, 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9590181\">Cell, 1998</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9705271\">J. Biol. Chem., 1998</a>&nbsp;&nbsp;  <a title=\"Nat. Genet., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10888888\">Nat. Genet., 2000</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11741547\">Mol. Cell, 2002</a>&nbsp;&nbsp;  <a title=\"Science, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15064416\">Science, 2004</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138438, "symbol": "MAML2", "locus": "11q21", "entrez_id": 84441, "chr": "chr11", "start": 95709762, "end": 96076344, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "mastermind like transcriptional coactivator 2", "description": "<p style=\"text-align: justify\"> Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Potentiates activation by NOTCH3 and NOTCH4 more efficiently than MAML1 or MAML3. </p>  <a title=\"Mol. Cell. Biol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12370315\">Mol. Cell. Biol., 2002</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12386158\">J. Biol. Chem., 2003</a>&nbsp;&nbsp;  <a title=\"Nat. Genet., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12539049\">Nat. Genet., 2003</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138437, "symbol": "BIRC3", "locus": "11q22.2", "entrez_id": 330, "chr": "chr11", "start": 102188215, "end": 102210134, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "baculoviral IAP repeat containing 3", "description": "<p style=\"text-align: justify\"> Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin- protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin- protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase- independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. </p>  <a title=\"PLoS ONE, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21931591\">PLoS ONE, 2012</a>&nbsp;&nbsp;  <a title=\"Cell Rep, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23453969\">Cell Rep, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138436, "symbol": "BIRC2", "locus": "11q22.2", "entrez_id": 329, "chr": "chr11", "start": 102217942, "end": 102249401, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "baculoviral IAP repeat containing 2", "description": "<p style=\"text-align: justify\"> Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling, and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin- protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin- protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, TRAF2, DIABLO/SMAC, MAP3K14/NIK, MAP3K5/ASK1, IKBKG/NEMO, IKBKE and MXD1/MAD1. Can also function as an E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase- dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Can stimulate the transcriptional activity of E2F1. Plays a role in the modulation of the cell cycle. </p>  <a title=\"Mol. Cell, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18082613\">Mol. Cell, 2008</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21145488\">Mol. Cell, 2011</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21653699\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21931591\">PLoS ONE, 2012</a>&nbsp;&nbsp;  <a title=\"Cell Rep, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23453969\">Cell Rep, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138435, "symbol": "GUCY1A2", "locus": "11q22.3", "entrez_id": 2977, "chr": "chr11", "start": 106544738, "end": 106889250, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "guanylate cyclase 1 soluble subunit alpha 2", "description": "Has guanylyl cyclase on binding to the beta-1 subunit", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138434, "symbol": "ATM", "locus": "11q22.3", "entrez_id": 472, "chr": "chr11", "start": 108093211, "end": 108239829, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ATM serine/threonine kinase", "description": "<p style=\"text-align: justify\"> Серин/треонин-протеинкиназа, действующая как сенсор повреждений ДНК, при обнаружении которых активирует сигнализацию контрольных точек клеточного цикла: при образовании двойных разрывов ДНК, запуске апоптоза и генотоксических воздействиях (ионизирующее ультрафиолетовое излучение (UVA)). АТМ узнает консенсусную последовательность [ST] –Q, фосфорилирует ‘Ser139 ' гистонов H2AX/H2AFX при двойных разрывах ДНК, тем самым регулируя механизм ответа на ее повреждение. АТМ также играет роль в переключении аллелей генов в предшественниках В-лимфоцитов, приводящем к экспрессии одного аллеля тяжелой цепи иммуноглобулина, для обеспечения клональности и специфического распознавания рецептором B-клеточного антигена (BCR), экспрессируемым на отдельных B-лимфоцитах. После введения разрывов ДНК комплексом RAG на одном аллеле гена иммуноглобулина АТМ опосредует перемещение второго аллеля в перицентромерный гетерохроматин, блокируя его доступность комплексу RAG и рекомбинацию. АТМ участвует в передаче сигналов и контроле клеточного цикла, реализуя опухолесупрессорную функцию. Действие АТМ необходимо для активации ABL1 и SAPK; АТМ фосфорилирует DYRK2, CHEK2, p53, FANCD2, NFKBIA, BRCA1, CTIP, NBN, TERF1, RAD9 и DCLRE1C. АТМ играет роль в транспорте везикул и/или белков, развитии Т-клеток, гонад и нервной ткани. АТМ участвует в деградации мРНК гистонов при репликации, играет роль в связывании концов ДНК. Фосфорилирует эффекторную киназу DYRK2 в ядре в ответ на генотоксические воздействия, предотвращает ее MDM2-опосредованное убиквитинирование и последующую протеасомную деградацию. Фосфорилирует транскрипционный фактор ATF2, который способствует функционированию АТМ в ответ на повреждение ДНК. </p>  <a title=\"Mol. Cell, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15916964\">Mol. Cell, 2005</a>&nbsp;&nbsp;  <a title=\"Nat. Struct. Mol. Biol., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16086026\">Nat. Struct. Mol. Biol., 2005</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16858402\">EMBO J., 2006</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17923702\">Mol. Cell. Biol., 2007</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19965871\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138433, "symbol": "SDHD", "locus": "11q23.1", "entrez_id": 6392, "chr": "chr11", "start": 111957497, "end": 111990353, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "succinate dehydrogenase complex subunit D", "description": "<p style=\"text-align: justify\"> Прикрепляющаяся к мембране субъединица сукцинатдегидрогеназы (SDH), которая входит в комплекс II электронно-транспортной цепи митохондрии и ответственна за перенос электронов с сукцината на убихинон (коэнзим Q). </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138432, "symbol": "KMT2A", "locus": "11q23.3", "entrez_id": 4297, "chr": "chr11", "start": 118307205, "end": 118397539, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "lysine methyltransferase 2A", "description": "<p style=\"text-align: justify\"> Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). In the MLL1/MLL complex, it specifically mediates H3K4me, a specific tag for epigenetic transcriptional activation. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'. Required for transcriptional activation of HOXA9. Promotes PPP1R15A-induced apoptosis. Plays a critical role in the control of circadian gene expression and is essential for the transcriptional activation mediated by the CLOCK-ARNTL/BMAL1 heterodimer. Establishes a permissive chromatin state for circadian transcription by mediating a rhythmic methylation of 'Lys-4' of histone H3 (H3K4me) and this histone modification directs the circadian acetylation at H3K9 and H3K14 allowing the recruitment of CLOCK-ARNTL/BMAL1 to chromatin (By similarity). </p>  <a title=\"Mol. Cell. Biol., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10490642\">Mol. Cell. Biol., 2000</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12453419\">Mol. Cell, 2003</a>&nbsp;&nbsp;  <a title=\"Cell, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15960975\">Cell, 2005</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19556245\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138431, "symbol": "CBL", "locus": "11q23.3", "entrez_id": 867, "chr": "chr11", "start": 119076752, "end": 119178859, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Cbl proto-oncogene", "description": "<p style=\"text-align: justify\"> Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. </p>  <a title=\"J. Biol. Chem., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15190072\">J. Biol. Chem., 2004</a>&nbsp;&nbsp;  <a title=\"FEBS J., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17509076\">FEBS J., 2007</a>&nbsp;&nbsp;  <a title=\"Bone, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18374639\">Bone, 2008</a>&nbsp;&nbsp;  <a title=\"Biochem. J., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19689429\">Biochem. J., 2009</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21596750\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138430, "symbol": "CHEK1", "locus": "11q24.2", "entrez_id": 1111, "chr": "chr11", "start": 125495036, "end": 125546150, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "checkpoint kinase 1", "description": "Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA. May also negatively regulate cell cycle progression during unperturbed cell cycles. This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome. Recognizes the substrate consensus sequence [R-X-X-S/T]. Binds to and phosphorylates CDC25A, CDC25B and CDC25C. Phosphorylation of CDC25A at 'Ser-178' and 'Thr-507' and phosphorylation of CDC25C at 'Ser-216' creates binding sites for 14-3-3 proteins which inhibit CDC25A and CDC25C. Phosphorylation of CDC25A at 'Ser-76', 'Ser- 124', 'Ser-178', 'Ser-279' and 'Ser-293' promotes proteolysis of CDC25A. Phosphorylation of CDC25A at 'Ser-76' primes the protein for subsequent phosphorylation at 'Ser-79', 'Ser-82' and 'Ser-88' by NEK11, which is required for polyubiquitination and degradation of CDCD25A. Inhibition of CDC25 leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. Also phosphorylates NEK6. Binds to and phosphorylates RAD51 at 'Thr-309', which promotes the release of RAD51 from BRCA2 and enhances the association of RAD51 with chromatin, thereby promoting DNA repair by homologous recombination. Phosphorylates multiple sites within the C-terminus of TP53, which promotes activation of TP53 by acetylation and promotes cell cycle arrest and suppression of cellular proliferation. Also promotes repair of DNA cross-links through phosphorylation of FANCE. Binds to and phosphorylates TLK1 at 'Ser-743', which prevents the TLK1-dependent phosphorylation of the chromatin assembly factor ASF1A. This may enhance chromatin assembly both in the presence or absence of DNA damage. May also play a role in replication fork maintenance through regulation of PCNA. May regulate the transcription of genes that regulate cell- cycle progression through the phosphorylation of histones. Phosphorylates histone H3.1 (to form H3T11ph), which leads to epigenetic inhibition of a subset of genes. May also phosphorylate RB1 to promote its interaction with the E2F family of transcription factors and subsequent cell cycle arrest", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138429, "symbol": "ETS1", "locus": "11q24.3", "entrez_id": 2113, "chr": "chr11", "start": 128328656, "end": 128457453, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ETS proto-oncogene 1, transcription factor", "description": "<p style=\"text-align: justify\"> Transcription factor. Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts. May control the differentiation, survival and proliferation of lymphoid cells. May also regulate angiogenesis through regulation of expression of genes controlling endothelial cell migration and invasion. </p>  <a title=\"Oncogene, 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10698492\">Oncogene, 2000</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11909962\">Mol. Cell. Biol., 2002</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15247905\">Oncogene, 2004</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15592518\">Oncogene, 2005</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138428, "symbol": "FLI1", "locus": "11q24.3", "entrez_id": 2313, "chr": "chr11", "start": 128556430, "end": 128683162, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Fli-1 proto-oncogene, ETS transcription factor", "description": "Sequence-specific transcriptional activator. Recognizes the DNA sequence 5'-C[CA]GGAAGT-3'", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138427, "symbol": "CCND2", "locus": "12p13.32", "entrez_id": 894, "chr": "chr12", "start": 4382938, "end": 4414516, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin D2", "description": "<p style=\"text-align: justify\"> Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D2/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex (By similarity). </p>", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138426, "symbol": "ING4", "locus": "12p13.31", "entrez_id": 51147, "chr": "chr12", "start": 6759446, "end": 6772314, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "inhibitor of growth family member 4", "description": "<p style=\"text-align: justify\"> Component of the HBO1 complex which has a histone H4- specific acetyltransferase activity, a reduced activity toward histone H3 and is responsible for the bulk of histone H4 acetylation in vivo. Through chromatin acetylation it may function in DNA replication. May inhibit tumor progression by modulating the transcriptional output of signaling pathways which regulate cell proliferation. Can suppress brain tumor angiogenesis through transcriptional repression of RELA/NFKB3 target genes when complexed with RELA. May also specifically suppress loss of contact inhibition elicited by activated oncogenes such as MYC. Represses hypoxia inducible factor's (HIF) activity by interacting with HIF prolyl hydroxylase 2 (EGLN1). Can enhance apoptosis induced by serum starvation in mammary epithelial cell line HC11 (By similarity). </p>  <a title=\"Nature, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15029197\">Nature, 2004</a>&nbsp;&nbsp;  <a title=\"FEBS Lett., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15251430\">FEBS Lett., 2004</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15528276\">Proc. Natl. Acad. Sci. U.S.A., 2004</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15897452\">Proc. Natl. Acad. Sci. U.S.A., 2005</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16387653\">Mol. Cell, 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138425, "symbol": "ZNF384", "locus": "12p13.31", "entrez_id": 171017, "chr": "chr12", "start": 6775643, "end": 6798738, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "zinc finger protein 384", "description": "<p style=\"text-align: justify\"> Transcription factor that binds the consensus DNA sequence [GC]AAAAA. Seems to bind and regulate the promoters of MMP1, MMP3, MMP7 and COL1A1 (By similarity). </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138424, "symbol": "KRAS", "locus": "12p12.1", "entrez_id": 3845, "chr": "chr12", "start": 25357723, "end": 25403870, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "KRAS proto-oncogene, GTPase", "description": "<p style=\"text-align: justify\"> Белки семейства Ras связывают ГТФ/ГДФ и обладают собственной ГТФазной активностью. Играют важную роль в регуляции клеточной пролиферации (PMID:23698361, 22711838). Являются промоторами онкогенеза, индуцируя подавление транскрипции генов опухолевых супрессоров в клеточных культурах колоректальных карцином (PMID:24623306). </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22711838\">Proc. Natl. Acad. Sci. U.S.A., 2012</a>&nbsp;&nbsp;  <a title=\"Nature, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23698361\">Nature, 2013</a>&nbsp;&nbsp;  <a title=\"Elife, 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24623306\">Elife, 2015</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138423, "symbol": "ADAMTS20", "locus": "12q12", "entrez_id": 80070, "chr": "chr12", "start": 43747669, "end": 43945724, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ADAM metallopeptidase with thrombospondin type 1 motif 20", "description": "May play a role in tissue-remodeling process occurring in both normal and pathological conditions. May have a protease- independent function in the transport from the endoplasmic reticulum to the Golgi apparatus of secretory cargos, mediated by the GON domain", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138422, "symbol": "ARID2", "locus": "12q12", "entrez_id": 196528, "chr": "chr12", "start": 46123448, "end": 46301823, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "AT-rich interaction domain 2", "description": "<p style=\"text-align: justify\"> Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes. May be involved in regulating transcriptional activation of cardiac genes. </p>  <a title=\"Biochem. Biophys. Res. Commun., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16782067\">Biochem. Biophys. Res. Commun., 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138421, "symbol": "KMT2D", "locus": "12q13.12", "entrez_id": 8085, "chr": "chr12", "start": 49412758, "end": 49453557, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "lysine methyltransferase 2D", "description": "<p style=\"text-align: justify\"> Histone methyltransferase. Methylates 'Lys-4' of histone H3 (H3K4me). H3K4me represents a specific tag for epigenetic transcriptional activation. Acts as a coactivator for estrogen receptor by being recruited by ESR1, thereby activating transcription. </p>  <a title=\"J. Biol. Chem., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16603732\">J. Biol. Chem., 2006</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17500065\">J. Biol. Chem., 2007</a>&nbsp;&nbsp;  <a title=\"Nature, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17851529\">Nature, 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138420, "symbol": "MDM2", "locus": "12q15", "entrez_id": 4193, "chr": "chr12", "start": 69201956, "end": 69239214, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "MDM2 proto-oncogene", "description": "<p style=\"text-align: justify\"> E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation (PubMed:12821780, PubMed:15053880, PubMed:15195100, PubMed:15632057, PubMed:16337594, PubMed:17290220, PubMed:19098711, PubMed:19219073, PubMed:19837670, PubMed:19965871, PubMed:20173098, PubMed:20385133, PubMed:20858735, PubMed:22128911). Ubiquitinates DCX, leading to DCX degradation and reduction of the dendritic spine density of olfactory bulb granule cells (By similarity). </p>  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19965871\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20173098\">Proc. Natl. Acad. Sci. U.S.A., 2010</a>&nbsp;&nbsp;  <a title=\"FEBS Lett., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20385133\">FEBS Lett., 2010</a>&nbsp;&nbsp;  <a title=\"Mol. Cancer Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20858735\">Mol. Cancer Res., 2011</a>&nbsp;&nbsp;  <a title=\"BMC Biol., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22128911\">BMC Biol., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138419, "symbol": "PTPN11", "locus": "12q24.13", "entrez_id": 5781, "chr": "chr12", "start": 112856155, "end": 112947717, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "protein tyrosine phosphatase, non-receptor type 11", "description": "<p style=\"text-align: justify\"> Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Positively regulates MAPK signal transduction pathway (PubMed:28074573). Dephosphorylates GAB1, ARHGAP35 and EGFR (PubMed:28074573). Dephosphorylates ROCK2 at 'Tyr-722' resulting in stimulatation of its RhoA binding activity. Dephosphorylates CDC73 (PubMed:26742426). </p>  <a title=\"Nat. Cell Biol., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10655584\">Nat. Cell Biol., 2000</a>&nbsp;&nbsp;  <a title=\"J. Cell Biol., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18559669\">J. Cell Biol., 2008</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18829466\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"Biochem. Biophys. Res. Commun., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26742426\">Biochem. Biophys. Res. Commun., 2016</a>&nbsp;&nbsp;  <a title=\"Hum. Mutat., 2018\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/28074573\">Hum. Mutat., 2018</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138418, "symbol": "HNF1A", "locus": "12q24.31", "entrez_id": 6927, "chr": "chr12", "start": 121416346, "end": 121440315, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "HNF1 homeobox A", "description": "<p style=\"text-align: justify\"> Транскрипционный активатор, который регулирует тканеспецифичную экспрессию нескольких генов, особенно в островковых клетках поджелудочной железы и в печени. Требуется для экспрессии нескольких печеночных генов. Связывается с перевернутым палиндромом </p>  <a title=\"Nat. Struct. Biol., 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10966642\">Nat. Struct. Biol., 2000</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12453420\">Mol. Cell, 2003</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138417, "symbol": "HCAR1", "locus": "12q24.31", "entrez_id": 27198, "chr": "chr12", "start": 123104824, "end": 123215390, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "hydroxycarboxylic acid receptor 1", "description": "<p style=\"text-align: justify\"> Acts as a receptor for L-lactate and mediates its anti- lipolytic effect through a G(i)-protein-mediated pathway. </p>  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19047060\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138416, "symbol": "EP400", "locus": "12q24.33", "entrez_id": 57634, "chr": "chr12", "start": 132434508, "end": 132565005, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "E1A binding protein p400", "description": "<p style=\"text-align: justify\"> Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. May be required for transcriptional activation of E2F1 and MYC target genes during cellular proliferation. The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400. May regulate ZNF42 transcription activity. Component of a SWR1-like complex that specifically mediates the removal of histone H2A.Z/H2AFZ from the nucleosome. </p>  <a title=\"Mol. Cell. Biol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14966270\">Mol. Cell. Biol., 2004</a>&nbsp;&nbsp;  <a title=\"Nature, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24463511\">Nature, 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138415, "symbol": "CDK8", "locus": "13q12.13", "entrez_id": 1024, "chr": "chr13", "start": 26828276, "end": 26979375, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin dependent kinase 8", "description": "<p style=\"text-align: justify\"> Component of the Mediator complex, a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Phosphorylates the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAp II), which may inhibit the formation of a transcription initiation complex. Phosphorylates CCNH leading to down-regulation of the TFIIH complex and transcriptional repression. Recruited through interaction with MAML1 to hyperphosphorylate the intracellular domain of NOTCH, leading to its degradation. </p>  <a title=\"Nature, 2000\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10993082\">Nature, 2000</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15546612\">Mol. Cell, 2005</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138074, "symbol": "NCOA4", "locus": "10q11.22", "entrez_id": 8031, "chr": "chr10", "start": 51565108, "end": 51590734, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nuclear receptor coactivator 4", "description": "<p style=\"text-align: justify\"> Enhances the androgen receptor transcriptional activity in prostate cancer cells. Ligand-independent coactivator of the peroxisome proliferator-activated receptor (PPAR) gamma. </p>  <a title=\"J. Biol. Chem., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10347167\">J. Biol. Chem., 1999</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138073, "symbol": "TET1", "locus": "10q21.3", "entrez_id": 80312, "chr": "chr10", "start": 70320413, "end": 70454239, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "tet methylcytosine dioxygenase 1", "description": "<p style=\"text-align: justify\"> Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5- hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Also mediates subsequent conversion of 5hmC into 5- formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position of cytosine bases is an epigenetic modification of the mammalian genome which plays an important role in transcriptional regulation. In addition to its role in DNA demethylation, plays a more general role in chromatin regulation. Preferentially binds to CpG-rich sequences at promoters of both transcriptionally active and Polycomb-repressed genes. Involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT. Also involved in transcription repression of a subset of genes through recruitment of transcriptional repressors to promoters. Involved in the balance between pluripotency and lineage commitment of cells it plays a role in embryonic stem cells maintenance and inner cell mass cell specification. Plays an important role in the tumorigenicity of glioblastoma cells. TET1-mediated production of 5hmC acts as a recruitment signal for the CHTOP-methylosome complex to selective sites on the chromosome, where it methylates H4R3 and activates the transcription of genes involved in glioblastomagenesis (PubMed:25284789). </p>  <a title=\"Science, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19372391\">Science, 2009</a>&nbsp;&nbsp;  <a title=\"Science, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19372393\">Science, 2009</a>&nbsp;&nbsp;  <a title=\"Cell, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21496894\">Cell, 2011</a>&nbsp;&nbsp;  <a title=\"Science, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21778364\">Science, 2011</a>&nbsp;&nbsp;  <a title=\"Cell Rep, 2015\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/25284789\">Cell Rep, 2015</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138072, "symbol": "KAT6B", "locus": "10q22.2", "entrez_id": 23522, "chr": "chr10", "start": 76585340, "end": 76792380, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "lysine acetyltransferase 6B", "description": "<p style=\"text-align: justify\"> Histone acetyltransferase which may be involved in both positive and negative regulation of transcription. Required for RUNX2-dependent transcriptional activation. May be involved in cerebral cortex development. Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. </p>  <a title=\"J. Biol. Chem., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10497217\">J. Biol. Chem., 1999</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11965546\">Oncogene, 2002</a>&nbsp;&nbsp;  <a title=\"Mol. Cell, 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16387653\">Mol. Cell, 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138071, "symbol": "BMPR1A", "locus": "10q23.2", "entrez_id": 657, "chr": "chr10", "start": 88516407, "end": 88692595, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "bone morphogenetic protein receptor type 1A", "description": "<p style=\"text-align: justify\"> On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively regulates chondrocyte differentiation through GDF5 interaction. Mediates induction of adipogenesis by GDF6. </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138070, "symbol": "PTEN", "locus": "10q23.31", "entrez_id": 5728, "chr": "chr10", "start": 89622870, "end": 89731687, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phosphatase and tensin homolog", "description": "<p style=\"text-align: justify\"> Опухолевый супрессор. Действует как протеинфосфатаза двойной специфичности, дефосфорилируя белки, фосфорилированные по остаткам тирозина, серина и треонина. Также действует как липидфосфатаза, удаляя фосфат в положении D3 инозитового кольца из фосфатидилинозитол-3,4,5-трифосфата, фосфатидилинозитол-3,4-дифосфата, фосфатидилинозитол-3-фосфата и инозитол-1,3,4,5-тетрасфосфата, в порядке убывания субстратной специфичности по результатам in vitro (PubMed: 26504226). Активность липидфосфатазы является критической для опухолесупрессорной функции PTEN. Является негативным регулятором сигнального пути PI3K/Akt/PKB, дефосфорилируя фосфоинозитиды и тем самым модулируя контроль клеточного цикла и выживание клеток. Нефосфорилированная форма взаимодействует с AIP1 для подавления активации Akt1. Дефосфорилирует фосфорилированную фокальную адгезионную киназу и ингибирует клеточную миграцию и интегрин-опосредованное движение клеток. Играет роль ключевого модулятора сигнального пути Akt/mTOR, контролирующего темп процесса интеграции нейронов во время нейрогенеза у новорожденных, включая правильное позиционирование нейронов, развитие дендритов и образование синапсов. PTEN может быть негативным регулятором передачи сигналов инсулина и метаболизма глюкозы в жировой ткани. Ядерная моноубиквитинированная форма PTEN обладает большим про-апоптическим действием, в то время как цитоплазматическая неубиквитинированная форма отличается меньшим опухолесупрессорным действием. В подвижных клетках PTEN подавляет образование латеральных псевдоподий и тем самым способствует поляризации клеток и их направленному движению. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26504226\">Proc. Natl. Acad. Sci. U.S.A., 2016</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138069, "symbol": "FAS", "locus": "10q23.31", "entrez_id": 355, "chr": "chr10", "start": 90750414, "end": 90775542, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Fas cell surface death receptor", "description": "<p style=\"text-align: justify\"> Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death- inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS- mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). </p>  <a title=\"J. Immunol., 1995\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7533181\">J. Immunol., 1995</a>&nbsp;&nbsp;  <a title=\"Nature, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19118384\">Nature, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138068, "symbol": "CYP2C19", "locus": "10q23.33", "entrez_id": 1557, "chr": "chr10", "start": 96447911, "end": 96613017, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cytochrome P450 family 2 subfamily C member 19", "description": "Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138067, "symbol": "BLNK", "locus": "10q24.1", "entrez_id": 29760, "chr": "chr10", "start": 97951458, "end": 98031344, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "B-cell linker", "description": "<p style=\"text-align: justify\"> Functions as a central linker protein, downstream of the B-cell receptor (BCR), bridging the SYK kinase to a multitude of signaling pathways and regulating biological outcomes of B-cell function and development. Plays a role in the activation of ERK/EPHB2, MAP kinase p38 and JNK. Modulates AP1 activation. Important for the activation of NF-kappa-B and NFAT. Plays an important role in BCR-mediated PLCG1 and PLCG2 activation and Ca(2+) mobilization and is required for trafficking of the BCR to late endosomes. However, does not seem to be required for pre-BCR- mediated activation of MAP kinase and phosphatidyl-inositol 3 (PI3) kinase signaling. May be required for the RAC1-JNK pathway. Plays a critical role in orchestrating the pro-B cell to pre-B cell transition. May play an important role in BCR-induced B-cell apoptosis. </p>  <a title=\"Immunity, 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9697839\">Immunity, 1998</a>&nbsp;&nbsp;  <a title=\"Science, 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10583958\">Science, 1999</a>&nbsp;&nbsp;  <a title=\"Immunology, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15270728\">Immunology, 2004</a>&nbsp;&nbsp;  <a title=\"Blood, 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16912232\">Blood, 2007</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138066, "symbol": "TLX1", "locus": "10q24.31", "entrez_id": 3195, "chr": "chr10", "start": 102889257, "end": 102897545, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "T-cell leukemia homeobox 1", "description": "Controls the genesis of the spleen. Binds to the DNA sequence 5'-GGCGGTAAGTGG-3'", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138065, "symbol": "NFKB2", "locus": "10q24.32", "entrez_id": 4791, "chr": "chr10", "start": 104153867, "end": 104162281, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nuclear factor kappa B subunit 2", "description": "<p style=\"text-align: justify\"> NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14- activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK- ARNTL/BMAL1 heterodimer. </p>  <a title=\"EMBO J., 1994\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7925301\">EMBO J., 1994</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138064, "symbol": "SUFU", "locus": "10q24.32", "entrez_id": 51684, "chr": "chr10", "start": 104263744, "end": 104393292, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "SUFU negative regulator of hedgehog signaling", "description": "<p style=\"text-align: justify\"> Negative regulator in the hedgehog signaling pathway. Down-regulates GLI1-mediated transactivation of target genes (PubMed:15367681, PubMed:24311597, PubMed:24217340). Down- regulates GLI2-mediated transactivation of target genes (PubMed:24311597, PubMed:24217340). Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome. Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein (PubMed:10806483, PubMed:24217340). Negative regulator of beta- catenin signaling. Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full length form of GLI3 (GLI3FL). GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state. Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R. When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A). Required for normal embryonic development. Required for the proper formation of hair follicles and the control of epidermal differentiation (By similarity). </p>  <a title=\"Genome Res., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12975309\">Genome Res., 2003</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15367681\">Mol. Cell. Biol., 2004</a>&nbsp;&nbsp;  <a title=\"Cell. Signal., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22365972\">Cell. Signal., 2012</a>&nbsp;&nbsp;  <a title=\"Nat Commun, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24217340\">Nat Commun, 2014</a>&nbsp;&nbsp;  <a title=\"Acta Crystallogr. D Biol. Crystallogr., 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24311597\">Acta Crystallogr. D Biol. Crystallogr., 2014</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138063, "symbol": "TCF7L2", "locus": "10q25.2-q25.3", "entrez_id": 6934, "chr": "chr10", "start": 114710009, "end": 114927437, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "transcription factor 7 like 2", "description": "<p style=\"text-align: justify\"> Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine. </p>  <a title=\"Science, 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9727977\">Science, 1998</a>&nbsp;&nbsp;  <a title=\"Cell, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12408868\">Cell, 2002</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12727872\">EMBO J., 2003</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19443654\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"EMBO Rep., 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22699938\">EMBO Rep., 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138062, "symbol": "FGFR2", "locus": "10q26.13", "entrez_id": 2263, "chr": "chr10", "start": 123237848, "end": 123357972, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "fibroblast growth factor receptor 2", "description": "<p style=\"text-align: justify\"> Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. </p>  <a title=\"Bone, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18374639\">Bone, 2008</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19103595\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"J. Invest. Dermatol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19387476\">J. Invest. Dermatol., 2009</a>&nbsp;&nbsp;  <a title=\"Cell. Signal., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19410646\">Cell. Signal., 2009</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21596750\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138061, "symbol": "ATF1", "locus": "12q13.12", "entrez_id": 466, "chr": "chr12", "start": 51157493, "end": 51214905, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "activating transcription factor 1", "description": "<p style=\"text-align: justify\"> This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Binds to the Tax-responsive element (TRE) of HTLV-I. Mediates PKA-induced stimulation of CRE-reporter genes. Represses the expression of FTH1 and other antioxidant detoxification genes. Triggers cell proliferation and transformation. </p>  <a title=\"Cancer Res., 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18794154\">Cancer Res., 2008</a>&nbsp;&nbsp;  <a title=\"J. Cell. Sci., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20980392\">J. Cell. Sci., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138060, "symbol": "SMUG1", "locus": "12q13.13", "entrez_id": 23583, "chr": "chr12", "start": 54558529, "end": 54582778, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "single-strand-selective monofunctional uracil-DNA glycosylase 1", "description": "<p style=\"text-align: justify\"> Recognizes base lesions in the genome and initiates base excision DNA repair. Acts as a monofunctional DNA glycosylase specific for uracil (U) residues in DNA with a preference for single-stranded DNA substrates. The activity is greater toward mismatches (U/G) compared to matches (U/A). Excises uracil (U), 5- formyluracil (fU) and uracil derivatives bearing an oxidized group at C5 [5-hydroxyuracil (hoU) and 5-hydroxymethyluracil (hmU)] in ssDNA and dsDNA, but not analogous cytosine derivatives (5- hydroxycytosine and 5-formylcytosine), nor other oxidized bases. The activity is damage-specific and salt-dependent. The substrate preference is the following: ssDNA > dsDNA (G pair) = dsDNA (A pair) at low salt concentration, and dsDNA (G pair) > dsDNA (A pair) > ssDNA at high salt concentration. </p>  <a title=\"Curr. Biol., 1999\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10074426\">Curr. Biol., 1999</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11526119\">J. Biol. Chem., 2001</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12161446\">J. Biol. Chem., 2002</a>&nbsp;&nbsp;  <a title=\"Biochemistry, 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12718543\">Biochemistry, 2003</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138059, "symbol": "ERBB3", "locus": "12q13.2", "entrez_id": 2065, "chr": "chr12", "start": 56473641, "end": 56497289, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "erb-b2 receptor tyrosine kinase 3", "description": "<p style=\"text-align: justify\"> Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778). May also be activated by CSPG5 (PubMed:15358134). </p>  <a title=\"Biochem. Biophys. Res. Commun., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15358134\">Biochem. Biophys. Res. Commun., 2004</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20682778\">J. Biol. Chem., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138058, "symbol": "DDIT3", "locus": "12q13.3", "entrez_id": 1649, "chr": "chr12", "start": 57910371, "end": 57914300, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "DNA damage inducible transcript 3", "description": "<p style=\"text-align: justify\"> Multifunctional transcription factor in ER stress response. Plays an essential role in the response to a wide variety of cell stresses and induces cell cycle arrest and apoptosis in response to ER stress. Plays a dual role both as an inhibitor of CCAAT/enhancer-binding protein (C/EBP) function and as an activator of other genes. Acts as a dominant-negative regulator of C/EBP-induced transcription: dimerizes with members of the C/EBP family, impairs their association with C/EBP binding sites in the promoter regions, and inhibits the expression of C/EBP regulated genes. Positively regulates the transcription of TRIB3, IL6, IL8, IL23, TNFRSF10B/DR5, PPP1R15A/GADD34, BBC3/PUMA, BCL2L11/BIM and ERO1L. Negatively regulates; expression of BCL2 and MYOD1, ATF4-dependent transcriptional activation of asparagine synthetase (ASNS), CEBPA-dependent transcriptional activation of hepcidin (HAMP) and CEBPB-mediated expression of peroxisome proliferator-activated receptor gamma (PPARG). Inhibits the canonical Wnt signaling pathway by binding to TCF7L2/TCF4, impairing its DNA-binding properties and repressing its transcriptional activity. Plays a regulatory role in the inflammatory response through the induction of caspase-11 (CASP4/CASP11) which induces the activation of caspase-1 (CASP1) and both these caspases increase the activation of pro-IL1B to mature IL1B which is involved in the inflammatory response. </p>  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18940792\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19672300\">PLoS ONE, 2010</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20829347\">J. Biol. Chem., 2011</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20876114\">Proc. Natl. Acad. Sci. U.S.A., 2010</a>&nbsp;&nbsp;  <a title=\"PLoS ONE, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22761832\">PLoS ONE, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138057, "symbol": "CDK4", "locus": "12q14.1", "entrez_id": 1019, "chr": "chr12", "start": 58141510, "end": 58149796, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin dependent kinase 4", "description": "<p style=\"text-align: justify\"> Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. </p>  <a title=\"EMBO J., 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9003781\">EMBO J., 1997</a>&nbsp;&nbsp;  <a title=\"Nature, 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15241418\">Nature, 2004</a>&nbsp;&nbsp;  <a title=\"Cell Struct. Funct., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18827403\">Cell Struct. Funct., 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138056, "symbol": "HRAS", "locus": "11p15.5", "entrez_id": 3265, "chr": "chr11", "start": 532242, "end": 537287, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "HRas proto-oncogene, GTPase", "description": "<p style=\"text-align: justify\"> Involved in the activation of Ras protein signal transduction (PubMed:22821884). Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:12740440, PubMed:14500341, PubMed:9020151). </p>  <a title=\"J. Biol. Chem., 1997\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9020151\">J. Biol. Chem., 1997</a>&nbsp;&nbsp;  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12740440\">Proc. Natl. Acad. Sci. U.S.A., 2003</a>&nbsp;&nbsp;  <a title=\"Cancer Res., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/14500341\">Cancer Res., 2003</a>&nbsp;&nbsp;  <a title=\"Am. J. Med. Genet. A, 2012\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/22821884\">Am. J. Med. Genet. A, 2012</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138055, "symbol": "IGF2", "locus": "11p15.5", "entrez_id": 3481, "chr": "chr11", "start": 2150342, "end": 2170833, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "insulin like growth factor 2", "description": "The insulin-like growth factors possess growth-promoting activity. In vitro, they are potent mitogens for cultured cells. IGF-II is influenced by placental lactogen and may play a role in fetal development", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138054, "symbol": "NUP98", "locus": "11p15.4", "entrez_id": 4928, "chr": "chr11", "start": 3692313, "end": 3819022, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nucleoporin 98", "description": "<p style=\"text-align: justify\"> Plays a role in the nuclear pore complex (NPC) assembly and/or maintenance. Nup98 and Nup96 are involved in the bidirectional transport across the NPC. May anchor NUP153 and TPR to the NPC. </p>  <a title=\"Mol. Biol. Cell, 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15229283\">Mol. Biol. Cell, 2005</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138053, "symbol": "RRM1", "locus": "11p15.4", "entrez_id": 6240, "chr": "chr11", "start": 4115937, "end": 4160106, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ribonucleotide reductase catalytic subunit M1", "description": "Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138052, "symbol": "FANCF", "locus": "11p14.3", "entrez_id": 2188, "chr": "chr11", "start": 22644079, "end": 22647387, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Fanconi anemia complementation group F", "description": "<p style=\"text-align: justify\"> DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability (By similarity). </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138051, "symbol": "JAK2", "locus": "9p24.1", "entrez_id": 3717, "chr": "chr9", "start": 4985033, "end": 5128183, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Janus kinase 2", "description": "<p style=\"text-align: justify\"> Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins (PubMed:7615558). Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins (PubMed:9618263). Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:20098430). Plays a role in cell cycle by phosphorylating CDKN1B (PubMed:21423214). Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin (PubMed:19783980). </p>  <a title=\"Biochem. Biophys. Res. Commun., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9618263\">Biochem. Biophys. Res. Commun., 1998</a>&nbsp;&nbsp;  <a title=\"J. Immunol., 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12023369\">J. Immunol., 2002</a>&nbsp;&nbsp;  <a title=\"Nature, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19783980\">Nature, 2009</a>&nbsp;&nbsp;  <a title=\"Nat. Med., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20098430\">Nat. Med., 2010</a>&nbsp;&nbsp;  <a title=\"Oncogene, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21423214\">Oncogene, 2011</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138050, "symbol": "PTPRD", "locus": "9p24.1-p23", "entrez_id": 5789, "chr": "chr9", "start": 8314246, "end": 10612723, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "protein tyrosine phosphatase, receptor type D", "description": "-", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138049, "symbol": "PSIP1", "locus": "9p22.3", "entrez_id": 11168, "chr": "chr9", "start": 15464064, "end": 15511017, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "PC4 and SFRS1 interacting protein 1", "description": "<p style=\"text-align: justify\"> Transcriptional coactivator involved in neuroepithelial stem cell differentiation and neurogenesis. Involved in particular in lens epithelial cell gene regulation and stress responses. May play an important role in lens epithelial to fiber cell terminal differentiation. May play a protective role during stress-induced apoptosis. Isoform 2 is a more general and stronger transcriptional coactivator. Isoform 2 may also act as an adapter to coordinate pre-mRNA splicing. Cellular cofactor for lentiviral integration. </p>  <a title=\"Exp. Eye Res., 2005\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15642333\">Exp. Eye Res., 2005</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138048, "symbol": "CDKN2A", "locus": "9p21.3", "entrez_id": 1029, "chr": "chr9", "start": 21967751, "end": 21995300, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin dependent kinase inhibitor 2A", "description": "<p style=\"text-align: justify\"> Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 1994\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/7972006\">Proc. Natl. Acad. Sci. U.S.A., 1994</a>&nbsp;&nbsp;  <a title=\"Mol. Cell. Biol., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16782892\">Mol. Cell. Biol., 2006</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138047, "symbol": "CDKN2B", "locus": "9p21.3", "entrez_id": 1030, "chr": "chr9", "start": 22002902, "end": 22009362, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "cyclin dependent kinase inhibitor 2B", "description": "Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138046, "symbol": "TAF1L", "locus": "9p21.1", "entrez_id": 138474, "chr": "chr9", "start": 32629452, "end": 32635667, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "TATA-box binding protein associated factor 1 like", "description": "<p style=\"text-align: justify\"> May act as a functional substitute for TAF1/TAFII250 during male meiosis, when sex chromosomes are transcriptionally silenced. </p>  <a title=\"Hum. Mol. Genet., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12217962\">Hum. Mol. Genet., 2003</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138045, "symbol": "FANCG", "locus": "9p13.3", "entrez_id": 2189, "chr": "chr9", "start": 35073832, "end": 35080013, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Fanconi anemia complementation group G", "description": "DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Candidate tumor suppressor gene", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138044, "symbol": "PAX5", "locus": "9p13.2", "entrez_id": 5079, "chr": "chr9", "start": 36833272, "end": 37034103, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "paired box 5", "description": "May play an important role in B-cell differentiation as well as neural development and spermatogenesis. Involved in the regulation of the CD19 gene, a B-lymphoid-specific target gene", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138043, "symbol": "GNAQ", "locus": "9q21.2", "entrez_id": 2776, "chr": "chr9", "start": 80331003, "end": 80646374, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "G protein subunit alpha q", "description": "<p style=\"text-align: justify\"> Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. Regulates B-cell selection and survival and is required to prevent B-cell-dependent autoimmunity. Regulates chemotaxis of BM-derived neutrophils and dendritic cells (in vitro) (By similarity). </p>", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138042, "symbol": "SYK", "locus": "9q22.2", "entrez_id": 6850, "chr": "chr9", "start": 93564069, "end": 93660831, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "spleen associated tyrosine kinase", "description": "<p style=\"text-align: justify\"> Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine- phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK. Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition. Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR plays also a role in T- cell receptor signaling. Plays also a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF-kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade. Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Also functions downstream of receptors mediating cell adhesion. Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG-mediated recruitment of leukocytes to inflammatory loci. Plays also a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen. Together with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response (By similarity). </p>  <a title=\"J. Biol. Chem., 1998\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/9535867\">J. Biol. Chem., 1998</a>&nbsp;&nbsp;  <a title=\"Immunity, 2002\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12387735\">Immunity, 2002</a>&nbsp;&nbsp;  <a title=\"EMBO J., 2003\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/12456653\">EMBO J., 2003</a>&nbsp;&nbsp;  <a title=\"FEBS Lett., 2004\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/15388330\">FEBS Lett., 2004</a>&nbsp;&nbsp;  <a title=\"Exp. Cell Res., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19909739\">Exp. Cell Res., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138041, "symbol": "FANCC", "locus": "9q22.32", "entrez_id": 2176, "chr": "chr9", "start": 97861336, "end": 98079991, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "Fanconi anemia complementation group C", "description": "<p style=\"text-align: justify\"> DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Upon IFNG induction, may facilitate STAT1 activation by recruiting STAT1 to IFNGR1. </p>  <a title=\"Blood, 2001\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/11520787\">Blood, 2001</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138040, "symbol": "PTCH1", "locus": "9q22.32", "entrez_id": 5727, "chr": "chr9", "start": 98205262, "end": 98279339, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "patched 1", "description": "<p style=\"text-align: justify\"> Acts as a receptor for sonic hedgehog (SHH), indian hedgehog (IHH) and desert hedgehog (DHH). Associates with the smoothened protein (SMO) to transduce the hedgehog's proteins signal. Seems to have a tumor suppressor function, as inactivation of this protein is probably a necessary, if not sufficient step for tumorigenesis. </p>  <a title=\"Cell Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21537345\">Cell Res., 2011</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138039, "symbol": "XPA", "locus": "9q22.33", "entrez_id": 7507, "chr": "chr9", "start": 100437191, "end": 100459639, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "XPA, DNA damage recognition and repair factor", "description": "<p style=\"text-align: justify\"> Involved in DNA excision repair. Initiates repair by binding to damaged sites with various affinities, depending on the photoproduct and the transcriptional state of the region. Required for UV-induced CHEK1 phosphorylation and the recruitment of CEP164 to cyclobutane pyrimidine dimmers (CPD), sites of DNA damage after UV irradiation. </p>  <a title=\"Cell Cycle, 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19197159\">Cell Cycle, 2009</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138038, "symbol": "TLR4", "locus": "9q33.1", "entrez_id": 7099, "chr": "chr9", "start": 120466610, "end": 120479149, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "toll like receptor 4", "description": "<p style=\"text-align: justify\"> Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:9237759, PubMed:10835634). Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+). Responses triggered by Ni(2+) require non-conserved histidines and are, therefore, species-specific (PubMed:20711192). Both M.tuberculosis HSP70 (dnaK) and HSP65 (groEL-2) act via this protein to stimulate NF-kappa-B expression (PubMed:15809303). In complex with TLR6, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-) (PubMed:23880187). Stimulation of monocytes in vitro with M.tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via TLR2, but also partially via this receptor (PubMed:16622205). </p>  <a title=\"Infect. Immun., 2006\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/16622205\">Infect. Immun., 2006</a>&nbsp;&nbsp;  <a title=\"Circ. Res., 2007\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/17478729\">Circ. Res., 2007</a>&nbsp;&nbsp;  <a title=\"Nat. Immunol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20037584\">Nat. Immunol., 2010</a>&nbsp;&nbsp;  <a title=\"Nat. Immunol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20711192\">Nat. Immunol., 2010</a>&nbsp;&nbsp;  <a title=\"Atherosclerosis, 2013\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/23880187\">Atherosclerosis, 2013</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138037, "symbol": "ABL1", "locus": "9q34.12", "entrez_id": 25, "chr": "chr9", "start": 133589333, "end": 133763062, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", "description": "<p style=\"text-align: justify\"> Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage- induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin- associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. </p>  <a title=\"Biochim. Biophys. Acta, 2008\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18328268\">Biochim. Biophys. Acta, 2008</a>&nbsp;&nbsp;  <a title=\"J. Biol. Chem., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/18945674\">J. Biol. Chem., 2009</a>&nbsp;&nbsp;  <a title=\"BMC Cell Biol., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19891780\">BMC Cell Biol., 2009</a>&nbsp;&nbsp;  <a title=\"Nat. Struct. Mol. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20357770\">Nat. Struct. Mol. Biol., 2010</a>&nbsp;&nbsp;  <a title=\"Curr. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20417104\">Curr. Biol., 2010</a>&nbsp;&nbsp;", "gene_type": "STR_NO_MUTATIONS"}, {"json_id": 138036, "symbol": "NUP214", "locus": "9q34.13", "entrez_id": 8021, "chr": "chr9", "start": 134000948, "end": 134110057, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "nucleoporin 214", "description": "<p style=\"text-align: justify\"> May serve as a docking site in the receptor-mediated import of substrates across the nuclear pore complex. </p>  <a title=\"Proc. Natl. Acad. Sci. U.S.A., 1994\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/8108440\">Proc. Natl. Acad. Sci. U.S.A., 1994</a>&nbsp;&nbsp;", "gene_type": "STR_POLYMORPHISM"}, {"json_id": 138035, "symbol": "BRCA1", "locus": "17q21.31", "entrez_id": 672, "chr": "chr17", "start": 41196312, "end": 41277500, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "BRCA1, DNA repair associated", "description": "<p style=\"text-align: justify;\">BRCA1 кодирует ядерный фосфопротеин, убиквитин-лигазу E3, которая играет роль в поддержании стабильности генома, а также действует как опухолевый супрессор. BRCA1 функционирует в комплексе с другими белками с опухолесупрессорнй функцией - сенсорами повреждений ДНК, образуя крупный многосубъединичный белковый комплекс - BRCA1-связанный комплекс слежения за геномом BASC (BRCA1-associated genome surveillance complex). BRCA1 связывается с РНК-полимеразой II и через С-концевой домен также взаимодействует с комплексами гистондеацетилазы. Таким образом, BRCA1&nbsp;участвует в транскрипции, репарации ДНК двухцепочечных разрывов и рекомбинации. BRCA1 регулирует нуклеацию центросомных микротрубочек. BRCA1 требуется&nbsp;для ареста клеточного цикла после воздействия ионизирующего излучения как в S-фазе, так и в фазе G2 клеточного цикла. Участвует в транскрипционной регуляции р21 в ответ на повреждение ДНК. BRCA1 может&nbsp;играть роль регулятора транскрипции. Мутации в BRCA1 ответственны приблизительно за 40% наследственных раков молочной железы и более 80% наследственных раков молочной железы и яичников.</p>\r\n<p><a title=\"Genes Dev., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19261748\">Genes Dev., 2009</a>&nbsp;&nbsp;&nbsp;<a title=\"Proc. Natl. Acad. Sci. U.S.A., 2009\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/19369211\">Proc. Natl. Acad. Sci. U.S.A., 2009</a>&nbsp;&nbsp;&nbsp;<a title=\"Br. J. Cancer, 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20160719\">Br. J. Cancer, 2010</a>&nbsp;&nbsp;&nbsp;<a title=\"Mol. Cell. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20351172\">Mol. Cell. Biol., 2010</a>&nbsp;&nbsp;&nbsp;<a title=\"Nat. Cell Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20364141\">Nat. Cell Biol., 2010</a>&nbsp;&nbsp;</p>", "gene_type": "STR_CLIN_SIGNIF"}, {"json_id": 138034, "symbol": "BRCA2", "locus": "13q13.1", "entrez_id": 675, "chr": "chr13", "start": 32889611, "end": 32973805, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "BRCA2, DNA repair associated", "description": "<p style=\"text-align: justify;\">BRCA2 участвует в поддержании стабильности генома, в частности, играет роль в пути гомологичной рекомбинации для репарации двухцепочечных разрывов ДНК. Белок BRCA2 содержит несколько последовательностей мотива70 аа (BRC), которые обеспечивают связывание с рекомбиназой RAD51 функционирующей в процессе репарации ДНК. BRCA2 связывает RAD51 и потенцирует репарацию ДНК по механизму рекомбинации, способствуя сборке RAD51 на одноцепочечной ДНК (оцДНК). BRCA2 действует путем позиционирования RAD51 на оцДНК&nbsp;в составе двухцепочечной ДНК, позволяя RAD51 вытеснять репликационный белок-A (RPA) из оцДНК&nbsp;и стабилизируя нити RAD51-оцДНК, блокируя гидролиз АТФ. BRCA2 является частью комплекса гомологичной репарации, образуемого скаффолд-белком PALB2, в состав которого входит RAD51C. BRCA2 может участвовать в активации контрольной точки S-фазы клеточного цикла. BRCA2 селективно связывается с оцДНК в составе дуплексов и структурах вилки репликации.&nbsp;<br />BRCA2 считается опухолесупрессорным геном, поскольку опухоли с мутациями BRCA2 обычно демонстрируют потерю гетерозиготности (LOH) аллеля дикого типа. Унаследованные мутации в BRCA2 увеличивают риск развития рака молочной железы или яичников в течение жизни.</p>\r\n<p style=\"text-align: justify;\"><a title=\"Nat. Struct. Mol. Biol., 2010\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/20729859\">Nat. Struct. Mol. Biol., 2010</a>&nbsp;&nbsp;&nbsp;<a title=\"Cancer Res., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21084279\">Cancer Res., 2011</a>&nbsp;&nbsp;&nbsp;<a title=\"Blood, 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21719596\">Blood, 2011</a>&nbsp;&nbsp;&nbsp;<a title=\"Cell Rep, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24485656\">Cell Rep, 2014</a>&nbsp;&nbsp;&nbsp;<a title=\"Nature, 2014\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/24896180\">Nature, 2014</a>&nbsp;&nbsp;</p>", "gene_type": "STR_CLIN_SIGNIF"}, {"json_id": 138033, "symbol": "PIK3CA", "locus": "3q26.32", "entrez_id": 5290, "chr": "chr3", "start": 178865902, "end": 178957881, "panel_coverage": "STR_FULL_COVERAGE", "full_name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", "description": "<p style=\"text-align: justify;\">Ген PIK3CA кодирует фосфоинозитид-3-киназу (PI3K) p110&alpha;, которая фосфорилирует фосфатидилинозитол и другие соединения с образованием фосфатидилинозитола 3,4,5-трифосфата (PIP3). PIP3 рекрутирует к мембране белки, содержащие домен PH, включая Akt1 и PDPK1. При этом активируются сигнальные каскады, регулирующие процессы клеточного роста и пролиферации, апоптоза и подвижности. PI3K участвует в внутриклеточной передаче сигналов в ответ на различные факторы роста. PI3K играет роль в активации Akt1 при стимуляции лигандами рецепторных тирозинкиназ, таких как EGF, инсулин, IGF1, VEGFA и PDGF. PI3K участвует в передаче сигналов через белки субстрата инсулинового рецептора (IRS). PI3K-опосредуемая сигнализация, активируемая VEGFA, регулирует RhoA-зависимые процессы миграции эндотелиальных клеток при ангиогенезе. Активация PI3K сигнализации требуется для лимфоангиогенеза, и, возможно, опосредуется путем связывания с RAS и вследствие его активации, вызванной дествием EGF и FGF2, но не PDGF. PI3K регулирует формирование инвадоподий через путь PDPK1/Akt1. Путь PI3K/Akt1 участвует в процессах кардиомиогенеза, регулирует васкулогенез через PDK1 и сигнальный путь протеинкиназы C. Предположительно играет роль в позитивной регуляции фагоцитоза и пиноцитоза. PI3K имеет активность серин-протеинкиназы: фосфорилирует PIK3R1, EIF4EBP1 и HRAS. J. Cell Biol., 2011 Hum. Mutat., 2016</p>\r\n<p><a title=\"J. Cell Biol., 2011\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/21708979\">J. Cell Biol., 2011</a>&nbsp;&nbsp; <a title=\"Hum. Mutat., 2016\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/26593112\">Hum. Mutat., 2016</a>&nbsp;&nbsp;</p>", "gene_type": "STR_CLIN_SIGNIF"}], "GeneticVariants": [{"db_titles": [], "db_links": [], "gene": 138033, "json_id": 25100, "variant_name": "PIK3CA WT", "variant_type": "STR_WILDTYPE", "variant_class": "STR_CLIN_SIGNIF", "chromosome": "chr3", "position": 178865902, "genome_version": "hg19", "ref_allele": null, "alt_allele": null, "ref_depth": null, "alt_depth": null, "aa_change": null, "codon_change": null, "germline_somatic": "STR_SOMATIC", "transcript": null, "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "<p>В результате таргетного экзонного секвенирования опухолевой ДНК потенциально патогенных вариантов в данном гене не обнаружено.</p>", "population_frequency": null, "allelic_frequency": null, "comment": "<p>Активирующие мутации в 9 и 20 кодирующих экзонах PIK3CA по разным данным определяются в 20-50% случаев гормонально рецепторно-положительного (HR+) HER2- рака молочной железы (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24981670\">24981670</a>,&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24467828\">24467828</a>,&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29902286\">29902286</a>).&nbsp;Наличие активирующих мутаций в 9,20 кодирующих экзонах PIK3CA (10, 21 экзон) связано с экспрессией рецепторов прогестерона (PR)&nbsp;(p=0,006), низким уровнем ki67&nbsp;&nbsp;&nbsp;(p=0,051), люминальным А подтипом рака молочной железы&nbsp;(p=0,039)&nbsp;(PMID:<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24981670\">24981670</a>).</p>\r\n<p>В исследовании BIG 1-98 сравнивалась эффективность адъювантной гормонотерапии Тамоксифеном, Летрозолом на протяжении 5 лет, Летрозол 2 года, затем Тамоксифен 3 года и Тамоксифен 2 года,затем Летрозол 3 года. В ретроспективном анализе изучалась роль различных молекулярно-генетических нарушений в чувствительности к гормонотерапии (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29902286\">29902286</a>). Наличие мутаций в 9 и 20 экзонах PIK3CA ассоциировалось уменьшением риска развития отдаленного рецидива&nbsp;(Отношение рисков (ОР) 0,57; 95% Доверительный интервал (ДИ), 0,38-0,85; p&thinsp;=0,006). Мутации в 9,20 экзонах PIK3CA были связаны со значительным уменьшением риска развития рецидива в группе Летрозола по сравнению с группой Тамоксифена (ОР 0,18; 95% ДИ, 0,06-0,50, p=0,002). Высокий уровень ki67 был предиктивным маркером эффективности Летрозола в подгруппе с мутациями PIK3CA (p =0,03).</p>\r\n<p>В исследовании BOLERO-2 изучалась эффективность комбинации Эверолимуса и Экземестана в терапии HR+ HER2- рака молочной железы. В ретроспективном анализе результатов исследования не было показано убедительных данных об эффективности Эверолимуса при наличии мутации в гене PIK3CA (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26503204\">26503204</a>). В группе с PIK3CA wt снижение риска развития прогрессирования составило 0,37 (95% ДИ, 0,25-0,55), в группе с наличием мутаций в гене PIK3CA 0,51 (95% ДИ, 0,34-0,77; p =0,35).&nbsp;</p>\r\n<p>В III фазе клинического исследования изучалась эффективность комбинации Фулвестранта и Бупарлисиба во второй и последующей линии терапии HR+ HER2- рака молочной железы у женщин в постменопаузе (PMID:<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29223745\">&nbsp;29223745</a>). В исследование было включено 432 пациентки, рандомизированных на 2 группы 2:1. Медианы выживаемости без прогрессирования составили 3,9 месяца в группе Бупарлисиба против 1,8 месяца в группе Плацебо (Отношение рисков, ОР, 0,67 (95% Доверительный интервал, ДИ, 0,53&ndash;0,84, p=0,0003). Медианы выживаемости без прогрессирования в группе с&nbsp;PIK3CA wt достоверно не отличались.</p>\r\n<p>В III фазе клинического исследования SOLAR-1 изучалась эффективность комбинации ингибитора PIK3CA- Алпелисиба и Фулвестранта во второй линии терапии метастатического ER+ HER2- рака молочной железы (DOI:&nbsp;<span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;https://www.nejm.org/doi/full/10.1056/NEJMoa1813904?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:515,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16776960},&quot;12&quot;:0}\"><a class=\"in-cell-link\" href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1813904?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed\" target=\"_blank\">10.1056/NEJMoa1813904</a></span>). В исследование были включены 572 пациентки, рандомизированных 1:1 в группы Алпелисиб+ Фулвестрант и Фулвестрант. Добавление Алпелисиба к Фулвестранту привело к достоверному увеличению медианы выживаемости без прогрессирования в подгруппе с наличием активирующих мутаций в гене PIK3CA, которая составила 11 месяцев (95% Доверительный интервал (ДИ), 7,5-14,5) в группе комбинации против 5,7 месяцев (95% ДИ, 3,7-7,4) в группе Фулвестранта (Отношение рисков (ОР) 0,65; 95% ДИ, 0,50-0,85; p&lt;0,001). В подгруппе с отсутствием активирующих мутаций в гене PIK3CA не наблюдалось достоверных различий между группами (ОР 0,85 95% ДИ, 0,58-1,25).</p>\r\n<p><em>Вывод: в связи с отсутствием активирующих мутаций в гене PIK3CA назначение ингибиторов PIK3CA не показано.&nbsp;</em></p>", "exon": null, "impact_so": null}, {"db_titles": [], "db_links": [], "gene": 138163, "json_id": 25331, "variant_name": "ESR1 WT", "variant_type": "STR_WILDTYPE", "variant_class": "STR_CLIN_SIGNIF", "chromosome": "chr6", "position": 151977826, "genome_version": "hg19", "ref_allele": null, "alt_allele": null, "ref_depth": null, "alt_depth": null, "aa_change": "WT", "codon_change": null, "germline_somatic": "STR_SOMATIC", "transcript": null, "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "<p style=\"text-align: justify;\">Мутации в гене&nbsp;<em>ESR1</em>&nbsp;встречаются в 15-40% случаев гормонпозитивного рака молочной железы. Наличие мутаций в гене ESR1 в плазме крови&nbsp; у пациенток с гормонположительным раком молочной железы, получавших гормонотерапию, ассоциировано с уменьшением медианы выживаемости без прогрессирования на фоне терапии нестероидными ингибиторами ароматазы (Относительный риск, ОР, 1,98; 95% доверительный интервал, ДИ, 1,12&ndash;3,51;&nbsp;<em>p</em>=0,2), но не связано с уменьшением медианы выживаемости без прогрессирования на фоне приема Фулвестранта (ОР, 1,03; 95% ДИ, 0,79&ndash;1,34;&nbsp;<em>р</em>=0,83)(PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30275706\">30275706</a>). В исследовании&nbsp;SoFEA было показано, что пациенты с наличием мутаций в гене&nbsp;<em>ESR1</em>&nbsp;ассоциировано с выигрышем от назначения Фулвестранта&nbsp;(n = 45) по сравнению с Экземестаном (n=18) во второй и последующих линиях гормонотерапии рака молочной железы (ОР&nbsp;0,52; 95% ДИ, 0,30-0,92; р=0,02) (PMID:&nbsp;<a title=\"PubMed link\" href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=27269946\" target=\"_blank\">27269946</a>). В исследовании&nbsp;PALOMA3&nbsp;было показано, что назначение комбинации Палбоциклиба и Фулвестранта связано с преимуществом в выживаемости без прогрессирования по сравнению с монотерапией Фулвестрантом как в группе с наличием мутаций в гене&nbsp;<em>ESR1</em>&nbsp;(ОР&nbsp;0,43; 95% ДИ, 0,25-0,74;&nbsp;<em>р</em>=0,002), так и при&nbsp;<em>ESR1</em>&nbsp;дикого типа группе&nbsp;(ОР, 0,49; 95% ДИ, 0,35-0,70; р&lt;0,001)(PMID:&nbsp;<a title=\"PubMed link\" href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=27269946\" target=\"_blank\">27269946</a>).</p>\r\n<p style=\"text-align: justify;\">Отсутствие мутаций в гене <em>ESR1</em> ассоциировано с чувствительностью к Фулвестранту, Экземестану, нестероидным ингибиторам ароматазы (Летрозол, Анастразол).</p>", "population_frequency": null, "allelic_frequency": null, "comment": "", "exon": null, "impact_so": null}, {"db_titles": ["rs1801265"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1801265"], "gene": 138396, "json_id": 25330, "variant_name": "DPYD p.R29C", "variant_type": "STR_SNV", "variant_class": "STR_CLIN_SIGNIF", "chromosome": "chr1", "position": 98348885, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 4, "alt_depth": 349, "aa_change": "p.Arg29Cys", "codon_change": "c.85C>T", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005270562.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "<p>STR_UNKNOWN_BIOL_SIGNIF</p>", "population_frequency": 0.7767, "allelic_frequency": 0.9887, "comment": "<p>Данный вариант известен как&nbsp;DPYD*9A. Гетерозиготность по этому аллелю ассоциирована с повышением риска развития умеренно выраженной тошноты и рвоты на фоне приема 5-Фторурацила&nbsp;(p&lt;0,05) (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/17848752\">17848752</a>).</p>", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs1799793"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1799793"], "gene": 138295, "json_id": 25329, "variant_name": "ERCC2 p.D312N", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr19", "position": 45867259, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 3, "alt_depth": 763, "aa_change": "p.Asp312Asn", "codon_change": "c.934G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000400.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "<p>STR_LIKELY_BENIGN</p>", "population_frequency": 0.355, "allelic_frequency": 0.9961, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["COSM3973479", "rs5030868"], "db_links": ["http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=3973479", "https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=5030868"], "gene": 138091, "json_id": 25328, "variant_name": "G6PD p.S218F", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chrX", "position": 153762634, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 269, "alt_depth": 255, "aa_change": "p.Ser218Phe", "codon_change": "c.653C>T", "germline_somatic": "STR_SOMATIC", "transcript": "NM_000402.3", "biolog_impact": "STR_PATHOGENIC", "biolog_impact_summary": "<p>STR_MUTATION_AFFECTS_PROTEIN_FUNCTION</p>", "population_frequency": 0.0008, "allelic_frequency": 0.4866, "comment": "", "exon": "6", "impact_so": "missense_variant"}, {"db_titles": ["rs6960867"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6960867"], "gene": 138153, "json_id": 25327, "variant_name": "AKAP9 p.N2792S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr7", "position": 91712698, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 265, "alt_depth": 270, "aa_change": "p.Asn2792Ser", "codon_change": "c.8375A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005751.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "<p>STR_LIKELY_BENIGN</p>", "population_frequency": 0.3899, "allelic_frequency": 0.5047, "comment": "", "exon": "33", "impact_so": "missense_variant"}, {"db_titles": ["rs1933437"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1933437"], "gene": 138414, "json_id": 25326, "variant_name": "FLT3 p.T227M", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr13", "position": 28624294, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 0, "alt_depth": 193, "aa_change": "p.Thr227Met", "codon_change": "c.680C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004119.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "<p>STR_LIKELY_BENIGN <br /> STR_AFFECTED_FUNC_REGIONS:</p>\r\n<p style=\"margin-left: 20px;\"><a href=\"http://www.uniprot.org/uniprot/P36888#family_and_domains\"> FLT3_HUMAN:TOPO_DOM:27-543 </a></p>", "population_frequency": 0.6074, "allelic_frequency": 1.0, "comment": "", "exon": "6", "impact_so": "missense_variant"}, {"db_titles": ["rs351855"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=351855"], "gene": 138186, "json_id": 25325, "variant_name": "FGFR4 p.G388R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 176520243, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 126, "alt_depth": 137, "aa_change": "p.Gly388Arg", "codon_change": "c.1162G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002011.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "<p>STR_LIKELY_BENIGN <br /> STR_AFFECTED_FUNC_REGIONS:</p>\r\n<p style=\"margin-left: 20px;\"><a href=\"http://www.uniprot.org/uniprot/P22455#family_and_domains\"> FGFR4_HUMAN:TRANSMEM:370-390 </a></p>", "population_frequency": 0.3002, "allelic_frequency": 0.5209, "comment": "", "exon": "9", "impact_so": "missense_variant"}, {"db_titles": ["rs2273535"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2273535"], "gene": 138257, "json_id": 25324, "variant_name": "AURKA p.F31I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr20", "position": 54961541, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 394, "alt_depth": 308, "aa_change": "p.Phe31Ile", "codon_change": "c.91T>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_003600.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "<p>STR_LIKELY_BENIGN</p>", "population_frequency": 0.2175, "allelic_frequency": 0.4387, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["rs3743674"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3743674"], "gene": 138346, "json_id": 25323, "variant_name": "CDH1 c.48+6C>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr16", "position": 68771372, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 165, "alt_depth": 42, "aa_change": "p.?", "codon_change": "c.48+6C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004360.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "<p>STR_UNKNOWN_BIOL_SIGNIF <br /> STR_AFFECTED_FUNC_REGIONS:</p>\r\n<p style=\"margin-left: 20px;\"><a href=\"http://www.uniprot.org/uniprot/P12830#family_and_domains\"> CADH1_HUMAN:SIGNAL:1-22 </a></p>", "population_frequency": 0.8777, "allelic_frequency": 0.2029, "comment": "", "exon": "1", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs2230037"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2230037"], "gene": 138091, "json_id": 25322, "variant_name": "G6PD c.1401C>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chrX", "position": 153760654, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 633, "alt_depth": 615, "aa_change": "p.=", "codon_change": "c.1401C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000402.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.114, "allelic_frequency": 0.4928, "comment": "", "exon": "11", "impact_so": "synonymous_variant"}, {"db_titles": ["rs34244923"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=34244923"], "gene": 138096, "json_id": 25321, "variant_name": "TBX22 p.E187K", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chrX", "position": 79281202, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 279, "alt_depth": 279, "aa_change": "p.Glu187Lys", "codon_change": "c.559G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001109878.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0645, "allelic_frequency": 0.5, "comment": "", "exon": "5", "impact_so": "missense_variant"}, {"db_titles": ["rs3088074"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3088074"], "gene": 138097, "json_id": 25320, "variant_name": "ATRX p.Q929E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chrX", "position": 76937963, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 209, "alt_depth": 216, "aa_change": "p.Gln929Glu", "codon_change": "c.2785C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000489.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.3125, "allelic_frequency": 0.5082, "comment": "", "exon": "9", "impact_so": "missense_variant"}, {"db_titles": ["rs28371717"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28371717"], "gene": 138241, "json_id": 25319, "variant_name": "CYP2D6 p.A237S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr22", "position": 42524310, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "A", "ref_depth": 237, "alt_depth": 93, "aa_change": "p.Ala237Ser", "codon_change": "c.709G>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000106.5", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0117, "allelic_frequency": 0.2818, "comment": "", "exon": "5", "impact_so": "missense_variant"}, {"db_titles": ["rs16947"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=16947"], "gene": 138241, "json_id": 25318, "variant_name": "CYP2D6 c.886C>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr22", "position": 42523943, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 356, "aa_change": "p.=", "codon_change": "c.886C>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000106.5", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "<p>STR_UNKNOWN_BIOL_SIGNIF</p>", "population_frequency": 0.6631, "allelic_frequency": 1.0, "comment": "", "exon": "6", "impact_so": "synonymous_variant"}, {"db_titles": ["rs150498069"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=150498069"], "gene": 138242, "json_id": 25317, "variant_name": "EP300 c.3105C>T", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr22", "position": 41548317, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 500, "alt_depth": 499, "aa_change": "p.=", "codon_change": "c.3105C>T", "germline_somatic": "STR_SOMATIC", "transcript": "NM_001429.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.0008, "allelic_frequency": 0.4995, "comment": "", "exon": "16", "impact_so": "synonymous_variant"}, {"db_titles": ["rs20551"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=20551"], "gene": 138242, "json_id": 25316, "variant_name": "EP300 p.I997V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr22", "position": 41548008, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 200, "alt_depth": 188, "aa_change": "p.Ile997Val", "codon_change": "c.2989A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001429.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.2796, "allelic_frequency": 0.4845, "comment": "", "exon": "15", "impact_so": "missense_variant"}, {"db_titles": ["rs3752462"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3752462"], "gene": 138244, "json_id": 25315, "variant_name": "MYH9 c.1554+7A>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr22", "position": 36710183, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 2, "alt_depth": 1176, "aa_change": "p.?", "codon_change": "c.1554+7A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002473.4", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.674, "allelic_frequency": 0.9983, "comment": "", "exon": "13", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs765649603"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=765649603"], "gene": 138248, "json_id": 25314, "variant_name": "MN1 p.P379L", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr22", "position": 28195396, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 243, "alt_depth": 221, "aa_change": "p.Pro379Leu", "codon_change": "c.1136C>T", "germline_somatic": "STR_SOMATIC", "transcript": "NM_002430.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0, "allelic_frequency": 0.4763, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs66569843"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=66569843"], "gene": 138250, "json_id": 25313, "variant_name": "BCR c.3458-7T>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr22", "position": 23656148, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "G", "ref_depth": 255, "alt_depth": 246, "aa_change": "p.?", "codon_change": "c.3458-7T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004327.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.2384, "allelic_frequency": 0.491, "comment": "", "exon": "20", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs140504"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=140504"], "gene": 138250, "json_id": 25312, "variant_name": "BCR p.N796S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr22", "position": 23627369, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 262, "aa_change": "p.Asn796Ser", "codon_change": "c.2387A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004327.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.8524, "allelic_frequency": 1.0, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["rs235330"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=235330"], "gene": 138253, "json_id": 25311, "variant_name": "ITGB2 p.Q354H", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr21", "position": 46314907, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "A", "ref_depth": 2, "alt_depth": 281, "aa_change": "p.Gln354His", "codon_change": "c.1062A>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000211.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.9999, "allelic_frequency": 0.9929, "comment": "", "exon": "9", "impact_so": "missense_variant"}, {"db_titles": ["rs1047972"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1047972"], "gene": 138257, "json_id": 25310, "variant_name": "AURKA p.I57V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr20", "position": 54961463, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 706, "alt_depth": 665, "aa_change": "p.Ile57Val", "codon_change": "c.169A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_003600.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.8348, "allelic_frequency": 0.485, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["rs753381"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=753381"], "gene": 138259, "json_id": 25309, "variant_name": "PLCG1 p.I813T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr20", "position": 39797465, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 0, "alt_depth": 418, "aa_change": "p.Ile813Thr", "codon_change": "c.2438T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002660.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.5467, "allelic_frequency": 1.0, "comment": "", "exon": "21", "impact_so": "missense_variant"}, {"db_titles": ["rs11615"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11615"], "gene": 138294, "json_id": 25308, "variant_name": "ERCC1 c.354T>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr19", "position": 45923653, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 439, "alt_depth": 423, "aa_change": "p.=", "codon_change": "c.354T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001166049.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.3745, "allelic_frequency": 0.4907, "comment": "", "exon": "4", "impact_so": "synonymous_variant"}, {"db_titles": ["rs13181"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=13181"], "gene": 138295, "json_id": 25307, "variant_name": "ERCC2 p.K751Q", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr19", "position": 45854919, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "G", "ref_depth": 11, "alt_depth": 1078, "aa_change": "p.Lys751Gln", "codon_change": "c.2251A>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000400.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "<p>STR_LIKELY_BENIGN</p>\r\n<p>GWAS:</p>\r\n<p style=\"margin-left: 20px;\">rs13181, lung carcinoma, p=9e-07, <a href=\"&quot;http:/www.pubmed.com/23108145\">PMID:23108145</a></p>", "population_frequency": 0.379, "allelic_frequency": 0.9899, "comment": "", "exon": "23", "impact_so": "missense_variant"}, {"db_titles": ["rs62130064"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=62130064"], "gene": 138312, "json_id": 25306, "variant_name": "TCF3 c.1814-8C>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr19", "position": 1611856, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 226, "alt_depth": 212, "aa_change": "p.?", "codon_change": "c.1814-8C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001136139.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.1979, "allelic_frequency": 0.484, "comment": "", "exon": "17", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs1943330"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1943330"], "gene": 138315, "json_id": 25305, "variant_name": "CDH20 p.P328H", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr18", "position": 59174759, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "A", "ref_depth": 11, "alt_depth": 40, "aa_change": "p.Pro328His", "codon_change": "c.983C>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_031891.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q9HBT6#family_and_domains\"> CAD20_HUMAN:TOPO_DOM:60-619 </a>", "population_frequency": 0.1388, "allelic_frequency": 0.7843, "comment": "", "exon": "5", "impact_so": "missense_variant"}, {"db_titles": ["rs2229080"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2229080"], "gene": 138317, "json_id": 25304, "variant_name": "DCC p.R201G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr18", "position": 50432602, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 591, "alt_depth": 194, "aa_change": "p.Arg201Gly", "codon_change": "c.601C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005215.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P43146#family_and_domains\"> DCC_HUMAN:TOPO_DOM:26-1097 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P43146#family_and_domains\"> DCC_HUMAN:DISULFID:161-212 </a>", "population_frequency": 0.3634, "allelic_frequency": 0.2471, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["rs9951523"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9951523"], "gene": 138317, "json_id": 25303, "variant_name": "DCC p.F23L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr18", "position": 49867224, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 5, "alt_depth": 663, "aa_change": "p.Phe23Leu", "codon_change": "c.67T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005215.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P43146#family_and_domains\"> DCC_HUMAN:SIGNAL:1-25 </a>", "population_frequency": 0.9832, "allelic_frequency": 0.9925, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs125555"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=125555"], "gene": 138319, "json_id": 25302, "variant_name": "MBD1 p.P401A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr18", "position": 47800179, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 10, "alt_depth": 437, "aa_change": "p.Pro401Ala", "codon_change": "c.1201C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001204136.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.2024, "allelic_frequency": 0.9776, "comment": "", "exon": "12", "impact_so": "missense_variant"}, {"db_titles": ["rs2289664"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2289664"], "gene": 138321, "json_id": 25301, "variant_name": "CDH2 p.N845S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr18", "position": 25532304, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 681, "alt_depth": 192, "aa_change": "p.Asn845Ser", "codon_change": "c.2534A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001792.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P19022#family_and_domains\"> CADH2_HUMAN:TOPO_DOM:746-906 </a>", "population_frequency": 0.0292, "allelic_frequency": 0.2199, "comment": "", "exon": "16", "impact_so": "missense_variant"}, {"db_titles": ["rs9674961"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9674961"], "gene": 138323, "json_id": 25300, "variant_name": "RNF213 p.S2334N", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78319136, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 1, "alt_depth": 379, "aa_change": "p.Ser2334Asn", "codon_change": "c.7001G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.6665, "allelic_frequency": 0.9974, "comment": "", "exon": "29", "impact_so": "missense_variant"}, {"db_titles": ["rs8074015"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8074015"], "gene": 138323, "json_id": 25299, "variant_name": "RNF213 p.D1331G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78306280, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 1001, "aa_change": "p.Asp1331Gly", "codon_change": "c.3992A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.6794, "allelic_frequency": 1.0, "comment": "", "exon": "21", "impact_so": "missense_variant"}, {"db_titles": ["rs9913636"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9913636"], "gene": 138323, "json_id": 25298, "variant_name": "RNF213 p.E1272Q", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78306102, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 118, "alt_depth": 121, "aa_change": "p.Glu1272Gln", "codon_change": "c.3814G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.4681, "allelic_frequency": 0.5063, "comment": "", "exon": "21", "impact_so": "missense_variant"}, {"db_titles": ["rs10782008"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10782008"], "gene": 138323, "json_id": 25297, "variant_name": "RNF213 p.V1195M", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78305871, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 1, "alt_depth": 707, "aa_change": "p.Val1195Met", "codon_change": "c.3583G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.64, "allelic_frequency": 0.9986, "comment": "", "exon": "21", "impact_so": "missense_variant"}, {"db_titles": ["rs8082521"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8082521"], "gene": 138323, "json_id": 25296, "variant_name": "RNF213 p.Q1133K", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78302157, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "A", "ref_depth": 0, "alt_depth": 557, "aa_change": "p.Gln1133Lys", "codon_change": "c.3397C>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.6796, "allelic_frequency": 1.0, "comment": "", "exon": "20", "impact_so": "missense_variant"}, {"db_titles": ["rs6565674"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6565674"], "gene": 138323, "json_id": 25295, "variant_name": "RNF213 p.N1045D", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78298938, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 4, "alt_depth": 981, "aa_change": "p.Asn1045Asp", "codon_change": "c.3133A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 1.0, "allelic_frequency": 0.9959, "comment": "", "exon": "18", "impact_so": "missense_variant"}, {"db_titles": ["rs61359568"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=61359568"], "gene": 138323, "json_id": 25294, "variant_name": "RNF213 p.A1041T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78298926, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 506, "alt_depth": 480, "aa_change": "p.Ala1041Thr", "codon_change": "c.3121G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0491, "allelic_frequency": 0.4868, "comment": "", "exon": "18", "impact_so": "missense_variant"}, {"db_titles": ["rs72849841"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=72849841"], "gene": 138323, "json_id": 25293, "variant_name": "RNF213 p.P729L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78272294, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 255, "alt_depth": 297, "aa_change": "p.Pro729Leu", "codon_change": "c.2186C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.1326, "allelic_frequency": 0.538, "comment": "", "exon": "11", "impact_so": "missense_variant"}, {"db_titles": ["rs2071214"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2071214"], "gene": 138324, "json_id": 25292, "variant_name": "BIRC5 p.E152K", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 76219591, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 15, "alt_depth": 1657, "aa_change": "p.Glu152Lys", "codon_change": "c.454G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001012271.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9478, "allelic_frequency": 0.991, "comment": "", "exon": "5", "impact_so": "missense_variant"}, {"db_titles": ["rs2627223"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2627223"], "gene": 138325, "json_id": 25291, "variant_name": "SEPT9 p.M576V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 75494705, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 1, "alt_depth": 542, "aa_change": "p.Met576Val", "codon_change": "c.1726A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001113491.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9365, "allelic_frequency": 0.9982, "comment": "", "exon": "12", "impact_so": "missense_variant"}, {"db_titles": ["rs34587622"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=34587622"], "gene": 138325, "json_id": 25290, "variant_name": "SEPT9 p.P145L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 75398498, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 125, "alt_depth": 120, "aa_change": "p.Pro145Leu", "codon_change": "c.434C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001113491.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.1152, "allelic_frequency": 0.4898, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["rs4986764"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4986764"], "gene": 138328, "json_id": 25289, "variant_name": "BRIP1 p.S919P", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 59763347, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 396, "alt_depth": 348, "aa_change": "p.Ser919Pro", "codon_change": "c.2755T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_032043.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.5873, "allelic_frequency": 0.4677, "comment": "", "exon": "19", "impact_so": "missense_variant"}, {"db_titles": ["rs1800215"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1800215"], "gene": 138330, "json_id": 25288, "variant_name": "COL1A1 p.T985A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 48265495, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 3, "alt_depth": 933, "aa_change": "p.Thr985Ala", "codon_change": "c.2953A>G", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005257058.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.9837, "allelic_frequency": 0.9968, "comment": "", "exon": "42", "impact_so": "missense_variant"}, {"db_titles": ["rs13306487"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=13306487"], "gene": 138331, "json_id": 25287, "variant_name": "ITGB3 p.R515Q", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr17", "position": 45369788, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 114, "alt_depth": 131, "aa_change": "p.Arg515Gln", "codon_change": "c.1544G>A", "germline_somatic": "STR_SOMATIC", "transcript": "NM_000212.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P05106#family_and_domains\"> ITB3_HUMAN:TOPO_DOM:27-718 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P05106#family_and_domains\"> ITB3_HUMAN:DISULFID:432-681 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P05106#family_and_domains\"> ITB3_HUMAN:REGION:463-629 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P05106#family_and_domains\"> ITB3_HUMAN:DISULFID:483-521 </a>", "population_frequency": 0.0004, "allelic_frequency": 0.5347, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["rs1058808"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1058808"], "gene": 138334, "json_id": 25286, "variant_name": "ERBB2 p.P1140A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 37884037, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 24, "alt_depth": 1296, "aa_change": "p.Pro1140Ala", "codon_change": "c.3418C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001005862.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P04626#family_and_domains\"> ERBB2_HUMAN:TOPO_DOM:676-1255 </a>", "population_frequency": 0.673, "allelic_frequency": 0.9818, "comment": "", "exon": "30", "impact_so": "missense_variant"}, {"db_titles": ["rs1059476"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1059476"], "gene": 138340, "json_id": 25285, "variant_name": "AURKB p.M257T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 8108331, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 403, "aa_change": "p.Met257Thr", "codon_change": "c.770T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256834.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.8867, "allelic_frequency": 1.0, "comment": "", "exon": "8", "impact_so": "missense_variant"}, {"db_titles": ["COSM246540", "rs137923123"], "db_links": ["http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=246540", "https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=137923123"], "gene": 138341, "json_id": 25284, "variant_name": "PER1 p.R450H", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 8051031, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 255, "alt_depth": 100, "aa_change": "p.Arg450His", "codon_change": "c.1349G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002616.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0013, "allelic_frequency": 0.2817, "comment": "", "exon": "11", "impact_so": "missense_variant"}, {"db_titles": ["rs2585405"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2585405"], "gene": 138341, "json_id": 25283, "variant_name": "PER1 p.A962P", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 8046772, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 0, "alt_depth": 249, "aa_change": "p.Ala962Pro", "codon_change": "c.2884G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002616.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9016, "allelic_frequency": 1.0, "comment": "", "exon": "19", "impact_so": "missense_variant"}, {"db_titles": ["rs2301582"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301582"], "gene": 138343, "json_id": 25282, "variant_name": "NLRP1 p.V1063M", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 5436263, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 203, "alt_depth": 96, "aa_change": "p.Val1063Met", "codon_change": "c.3187G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001033053.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.3981, "allelic_frequency": 0.3211, "comment": "", "exon": "11", "impact_so": "missense_variant"}, {"db_titles": ["rs35195"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=35195"], "gene": 138348, "json_id": 25281, "variant_name": "CDH11 p.T255M", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr16", "position": 65025718, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 1, "alt_depth": 610, "aa_change": "p.Thr255Met", "codon_change": "c.764C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001797.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P55287#family_and_domains\"> CAD11_HUMAN:TOPO_DOM:54-617 </a>", "population_frequency": 0.3527, "allelic_frequency": 0.9984, "comment": "", "exon": "6", "impact_so": "missense_variant"}, {"db_titles": ["rs35213"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=35213"], "gene": 138348, "json_id": 25280, "variant_name": "CDH11 p.S373A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr16", "position": 65016087, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "C", "ref_depth": 5, "alt_depth": 1201, "aa_change": "p.Ser373Ala", "codon_change": "c.1117T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001797.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P55287#family_and_domains\"> CAD11_HUMAN:TOPO_DOM:54-617 </a>", "population_frequency": 0.811, "allelic_frequency": 0.9959, "comment": "", "exon": "8", "impact_so": "missense_variant"}, {"db_titles": ["rs16967494"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=16967494"], "gene": 138353, "json_id": 25279, "variant_name": "MYH11 p.A1241T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr16", "position": 15820863, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 897, "alt_depth": 585, "aa_change": "p.Ala1241Thr", "codon_change": "c.3721G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001040113.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.2736, "allelic_frequency": 0.3947, "comment": "", "exon": "29", "impact_so": "missense_variant"}, {"db_titles": ["rs1800067"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1800067"], "gene": 138354, "json_id": 25278, "variant_name": "ERCC4 p.R415Q", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr16", "position": 14029033, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 218, "alt_depth": 288, "aa_change": "p.Arg415Gln", "codon_change": "c.1244G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005236.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q92889#family_and_domains\"> XPF_HUMAN:REGION:1-457 </a>", "population_frequency": 0.0765, "allelic_frequency": 0.5692, "comment": "", "exon": "8", "impact_so": "missense_variant"}, {"db_titles": ["rs254942"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=254942"], "gene": 138354, "json_id": 25277, "variant_name": "ERCC4 c.974-7G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr16", "position": 14026007, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 3, "alt_depth": 2060, "aa_change": "p.?", "codon_change": "c.974-7G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005236.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q92889#family_and_domains\"> XPF_HUMAN:REGION:1-457 </a>", "population_frequency": 0.9807, "allelic_frequency": 0.9985, "comment": "", "exon": "5", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs5742915"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=5742915"], "gene": 138362, "json_id": 25276, "variant_name": "PML p.F645L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr15", "position": 74336633, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 498, "alt_depth": 477, "aa_change": "p.Phe645Leu", "codon_change": "c.1933T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033238.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.4603, "allelic_frequency": 0.4892, "comment": "", "exon": "9", "impact_so": "missense_variant"}, {"db_titles": ["rs149443794"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=149443794"], "gene": 138365, "json_id": 25275, "variant_name": "TGM7 p.V103L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr15", "position": 43585039, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 304, "alt_depth": 139, "aa_change": "p.Val103Leu", "codon_change": "c.307G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_052955.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0113, "allelic_frequency": 0.3138, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["rs17747633"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=17747633"], "gene": 138367, "json_id": 25274, "variant_name": "KNL1 p.K1259E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr15", "position": 40916237, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 266, "alt_depth": 89, "aa_change": "p.Lys1259Glu", "codon_change": "c.3775A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_144508.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.4324, "allelic_frequency": 0.2507, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["rs8040502"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8040502"], "gene": 138367, "json_id": 25273, "variant_name": "KNL1 p.R910G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr15", "position": 40915190, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 190, "alt_depth": 77, "aa_change": "p.Arg910Gly", "codon_change": "c.2728A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_144508.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NG31#family_and_domains\"> KNL1_HUMAN:REGION:855-1201 </a>", "population_frequency": 0.8407, "allelic_frequency": 0.2884, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["rs2412541"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2412541"], "gene": 138367, "json_id": 25272, "variant_name": "KNL1 p.A460S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr15", "position": 40913840, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "T", "ref_depth": 316, "alt_depth": 88, "aa_change": "p.Ala460Ser", "codon_change": "c.1378G>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_144508.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NG31#family_and_domains\"> KNL1_HUMAN:REGION:1-728 </a>", "population_frequency": 0.84, "allelic_frequency": 0.2178, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["rs7177192"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7177192"], "gene": 138367, "json_id": 25271, "variant_name": "KNL1 p.R43T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr15", "position": 40898643, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 68, "alt_depth": 35, "aa_change": "p.Arg43Thr", "codon_change": "c.128G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_144508.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NG31#family_and_domains\"> KNL1_HUMAN:REGION:1-728 </a>", "population_frequency": 0.8403, "allelic_frequency": 0.3398, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["rs8005905"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8005905"], "gene": 138371, "json_id": 25270, "variant_name": "HSP90AA1 p.M71L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr14", "position": 102568367, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "A", "ref_depth": 141, "alt_depth": 480, "aa_change": "p.Met71Leu", "codon_change": "c.211A>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001017963.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.8909, "allelic_frequency": 0.7729, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs35007347"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=35007347"], "gene": 138375, "json_id": 25269, "variant_name": "TRIP11 p.R1576H", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr14", "position": 92465749, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 149, "alt_depth": 47, "aa_change": "p.Arg1576His", "codon_change": "c.4727G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004239.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q15643#family_and_domains\"> TRIPB_HUMAN:COILED:52-1773 </a>", "population_frequency": 0.0239, "allelic_frequency": 0.2398, "comment": "", "exon": "13", "impact_so": "missense_variant"}, {"db_titles": ["rs1991517"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1991517"], "gene": 138376, "json_id": 25268, "variant_name": "TSHR p.E727D", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr14", "position": 81610583, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 8, "alt_depth": 1568, "aa_change": "p.Glu727Asp", "codon_change": "c.2181G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000369.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9131, "allelic_frequency": 0.9949, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["rs3783941"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3783941"], "gene": 138376, "json_id": 25267, "variant_name": "TSHR p.R248S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr14", "position": 81575005, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "A", "ref_depth": 0, "alt_depth": 683, "aa_change": "p.Arg248Ser", "codon_change": "c.742C>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001018036.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.6535, "allelic_frequency": 1.0, "comment": "", "exon": "9", "impact_so": "missense_variant"}, {"db_titles": ["rs1805097"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1805097"], "gene": 138409, "json_id": 25266, "variant_name": "IRS2 p.G1057D", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr13", "position": 110435231, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 86, "alt_depth": 56, "aa_change": "p.Gly1057Asp", "codon_change": "c.3170G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_003749.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.3413, "allelic_frequency": 0.3944, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs2491231"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2491231"], "gene": 138414, "json_id": 25265, "variant_name": "FLT3 c.1310-3T>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr13", "position": 28610183, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 557, "aa_change": "p.?", "codon_change": "c.1310-3T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004119.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P36888#family_and_domains\"> FLT3_HUMAN:TOPO_DOM:27-543 </a>", "population_frequency": 0.7738, "allelic_frequency": 1.0, "comment": "", "exon": "10", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs1169304"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1169304"], "gene": 138418, "json_id": 25264, "variant_name": "HNF1A p.L551S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr12", "position": 121437221, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 2, "alt_depth": 191, "aa_change": "p.Leu551Ser", "codon_change": "c.1652T>C", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005253931.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.8158, "allelic_frequency": 0.9896, "comment": "", "exon": "8", "impact_so": "missense_variant"}, {"db_titles": ["rs2271194"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2271194"], "gene": 138059, "json_id": 25263, "variant_name": "ERBB3 c.234+8A>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr12", "position": 56477694, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 2, "alt_depth": 588, "aa_change": "p.?", "codon_change": "c.234+8A>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001005915.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P21860#family_and_domains\"> ERBB3_HUMAN:TOPO_DOM:20-643 </a>", "population_frequency": 0.5872, "allelic_frequency": 0.9966, "comment": "", "exon": "2", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs3217805"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3217805"], "gene": 138427, "json_id": 25262, "variant_name": "CCND2 c.570C>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr12", "position": 4388084, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 178, "alt_depth": 324, "aa_change": "p.=", "codon_change": "c.570C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001759.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.391, "allelic_frequency": 0.6454, "comment": "", "exon": "3", "impact_so": "splice_region_variant&synonymous_variant"}, {"db_titles": ["rs506504"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=506504"], "gene": 138430, "json_id": 25261, "variant_name": "CHEK1 p.I471V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr11", "position": 125525195, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 507, "alt_depth": 197, "aa_change": "p.Ile471Val", "codon_change": "c.1411A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001114121.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/O14757#family_and_domains\"> CHK1_HUMAN:REGION:391-476 </a>", "population_frequency": 0.9627, "allelic_frequency": 0.2798, "comment": "", "exon": "13", "impact_so": "missense_variant"}, {"db_titles": ["rs910332"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=910332"], "gene": 138380, "json_id": 25260, "variant_name": "BCL2L2 p.Q133R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr14", "position": 23777374, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 1, "alt_depth": 732, "aa_change": "p.Gln133Arg", "codon_change": "c.398A>G", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005267966.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.996, "allelic_frequency": 0.9986, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["rs659243"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=659243"], "gene": 138434, "json_id": 25259, "variant_name": "ATM p.N1983S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr11", "position": 108183167, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 83, "aa_change": "p.Asn1983Ser", "codon_change": "c.5948A>G", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005271561.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 1.0, "allelic_frequency": 1.0, "comment": "", "exon": "40", "impact_so": "missense_variant"}, {"db_titles": ["rs7123133"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7123133"], "gene": 138438, "json_id": 25258, "variant_name": "MAML2 p.P896T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr11", "position": 95712897, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "T", "ref_depth": 139, "alt_depth": 432, "aa_change": "p.Pro896Thr", "codon_change": "c.2686C>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_032427.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.1056, "allelic_frequency": 0.7566, "comment": "", "exon": "5", "impact_so": "missense_variant"}, {"db_titles": ["rs535801"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=535801"], "gene": 138439, "json_id": 25257, "variant_name": "MRE11 c.403-6G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr11", "position": 94212048, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 347, "alt_depth": 106, "aa_change": "p.?", "codon_change": "c.403-6G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005590.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.3063, "allelic_frequency": 0.234, "comment": "", "exon": "5", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs9344"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9344"], "gene": 138441, "json_id": 25256, "variant_name": "CCND1 c.723G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr11", "position": 69462910, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 351, "alt_depth": 3041, "aa_change": "p.=", "codon_change": "c.723G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_053056.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.4675, "allelic_frequency": 0.8965, "comment": "", "exon": "4", "impact_so": "splice_region_variant&synonymous_variant"}, {"db_titles": ["COSM23054", "rs607969"], "db_links": ["http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=23054", "https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=607969"], "gene": 138442, "json_id": 25255, "variant_name": "MEN1 p.R176Q", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr11", "position": 64575505, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 188, "alt_depth": 200, "aa_change": "p.Arg176Gln", "codon_change": "c.527G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000244.3", "biolog_impact": "STR_PATHOGENIC", "biolog_impact_summary": "STR_MUTATION_AFFECTS_PROTEIN_FUNCTION", "population_frequency": 0.0198, "allelic_frequency": 0.5155, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["COSM255213", "rs2959656"], "db_links": ["http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=255213", "https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2959656"], "gene": 138442, "json_id": 25254, "variant_name": "MEN1 p.T541A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr11", "position": 64572018, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 1, "alt_depth": 361, "aa_change": "p.Thr541Ala", "codon_change": "c.1621A>G", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005274001.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9959, "allelic_frequency": 0.9972, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["rs117329700"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=117329700"], "gene": 138444, "json_id": 25253, "variant_name": "EXT2 p.E311K", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr11", "position": 44146427, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 126, "alt_depth": 138, "aa_change": "p.Glu311Lys", "codon_change": "c.931G>A", "germline_somatic": "STR_SOMATIC", "transcript": "NM_000401.3", "biolog_impact": "STR_PATHOGENIC", "biolog_impact_summary": "STR_MUTATION_AFFECTS_PROTEIN_FUNCTION <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q93063#family_and_domains\"> EXT2_HUMAN:TOPO_DOM:47-718 </a>", "population_frequency": 8.9611e-06, "allelic_frequency": 0.5227, "comment": "", "exon": "5", "impact_so": "missense_variant"}, {"db_titles": ["rs3998860"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3998860"], "gene": 138073, "json_id": 25252, "variant_name": "TET1 p.I1123M", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr10", "position": 70405855, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 1, "alt_depth": 284, "aa_change": "p.Ile1123Met", "codon_change": "c.3369A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_030625.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.8201, "allelic_frequency": 0.9965, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["rs10823229"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10823229"], "gene": 138073, "json_id": 25251, "variant_name": "TET1 p.D162G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr10", "position": 70332580, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 174, "alt_depth": 189, "aa_change": "p.Asp162Gly", "codon_change": "c.485A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_030625.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.3867, "allelic_frequency": 0.5207, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs10761581"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10761581"], "gene": 138074, "json_id": 25250, "variant_name": "NCOA4 p.F8V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr10", "position": 51568378, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "G", "ref_depth": 495, "alt_depth": 458, "aa_change": "p.Phe8Val", "codon_change": "c.22T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001145260.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.4326, "allelic_frequency": 0.4806, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": [], "db_links": [], "gene": 138077, "json_id": 25249, "variant_name": "MLLT10 p.H1034N", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr10", "position": 22029103, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "A", "ref_depth": 364, "alt_depth": 404, "aa_change": "p.His1034Asn", "codon_change": "c.3100C>A", "germline_somatic": "STR_SOMATIC", "transcript": "NM_001195626.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0, "allelic_frequency": 0.526, "comment": "", "exon": "21", "impact_so": "missense_variant"}, {"db_titles": ["rs9411208"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9411208"], "gene": 138084, "json_id": 25248, "variant_name": "NOTCH1 c.1441+7C>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr9", "position": 139412197, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 9, "alt_depth": 347, "aa_change": "p.?", "codon_change": "c.1441+7C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_017617.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P46531#family_and_domains\"> NOTC1_HUMAN:TOPO_DOM:19-1735 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P46531#family_and_domains\"> NOTC1_HUMAN:DISULFID:478-487 </a>", "population_frequency": 0.4597, "allelic_frequency": 0.9747, "comment": "", "exon": "8", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs3125001"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3125001"], "gene": 138084, "json_id": 25247, "variant_name": "NOTCH1 c.2588-4G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr9", "position": 139405261, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 2, "alt_depth": 427, "aa_change": "p.?", "codon_change": "c.2588-4G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_017617.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P46531#family_and_domains\"> NOTC1_HUMAN:TOPO_DOM:19-1735 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P46531#family_and_domains\"> NOTC1_HUMAN:DISULFID:857-866 </a>", "population_frequency": 0.3827, "allelic_frequency": 0.9953, "comment": "", "exon": "16", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs103612"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=103612"], "gene": 138036, "json_id": 25246, "variant_name": "NUP214 p.P574S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr9", "position": 134020092, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 10, "alt_depth": 926, "aa_change": "p.Pro574Ser", "codon_change": "c.1720C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005085.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P35658#family_and_domains\"> NU214_HUMAN:REGION:481-2076 </a>", "population_frequency": 0.6767, "allelic_frequency": 0.9893, "comment": "", "exon": "12", "impact_so": "missense_variant"}, {"db_titles": ["rs357564"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=357564"], "gene": 138040, "json_id": 25245, "variant_name": "PTCH1 p.P1315L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr9", "position": 98209594, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 511, "alt_depth": 405, "aa_change": "p.Pro1315Leu", "codon_change": "c.3944C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000264.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q13635#family_and_domains\"> PTC1_HUMAN:TOPO_DOM:1176-1447 </a>", "population_frequency": 0.3384, "allelic_frequency": 0.4421, "comment": "", "exon": "23", "impact_so": "missense_variant"}, {"db_titles": ["rs3780135", "COSM4163845"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3780135", "http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=4163845"], "gene": 138044, "json_id": 25244, "variant_name": "PAX5 p.T293I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr9", "position": 36840623, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 4, "alt_depth": 731, "aa_change": "p.Thr293Ile", "codon_change": "c.878C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001280549.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9443, "allelic_frequency": 0.9946, "comment": "", "exon": "8", "impact_so": "missense_variant"}, {"db_titles": ["rs4925828"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4925828"], "gene": 138382, "json_id": 25243, "variant_name": "RECQL4 p.L1043P", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr8", "position": 145737636, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 10, "alt_depth": 570, "aa_change": "p.Leu1043Pro", "codon_change": "c.3128T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004260.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.9994, "allelic_frequency": 0.9828, "comment": "", "exon": "18", "impact_so": "missense_variant"}, {"db_titles": ["rs2219898"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2219898"], "gene": 138404, "json_id": 25242, "variant_name": "CSMD3 p.I219M", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr8", "position": 114186003, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 680, "alt_depth": 473, "aa_change": "p.Ile219Met", "codon_change": "c.657A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_052900.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q7Z407#family_and_domains\"> CSMD3_HUMAN:TOPO_DOM:64-3630 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q7Z407#family_and_domains\"> CSMD3_HUMAN:DISULFID:204-235 </a>", "population_frequency": 0.2636, "allelic_frequency": 0.4102, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["COSM7220651", "rs10955625"], "db_links": ["http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=7220651", "https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10955625"], "gene": 138404, "json_id": 25241, "variant_name": "CSMD3 c.4584-3C>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr8", "position": 113516209, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 0, "alt_depth": 255, "aa_change": "p.?", "codon_change": "c.4584-3C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_052900.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q7Z407#family_and_domains\"> CSMD3_HUMAN:TOPO_DOM:64-3630 </a>", "population_frequency": 0.5636, "allelic_frequency": 1.0, "comment": "", "exon": "28", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs4876462"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4876462"], "gene": 138404, "json_id": 25240, "variant_name": "CSMD3 c.7934-8T>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr8", "position": 113308243, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 157, "alt_depth": 101, "aa_change": "p.?", "codon_change": "c.7934-8T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_052900.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q7Z407#family_and_domains\"> CSMD3_HUMAN:TOPO_DOM:64-3630 </a>", "population_frequency": 0.4716, "allelic_frequency": 0.3915, "comment": "", "exon": "51", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs2228591"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2228591"], "gene": 138383, "json_id": 25239, "variant_name": "NCOA2 p.M1282I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr8", "position": 71039118, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 518, "alt_depth": 393, "aa_change": "p.Met1282Ile", "codon_change": "c.3846G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_006540.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0532, "allelic_frequency": 0.4314, "comment": "", "exon": "19", "impact_so": "missense_variant"}, {"db_titles": ["rs1801195"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1801195"], "gene": 138391, "json_id": 25238, "variant_name": "WRN p.L1074F", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr8", "position": 30999280, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "T", "ref_depth": 173, "alt_depth": 214, "aa_change": "p.Leu1074Phe", "codon_change": "c.3222G>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000553.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.4422, "allelic_frequency": 0.553, "comment": "", "exon": "26", "impact_so": "missense_variant"}, {"db_titles": ["rs2737335"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2737335"], "gene": 138391, "json_id": 25237, "variant_name": "WRN c.3138+7G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr8", "position": 30999123, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 208, "alt_depth": 235, "aa_change": "p.?", "codon_change": "c.3138+7G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000553.4", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.441, "allelic_frequency": 0.5305, "comment": "", "exon": "25", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs3024239"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3024239"], "gene": 138391, "json_id": 25236, "variant_name": "WRN c.3138+6C>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr8", "position": 30999122, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 253, "alt_depth": 190, "aa_change": "p.?", "codon_change": "c.3138+6C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000553.4", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.4967, "allelic_frequency": 0.4289, "comment": "", "exon": "25", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs1800391"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1800391"], "gene": 138391, "json_id": 25235, "variant_name": "WRN p.M387I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr8", "position": 30938704, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 369, "alt_depth": 260, "aa_change": "p.Met387Ile", "codon_change": "c.1161G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000553.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.083, "allelic_frequency": 0.4134, "comment": "", "exon": "9", "impact_so": "missense_variant"}, {"db_titles": ["rs56850341"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=56850341"], "gene": 138393, "json_id": 25234, "variant_name": "KMT2C p.L291F", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr7", "position": 151970931, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 109, "alt_depth": 209, "aa_change": "p.Leu291Phe", "codon_change": "c.871C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_170606.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NEZ4#family_and_domains\"> KMT2C_HUMAN:ZN_FING:283-331 </a>", "population_frequency": 0.4999, "allelic_frequency": 0.6572, "comment": "", "exon": "7", "impact_so": "missense_variant"}, {"db_titles": [], "db_links": [], "gene": 138393, "json_id": 25233, "variant_name": "KMT2C p.P2163L", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr7", "position": 151878457, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 282, "alt_depth": 255, "aa_change": "p.Pro2163Leu", "codon_change": "c.6488C>T", "germline_somatic": "STR_SOMATIC", "transcript": "NM_170606.2", "biolog_impact": "STR_PATHOGENIC", "biolog_impact_summary": "STR_MUTATION_AFFECTS_PROTEIN_FUNCTION", "population_frequency": 0.0, "allelic_frequency": 0.4749, "comment": "", "exon": "36", "impact_so": "missense_variant"}, {"db_titles": ["rs41277434"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=41277434"], "gene": 138394, "json_id": 25232, "variant_name": "EZH2 c.2095+6T>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr7", "position": 148506396, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "C", "ref_depth": 277, "alt_depth": 268, "aa_change": "p.?", "codon_change": "c.2095+6T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001203247.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.0524, "allelic_frequency": 0.4917, "comment": "", "exon": "18", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs367623635"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=367623635"], "gene": 138145, "json_id": 25231, "variant_name": "GRM8 p.M659V", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr7", "position": 126173461, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 198, "alt_depth": 203, "aa_change": "p.Met659Val", "codon_change": "c.1975A>G", "germline_somatic": "STR_SOMATIC", "transcript": "NM_000845.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/O00222#family_and_domains\"> GRM8_HUMAN:TRANSMEM:648-668 </a>", "population_frequency": 0.0001, "allelic_frequency": 0.5062, "comment": "", "exon": "8", "impact_so": "missense_variant"}, {"db_titles": ["rs160384"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=160384"], "gene": 138150, "json_id": 25230, "variant_name": "TRRAP c.6469-4G>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr7", "position": 98558880, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 0, "alt_depth": 368, "aa_change": "p.?", "codon_change": "c.6469-4G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001244580.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q9Y4A5#family_and_domains\"> TRRAP_HUMAN:REGION:2010-2388 </a>", "population_frequency": 0.9151, "allelic_frequency": 1.0, "comment": "", "exon": "44", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs1063242"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1063242"], "gene": 138153, "json_id": 25229, "variant_name": "AKAP9 p.P2979S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr7", "position": 91714911, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 8, "alt_depth": 419, "aa_change": "p.Pro2979Ser", "codon_change": "c.8935C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005751.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9963, "allelic_frequency": 0.9813, "comment": "", "exon": "36", "impact_so": "missense_variant"}, {"db_titles": ["rs6964587"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6964587"], "gene": 138153, "json_id": 25228, "variant_name": "AKAP9 p.M463I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr7", "position": 91630620, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "T", "ref_depth": 185, "alt_depth": 98, "aa_change": "p.Met463Ile", "codon_change": "c.1389G>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005751.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q99996#family_and_domains\"> AKAP9_HUMAN:COILED:152-902 </a> <p> GWAS: <p style=\"margin-left: 20px\"> rs6964587, breast carcinoma, p=5e-07, <a href=\"http://www.pubmed.com/25751625>PMID:25751625</a><p  style=\"margin-left: 20px\">rs6964587, breast carcinoma, p=9e-11, <a href=\"http://www.pubmed.com/29059683>PMID:29059683</a>", "population_frequency": 0.3908, "allelic_frequency": 0.3463, "comment": "", "exon": "8", "impact_so": "missense_variant"}, {"db_titles": ["rs1805321"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1805321"], "gene": 138158, "json_id": 25227, "variant_name": "PMS2 p.P470S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr7", "position": 6026988, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 593, "alt_depth": 621, "aa_change": "p.Pro470Ser", "codon_change": "c.1408C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000535.5", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.4157, "allelic_frequency": 0.5115, "comment": "", "exon": "11", "impact_so": "missense_variant"}, {"db_titles": ["rs9347162"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9347162"], "gene": 138160, "json_id": 25226, "variant_name": "RPS6KA2 p.E32G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 167271716, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 193, "alt_depth": 679, "aa_change": "p.Glu32Gly", "codon_change": "c.95A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001006932.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.7474, "allelic_frequency": 0.7787, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs943687"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=943687"], "gene": 138160, "json_id": 25225, "variant_name": "RPS6KA2 p.T34A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 167271711, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 3, "alt_depth": 865, "aa_change": "p.Thr34Ala", "codon_change": "c.100A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001006932.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9917, "allelic_frequency": 0.9965, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs2297370"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2297370"], "gene": 138161, "json_id": 25224, "variant_name": "IGF2R c.6996-5T>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 160524773, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "A", "ref_depth": 579, "alt_depth": 245, "aa_change": "p.?", "codon_change": "c.6996-5T>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000876.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P11717#family_and_domains\"> MPRI_HUMAN:TOPO_DOM:2328-2491 </a>", "population_frequency": 0.2302, "allelic_frequency": 0.2973, "comment": "", "exon": "46", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs8191933"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8191933"], "gene": 138161, "json_id": 25223, "variant_name": "IGF2R c.6657C>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 160517472, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 142, "alt_depth": 54, "aa_change": "p.=", "codon_change": "c.6657C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000876.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P11717#family_and_domains\"> MPRI_HUMAN:TOPO_DOM:41-2304 </a>", "population_frequency": 0.0091, "allelic_frequency": 0.2755, "comment": "", "exon": "45", "impact_so": "splice_region_variant&synonymous_variant"}, {"db_titles": ["rs8191754"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8191754"], "gene": 138161, "json_id": 25222, "variant_name": "IGF2R p.L252V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 160448324, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 85, "alt_depth": 226, "aa_change": "p.Leu252Val", "codon_change": "c.754C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000876.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P11717#family_and_domains\"> MPRI_HUMAN:TOPO_DOM:41-2304 </a>", "population_frequency": 0.1332, "allelic_frequency": 0.7267, "comment": "", "exon": "6", "impact_so": "missense_variant"}, {"db_titles": ["rs9397106"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9397106"], "gene": 138162, "json_id": 25221, "variant_name": "SYNE1 c.1068+4T>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152809527, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 22, "alt_depth": 52, "aa_change": "p.?", "codon_change": "c.1068+4T>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033071.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.4257, "allelic_frequency": 0.7027, "comment": "", "exon": "12", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs214950"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=214950"], "gene": 138162, "json_id": 25220, "variant_name": "SYNE1 p.A2802V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152708310, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 65, "alt_depth": 149, "aa_change": "p.Ala2802Val", "codon_change": "c.8405C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033071.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.2241, "allelic_frequency": 0.6963, "comment": "", "exon": "54", "impact_so": "missense_variant"}, {"db_titles": ["rs9397102"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9397102"], "gene": 138162, "json_id": 25219, "variant_name": "SYNE1 c.10881+6T>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152675854, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 618, "alt_depth": 263, "aa_change": "p.?", "codon_change": "c.10881+6T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033071.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.6049, "allelic_frequency": 0.2985, "comment": "", "exon": "67", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs9639168"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9639168"], "gene": 138157, "json_id": 25218, "variant_name": "ETV1 p.S100G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr7", "position": 13978809, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 204, "alt_depth": 186, "aa_change": "p.Ser100Gly", "codon_change": "c.298A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001163147.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.347, "allelic_frequency": 0.4769, "comment": "", "exon": "6", "impact_so": "missense_variant"}, {"db_titles": ["rs9478320"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9478320"], "gene": 138162, "json_id": 25217, "variant_name": "SYNE1 c.11734-5T>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152671475, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "C", "ref_depth": 423, "alt_depth": 177, "aa_change": "p.?", "codon_change": "c.11734-5T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_182961.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.6049, "allelic_frequency": 0.295, "comment": "", "exon": "71", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs4645434"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4645434"], "gene": 138162, "json_id": 25216, "variant_name": "SYNE1 p.E3989D", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152665261, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "A", "ref_depth": 205, "alt_depth": 76, "aa_change": "p.Glu3989Asp", "codon_change": "c.11967G>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033071.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.6078, "allelic_frequency": 0.2705, "comment": "", "exon": "73", "impact_so": "missense_variant"}, {"db_titles": ["rs9479297"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9479297"], "gene": 138162, "json_id": 25215, "variant_name": "SYNE1 p.K4050R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152658142, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 12, "alt_depth": 274, "aa_change": "p.Lys4050Arg", "codon_change": "c.12149A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033071.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.7459, "allelic_frequency": 0.958, "comment": "", "exon": "75", "impact_so": "missense_variant"}, {"db_titles": ["rs141202420"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=141202420"], "gene": 138162, "json_id": 25214, "variant_name": "SYNE1 c.12351C>T", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr6", "position": 152655373, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 133, "alt_depth": 342, "aa_change": "p.=", "codon_change": "c.12351C>T", "germline_somatic": "STR_SOMATIC", "transcript": "NM_033071.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.0007, "allelic_frequency": 0.72, "comment": "", "exon": "76", "impact_so": "synonymous_variant"}, {"db_titles": ["rs111511993"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=111511993"], "gene": 138162, "json_id": 25213, "variant_name": "SYNE1 c.13359C>T", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr6", "position": 152652248, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 217, "alt_depth": 459, "aa_change": "p.=", "codon_change": "c.13359C>T", "germline_somatic": "STR_SOMATIC", "transcript": "NM_033071.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.0007, "allelic_frequency": 0.679, "comment": "", "exon": "77", "impact_so": "synonymous_variant"}, {"db_titles": ["rs6911096"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6911096"], "gene": 138162, "json_id": 25212, "variant_name": "SYNE1 p.S4525T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152652034, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 8, "alt_depth": 294, "aa_change": "p.Ser4525Thr", "codon_change": "c.13573T>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033071.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.7561, "allelic_frequency": 0.9735, "comment": "", "exon": "77", "impact_so": "missense_variant"}, {"db_titles": ["rs2306916"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2306916"], "gene": 138162, "json_id": 25211, "variant_name": "SYNE1 p.L4944M", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152647681, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 8, "alt_depth": 341, "aa_change": "p.Leu4944Met", "codon_change": "c.14830T>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033071.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.7562, "allelic_frequency": 0.9771, "comment": "", "exon": "78", "impact_so": "missense_variant"}, {"db_titles": ["rs9383985"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=9383985"], "gene": 138162, "json_id": 25210, "variant_name": "SYNE1 c.17133+7G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152629617, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 317, "alt_depth": 174, "aa_change": "p.?", "codon_change": "c.17133+7G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033071.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.3209, "allelic_frequency": 0.3544, "comment": "", "exon": "90", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs113962905"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=113962905"], "gene": 138162, "json_id": 25209, "variant_name": "SYNE1 p.A5862T", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr6", "position": 152615148, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 195, "alt_depth": 508, "aa_change": "p.Ala5862Thr", "codon_change": "c.17584G>A", "germline_somatic": "STR_SOMATIC", "transcript": "NM_033071.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.0009, "allelic_frequency": 0.7226, "comment": "", "exon": "93", "impact_so": "missense_variant"}, {"db_titles": ["rs2147377"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2147377"], "gene": 138162, "json_id": 25208, "variant_name": "SYNE1 p.F7231V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 152540278, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "C", "ref_depth": 35, "alt_depth": 441, "aa_change": "p.Phe7231Val", "codon_change": "c.21691T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_033071.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:TOPO_DOM:1-8746 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q8NF91#family_and_domains\"> SYNE1_HUMAN:COILED:314-8666 </a>", "population_frequency": 0.9878, "allelic_frequency": 0.9265, "comment": "", "exon": "119", "impact_so": "missense_variant"}, {"db_titles": ["rs2243384"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2243384"], "gene": 138167, "json_id": 25207, "variant_name": "ROS1 c.3855-5T>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 117678083, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 238, "aa_change": "p.?", "codon_change": "c.3855-5T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002944.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P08922#family_and_domains\"> ROS1_HUMAN:TOPO_DOM:28-1859 </a>", "population_frequency": 0.5223, "allelic_frequency": 1.0, "comment": "", "exon": "24", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs811925"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=811925"], "gene": 138169, "json_id": 25206, "variant_name": "PRDM1 p.D203E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 106547372, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 418, "alt_depth": 130, "aa_change": "p.Asp203Glu", "codon_change": "c.609C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.1748, "allelic_frequency": 0.2372, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["rs1932618"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1932618"], "gene": 138172, "json_id": 25205, "variant_name": "ADGRB3 p.N503S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 69666684, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 2, "alt_depth": 560, "aa_change": "p.Asn503Ser", "codon_change": "c.1508A>G", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005248752.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/O60242#family_and_domains\"> AGRB3_HUMAN:TOPO_DOM:25-880 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/O60242#family_and_domains\"> AGRB3_HUMAN:DISULFID:471-507 </a>", "population_frequency": 0.8671, "allelic_frequency": 0.9964, "comment": "", "exon": "7", "impact_so": "missense_variant"}, {"db_titles": ["rs6459166"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6459166"], "gene": 138173, "json_id": 25204, "variant_name": "DST p.V2011L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 56482801, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 14, "alt_depth": 1191, "aa_change": "p.Val2011Leu", "codon_change": "c.6031G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001723.5", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.4101, "allelic_frequency": 0.9884, "comment": "", "exon": "23", "impact_so": "missense_variant"}, {"db_titles": ["rs4712138"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4712138"], "gene": 138173, "json_id": 25203, "variant_name": "DST p.Q1812R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 56463410, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 1, "alt_depth": 643, "aa_change": "p.Gln1812Arg", "codon_change": "c.5435A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001144769.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.3842, "allelic_frequency": 0.9984, "comment": "", "exon": "40", "impact_so": "missense_variant"}, {"db_titles": ["rs11756977"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11756977"], "gene": 138173, "json_id": 25202, "variant_name": "DST p.R2795H", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 56420538, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 577, "alt_depth": 620, "aa_change": "p.Arg2795His", "codon_change": "c.8384G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001144769.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.2871, "allelic_frequency": 0.518, "comment": "", "exon": "54", "impact_so": "missense_variant"}, {"db_titles": ["rs4715631"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4715631"], "gene": 138173, "json_id": 25201, "variant_name": "DST p.T3230A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 56417545, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 149, "alt_depth": 129, "aa_change": "p.Thr3230Ala", "codon_change": "c.9688A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001144769.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.7122, "allelic_frequency": 0.464, "comment": "", "exon": "55", "impact_so": "missense_variant"}, {"db_titles": ["rs4715630"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4715630"], "gene": 138173, "json_id": 25200, "variant_name": "DST p.M3317I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 56417282, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 312, "alt_depth": 268, "aa_change": "p.Met3317Ile", "codon_change": "c.9951G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001144769.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.7455, "allelic_frequency": 0.4621, "comment": "", "exon": "55", "impact_so": "missense_variant"}, {"db_titles": [], "db_links": [], "gene": 138173, "json_id": 25199, "variant_name": "DST p.Q5116L", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr6", "position": 56341107, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "A", "ref_depth": 208, "alt_depth": 49, "aa_change": "p.Gln5116Leu", "codon_change": "c.15347A>T", "germline_somatic": "STR_SOMATIC", "transcript": "NM_001144769.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0, "allelic_frequency": 0.1907, "comment": "", "exon": "86", "impact_so": "missense_variant"}, {"db_titles": ["rs11758339"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11758339"], "gene": 138173, "json_id": 25198, "variant_name": "DST p.A5546T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 56327849, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 409, "alt_depth": 390, "aa_change": "p.Ala5546Thr", "codon_change": "c.16636G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001144769.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.2544, "allelic_frequency": 0.4881, "comment": "", "exon": "95", "impact_so": "missense_variant"}, {"db_titles": ["rs62406032"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=62406032"], "gene": 138175, "json_id": 25197, "variant_name": "PKHD1 p.N830S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 51910905, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 523, "alt_depth": 497, "aa_change": "p.Asn830Ser", "codon_change": "c.2489A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_138694.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P08F94#family_and_domains\"> PKHD1_HUMAN:TOPO_DOM:24-3858 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P08F94#family_and_domains\"> PKHD1_HUMAN:CARBOHYD:830-830 </a>", "population_frequency": 0.0684, "allelic_frequency": 0.4873, "comment": "", "exon": "24", "impact_so": "missense_variant"}, {"db_titles": ["rs2435322"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2435322"], "gene": 138175, "json_id": 25196, "variant_name": "PKHD1 p.L1870V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 51875250, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "C", "ref_depth": 5, "alt_depth": 674, "aa_change": "p.Leu1870Val", "codon_change": "c.5608T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_138694.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P08F94#family_and_domains\"> PKHD1_HUMAN:TOPO_DOM:24-3858 </a>", "population_frequency": 0.9996, "allelic_frequency": 0.9926, "comment": "", "exon": "35", "impact_so": "missense_variant"}, {"db_titles": ["rs7452724"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7452724"], "gene": 138175, "json_id": 25195, "variant_name": "PKHD1 c.7734-4T>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 51720872, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 209, "alt_depth": 189, "aa_change": "p.?", "codon_change": "c.7734-4T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_138694.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P08F94#family_and_domains\"> PKHD1_HUMAN:TOPO_DOM:24-3858 </a>", "population_frequency": 0.3149, "allelic_frequency": 0.4749, "comment": "", "exon": "48", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs915894"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=915894"], "gene": 138180, "json_id": 25194, "variant_name": "NOTCH4 p.K117Q", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 32190390, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "G", "ref_depth": 332, "alt_depth": 312, "aa_change": "p.Lys117Gln", "codon_change": "c.349A>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004557.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.3563, "allelic_frequency": 0.4845, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["rs520692"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=520692"], "gene": 138180, "json_id": 25193, "variant_name": "NOTCH4 p.D272G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 32188640, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 289, "alt_depth": 275, "aa_change": "p.Asp272Gly", "codon_change": "c.815A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004557.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.3297, "allelic_frequency": 0.4876, "comment": "", "exon": "5", "impact_so": "missense_variant"}, {"db_titles": ["rs422951"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=422951"], "gene": 138180, "json_id": 25192, "variant_name": "NOTCH4 p.T320A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 32188383, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 449, "alt_depth": 365, "aa_change": "p.Thr320Ala", "codon_change": "c.958A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004557.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.4561, "allelic_frequency": 0.4484, "comment": "", "exon": "6", "impact_so": "missense_variant"}, {"db_titles": ["rs8192573"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8192573"], "gene": 138180, "json_id": 25191, "variant_name": "NOTCH4 p.R1346P", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 32168996, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 146, "alt_depth": 103, "aa_change": "p.Arg1346Pro", "codon_change": "c.4037G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004557.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0113, "allelic_frequency": 0.4137, "comment": "", "exon": "22", "impact_so": "missense_variant"}, {"db_titles": ["rs2394882"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2394882"], "gene": 138181, "json_id": 25190, "variant_name": "POU5F1 c.307-5T>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr6", "position": 31132649, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "C", "ref_depth": 5, "alt_depth": 286, "aa_change": "p.?", "codon_change": "c.307-5T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001173531.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.6594, "allelic_frequency": 0.9828, "comment": "", "exon": "4", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs448012"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=448012"], "gene": 138184, "json_id": 25189, "variant_name": "FLT4 p.H890Q", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 180046344, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 298, "alt_depth": 206, "aa_change": "p.His890Gln", "codon_change": "c.2670C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002020.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P35916#family_and_domains\"> VGFR3_HUMAN:TOPO_DOM:797-1363 </a>", "population_frequency": 0.6354, "allelic_frequency": 0.4087, "comment": "", "exon": "19", "impact_so": "missense_variant"}, {"db_titles": ["rs31776"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=31776"], "gene": 138186, "json_id": 25188, "variant_name": "FGFR4 c.2016-8A>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 176523597, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 76, "alt_depth": 76, "aa_change": "p.?", "codon_change": "c.2016-8A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002011.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P22455#family_and_domains\"> FGFR4_HUMAN:TOPO_DOM:391-802 </a>", "population_frequency": 0.716, "allelic_frequency": 0.5, "comment": "", "exon": "15", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs42409"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=42409"], "gene": 138186, "json_id": 25187, "variant_name": "FGFR4 c.1821+4C>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 176522728, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 440, "alt_depth": 419, "aa_change": "p.?", "codon_change": "c.1821+4C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002011.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P22455#family_and_domains\"> FGFR4_HUMAN:TOPO_DOM:391-802 </a>", "population_frequency": 0.6793, "allelic_frequency": 0.4878, "comment": "", "exon": "13", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs376618"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=376618"], "gene": 138186, "json_id": 25186, "variant_name": "FGFR4 p.P136L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 176517797, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 790, "alt_depth": 846, "aa_change": "p.Pro136Leu", "codon_change": "c.407C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002011.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P22455#family_and_domains\"> FGFR4_HUMAN:TOPO_DOM:22-369 </a>", "population_frequency": 0.7509, "allelic_frequency": 0.5171, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["rs10079250"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10079250"], "gene": 138189, "json_id": 25185, "variant_name": "CSF1R p.H362R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 149450132, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 1014, "alt_depth": 849, "aa_change": "p.His362Arg", "codon_change": "c.1085A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005211.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P07333#family_and_domains\"> CSF1R_HUMAN:TOPO_DOM:20-517 </a>", "population_frequency": 0.0701, "allelic_frequency": 0.4557, "comment": "", "exon": "8", "impact_so": "missense_variant&splice_region_variant"}, {"db_titles": ["rs41424145"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=41424145"], "gene": 138189, "json_id": 25184, "variant_name": "CSF1R c.1626+3G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 149447775, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 148, "alt_depth": 145, "aa_change": "p.?", "codon_change": "c.1626+3G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_005211.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P07333#family_and_domains\"> CSF1R_HUMAN:TOPO_DOM:539-972 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P07333#family_and_domains\"> CSF1R_HUMAN:REGION:542-574 </a>", "population_frequency": 0.0022, "allelic_frequency": 0.4949, "comment": "", "exon": "11", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs288028"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=288028"], "gene": 138190, "json_id": 25183, "variant_name": "CTNNA1 c.1143+8G>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 138221989, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 0, "alt_depth": 85, "aa_change": "p.?", "codon_change": "c.1143+8G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001903.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P35221#family_and_domains\"> CTNA1_HUMAN:REGION:325-394 </a>", "population_frequency": 0.2984, "allelic_frequency": 1.0, "comment": "", "exon": "8", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs2229995"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2229995"], "gene": 138192, "json_id": 25182, "variant_name": "APC p.G2502S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 112178795, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 51, "alt_depth": 35, "aa_change": "p.Gly2502Ser", "codon_change": "c.7504G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000038.5", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0233, "allelic_frequency": 0.407, "comment": "", "exon": "16", "impact_so": "missense_variant"}, {"db_titles": ["rs1288233617"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1288233617"], "gene": 138196, "json_id": 25181, "variant_name": "GDNF p.G9C", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr5", "position": 37835736, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "A", "ref_depth": 794, "alt_depth": 832, "aa_change": "p.Gly9Cys", "codon_change": "c.25G>T", "germline_somatic": "STR_SOMATIC", "transcript": "NM_001190468.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.0, "allelic_frequency": 0.5117, "comment": "", "exon": "1", "impact_so": "missense_variant&splice_region_variant"}, {"db_titles": ["rs3194051"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3194051"], "gene": 138197, "json_id": 25180, "variant_name": "IL7R p.I356V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 35876274, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 744, "alt_depth": 796, "aa_change": "p.Ile356Val", "codon_change": "c.1066A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002185.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P16871#family_and_domains\"> IL7RA_HUMAN:TOPO_DOM:265-459 </a>", "population_frequency": 0.2725, "allelic_frequency": 0.5169, "comment": "", "exon": "8", "impact_so": "missense_variant"}, {"db_titles": ["rs1494555"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1494555"], "gene": 138197, "json_id": 25179, "variant_name": "IL7R p.V138I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 35871190, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 677, "alt_depth": 533, "aa_change": "p.Val138Ile", "codon_change": "c.412G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002185.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P16871#family_and_domains\"> IL7RA_HUMAN:TOPO_DOM:21-239 </a>", "population_frequency": 0.6791, "allelic_frequency": 0.4405, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["rs1494558"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1494558"], "gene": 138197, "json_id": 25178, "variant_name": "IL7R p.I66T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 35861068, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 650, "alt_depth": 650, "aa_change": "p.Ile66Thr", "codon_change": "c.197T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002185.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P16871#family_and_domains\"> IL7RA_HUMAN:TOPO_DOM:21-239 </a>", "population_frequency": 0.6743, "allelic_frequency": 0.5, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs1532268"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1532268"], "gene": 138198, "json_id": 25177, "variant_name": "MTRR p.S175L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 7878179, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 423, "alt_depth": 366, "aa_change": "p.Ser175Leu", "codon_change": "c.524C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002454.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q9UBK8#family_and_domains\"> MTRR_HUMAN:REGION:193-274 </a>", "population_frequency": 0.364, "allelic_frequency": 0.4639, "comment": "", "exon": "5", "impact_so": "missense_variant"}, {"db_titles": ["rs34635677"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=34635677"], "gene": 138199, "json_id": 25176, "variant_name": "SDHA p.D38V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 223646, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 227, "alt_depth": 237, "aa_change": "p.Asp38Val", "codon_change": "c.113A>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004168.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P31040#family_and_domains\"> SDHA_HUMAN:TRANSIT:1-42 </a>", "population_frequency": 0.0458, "allelic_frequency": 0.5108, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs1397548"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1397548"], "gene": 138205, "json_id": 25175, "variant_name": "ADGRL3 c.2811A>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr4", "position": 62845490, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 204, "aa_change": "p.=", "codon_change": "c.2811A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_015236.4", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.7417, "allelic_frequency": 1.0, "comment": "", "exon": "15", "impact_so": "splice_region_variant&synonymous_variant"}, {"db_titles": ["rs2305339"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2305339"], "gene": 138205, "json_id": 25174, "variant_name": "ADGRL3 c.1909-4G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr4", "position": 62800554, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 2, "alt_depth": 1049, "aa_change": "p.?", "codon_change": "c.1909-4G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_015236.4", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.7424, "allelic_frequency": 0.9981, "comment": "", "exon": "10", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": [], "db_links": [], "gene": 138210, "json_id": 25173, "variant_name": "RHOH p.S3C", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr4", "position": 40245013, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 344, "alt_depth": 119, "aa_change": "p.Ser3Cys", "codon_change": "c.7A>T", "germline_somatic": "STR_SOMATIC", "transcript": "NM_001278359.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0, "allelic_frequency": 0.257, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["COSM3696552", "rs61735104"], "db_links": ["http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=3696552", "https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=61735104"], "gene": 138212, "json_id": 25172, "variant_name": "FGFR3 p.P449S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr4", "position": 1806629, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 343, "alt_depth": 259, "aa_change": "p.Pro449Ser", "codon_change": "c.1345C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000142.4", "biolog_impact": "STR_PATHOGENIC", "biolog_impact_summary": "STR_MUTATION_AFFECTS_PROTEIN_FUNCTION <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P22607#family_and_domains\"> FGFR3_HUMAN:TOPO_DOM:397-806 </a>", "population_frequency": 0.007, "allelic_frequency": 0.4302, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["rs2227928"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2227928"], "gene": 138217, "json_id": 25171, "variant_name": "ATR p.M211T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 142281612, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 7, "alt_depth": 834, "aa_change": "p.Met211Thr", "codon_change": "c.632T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001184.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.5799, "allelic_frequency": 0.9917, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["rs2229033"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2229033"], "gene": 138217, "json_id": 25170, "variant_name": "ATR p.K297N", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 142281353, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 228, "alt_depth": 224, "aa_change": "p.Lys297Asn", "codon_change": "c.891G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001184.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0153, "allelic_frequency": 0.4956, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["rs11719685"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11719685"], "gene": 138226, "json_id": 25169, "variant_name": "PBRM1 c.996-4G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 52676065, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 0, "alt_depth": 92, "aa_change": "p.?", "codon_change": "c.996-4G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_018313.4", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.3526, "allelic_frequency": 1.0, "comment": "", "exon": "10", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["COSM4770176", "rs34372721"], "db_links": ["http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=4770176", "https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=34372721"], "gene": 138226, "json_id": 25168, "variant_name": "PBRM1 c.4576+5_4576+6insGAG", "variant_type": "STR_INDEL", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 52584431, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "TCTC", "ref_depth": 5, "alt_depth": 261, "aa_change": "p.?", "codon_change": "c.4576+5_4576+6insGAG", "germline_somatic": "STR_GERMLINE", "transcript": "NM_018313.4", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5061, "allelic_frequency": 0.9812, "comment": "", "exon": "29", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs76208147"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=76208147"], "gene": 138228, "json_id": 25167, "variant_name": "SETD2 p.M1080I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 47162886, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 215, "alt_depth": 219, "aa_change": "p.Met1080Ile", "codon_change": "c.3240G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_014159.6", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.019, "allelic_frequency": 0.5046, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["COSM5713079", "rs10662431"], "db_links": ["http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=5713079", "https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10662431"], "gene": 138229, "json_id": 25166, "variant_name": "LTF p.R23dup", "variant_type": "STR_INDEL", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 46501284, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "CCTT", "ref_depth": 0, "alt_depth": 1148, "aa_change": "p.R23dup", "codon_change": "c.68_69insAAG", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002343.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.971, "allelic_frequency": 1.0, "comment": "", "exon": "2", "impact_so": "disruptive_inframe_insertion&direct_tandem_duplication"}, {"db_titles": ["rs2073495"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2073495"], "gene": 138229, "json_id": 25165, "variant_name": "LTF p.E535D", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 46480958, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 1, "alt_depth": 730, "aa_change": "p.Glu535Asp", "codon_change": "c.1605G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001199149.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P02788#family_and_domains\"> TRFL_HUMAN:DISULFID:424-705 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P02788#family_and_domains\"> TRFL_HUMAN:DISULFID:502-696 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P02788#family_and_domains\"> TRFL_HUMAN:DISULFID:446-668 </a>", "population_frequency": 0.3385, "allelic_frequency": 0.9986, "comment": "", "exon": "15", "impact_so": "missense_variant"}, {"db_titles": ["rs1118148"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1118148"], "gene": 138232, "json_id": 25164, "variant_name": "ITGA9 c.2234+7G>C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 37778481, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 206, "alt_depth": 138, "aa_change": "p.?", "codon_change": "c.2234+7G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002207.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q13797#family_and_domains\"> ITA9_HUMAN:TOPO_DOM:30-981 </a>", "population_frequency": 0.2473, "allelic_frequency": 0.4012, "comment": "", "exon": "20", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs267561"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=267561"], "gene": 138232, "json_id": 25163, "variant_name": "ITGA9 p.G507E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 37574951, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 243, "alt_depth": 266, "aa_change": "p.Gly507Glu", "codon_change": "c.1520G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002207.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q13797#family_and_domains\"> ITA9_HUMAN:TOPO_DOM:30-981 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q13797#family_and_domains\"> ITA9_HUMAN:DISULFID:497-555 </a>", "population_frequency": 0.575, "allelic_frequency": 0.5226, "comment": "", "exon": "14", "impact_so": "missense_variant"}, {"db_titles": ["rs11466512"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=11466512"], "gene": 138234, "json_id": 25162, "variant_name": "TGFBR2 c.530-4T>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 30713126, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "A", "ref_depth": 353, "alt_depth": 357, "aa_change": "p.?", "codon_change": "c.530-4T>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001024847.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P37173#family_and_domains\"> TGFR2_HUMAN:TOPO_DOM:23-166 </a>", "population_frequency": 0.311, "allelic_frequency": 0.5028, "comment": "", "exon": "4", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs1155705"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1155705"], "gene": 138234, "json_id": 25161, "variant_name": "TGFBR2 c.338+7A>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 30686414, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 230, "alt_depth": 225, "aa_change": "p.?", "codon_change": "c.338+7A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001024847.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P37173#family_and_domains\"> TGFR2_HUMAN:TOPO_DOM:23-166 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/P37173#family_and_domains\"> TGFR2_HUMAN:DISULFID:77-101 </a>", "population_frequency": 0.3413, "allelic_frequency": 0.4945, "comment": "", "exon": "3", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs1801282"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1801282"], "gene": 138237, "json_id": 25160, "variant_name": "PPARG p.P12A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 12393125, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 540, "alt_depth": 489, "aa_change": "p.Pro12Ala", "codon_change": "c.34C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_015869.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.124, "allelic_frequency": 0.4752, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs72492997"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=72492997"], "gene": 138239, "json_id": 25159, "variant_name": "FANCD2 c.1137G>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 10088266, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "T", "ref_depth": 765, "alt_depth": 1040, "aa_change": "p.=", "codon_change": "c.1137G>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001018115.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.1901, "allelic_frequency": 0.5762, "comment": "", "exon": "15", "impact_so": "splice_region_variant&synonymous_variant"}, {"db_titles": ["rs1250259"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1250259"], "gene": 138268, "json_id": 25158, "variant_name": "FN1 p.Q15L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 216300482, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "A", "ref_depth": 1, "alt_depth": 492, "aa_change": "p.Gln15Leu", "codon_change": "c.44A>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002026.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P02751#family_and_domains\"> FINC_HUMAN:SIGNAL:1-31 </a>", "population_frequency": 0.7413, "allelic_frequency": 0.998, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs3796123"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3796123"], "gene": 138268, "json_id": 25157, "variant_name": "FN1 c.1819+7A>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 216283958, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "A", "ref_depth": 2, "alt_depth": 510, "aa_change": "p.?", "codon_change": "c.1819+7A>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002026.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P02751#family_and_domains\"> FINC_HUMAN:REGION:308-608 </a>", "population_frequency": 0.2342, "allelic_frequency": 0.9961, "comment": "", "exon": "12", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs2577301"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2577301"], "gene": 138268, "json_id": 25156, "variant_name": "FN1 p.T817P", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 216272900, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "G", "ref_depth": 0, "alt_depth": 589, "aa_change": "p.Thr817Pro", "codon_change": "c.2449A>C", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005246397.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 1.0, "allelic_frequency": 1.0, "comment": "", "exon": "17", "impact_so": "missense_variant"}, {"db_titles": ["rs1250209"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1250209"], "gene": 138268, "json_id": 25155, "variant_name": "FN1 p.V2261I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 216235089, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 1, "alt_depth": 444, "aa_change": "p.Val2261Ile", "codon_change": "c.6781G>A", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005246397.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 1.0, "allelic_frequency": 0.9978, "comment": "", "exon": "41", "impact_so": "missense_variant"}, {"db_titles": ["rs12990449"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12990449"], "gene": 138276, "json_id": 25154, "variant_name": "LRP1B p.Q48R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 142567910, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 33, "alt_depth": 35, "aa_change": "p.Gln48Arg", "codon_change": "c.143A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_018557.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q9NZR2#family_and_domains\"> LRP1B_HUMAN:TOPO_DOM:25-4444 </a><p  style=\"margin-left: 20px\"><a href=\"http://www.uniprot.org/uniprot/Q9NZR2#family_and_domains\"> LRP1B_HUMAN:DISULFID:39-58 </a>", "population_frequency": 0.217, "allelic_frequency": 0.5147, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs996361"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=996361"], "gene": 138276, "json_id": 25153, "variant_name": "LRP1B c.5500+5A>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 141533662, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 1, "alt_depth": 222, "aa_change": "p.?", "codon_change": "c.5500+5A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_018557.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q9NZR2#family_and_domains\"> LRP1B_HUMAN:TOPO_DOM:25-4444 </a>", "population_frequency": 0.8748, "allelic_frequency": 0.9955, "comment": "", "exon": "33", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": [], "db_links": [], "gene": 138278, "json_id": 25152, "variant_name": "PAX8 p.P428T", "variant_type": "STR_SNV", "variant_class": "STR_VUS", "chromosome": "chr2", "position": 113976181, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "T", "ref_depth": 535, "alt_depth": 209, "aa_change": "p.Pro428Thr", "codon_change": "c.1282C>A", "germline_somatic": "STR_SOMATIC", "transcript": "NM_003466.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0, "allelic_frequency": 0.2809, "comment": "", "exon": "12", "impact_so": "missense_variant"}, {"db_titles": ["rs4851223"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4851223"], "gene": 138279, "json_id": 25151, "variant_name": "AFF3 p.S512N", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 100343557, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 2, "alt_depth": 1306, "aa_change": "p.Ser512Asn", "codon_change": "c.1535G>A", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005263941.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 1.0, "allelic_frequency": 0.9985, "comment": "", "exon": "11", "impact_so": "missense_variant"}, {"db_titles": ["rs2286700"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2286700"], "gene": 138286, "json_id": 25150, "variant_name": "EML4 c.2168-4A>T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 42556022, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 23, "alt_depth": 2259, "aa_change": "p.?", "codon_change": "c.2168-4A>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001145076.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.2807, "allelic_frequency": 0.9899, "comment": "", "exon": "20", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs28651764"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28651764"], "gene": 138286, "json_id": 25149, "variant_name": "EML4 p.K340R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 42515437, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 32, "alt_depth": 421, "aa_change": "p.Lys340Arg", "codon_change": "c.1019A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001145076.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.3159, "allelic_frequency": 0.9294, "comment": "", "exon": "10", "impact_so": "missense_variant"}, {"db_titles": ["rs10202624"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10202624"], "gene": 138286, "json_id": 25148, "variant_name": "EML4 p.I393V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 42515388, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 158, "aa_change": "p.Ile393Val", "codon_change": "c.1177A>G", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005264267.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9071, "allelic_frequency": 1.0, "comment": "", "exon": "12", "impact_so": "missense_variant"}, {"db_titles": ["rs6736913"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6736913"], "gene": 138286, "json_id": 25147, "variant_name": "EML4 p.K294E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 42510018, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 14, "alt_depth": 914, "aa_change": "p.Lys294Glu", "codon_change": "c.880A>G", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005264267.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9847, "allelic_frequency": 0.9849, "comment": "", "exon": "9", "impact_so": "missense_variant"}, {"db_titles": ["rs35093491"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=35093491"], "gene": 138287, "json_id": 25146, "variant_name": "ALK p.V476A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 29543736, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 280, "alt_depth": 224, "aa_change": "p.Val476Ala", "codon_change": "c.1427T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004304.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q9UM73#family_and_domains\"> ALK_HUMAN:TOPO_DOM:19-1038 </a>", "population_frequency": 0.0385, "allelic_frequency": 0.4444, "comment": "", "exon": "7", "impact_so": "missense_variant"}, {"db_titles": ["rs1670283"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1670283"], "gene": 138287, "json_id": 25145, "variant_name": "ALK p.I1461V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 29416572, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 3, "alt_depth": 1358, "aa_change": "p.Ile1461Val", "codon_change": "c.4381A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004304.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q9UM73#family_and_domains\"> ALK_HUMAN:TOPO_DOM:1060-1620 </a>", "population_frequency": 0.9998, "allelic_frequency": 0.9978, "comment": "", "exon": "29", "impact_so": "missense_variant"}, {"db_titles": ["rs1881421"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1881421"], "gene": 138287, "json_id": 25144, "variant_name": "ALK p.D1529E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 29416366, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 1, "alt_depth": 419, "aa_change": "p.Asp1529Glu", "codon_change": "c.4587C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_004304.4", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q9UM73#family_and_domains\"> ALK_HUMAN:TOPO_DOM:1060-1620 </a>", "population_frequency": 0.3594, "allelic_frequency": 0.9976, "comment": "", "exon": "29", "impact_so": "missense_variant"}, {"db_titles": ["rs2292459"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2292459"], "gene": 138109, "json_id": 25143, "variant_name": "PIK3C2B c.2773-7G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 204413297, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 0, "alt_depth": 1341, "aa_change": "p.?", "codon_change": "c.2773-7G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002646.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.8039, "allelic_frequency": 1.0, "comment": "", "exon": "18", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs201231411"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=201231411"], "gene": 138111, "json_id": 25142, "variant_name": "PTGS2 c.724-10_724-7del", "variant_type": "STR_INDEL", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 186645851, "genome_version": "hg19", "ref_allele": "AAAAT", "alt_allele": "A", "ref_depth": 61, "alt_depth": 48, "aa_change": "p.?", "codon_change": "c.724-10_724-7del", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000963.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.0535, "allelic_frequency": 0.4404, "comment": "", "exon": "6", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs3753565"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3753565"], "gene": 138112, "json_id": 25141, "variant_name": "TPR p.S960N", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 186316488, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 156, "alt_depth": 94, "aa_change": "p.Ser960Asn", "codon_change": "c.2879G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_003292.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P12270#family_and_domains\"> TPR_HUMAN:COILED:661-1173 </a>", "population_frequency": 0.1587, "allelic_frequency": 0.376, "comment": "", "exon": "22", "impact_so": "missense_variant"}, {"db_titles": ["rs486907"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=486907"], "gene": 138114, "json_id": 25140, "variant_name": "RNASEL p.R462Q", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 182554557, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 491, "alt_depth": 321, "aa_change": "p.Arg462Gln", "codon_change": "c.1385G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_021133.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.3688, "allelic_frequency": 0.3953, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs627928"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=627928"], "gene": 138114, "json_id": 25139, "variant_name": "RNASEL p.D541E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 182551337, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "C", "ref_depth": 386, "alt_depth": 240, "aa_change": "p.Asp541Glu", "codon_change": "c.1623T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_021133.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.5622, "allelic_frequency": 0.3834, "comment": "", "exon": "4", "impact_so": "missense_variant"}, {"db_titles": ["rs1318056"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1318056"], "gene": 138115, "json_id": 25138, "variant_name": "ABL2 p.S12T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 179112145, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 400, "alt_depth": 213, "aa_change": "p.Ser12Thr", "codon_change": "c.35G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001136000.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/P42684#family_and_domains\"> ABL2_HUMAN:REGION:2-106 </a>", "population_frequency": 0.0847, "allelic_frequency": 0.3475, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs2275558"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2275558"], "gene": 138116, "json_id": 25137, "variant_name": "PBX1 p.G21S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 164529120, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 52, "alt_depth": 23, "aa_change": "p.Gly21Ser", "codon_change": "c.61G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001204961.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.2165, "allelic_frequency": 0.3067, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs2274616"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2274616"], "gene": 138125, "json_id": 25136, "variant_name": "ITGA10 p.R725Q", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 145536082, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 253, "alt_depth": 1125, "aa_change": "p.Arg725Gln", "codon_change": "c.2174G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_003637.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.1552, "allelic_frequency": 0.8164, "comment": "", "exon": "17", "impact_so": "missense_variant"}, {"db_titles": ["rs2762779"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2762779"], "gene": 138126, "json_id": 25135, "variant_name": "PDE4DIP p.W60*", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 145075683, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 1189, "alt_depth": 503, "aa_change": "p.W60*", "codon_change": "c.180G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_022359.5", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.4997, "allelic_frequency": 0.2973, "comment": "", "exon": "1", "impact_so": "stop_gained"}, {"db_titles": ["rs1664022"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1664022"], "gene": 138126, "json_id": 25134, "variant_name": "PDE4DIP p.R25L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144994658, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "A", "ref_depth": 1431, "alt_depth": 824, "aa_change": "p.Arg25Leu", "codon_change": "c.74G>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002810.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.3654, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs41315685"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=41315685"], "gene": 138126, "json_id": 25133, "variant_name": "PDE4DIP p.L83Q", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144931461, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 419, "alt_depth": 295, "aa_change": "p.Leu83Gln", "codon_change": "c.248T>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002811.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.2464, "allelic_frequency": 0.4132, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs2798893"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2798893"], "gene": 138126, "json_id": 25132, "variant_name": "PDE4DIP p.A106V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144931392, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 828, "alt_depth": 572, "aa_change": "p.Ala106Val", "codon_change": "c.317C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002811.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.4086, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs2762745"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2762745"], "gene": 138126, "json_id": 25131, "variant_name": "PDE4DIP p.A127T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144931330, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 443, "alt_depth": 324, "aa_change": "p.Ala127Thr", "codon_change": "c.379G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002811.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.4224, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs41315684"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=41315684"], "gene": 138126, "json_id": 25130, "variant_name": "PDE4DIP p.T208A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144931087, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 1329, "alt_depth": 929, "aa_change": "p.Thr208Ala", "codon_change": "c.622A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002811.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.2299, "allelic_frequency": 0.4114, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs2147326"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2147326"], "gene": 138126, "json_id": 25129, "variant_name": "PDE4DIP p.K257E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144930940, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 686, "alt_depth": 456, "aa_change": "p.Lys257Glu", "codon_change": "c.769A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002811.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.3993, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs1359300"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1359300"], "gene": 138126, "json_id": 25128, "variant_name": "PDE4DIP p.S438L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144922583, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 352, "alt_depth": 220, "aa_change": "p.Ser438Leu", "codon_change": "c.1313C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002811.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.3846, "comment": "", "exon": "3", "impact_so": "missense_variant"}, {"db_titles": ["rs1061308"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1061308"], "gene": 138126, "json_id": 25127, "variant_name": "PDE4DIP p.E573V", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144918957, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "A", "ref_depth": 948, "alt_depth": 592, "aa_change": "p.Glu573Val", "codon_change": "c.1718A>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002811.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.3844, "comment": "", "exon": "6", "impact_so": "missense_variant"}, {"db_titles": ["rs1747930"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1747930"], "gene": 138126, "json_id": 25126, "variant_name": "PDE4DIP p.S699T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144916748, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "G", "ref_depth": 486, "alt_depth": 311, "aa_change": "p.Ser699Thr", "codon_change": "c.2096G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002811.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.3902, "comment": "", "exon": "9", "impact_so": "missense_variant&splice_region_variant"}, {"db_titles": ["rs1629011"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1629011"], "gene": 138126, "json_id": 25125, "variant_name": "PDE4DIP p.R844H", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144912233, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 470, "alt_depth": 325, "aa_change": "p.Arg844His", "codon_change": "c.2531G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001002811.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.4088, "comment": "", "exon": "11", "impact_so": "missense_variant"}, {"db_titles": ["rs1698624"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1698624"], "gene": 138126, "json_id": 25124, "variant_name": "PDE4DIP p.F1079I", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144886197, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 744, "alt_depth": 451, "aa_change": "p.Phe1079Ile", "codon_change": "c.3235T>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.3774, "comment": "", "exon": "26", "impact_so": "missense_variant"}, {"db_titles": ["rs1343472"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1343472"], "gene": 138126, "json_id": 25123, "variant_name": "PDE4DIP c.3335+5G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144886092, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 224, "alt_depth": 176, "aa_change": "p.?", "codon_change": "c.3335+5G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.44, "comment": "", "exon": "26", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs139206262"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=139206262"], "gene": 138198, "json_id": 25122, "variant_name": "MTRR c.1653G>A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr5", "position": 7895942, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 283, "alt_depth": 324, "aa_change": "p.=", "codon_change": "c.1653G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_002454.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.0126, "allelic_frequency": 0.5338, "comment": "", "exon": "12", "impact_so": "synonymous_variant"}, {"db_titles": ["rs1698647"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1698647"], "gene": 138126, "json_id": 25121, "variant_name": "PDE4DIP p.A1132T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144882823, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 427, "alt_depth": 332, "aa_change": "p.Ala1132Thr", "codon_change": "c.3394G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.4374, "comment": "", "exon": "27", "impact_so": "missense_variant"}, {"db_titles": ["rs12568796"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12568796"], "gene": 138126, "json_id": 25120, "variant_name": "PDE4DIP p.K1222E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144880832, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 523, "alt_depth": 336, "aa_change": "p.Lys1222Glu", "codon_change": "c.3664A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.2529, "allelic_frequency": 0.3912, "comment": "", "exon": "29", "impact_so": "missense_variant"}, {"db_titles": ["rs2798901"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2798901"], "gene": 138126, "json_id": 25119, "variant_name": "PDE4DIP p.W1559R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144879264, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 0, "alt_depth": 1820, "aa_change": "p.Trp1559Arg", "codon_change": "c.4675T>C", "germline_somatic": "STR_GERMLINE", "transcript": "XM_005272981.1", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.639, "allelic_frequency": 1.0, "comment": "", "exon": "23", "impact_so": "missense_variant"}, {"db_titles": ["rs1778120"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1778120"], "gene": 138126, "json_id": 25118, "variant_name": "PDE4DIP p.K1410E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144879090, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 1547, "alt_depth": 978, "aa_change": "p.Lys1410Glu", "codon_change": "c.4228A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.2639, "allelic_frequency": 0.3873, "comment": "", "exon": "30", "impact_so": "missense_variant"}, {"db_titles": ["rs1778155"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1778155"], "gene": 138126, "json_id": 25117, "variant_name": "PDE4DIP p.H1554R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144874815, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 727, "alt_depth": 505, "aa_change": "p.His1554Arg", "codon_change": "c.4661A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.3737, "allelic_frequency": 0.4099, "comment": "", "exon": "33", "impact_so": "missense_variant"}, {"db_titles": ["rs1698606"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1698606"], "gene": 138126, "json_id": 25116, "variant_name": "PDE4DIP c.5081-8T>G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144871889, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "C", "ref_depth": 165, "alt_depth": 132, "aa_change": "p.?", "codon_change": "c.5081-8T>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198834.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.4444, "comment": "", "exon": "31", "impact_so": "splice_region_variant&coding_transcript_intron_variant"}, {"db_titles": ["rs1778158"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1778158"], "gene": 138126, "json_id": 25115, "variant_name": "PDE4DIP p.L1727P", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144871782, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 357, "alt_depth": 102, "aa_change": "p.Leu1727Pro", "codon_change": "c.5180T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198834.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.2222, "comment": "", "exon": "32", "impact_so": "missense_variant"}, {"db_titles": ["rs1778159"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1778159"], "gene": 138126, "json_id": 25114, "variant_name": "PDE4DIP p.V1736E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144871755, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "T", "ref_depth": 585, "alt_depth": 129, "aa_change": "p.Val1736Glu", "codon_change": "c.5207T>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198834.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.1807, "comment": "", "exon": "32", "impact_so": "missense_variant"}, {"db_titles": ["rs1698605"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1698605"], "gene": 138126, "json_id": 25113, "variant_name": "PDE4DIP p.A1742S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144871738, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "A", "ref_depth": 612, "alt_depth": 159, "aa_change": "p.Ala1742Ser", "codon_change": "c.5224G>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198834.3", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.2062, "comment": "", "exon": "32", "impact_so": "missense_variant"}, {"db_titles": ["rs1620560"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1620560"], "gene": 138126, "json_id": 25112, "variant_name": "PDE4DIP p.R1761C", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144866643, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 1826, "alt_depth": 378, "aa_change": "p.Arg1761Cys", "codon_change": "c.5281C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.1715, "comment": "", "exon": "36", "impact_so": "missense_variant"}, {"db_titles": ["rs1613780"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1613780"], "gene": 138126, "json_id": 25111, "variant_name": "PDE4DIP p.D1804E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144865850, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "T", "ref_depth": 287, "alt_depth": 156, "aa_change": "p.Asp1804Glu", "codon_change": "c.5412C>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.5, "allelic_frequency": 0.3521, "comment": "", "exon": "37", "impact_so": "missense_variant"}, {"db_titles": ["rs71225704"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=71225704"], "gene": 138126, "json_id": 25110, "variant_name": "PDE4DIP p.E1895G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144863401, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 340, "alt_depth": 107, "aa_change": "p.Glu1895Gly", "codon_change": "c.5684A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.1729, "allelic_frequency": 0.2394, "comment": "", "exon": "39", "impact_so": "missense_variant"}, {"db_titles": ["rs111880480"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=111880480"], "gene": 138126, "json_id": 25109, "variant_name": "PDE4DIP p.N1959K", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144859889, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "T", "ref_depth": 2084, "alt_depth": 265, "aa_change": "p.Asn1959Lys", "codon_change": "c.5877C>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.0077, "allelic_frequency": 0.1128, "comment": "", "exon": "40", "impact_so": "missense_variant"}, {"db_titles": ["rs78371650"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=78371650"], "gene": 138126, "json_id": 25108, "variant_name": "PDE4DIP p.T2191A", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 144854581, "genome_version": "hg19", "ref_allele": "T", "alt_allele": "C", "ref_depth": 308, "alt_depth": 139, "aa_change": "p.Thr2191Ala", "codon_change": "c.6571A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001198832.2", "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "STR_UNKNOWN_BIOL_SIGNIF", "population_frequency": 0.4821, "allelic_frequency": 0.311, "comment": "", "exon": "44", "impact_so": "missense_variant"}, {"db_titles": ["rs6537825"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6537825"], "gene": 138129, "json_id": 25107, "variant_name": "TRIM33 p.I840T", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 114948281, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 146, "alt_depth": 111, "aa_change": "p.Ile840Thr", "codon_change": "c.2519T>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_015906.3", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.9275, "allelic_frequency": 0.4319, "comment": "", "exon": "15", "impact_so": "missense_variant"}, {"db_titles": ["rs3134614"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3134614"], "gene": 138133, "json_id": 25106, "variant_name": "MYCL p.T362S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 40363054, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 100, "alt_depth": 106, "aa_change": "p.Thr362Ser", "codon_change": "c.1085C>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001033081.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.8729, "allelic_frequency": 0.5146, "comment": "", "exon": "2", "impact_so": "missense_variant"}, {"db_titles": ["rs4870"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4870"], "gene": 138141, "json_id": 25105, "variant_name": "TNFRSF14 p.K17R", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr1", "position": 2488153, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 149, "alt_depth": 200, "aa_change": "p.Lys17Arg", "codon_change": "c.50A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_003820.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN <br> STR_AFFECTED_FUNC_REGIONS:<p style=\"margin-left: 20px\"> <a href=\"http://www.uniprot.org/uniprot/Q92956#family_and_domains\"> TNR14_HUMAN:SIGNAL:1-38 </a>", "population_frequency": 0.4662, "allelic_frequency": 0.5731, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": ["rs3864017"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3864017"], "gene": 138239, "json_id": 25104, "variant_name": "FANCD2 p.P714L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 10106532, "genome_version": "hg19", "ref_allele": "C", "alt_allele": "T", "ref_depth": 440, "alt_depth": 86, "aa_change": "p.Pro714Leu", "codon_change": "c.2141C>T", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001018115.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.1408, "allelic_frequency": 0.1635, "comment": "", "exon": "23", "impact_so": "missense_variant"}, {"db_titles": ["rs73126218"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=73126218"], "gene": 138239, "json_id": 25103, "variant_name": "FANCD2 p.N405S", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr3", "position": 10088343, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 791, "alt_depth": 294, "aa_change": "p.Asn405Ser", "codon_change": "c.1214A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001018115.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.2933, "allelic_frequency": 0.271, "comment": "", "exon": "15", "impact_so": "missense_variant"}, {"db_titles": ["rs1042821"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1042821"], "gene": 138284, "json_id": 25102, "variant_name": "MSH6 p.G39E", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr2", "position": 48010488, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "A", "ref_depth": 85, "alt_depth": 68, "aa_change": "p.Gly39Glu", "codon_change": "c.116G>A", "germline_somatic": "STR_GERMLINE", "transcript": "NM_000179.2", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.1805, "allelic_frequency": 0.4444, "comment": "", "exon": "1", "impact_so": "missense_variant"}, {"db_titles": [], "db_links": [], "gene": 138034, "json_id": 25101, "variant_name": "BRCA2 WT", "variant_type": "STR_WILDTYPE", "variant_class": "STR_CLIN_SIGNIF", "chromosome": "chr13", "position": 32889611, "genome_version": "hg19", "ref_allele": null, "alt_allele": null, "ref_depth": null, "alt_depth": null, "aa_change": null, "codon_change": null, "germline_somatic": "STR_SOMATIC", "transcript": null, "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "<p>В результате таргетного экзонного секвенирования опухолевой ДНК потенциально патогенных вариантов в данном гене не обнаружено.</p>", "population_frequency": null, "allelic_frequency": null, "comment": "", "exon": null, "impact_so": null}, {"db_titles": [], "db_links": [], "gene": 138035, "json_id": 25099, "variant_name": "BRCA1 WT", "variant_type": "STR_WILDTYPE", "variant_class": "STR_CLIN_SIGNIF", "chromosome": "chr17", "position": 41196312, "genome_version": "hg19", "ref_allele": null, "alt_allele": null, "ref_depth": null, "alt_depth": null, "aa_change": null, "codon_change": null, "germline_somatic": "STR_SOMATIC", "transcript": null, "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "<p>В результате таргетного экзонного секвенирования опухолевой ДНК потенциально патогенных вариантов в данном гене не обнаружено.</p>", "population_frequency": null, "allelic_frequency": null, "comment": "", "exon": null, "impact_so": null}, {"db_titles": ["rs61740658"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=61740658"], "gene": 138323, "json_id": 25098, "variant_name": "RNF213 p.E3915G", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78337584, "genome_version": "hg19", "ref_allele": "A", "alt_allele": "G", "ref_depth": 402, "alt_depth": 332, "aa_change": "p.Glu3915Gly", "codon_change": "c.11744A>G", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.0831, "allelic_frequency": 0.4523, "comment": "", "exon": "41", "impact_so": "missense_variant"}, {"db_titles": ["rs35332090"], "db_links": ["https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=35332090"], "gene": 138323, "json_id": 25097, "variant_name": "RNF213 p.V3838L", "variant_type": "STR_SNV", "variant_class": "STR_POLYMORPHISM", "chromosome": "chr17", "position": 78337058, "genome_version": "hg19", "ref_allele": "G", "alt_allele": "C", "ref_depth": 311, "alt_depth": 267, "aa_change": "p.Val3838Leu", "codon_change": "c.11512G>C", "germline_somatic": "STR_GERMLINE", "transcript": "NM_001256071.1", "biolog_impact": "STR_LIKELY_BENIGN", "biolog_impact_summary": "STR_LIKELY_BENIGN", "population_frequency": 0.1006, "allelic_frequency": 0.4619, "comment": "", "exon": "40", "impact_so": "missense_variant"}, {"db_titles": [], "db_links": [], "gene": 138081, "json_id": 25096, "variant_name": "HACK_DUMMY-", "variant_type": "STR_WILDTYPE", "variant_class": "STR_CLIN_SIGNIF", "chromosome": "chr6", "position": 1, "genome_version": "hg19", "ref_allele": null, "alt_allele": null, "ref_depth": null, "alt_depth": null, "aa_change": null, "codon_change": null, "germline_somatic": "STR_GERMLINE", "transcript": null, "biolog_impact": "STR_UNKNOWN", "biolog_impact_summary": "<p>-</p>", "population_frequency": null, "allelic_frequency": null, "comment": "", "exon": null, "impact_so": null}], "StructuredOtherAssays": [{"json_id": 1600, "assay": "CK 5/6", "value": "отсутствие экспрессии", "stdvalue": "LOSS, UNDEREXPRESSION", "assay_result_name": "CK5/6 отриц. экспрессия", "description": "Сочетание окраски на эпителиальные маркеры цитокератины 5 (CK5) и 6 (СК6) используют  для определения базальноподобного подтипа инвазивного протокового рака молочной железы, который обычно характеризуется набором маркеров CK5/6+, ER-, PR-, HER2-, EGFR+, часто ассоциируется с более неблагоприятным прогнозом течения заболевания, нарушениями в BRCA1/2 и метастазированиию в головной мозг. CK5/6 положителен подтип протоковой карциномы in situ (DCIS) с неблагоприятным прогнозом. Данный ИГХ-маркер используют для отличия обычной протоковой гиперплазии молочной железы (CK5/6+ сильное окрашивание) от папиллярных DCIS (CK5/6 отрицательны). p63+ и CK5/6+  низкодифференцированные метастатические карциномы, вероятно, имеют первичное плоскоклеточное происхождение. Окраску на CK5/6 применяют для дифференцирования эпителиоидной мезотелиомы (CK5/6+ детектируется как цитоплазматическое окрашивание, более интенсивное в перинуклеарном пространстве) от аденокарцином легкого (как правило, CK5/6 отрицательных). Маркер используют для отличия плоскоклеточной карциномы кожи (CK5/6+) от поверхностной эпителиоидной саркомы, где наблюдается фокальная положительная реакция на CK5/6.", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": ""}, {"json_id": 1601, "assay": "CD4", "value": "Экспрессия CD4 в Т-лимфоцитах. Соотношение CD4:CD8 примерно 3:1.", "stdvalue": "EXPRESSION", "assay_result_name": "CD4 полож. экспрессия", "description": "<p>CD4 (кластер дифференцировки 4) представляет собой одноцепочечный трансмембранный гликопротеин. CD4 обнаруживается на поверхности множества Т-клеток (Т-хелперов и T-reg) и&nbsp;является корецептором&nbsp;Т-клеточного рецептора (TCR). Данный комплекс взаимодействует с MHC II и антигеном на поверхности антигенпредставляющих клеток. CD4 также присутствует на поверхности 80% тимоцитов и на более низком уровне экспрессируется моноцитами. CD4 используется для классификации лимфом и воспалительных заболеваний.</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": ""}, {"json_id": 1602, "assay": "p16", "value": "отсутствие экспрессии", "stdvalue": "LOSS, UNDEREXPRESSION", "assay_result_name": "p16 отриц. экспрессия", "description": "<p>Опухолевый супрессор p16, кодируемый геном&nbsp;CDKN2A,&nbsp;выполняет функцию ингибитора&nbsp;перехода из фазы G1 в фазу S клеточного цикла посредством блокирования активности циклинзависимых киназ CDK4 и CDK6, что препятствует фосфорилированию pRb и его диссоциации из комплекса с траснкрипционным фактором&nbsp;E2F.&nbsp; Экспрессия р16 снижается или исчезает во многих опухолях&nbsp;вследствие эпигенетических или генетических нарушений, чаще - по причине метилирования промотора гена, в более редких случаях из-за мутаций.&nbsp;Негативное иммуногистохимическое окрашивание наблюдается в опухолях с потерей экспрессии р16 или нарушением его функции. Снижение экспрессии р16 отмечается при раке молочной железы, колоректальном раке, раке головы и шеи, меланоме. Позитивная окраска р16 характерна для опухолей, развитие которых ассоциировано с инфекцией вирусом паппилломы человека (HPV), р16 является суррогатным маркером данной инфекции. Используется при диагностике HPV-ассоциированных опухолей - орофарингеального рака и аногенитальных типов рака, типирования различных гинекологических&nbsp;новообразований.</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": "<p>По данным ретроспективного исследования потеря экспрессии p16 ассоциирована с положительным статусом ER и PR (p=0,007&nbsp;и p=0,027), а также с увеличением общем выживаемости пациентов&nbsp;(Отношение рисков (ОР) 0,63, 95% Доверительный интервал (ДИ), 0,41-0,97, p=0,039) (PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Prognostic+Value+of+the+Immunohistochemical+Expression+of+Phosphorylated+RB+and+p16+Proteins+in+Association+with+Cyclin+D1+and+the+p53+Pathway+in+a+Large+Cohort+of+Patients+with+Breast+Cancer+Treated+with+Taxane-based+Adjuvant+Chemotherapy\">28551632</a>).&nbsp;</p>\r\n<p>Во II фазе исследования PALOMA-1 планировалось изучить влияние экспрессии p16 на эффективность комбинации Летрозола и Палбоциклиба (PMID:<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25524798\">&nbsp;25524798</a>). Гетеро- и гомозиготная потеря p16 были обнаружены в 36% случаев. Набор в когорту 2 с потерей экспрессии p16 и/или амплификацией cyclinD1 был остановлен в связи с нецелесообразностью, поскольку альтерации в p16 не влияли на эффективность Палбоциклиба в общей когорте пациентов (0,37 ОР, 95% ДИ, 0,10&ndash;1,40, p=0,13).</p>\r\n<p>Схожие данные были получены в III фазе исследования MONALEESA-2 для Рибоциклиба (PMID: <a href=\"https://academic.oup.com/annonc/article/29/7/1541/4989216\">29718092</a>).</p>\r\n<p>Таким образом, потеря экспрессии p16 ассоциирована с благоприятным прогнозом и экспрессией ER, PR при раке молочной железы и не влияет на эффективность ингибиторов CDK4/6.</p>"}, {"json_id": 1603, "assay": "MDM2", "value": "экспрессия", "stdvalue": "EXPRESSION", "assay_result_name": "MDM2 полож. экспрессия", "description": "Е3 убиквитин-протеин лигаза, которая опосредует убиквитинирование р53, что приводит к его протеасомной деградации. MDM2 ингибирует p53- и p73-опосредованный арест клеточного цикла и апоптоз. Ген MDM2 часто амплифицирован в высокодифференцированных липосаркомах и дедифференцированных липосаркомах. Иммуногистохимическое окашивание MDM2 коррелирует с амплификацией гена. ИГХ-анализ MDM2 используется для различения высокодифференцированной липосаркомы (MDM2-положительная, чувствительность FISH - 90%) от доброкачественных липом  (MDM2-отрицательных). В отличие от низкодифференцированных сарком, дедифференцированные липосаркомы обычно являются MDM2-позитивными. Окрашивание на MDM2 помогает дифференцировать остеосаркому низкой степени злокачественности (MDM2-положительную) от доброкачественных фиброзных и фиброзно-костных поражений (MDM2-отрицательных).", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": ""}, {"json_id": 967, "assay": "HER-2", "value": "0 баллов (нет окрашивания или слабо заметное неполное мембранное окрашивание менее 10% клеток опухоли)", "stdvalue": "LOSS, UNDEREXPRESSION", "assay_result_name": "HER2 отриц. экспрессия", "description": "<p>HER2 (также называемый HER-2/neu, c-erbB2, ERBB2) представляет собой трансмембранный рецептор с тирозинкиназной активностью. При злокачественных новообразованиях человека HER2 активируется посредством амплификации гена, что приводит к 10-100-кратному повышению его экспрессии. HER2 гиперэкспрессирован в 15-25% случаев первичного рака молочной железы. Также гиперэкспрессия HER2 может быть обнаружена при раке желудка, колоректальном раке, эпителиальных опухолях яичников. Амплификация HER2 и гиперэкспрессия в опухолевой ткани являются маркерами чувствительности опухолей различных гистологических типов к анти-HER2 терапии (Трастузумаб, Лапатиниб и т. д.).</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": "<p>Нет показаний к анти-HER2 терапии.</p>"}, {"json_id": 968, "assay": "AR", "value": "экспрессия", "stdvalue": "EXPRESSION", "assay_result_name": "AR полож. экспрессия", "description": "<p>Андрогеновый рецептор (AR) относится к суперсемейству ядерных рецепторов, лиганд-чувствительных регуляторов транскрипции. Он функционирует в ядре, опосредуя действие андрогенов. Экспрессия AR обычно наблюдается в опухолях молочной железы. Более 77% инвазивных опухолей молочной железы определяются как AR-положительные (AR+), когда по результатам иммуногистохимического анализа в раковых клетках отмечается не менее 10% ядерного окрашивания AR. Существуют данные о том, что положительный AR-статус является фактором прогноза эффективности антагонистов андрогенных рецепторов.</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": "<p>Положительная экспрессия AR наблюдается в около 70-90% образцов люминального рака молочной железы (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29078133\">29078133</a>,&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24273215\">24273215</a>), что по данным мета-анализа ассоциировано с увеличением 3х- и 5ти-летней выживаемости&nbsp;(Относительный риск (ОР) - 0,47, 95%&nbsp;Доверительный интервал&nbsp;(ДИ) 0,39-0,58, p&lt;0,001; и OР - 0,40, 95% ДИ 0,29-0,56, р&lt;0,001)(PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24273215\">24273215</a>). Экспрессия AR у ER-положительных пациенток с раком молочной железы ассоциирована с отсутствием поражения лимфоузлов и достоверным увеличением выживаемости до прогрессирования&nbsp;(Отношение рисков&nbsp;0,444, 95%ДИ 0,258&ndash;0,765, p=0,003)(PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/20127405\">20127405</a>).</p>\r\n<p>Положительная экспрессия AR при ER+ раке молочной железы ассоциирована с инфильтрацией микроокружения регуляторными Т-лимфоцитами (p &lt; 0,01) с низкой цитолитической активностью и низкой частотой полных патоморфозов после неоадъювантной терапии, но лучшей общей выживаемостью (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/31151151\">31151151</a>).</p>"}, {"json_id": 970, "assay": "PTEN", "value": "экспрессия", "stdvalue": "EXPRESSION", "assay_result_name": "PTEN полож. экспрессия", "description": "<p>Ген PTEN кодирует липидную фосфатазу, которая подавляет активность Akt путем дефосфорилирования фосфатидилинозитола 3,4,5-трифосфата (PIP3). PTEN является опухолевым супрессором, функционирует как регулятор клеточного цикла и апоптоза. Инактивирующие мутации гена PTEN могут привести к активации сигнального пути PI3K/Akt/mTOR. В норме PTEN экспрессируется практически во всех тканях. Позитивная окраска наблюдается также в различных карциномах. Часто обнаруживаемая в карциномах негативная окраска на PTEN ассоциирована с нарушением функции гена и потерей экспрессии. Исследования продемонстрировали, что снижение экспрессии PTEN происходит при распространенных формах рака молочной железы и простаты. Кроме того, низкий уровень экспрессии PTEN ассоциирован с низкой эффективностью Трастузумаба в лечении HER2-позитивных злокачественных образований.</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": "<p>По данным крупного ретроспективного исследования потеря PTEN ассоциирована с наличием неблагоприятных прогностических факторов при раке молочной железы (опухоль &gt; 2 см, поражение лимфатических узлов) и укорочением медианы выживаемости без прогрессирования и общей выживаемости&nbsp;(Отношение рисков - 1,63, 95% Доверительный интервал (ДИ)&nbsp;= 1,04-2,22, р&lt;0,00001;&nbsp;Отношение рисков - 1,41, 95%&nbsp;ДИ 1,08-1,73, р&lt;0,0001, соответственно)(PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28410191\">28410191</a>). По данным ретроспективного исследования потеря экспрессии PTEN ассоциирована с низкой чувствительностью к Тамоксифену при гормонзависимом раке молочной железы (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22892847\">22892847</a>). Данные о взаимосвязи потери экспрессии PTEN и резистентности к гормонотерапии также подтверждены на клеточных культурах рака молочной железы (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/21170675\">21170675</a>). На мышиных моделях показано, что потеря функции PTEN связана с чувствительностью опухоли к Палбоциклибу (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28349562\">28349562</a>).&nbsp;</p>\r\n<p><em>Таким образом, положительная экспрессия PTEN является положительным прогностическим маркером при люминальном подтипе рака молочной железы.</em></p>"}, {"json_id": 971, "assay": "PD-L1", "value": "TPS 0%,  TIL 0%", "stdvalue": "LOSS, UNDEREXPRESSION", "assay_result_name": "PD-L1 отсуств. экспресссии", "description": "<p>PD-L1- ключевой регулятор иммунологического ответа, который участвует в ускользании опухоли из под влияния иммунной системы. Оценка экспрессии PD-L1 на поверхности опухолевых клеток является важным прогностическим маркером при назначении анти-PD-1 препаратов (ниволумаб, пембролизумаб) для лечения различных злокачественных опухолей. PD-L1 представляет собой регуляторную молекулу, которая может быть продуцирована опухолевыми клетками для подавления иммунной реакции. PD-1 (белок запрограммированной гибели клеток/Programmed cell Death-1) - рецептор лиганда PD-L1, экспрессируется на поверхности активированных цитотоксических Т-лимфоцитов. При активации данного рецептора при взаимодействии с лигандами (PD-L1, PD-L2) подавляется активация Т-лимфоцитов и индуцируется их апоптоз. Оценка уровня синтеза белка PD-L1 в опухоли может иметь прогностическое и/или терапевтическое значение у некоторых больных раком. Детекция PD-L1 на мембранах опухолевых клеток способствует стратификации пациентов, которые получат наибольшую пользу от терапии ингибиторами контрольных точек иммунитета - антителами к PD-1 или PD-L1.</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": "<p>-PD-L1 экспрессия на &lt;1% опухолевых клеток.&nbsp;Опираясь на результаты исследований Keynote-012 и 086, невозможно дать оценку влияния экспрессии PD-L1 на поверхности опухолевых клеток на частоту объективного ответа и общую выживаемость пациенток с тройным негативным раком молочной железы, получающих анти-PD-1 терапию (PMID:&nbsp;<a title=\"PubMed link\" href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=27138582\" target=\"_blank\">27138582</a>,<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=KEYNOTE-086+cohort+B%3A+Pembrolizumab+monotherapy+for+PD-L1%E2%80%93positive%2C+previously+untreated%2C+metastatic+triple-negative+breast+cancer+(mTNBC)\">&nbsp;30475947</a>). Однако, стоит заметить, что в общей популяции пациенток с тройным негативным раком молочной железы объективный ответ наблюдается лишь в 5% случаев.&nbsp;Данных по эффективности иммунотерапии при люминальном В подтипе рака молочной железы не опубликовано.</p>\r\n<p>-&nbsp;PD-L1 экспрессия на &lt;1% иммунных клеток.&nbsp;В III фазе клинического исследования была изучена эффективность комбинации Атезолизумаба (анти-PD-L1) с Наб-паклитакселом в лечении метастатического тройного негативного рака молочной железы (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30345906\">30345906</a>). Медиана выживаемости без прогрессирования составила 7,2 месяца в группе Атезолизумабом плюс Наб-паклитаксел по сравнению с 5,5 месяцами в группе плацебо + Наб-паклитаксел (отношение рисков, ОР, для прогрессии 0,80; доверительный интервал, ДИ, 0,69-0,92; р=0,002); среди пациентов с опухолями с экспрессией PD-L1 &gt;1% на поверхности клеток микроокружения медиана выживаемости без прогрессирования составила 7,5 месяца в группе комбинации и 5,0 месяцев в группе Наб-паклитаксела (ОР прогрессирования 0,62; 95% ДИ, 0,49-0,78; р&lt;0,001). Медиана общей выживаемости составила 21,3 месяца в группе Атезолизумаба и Наб-паклитаксела и 17,6 месяца - для плацебо и Наб-паклитаксела в общей популяции (ОР 0,84; 95% ДИ 0,69-1,02; р=0,08); среди пациентов с PD-L1-позитивными опухолями медиана общей выживаемости составила 25,0 и 15,5 месяцев, соответственно (ОР 0,62; 95% ДИ 0,45-0,86). Назначение комбинации Атезолизумаб+Наб-Паклитаксел имело статистически значимое преимущество в выживаемости без прогрессирования и общей выживаемости по сравнению с монотерапией Наб-паклитакселом в группе с экспрессией PD-L1 на 1% и более клеток микроокружения опухоли.</p>"}, {"json_id": 978, "assay": "Ki-67", "value": "45.0%", "stdvalue": "EXPRESSION", "assay_result_name": "высокий индекс пролиферации Ki-67", "description": "Белок Ki-67 (также известный как MKI67) является специфическим маркером пролиферации. В интерфазе антиген Ki-67 может быть обнаружен исключительно в ядре клетки, тогда как при митозе большая часть белка перемещается на поверхность хромосом. Белок Ki-67 присутствует во всех активных фазах клеточного цикла (G1, S, G2 и митоз), но отсутствует в покоящихся клетках (G0). Клеточное содержание белка Ki-67 заметно увеличивается во время перехода через S-фазу клеточного цикла. При раке молочной железы Ki-67 используется как маркер для определения группы пациентов с ER-положительным раком молочной железы, которые получают большую пользу от адъювантной химиотерапии.", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": ""}, {"json_id": 979, "assay": "PR", "value": "6 (TS) по Allred", "stdvalue": "EXPRESSION", "assay_result_name": "PR полож. экспрессия", "description": "Рецептор прогестерона (PR) принадлежит к семейству ядерных рецепторов и является гормонзависимым фактором транскрипции. PR преимущественно экспрессируется в гормончувствительных тканях, в опухолях женских репродуктивных органов (молочная железа, эндометрий и яичник). Около половины карцином молочной железы являются гормонпозитивными (ER+/PR+). Применение антител к PR аналогично применению антител к ER - используется при стандартной диагностике и типировании рака молочной железы (РМЖ), для выявления PR-положительных опухолей (часто  - очагов их метастазирования) и прогнозирования терапевтического ответа при РМЖ.", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": ""}, {"json_id": 980, "assay": "ER", "value": "5 (TS) по Allred", "stdvalue": "EXPRESSION", "assay_result_name": "ER полож. экспрессия", "description": "ИГХ-реакция на ER (рецептор эстрогена) используется при рутинном анализе образцов рака молочной железы, является предиктивным биомаркером эффективности Тамоксифена или других антиэстрогенов.\r\nТакже служит прогностическим маркером для выживаемости (ER + является благоприятным фактором прогноза). ER+ относительно специфичная реакция для молочной железы (но есть многочисленные исключения). Используется для различия эндоцервикальной (ER-) и эндометриальной (ER +) аденокарцином.\r\nER-позитивное окрашивание наблюдается при карциномах молочной железы (варьируется в зависимости от подтипа и степени злокачественности опухоли) - высоко дифференцированные опухоли, как правило, ER-положительные. ER экспрессируется в аденокарциномах эндометрия (75%), серозных, муцинозных и эндометриоидных аденокарциномах яичников, папиллярном уротелиальном раке мочевого пузыря (10-20%) и переходно-клеточном раке яичников (90%).\r\nПоложительным окрашиванием ER считается ядерная реакция, только цитоплазматическое окрашивание является отрицательным результатом.", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": ""}, {"json_id": 966, "assay": "TMB", "value": "7,5 мутаций/Mб", "stdvalue": "TMB_LOW", "assay_result_name": "низкий уровень TMB (7,5 мутаций/Mб)", "description": "<p>Показатель мутационной нагрузки опухоли (Tumor Mutational Burden, TMB) отражает количество мутаций, обнаруженных в опухоли. ТМВ определяется как число соматических мутаций на миллион оснований (Мб) ДНК. Этот тип биомаркера используется для прогнозирования эффективности иммунотерапии (ингибиторов иммунных контрольных точек). Опухоли с относительно высокими значениями TMB считаются более иммуногенными. В представленном анализе используется расчет TMB согласно работе Chalmers et al, 2017. Однако, в настоящее время отсутствует стандартизация для расчета TMB, также для многих типов опухолей не установлены диапазоны значений TMB, соответствующие высокой и низкой мутационной нагрузке.</p>", "technique": "STR_ASSAY_TMB", "sample": "STR_SAMPLE_FFPE", "comment": "<p>Мутационная нагрузка менее 10 мутаций на мегабазу (мут/Mб) относится к низкому показателю TMB. Влияние молекулярно-генетических подтипов рака молочной железы на TMB было изучено в крупном клиническом исследовании, включившем 3871 случаев метастатического рака молочной железы, в том числе 1388 ER+ HER2- случаев (<a href=\"https://meetinglibrary.asco.org/record/174797/abstract\">ASCO</a>). В 8% случаев ER+ HER2- рака молочной железы&nbsp;было обнаружено&nbsp;TMB&gt;10 мутаций/Мб, в том числе в 3% случаев TMB&gt;20 мут/Мб.&nbsp;В ретроспективных клинических исследованиях было показано, что высокая соматическая мутационная нагрузка и инфильтрация опухоли лимфоцитами ассоциированы с достоверным уменьшением общей выживаемости при ER+ HER- подтипах рака молочной железы (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24839032\">24839032</a>,&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29233559\">29233559</a>). Также в крупном ретроспективном исследовании MSK-IMPACT изучалось влияние TMB на прогноз при различных злокачественных опухолях (PMID: <a href=\"https://www.nature.com/articles/s41588-018-0312-8\">30643254</a>). В исследование были включены 1662 пациента, получавших ранее иммунотерапию, и 5371 пациентов не получавших ранее иммунотерапию.&nbsp; В подгрупповом анализе изучалось влияние TMB на общую выживаемость у пациентов, получивших иммунотерапию, в подгруппе ER+ HER2- рака молочной железы (N=24) была получена тенденция к ухудшению общей выживаемости при TMB&gt; 10 мут/Мб. Отсутствие достоверных данных в данном исследовании может быть обсловлено небольшой выборкой.</p>\r\n<p>В клиническом исследовании TAPUR изучалась эффективность Пембролизумаба в лечении метастатического рака молочной железы с высокой TMB (&gt;9 мут/Мб) (<a href=\"http://abstracts.asco.org/239/AbstView_239_250471.html\">ASCO</a>). В исследование были включены 28 пациенток с метастатическим раком молочной железы, 8 из них получали Пембролизумаб в дозе 2 мг/кг каждые 3 недели, 20 из них получали 200 мг Пембролизумаба каждые 3 недели. 93% пациенток получили 3 и более линий системной терапии перед включением в исследование. Частота объективного ответа составила 21%, частота контроля заболевания 37%. Медиана выживаемости без прогрессирования составила 10,6 недель, медиана общей выживаемости 31,6 недель. Статистическая гипотеза данного исследования была выполнена, исследования по эффективности Пембролизумаба у пациенток с высоким TMB при раке молочной железы будут продолжены.</p>\r\n<p>На данный момент инициировано исследование по изучению эффективности комбинации Ниволумаба и Ипилимумаба при метастатическом HER2- раке молочной железы с TMB не менее 10 мут/Мб (<a href=\"https://meetinglibrary.asco.org/record/177518/abstract\">ASCO</a>).</p>\r\n<p><em>Таким образом, низкий уровень TMB ассоциирован с хорошим прогнозом при метастатическом ER+ HER2- раке молочной железы. Эффективность иммунотерапии в этой когорте пациенток не изучалась.</em></p>"}, {"json_id": 975, "assay": "BCL2", "value": "экспрессия", "stdvalue": "EXPRESSION", "assay_result_name": "BCL2 полож. экспрессия", "description": "<p style=\"text-align: justify;\">Семейство BCL-2 представляет собой группу белков-регуляторов апоптотической программы. Считается, что конститутивная экспрессия BCL2, такая, как в случае транслокации BCL2 в локус тяжелой цепи Ig, является причиной фолликулярной лимфомы. В норме окраска на BCL2 характерна для: 1) клеток лимфатического узла: В-лимфоцитов в мантийной зоне и клеток в областях зон Т-клеток, 2) клеток коры надпочечника, меланоцитов, тимус-медуллярных клеток, клеток щитовидной железы, 3) незрелых мелких ганглиозных клеток. Маркер используется для дифференциации фолликулярной гиперплазии лимфатического узла (зародышевые центры являются BCL2-отрицательными) от фолликулярной лимфомы (зародышевые центры - BCL2 +); BCL2 обычно гиперэкспрессирован при фолликулярной лимфоме вследствие траслокации t (14,18) (q32; q21); однако, некоторые фолликулярные лимфомы являются BCL2-отрицательными.</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": "<p style=\"text-align: justify;\">В ретроспективном исследовании оценивали прогностическую значимость и частоту экспрессии BCL-2 при различных подтипах рака молочной железы (PMID:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056973/\">&nbsp;28701032</a>). В исследование были включены 1096 образцов рака молочной железы, 784&nbsp;&nbsp;(71,5%) инвазивного протокового рака молочной железы, 202 (18,4%) образцов долькового рака молочной железы. Все образцы были классифицированы по молекулярно-генетическим подтипам: 599 (54,7%) люминальный А, 154 (14,1%) люминальный В, 39 (3,6%) HER-2 позитивный и 160 (14,6%) тройной негативный. 73% случаев люминального А и В подтипов имели высокую экспрессию BCL-2 по сравнению с 8,9% при нелюминальных подтипах. В подгруппе с высокой экспрессией BCL-2 5ти-летняя общая выживаемость составила 86,1% по сравнению с 71,8% при низкой экспрессией BCL-2 (p=0,006).</p>\r\n<p style=\"text-align: justify;\">В другом рероспективном исследовании изучалось влияние&nbsp; экспрессии BCL-2 на общую выживаемость у молодых пациенток (&lt;40 лет) с раком молочной железы (PMID:<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30583683\">&nbsp;30583683</a>). Основными подтипами, включеннымми в исследование были люминальный В и тройной негативный. Положительная экспрессия BCL-2 коррелировала с положительной экспрессией ER и PR (p&lt;0,001). Положительная экспрессия BCL-2 была ассоциирована с увеличением общей выживаемости (p=0,004).</p>\r\n<p style=\"text-align: justify;\">На&nbsp; мышиных моделях был показан потенциальный синергизм ингибитора BCL-2 - Венетоклакса и Тамоксифена в лечении ER+ BCL2+ рака молочной железы (PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29146569\">29146569</a>). Венетоклакс в монотерапии имел минимальную эффективность, однако комбинация Венетокслакса с Тамоксифеном показала наибольшую дозозависимую эффективность.</p>\r\n<p style=\"text-align: justify;\">В клиническом исследовании 1b фазы изучалась эффективность ингибитора BCL2 - Венетоклакса в комбинации с Тамоксифеном в лечении ER+ HER2- BCL2+ рака молочной железы (PM<span class=\"metadata-label\">ID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/30518523\">30518523</a></span>). В исследование были включены 33 пациентки, 15 - в когорту с&nbsp;дозоэскалацией&nbsp;Венетоклакса (200-800 мг в сутки), 91% пациенток были в постменопаузе. 11 (33,3%) пациенток получили данное лечение в качестве 1 линии, 22 (66,7%) пациентки ранее получали химио- или гормонотерапию, из которых 15 (45%) получили более 2х линий терапии. Согластно критериям ESMO-ABC4 первичная гормонорезистентность наблюдалась у 3 пациенток, вторичная гормонорезистентность у 24 пациенток и 6 имели поздний рецидив после адъювантной гормонотерапии и были расценены как гормоночувствительные, 63% пациенток получили Тамоксифен в адъювантном режиме или в качестве гормонотерапии до включения в исследование. Наиболее эффективной дозой оказалась ежедневный прием 800 мг Венетоклакса и стандартного режима приема Тамоксифена (20 мг в сутки), который был рекомендован для последующих исследований. Частота объективных ответов составила 45% (n=15) в общей когорте, 27% (n=4 из 15) в группе дозоэскалации. В группе&nbsp;дозоэкспансии (Венетоклакс 800 мг в сутки и Тамоксифен 20 мг в сутки) у пациенток с измеряемыми очагами заболевания частота объективных ответов составила 54% (n=13) и частота стабилизаций заболевания 21% (n=5). Контроль за заболеванием (Объективный ответ+стабилизация) был достигнут у 1 из 3х пациенток с первичной гормонорезистентностью и у 16 из 24 со вторичной гормональной резистентностью. Выживаемость без прогрессирования составила 51 неделю в группе дозоэкспансии и 23 недели в группе дозоэскалации (ежедневный прием менее 800 мг Венетоклакса). На эффективность терапии не влияло наличие или отсутствие мутаций в генах <em>PIK3CA</em>, <em>ESR1</em>, <em>GATA3</em>, <em>PTEN </em>и&nbsp;<em>MAP3K1</em>. Прием Венетоклакса влиял на микроокружение опухоли, вызывая деплецию В-лимфоцитов и статистически значимо не влияя на количество Т-лимфоцитов.</p>\r\n<p style=\"text-align: justify;\">На данный момент инициированы клинические исследования по изучению эффективности Венетоклакса в комбинации с Летрозолом и Палбоциклибом (<a href=\"https://clinicaltrials.gov/ct2/show/NCT03900884\">NCT03900884</a>) и Фулвестрантом (<a href=\"https://clinicaltrials.gov/ct2/show/study/NCT03584009\">NCT03584009</a>) в лечении ER+ HER2- рака молочной железы.</p>"}, {"json_id": 1604, "assay": "CK7", "value": "экспрессия", "stdvalue": "EXPRESSION", "assay_result_name": "CK7 полож. экспрессия", "description": "Кератин II типа простого неороговевающего эпителия с молекулярной массой 51,4 кДа. Мембранный/цитоплазматический маркер, экспрессия которого детектируется во многих типах нормального эпителия и в эпителиальных опухолях. Несмотря на высокую неспецифичность экспрессии, CK7 полезен как часть панели для определения первичного очага метастатического рака. Экспрессия СК7 обычно выражена (с некоторыми вариациями) в аденокарциномах легких, молочной железы, щитовидной железы, эндометрия, шейки матки, яичников, слюнных желез и верхних отделов желудочно-кишечного тракта, карциноме уротелия почек, папиллярной почечно-клеточной карциноме и отмечается при болезни Педжета. Экспрессия СК7 обычно отрицательна при колоректальном, гепатоцеллюлярном, простатическом типах рака и в плоскоклеточном раке, также СК7-отрицательны адренокортикальные опухоли и карциномы Меркеля. Паттерны экспрессии СК7/СК20, используемые в онкопатологии:\r\nСК7+/СК20+ - в карциномах желчного протока (часто внепеченочных протоков/желчного пузыря), в муцинозных карциномах легкого и бронхиолоальвеолярных карциномах, в карциномах поджелудочной железы и уротелия, также в первичных муцинозных опухолях яичника (74%), верхней части желудочно-кишечного тракта, ЖКТ (78%) и эндоцервикса (88%);\r\nCK7+/CK20- - при карциномах желчного протока (внутрипеченочных), молочной железы, эндоцервикальных и эндометриальных аденокарциномах, карциномах пищевода (дистальных), легких (не муцинозных бронхиолоальвеолярных), слюнных желез и щитовидной железы, а также при мезотелиомах;\r\nCK7-/CK20+ - при карциномах толстой кишки (особенно ранней стадии), CK20 обладает меньшей чувствительностью для низкодифференцированного рака толстой кишки, первичных муцинозных опухолей нижних отделов ЖКТ (79%) и первичным аденокарциномам мочевого пузыря (29%);\r\nCK7-/CK20- - при карциномах коры надпочечников и предстательной железы.\r\nПокраска на CK7 и CK20 применяется при дифференциальной диагностике: первичной карциномы легких (CK7+/CK20-) с метастазами рака толстой кишки в легких (CK7-/CK20+); карциномы толстой кишки (80% являются CK20+) с низкодифференцированной карциномой предстательной железы (90% из них- CK20-) при биопсии; карциномы из клеток Меркеля (CK20+ dot-like-паттерн, TTF1-) с метастатическим мелкоклеточным раком легкого (CK20-, TTF1+); анального рака (CK7+/CK20-) с распространением рака толстой кишки (CK7-/CK20+); сегменты пищевода Барретта с интестинальной метаплазией кардии, аденокарциномы дистального отдела пищевода (CK7+/CK19+ 90%, CK7+/CK20- 74%) с аденокарциномой проксимального отдела желудка (CK7+/CK19+ 44%, CK7+/CK20- 24%).", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": ""}, {"json_id": 1605, "assay": "BCL6", "value": "отсутствие экспрессии", "stdvalue": "LOSS, UNDEREXPRESSION", "assay_result_name": "BCL6 отриц. экспрессия", "description": "<p style=\"text-align: justify;\">BCL6 - транскрипционный фактор, который экспрессируется в герминативных центрах лимфатических узлов и внутрифолликулярных CD4+ T-клетках. Защищает В-клетки герминативного центра от апоптоза, вызванного повреждением ДНК, во время соматической гипермутации и рекомбинации генов иммуноглобулинов Ig. BCL6 используется патологами в качестве маркера герминативного центра лимфоузлов. BCL6-позитивное окрашивание является маркером различных типов лимфом: ангиоиммунобластная Т-клеточная лимфома, лимфома Беркитта, диффузная крупноклеточная В-клеточная лимфома, фолликулярная лимфома, лимфома Ходжкина, нейробластома, плазмабластическая лимфома типа слизистой оболочки полости рта, первичная кожная фолликулярная лимфома и др. Ядерное окрашивание считается положительным.</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": "<p style=\"text-align: justify;\">Данные о влиянии экспрессии BCL-6 на прогноз пациенток с раком молочной железы различны. В ретроспективном исследовании было показано, что положительная&nbsp;экспрессия BCL-6 ассоциирована с тройным негативным подтипом рака молочной железы и рассматривается как отрицательный&nbsp;прогностический фактор (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28208987\">28208987</a>). Однако в другом исследовании положительная экспрессия BCL-6 наряду с высоким соотношением Th1/Th2 лимфоцитов является благоприятным прогностическим фактором при раке молочной железы и колоректальном раке (PMID: <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/31227749\">31227749</a>). Стоит отметить, что в этом исследовании не было разделения на молекулярно-генетические подтипы рака молочной железы, что затрудняет анализ результатов, полученных авторами.</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>"}, {"json_id": 1606, "assay": "CD8", "value": "Экспрессия CD8 в Т-лимфоцитах. Соотношение CD4:CD8 примерно 3:1.", "stdvalue": "EXPRESSION", "assay_result_name": "CD8 полож. экспрессия", "description": "<p>CD8 (кластер дифференцировки 8) представляет собой гликопротеин, экспрессирующийся на клеточной поверхности большинства цитотоксических Т-лимфоцитов. Антиген CD8&nbsp;является корецептором Т-клеточного рецептора (TCR) на Т-лимфоците, данный комплекс участвует в процессе антигенпрезентации и взаимодействии с комплексом MHC I-антиген на поверхности клетки мишени. CD8 обнаруживается в подмножестве цитотоксических Т-лимфоцитов и T-reg. CD8 также обнаруживается на&nbsp; поверхности мембраны естественных киллеров (NK- клеткок) и тимоцитов. CD8&nbsp;представлен либо гомодимером, состоящим из двух альфа-цепей, либо гетеродимером, состоящим из одной альфа-и одной бета-цепи. Как альфа-, так и бета-цепи имеют значительную гомологию с легкими цепями иммуноглобулина. Большинство CD8 + T-клеток экспрессируют альфа / бета-гетеродимерную форму CD8. [Www.thermofisher.com]</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": ""}, {"json_id": 1607, "assay": "CDK4", "value": "экспрессия", "stdvalue": "EXPRESSION", "assay_result_name": "Cdk4 полож. экспрессия", "description": "<p>CDK4 в комплексе с циклином D1 регулирует переход клеток&nbsp;из G1 в S фазу клеточного цикла.&nbsp;Взаимодействие с циклином D1 (CCND1)&nbsp;повышает активность Cdk4, тогда как связывание с p16 снижает активность Cdk4. Активация CDK4 и CCND1 в опухолевых клетках чаще всего является следствием соматических генетических нарушений. Экспрессия CDK4 является неблагоприятным прогностическим фактором при мультиформной глиобластоме и не имеет прогностического значения при инвазивной карциноме молочной железы.</p>", "technique": "STR_ASSAY_IHC", "sample": "STR_SAMPLE_FFPE", "comment": "<p>По данным ретроспективного исследования, включившего 1117 пациенток с раком молочной железы, положительная экспрессия CDK4 ассоциирована с достоверным уменьшением 5-ти летней выживаемостью без прогрессирования при ER+ HER2- раке молочной железы (Отношение рисков 1,52; 1,24-1,87) (PMID:&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=27759034\"><span class=\"highlight\">27759034</span>&nbsp;</a>). Влияние экспрессии CDK4 на чувствительность к ингибиторам CDK4/6 не подтверждена в клинических исследованиях.</p>"}]}